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ABSTRACT
T his study investigates the use o f  cellular p ro m o ters  in the con tex t o t an enhancer- 
deleted m urine retroviral vec to r suitable for applicadon in gene therapy p ro to co ls  to r 
treating diseases that affect the m veloid lineage (Schwickerath (7 <7/., 2004). A lthough  the 
theory  and practice su rround ing  enhancer-deleted  and selt-inactivating vectors has been 
know n for som e time, only recently have their attribu tes been considered  to be o t 
prim ary im portance.
O u r m odel system  for the developm ent o t gene therapy has been  chronic 
granu lom atous d isease /d iso rd e r (C G D ), an inherited  cond ition  attec ting  the ability o t 
neu troph ils to kill invading pathogens, w ith potentially tatal consequences. T h e  disease 
is caused by m utations in any one o f  several co m ponen ts re te rred  to as gp9  1 ', p6~ \
p4~ ' o r p22; which to g e th er w ith rac2 m ake up the X A D P H  oxidase com plex 
p resen t in n eu troph ils  and o th e r phagocytes (Casimir and Teahan, 1994; G o ld b la tt and 
T hrasher, 2000; Seger and R zekow itz , 1994; T h rash er et ah, 1992; T h rash er et ah, 1993; 
T h rash er et ah, 1994).
T his p ro ject aim ed to im prove the transcrip tiona l o u tp u t and saletv o t retroviral vectors 
in myeloid cells, the cell type a ttec red  in C G D  and to identity  suitable tissue specitic and 
inducible p ro m o ters  to r m veloid specitic gene expression , w hich were em ployed to r the 
expression o f  p 4 7 ' N (Rodawav et ah, 1990; Teahan et ah, 1990), the m ajor cause o t the 
autosom al recessive to rm  o t the disease.
"ho prove the tunctionalitv  o t ou r co n stru c ts  in vivo, we m ade use o t a p 4 7'" N deficient 
m ouse as a disease m odel to r  C G D , w hich lacks phagocyte superoxide p ro d u c tio n , thus 
reflecting an identical p h eno type  to  that seen in hum an C G D  (Jackson et ah, 1995; 
M essina et ah, 2002; M itchison et ah, 2005).
We conclude to have developed  an enhancer-deleted  retroviral vector that could provide 
the basis for a new  generation  o t retroviral vectors with im proved satetv, bv essentially 
retaining high titre and d em o n stra ted  transcrip tional activity in mveloid cells, capable ot 
reconstitu ting  verv high levels o t oxidase activity, com parable to that ob ta ined  trom  
norm al cells.
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1 I n t r o d u c t i o n
H aem atopoietic  stem  cell transp lan ta tion  from  a fully m atched  d o n o r offers only a 
possible cure for infants b o rn  w ith inherited  im m une deficiencies, w ho otherw ise may 
n o t survive beyond the first vears o f  life. W here a m atched d o n o r cannot be found , 
hap lo idendcal transplan ts from  parental don o rs may be suitable; how ever these are 
associated w ith g reater com plications and lower success rates. H ence an alternative 
therapeutic  o p d o n  based on  gene therapy has been an intensive field of advanced 
research over the past 25 vears (C one and M ulligan, 1984; S tuhlm ann et al., 1984), w hich 
just recendv resulted in several clinical trials (Blaese et al., 1995; B ordignon et al., 1995; 
Cavazzana-C alvo et al., 2000b; O tt  e t al., 2006).
T h e  fundam ental basis o f  gene therapy  is the successful in tro d u cd o n  o f  a gene in to  
som adc cells, followed bv lo n g -term  expression  o f  therapeudc  levels o f  the required 
protein . Theoreticallv, diseases caused bv know n m o n o g en ed c  defects, could be treated 
and potentially  cured by the in se rd o n  and expression  o f  a norm al copy o f  the m utan t 
gene in the host cells. W ith the ability to genetically m odify  h aem atopo iedc stem  cells, 
which have the po tendal for self-renew al, the tools are available to r  durable expression 
o f  therapeutic transgenes in all lineages o f  m ature b lood  cells for the lifetim e o f  the 
patient. In  this con tex t, au to logous b one  m arrow  transp lan ta tion  com bined  w ith viral 
gene transfer has m anv po ten tial applications to r a w ide range of b lood  diseases. T his 
idea o f  gene therapy  provides the basic fram ew ork for the future therapy of m onogen ic  
diseases (B renner, 1996).
A lthough m ost clinical trials in gene therapy have been aim ed at the trea tm en t of 
various types o f  cancer, the m ost pop u lar candidates for gene therapy are com m only  the 
inherited single gene disorders, prim arily cvstic fibrosis, haem ophilia, D uch en n e  
m uscular dystrophy, and in particu lar b lood  disorders, due to accessibility of bone 
m arrow  and therefore , the gene therapy targets, the stem  cells. H ence, the second g ro u p  
of inherited  diseases m ost com m only  targeted has been severe com bined  
im m unodeficiency syndrom e, like adenosine deam inase deficiency (ADA-SC1D) and X- 
linked severe com bined  im m unodeficiency  (X -SCID ) represen ting  ab o u t 20%  o f  all
Chapter 1: Introduction
trials for m onogenic diseases carried  o u t until today (Edelstein  et al., 2004) and 
represen ts the only g ro u p  in w hich gene therapy has show n any lasting and clinically 
m eaningful therapeu tic  benefits (Cayazzana-Calyo et al., 2000b; C ayazzana-C alyo et al., 
2001; O tt et al., 2006; T h rash er et al., 2006). In  particular, chronic g ranu lom atous 
d iso rder (C G D ), an im m une deficiency syndrom e associated w ith defectiye n eu troph il 
function  has also proven  a good  candidate for gene therapy due to its significant 
m orbid ity  and m ortality  as well as a detailed accum ulated know ledge o f  the genetics and 
b iochem istry  o f  this disorder.
T h e  w ork  described in this thesis has been  part o f  a p rogram m e o f  research focused on  
the developm ent o f  gene therapy approaches to the trea tm en t o f  CG D.
1.1 Background: Chronic Granulomatous Disorder (CGD)
C hronic granu lom atous disease (C G D ) is a rare inherited  im m unodeficiency  cond ition  
that affects phagocytes o f  the innate im m une system . T h e  disease is characterized  by a 
greatly increased susceptibility to severe bacterial and fungal infections, w ith the m ain 
pathogens being Aspergillus, Burkboldena cepacia, and Staphylococcus aureus that are 
th reaten ing  to people w ith C G D . T h e  im m unodeficiency  results from  a failure in the 
resp iratory  bu rs t o f  the professional phagocytes (particularly neutrophils, as well as 
m acrophages and m onocytes, bu t also o th e r non-phagocy tic  cells, including eosinophils 
and B lym phocytes) to  p roduce  superoxide ions ( O ,) and their derivates, w hich p ro tec t 
cells from  bacterial invasion (H evw orth  et al., 2003; M eischl and Roos, 1998; Roos, 1994; 
T h rash er et al., 1994). T h e  d iso rder derives from  m utations in any o f  the 4 genes 
encoding  the p ro te in  subunits o t the phagocyte nicotinam ide adenine d inucleo tide 
p ho sp h ate  (N A D P H ) oxidase (also referred  to  as the respiratory  bu rst oxidase), the 
enzym e that generates m icrobicidal (and pro-inflam m atory) oxygen radicals (Babior, 
1999). T h e  N A D P H  oxidase is the electron d o n o r and catalyses a one-electron  
reduction of oxygen to  form  superoxide in stim ulated norm al phagocytes. W hilst 
superoxide (O . ) itself has little m icrobicidal activity, its derivates (e.g. hydrogen peroxide 
(IT O ,), hypohalous acids, and hydroxyl radical (O H )) are toxic and p o ten t m icrobicides 
that are essential for killing m any invading m icroorganism s. In con trast, phagocytes o t
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C G D  patients are characterised by an absence o r in som e cases very low  level o f  
intracellular superoxide p ro d u c tio n  (N oack et a l, 1999). A ffected  individuals 
consequendv  develop recu rren t, som etim es fatal, bacterial and fungal in fecdons, chronic 
g ranu lom atous processes, and au to im m une d isorders (Foster et al., 1998). O verall, C G D  
has a m inim um  estim ated incidence o f  approxim ately betw een 1 in 200000 and 1 in 
250000 live b irth  and is norm allv  diagnosed in infancy o r early ch ildhood (\\ m kelstein et 
a l, 2000).
1.1.1 Phagocytosis
T he killing o f  pathogens by phagocytic cells o f  the b lood , in pardcular m acrophages 
and neutrophils, is an essendal fu n cd o n  o f  the innate im m une response (C ohen, 1994).
M acrophages reside in dssues th ro u g h o u t the body and are particularly ab u n d an t in 
areas w here in fecdons are likelv to  occu r and are the first phagocytic cells to  en co u n te r 
invading pathogens. T he  o th e r m ajor phagocvdc cell type are the neu troph ils, and also 
m onocvtes and eosinophils w hich are ab u n d an t in b lood  bu t are n o t p resen t in healthy 
dssues. N eu troph ils are rapidlv recru ited  by chem otactic  signals to  sites o l in fec tion  by 
activated m acrophages as well as bv m olecules released bv pa th o g en s them selves, e.g. 
fo rm ylm eth ion ine-con ta in ing  peptides and accum ulate to g eth er w ith m onocy tes and 
eosinophils at the site o f  in fection  to ingest invading m icrobes and fragm ents o f  
dam aged tissue by phagocytosis (B okoch, 1995).
Phagocvtosis is triggered bv adherence o l a particle to the surface o f  the plasm a 
m em brane o f  a phagocytic cell. N eu troph ils  and m acrophages display an array o f  cell- 
surface recep to rs that enable them  to  recognise and engulf pathogens. T hese  include 
pa tte rn  recognition  recep to rs such as toll-like receptors (TLRs) and cell-surface 
receptors for the co n stan t Fc p o rtio n  o l IgG  antibodies p roduced  bv the adaptive 
im m une svstem , as well as for the C 3b co m p o n en t o t com plem ent. O th e r phagocyte 
receptors adhere to m an n o se-te rm in ated  oligosaccharides and fibronectin . C om m only, 
bacteria and viruses are coated (opsonised) o r displav one o r an o th er o l these 
substances, like antibodv IgG, C3b, fibronectin  o r m annose on  their surtace, w hich 
increase the rate o f  adherence and ingestion o f  the pathogen . O pson isa tion  is also used
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for extracellular killing, such as a v irus-infected  host cell, a cancer cell, o r pathogen ic 
organism s w hich are too  big to  be ingested. In  this case, the phagocydc cell b inds to  the 
opson ised  body via its Fc recep to rs and em pdes the co n ten t o f  its lysosom es directly 
o n to  the surface o f  the andbody-coated  target.
F o r smaller panicles and intracellular destrucdon, ligand binding to any o f  these receptors 
induces acun polym erization at the site o f  pathogen attachm ent, and causes the plasm a 
m em brane o f  the phagocytic cells to surround the pathogen and engulf it in a large in a 
m em branous vesicle, the phagosom e (Figure 1). O nce the pathogen has been 
phagocytosed, the phagosom e m igrates into the cytoplasm a and fuses w ith lysosomal 
granules. T he  lvsosomes carry a highly m icrobiocidal, acidic and digestive cocktail, a 
com bination o f  lysosomal enzym es and oxygen radicals.
Figure  1: Schem a tic  re p re se n ta t io n  o t  phagocy tosis  bv a m ac ro p h ag e
(1) A b a c te r iu m ,  w h ic h  m ay  o r  m ay n o t  be o p so n ise d ,  is engu lfed  by the  p ro cess  
o t  end o cy to s is .  (2) T h e  b a c te r iu m  is inges ted  in a m e m b r a n o u s  vesicle called the  
p h a g o so m e .  (3) D igest ive  ly sosom es  (granules) m erg e  w ith  the  p h a g o s o m e  and  
release their  c o n te n t s  (p ro teases  and  oxygen radicals), and  fo rm  a s t ru c tu re  
called the  p h a g o ly so so m e .  (4) T h e  killing and  d iges tion  o t  the bacteria l  cell 
takes place in the  p h ag o ly so so m e .  (5) T h e  m a c ro p h a g e  egests debris  while 
p ro cess in g  the  antigenic  c o m p o n e n t s  o t  the  b ac te r iu m ,  wh ich  it re tu rns  to  its 
surface  in assoc ia t ion  w ith  M H C  II to r  antigen p re sen ta t io n  to T i l  cells 
(adap ted  t ro m  \vw w .tex tbookofb ac te r io lo g v .n e t) .
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M icrobicidial killing is m ediated by the release o f  digestive products into the vacuole o f  
the phagolvsosom e. T hese cytotoxic agents are proteolytic enzymes derived from  
lysosomal granules that have fused with the phagocytic vacuole, and toxic oxygen radical 
species generated bv the m em brane-bound  N A D P H  oxidase com plex.
Phagocytosis is accom panied by an increase in oxygen consum ption  described as the 
‘respiratory b u rs t’, w hich is caused by activation o f  the N A D P H  oxidase enzym e com plex 
that catalyses the reduction o f  m olecular oxvgen (O t) to superoxide ( 0 2 ) (Casimir and 
T eahan, 1994; Jones, 1994; Leusen et al., 1996; T hrasher et al., 1994). W hile superoxide is 
unstable at physiological pH , it rapidly dism utates in the presence o l w ater to produces 
hydrogen peroxide (H X ^J. H ydrogen peroxide is limited in its destructive capacity', but 
acts as a substrate for the generation o f  highly toxic oxygen-derived com pounds, e.g. the 
anti-m icrobial agent hypochlorite (HOCl~) by m yeloperoxidase and additional reactive 
oxvgen species, w hich can be generated  from  H 20 2 and 0 2 in subsequent reactions, like 
hydroxyl radicals (O H ) and nitric oxide (N O ) (Rosen et al., 1995). In  addition, p ro to n  
consum ption  in the phagocytic vacuole following electron transfer causes a pH  rise that is 
an im portan t factor in pathogen killing (Segal et al., 1981). This increase buffers the acidic 
environm ent for optim al activity and function o f  m any degradative lysosomal enzym es, 
w hich whilst stored at pH  5.0, function optim ally at neutral pH .
W hereas m acrophages generally survive this killing frenzy bv egesting digested  debris 
and inserting  the m icrobial antigenic co m p o n en ts  in to  their plasm a m em b ran e  for 
p resen ta tion  to  lym phocytes in the im m unological response and con tinue to  patro l 
tissues for o th er pathogens, neu troph ils usually die and lvse, w hich fo rm  the distinctive 
tint o f  the pus that fo rm s in acutely infected  w ounds.
1.1.2 The phagocytic NADPH oxidase
T he N A D P H -oxidase , w hich was first described in 1973 (Babior et al., 1973), is a 
phagosom al and plasm a m em brane-associa ted  enzym e com plex that is ab u n d an t in 
neutrophils, m o n o cv tes/m acro p h ag es and eosinophils, though  low level expression  has 
also been detected  in B -lvm phocyte popu lations (Maly et al., 1989).
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1.1.2.1 Activation of the NADPH oxidase complex
T h e  oxidase com plex is d o rm an t in resdng neutrophils b u t rapidly assem bled w hen cells 
are acdvated by a variety o f  in flam m atory  stimuli (N auseef, 2004). Stimuli include the 
constan t (Fc) region o f  p a th o g en -b o u n d  andbody, com plem en t fragm ents generated  
following path o g en -an d b o d v  in teraction , pepddes generated  by pa thogen  deg radadon , 
factors released by inflam ed dssue such as neutrophil-activadng factors N A P-1 and 
N A P -2 , and bioacdve lipids. A cdvation is m ediated by surface recep to r b inding  that 
sum ulates hetero trim eric  G  pro te in  d issociadon, and triggers a variety o f  signal 
transducdon  pathways (C ockcroft et al., 1984; C ockcroft and G o m p erts , 1985; 
M aridonneau-Parin i et al., 1986). A n u m b er o f  artidcial agents are also capable o f  
sdm uladng oxidase acdvity including  p h o rb o l esters such as PM A.
1.1.2.2 Components of the NADPH oxidase complex
T he N A D P H  oxidase com plex is m ade up o f  six subunits. T hese  are, five unique 
“phox■” pro te in  com ponen ts, w hich can be separated in to  the m em b ran e-b o u n d  redox 
centre o f  the oxidase: the flavocvtochrom e w hich is arranged as a 1:1 he terod im er 
o f  two subunits, p22/w,A (a -su b u n it, 22kD a) and gp91/’/"A (P-subunit, 91kD a) (H uang et 
al., 1995) and the soluble cytosolic factors: p4(y/fA, p47/Vm, p67'v"A plus the small 
rbo-related G T P -b in d in g  p ro te in  p21 rac (Racl and Rac2), w hich translocates to  the 
m em brane upon  cell acdvadon  (A bo et al., 1994; Clark, 1999; N auseef, 2004; Segal and 
A bo, 1993). T h e  affix phox  is an abbrev iadon  for phagocvte oxidase (Babior, 1999).
1.1.2.3 The membrane-bound redox centre: flavocytochrome b558
M utual in teracdon  o f  the co m p o n en ts  is necessary for assem bly o f  the m ature N A D P I1 
oxidase com plex. 'This was indicated  by cells derived from  m ost C G D  patien ts w ho  had 
p22 '7"A and gp91/'"'A m issing o r a m olecular lesion to either subunit (Parkos et a/., 1987; 
Parkos etal., 1989; Segal, 1987; Yu eta/., 1997).
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T he fo rm ation  o f  gp91/0/YA p ro te in  is subject to the inco rp o ra tio n  o f  two non-identical 
haem  groups for each h eterod im er w ith in  m em brane spanning a  helices, one located  
near the inside, and the o th er tow ards the outside o f  the cell (Yu et a i, 1997). T h e  
b inding site positions for the substrate N A D P H , and for the electron carrier FAD  
(flavin adenine dinucleotide) have been  show n to exist w ithin the C -term inal region o f  
the gp91/>/'ftV g lvcoprotein , though  p67/>/'ftV has also been show n to contain  an additional 
N A D P H -b in d in g  site (Smith et al., 1996b).
T h e  transfer o f  electrons across the cell m em brane is m ediated by the haem  groups o f  
the flavocvtochrom e , w hich constitu tes the entire electron transporting  apparatus 
o f  the N A D PH -oxidase. T h e  m idpo in t redox poten tial o f  the assem bled com plex is 
sufficientlv low (-245mV) to  catalyse the fo rm ation  o f  superoxide anions (O f) by one- 
electron reduction  o f  m olecular oxygen (O J  by transm em brane passage o f  electrons 
from  N A D P H  to m olecular 0 2. (Babior, 2004; N auseef, 1999; N auseef, 2004).
N A D P H  + 2 0 2 ^  N A D P + + 2 O f  + H 4
T his fo rm ation  o f  superoxide is the p recu rso r for the generation  o f  p o ten t oxidant 
com p o u n d s as described. D ue to the observation  that the electron  tran sp o rt can be 
sustained for several m inutes, the existence o f  a charge com pensa ting  m echan ism  was 
discovered, w ith the m em brane-spann ing  N -term inal region o f  the flavocvtochrom e 
been identified as the site o f  a charge-com pensating  H +  ion conductance du ring  the 
respiratory  burst and to be responsible for the regulation o f  the phagosom al pH . Its 
additional function  is to neutralise harm fu l acidification o f  the cytosol and to bu ffer the 
phagosom e for optim al activity of secreted proteolytic granule enzym es (Banfi et al., 
1999; H enderson  et al., 1995; H enderson  et al., 1997; H enderson  and M eech, 1999; 
N anda et al., 1993; N an d a  et al., 1994; Q u  et al., 1994; Segal et al., 1981). M ore recently, 
it has been established that the com pensa ting  charge p roduced  bv H +  ions from  the 
cytoplasm  is fu rther su p p o rted  bv K +  channels, w hich provide a vital self-regulating 
m echanism  that is also required to elevate the vacuolar pH . Consequently, m icrobial 
killing is achieved th rough  a com bination  of N A D P H  oxidase activity and proteolytic 
enzym es acting at neutral pi I (Segal, 2005).
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1.1.2.4 The cytosolic components of the NADPH oxidase
T he soluble co m p o n en ts  o f  the N A D P H  oxidase com plex, w hich are found  in the 
cytosol o f  resdng  phagocytes as a m uld-p ro te in  com plex, are: p4CP/,ft\  p47/,Aft\  and p67/,/,ftx 
and the guanosine triphosphate-b ind ing  p ro te in  p21 rac.
1.1.2.5 The cytosolic factor p47phox
T h e  p47/’/"A pro te in  was originally identified as a 47kD a p h o sp h o p ro te in  based on its 
absence from  the neu troph il cytosol o f  paden ts w ith autosom al recessiye chronic 
g ranu lom atous disease (A R -C G D ) (Segal et al., 1985). F or the N A D P H  oxidase to 
function  the p47M,A co m p o n en t is absolutely essendal. In  resdng  cells, it has been 
show n th a t cytosolic p47w,4X is associated w ith equim olar am ounts o f  p 61phax and p4(P"ft' 
in the fo rm  o f  a 240kD a (Park et al., 1992) to  290kD a (H eyw orth et al., 2003) m uld- 
p ro te in  com plex, bu t also exists in its free form  (Park et al., 1994). O n  acdyadon, this 
cytosolic com plex is translocated  to  the p lasm a m em brane w here p47;)'/A in teracts w ith 
b o th  subunits o f  the phagocyte cy tochrom e b55S (D eL eo et al., 1995a; D eL eo  et al., 
1995b; D eL eo et al., 1999; H eyw orth  et al., 1991; N akanishi et al., 1992; S um im oto  et 
al., 2004; Takeya and Sum im oto, 2003).
T he  am ino-acid sequence o f  p47'v"A has been identified to carry two .c/r-homology 
region 3 (SH3) dom ains, w hich are know n to m ediate p ro te in -p ro te in  in te racd o n  by 
binding to proline-rich  sequences. T h e  p67/’"fA, p22M<’A and p47/,A,A am ino-acid sequences 
contain proline-rich regions, and in teracdons w ith p47/,/,A is th o u g h t to be m ediated  by 
SH 3-proline b inding (de, I et al., 1996; de, I et al., 1997; Leto et al., 1994; S um im oto  et 
al., 1996). In  add idon , the in te racdon  o f  the p47/,/"A pro tein  w ith the cy tochrom e /y,v is 
also m ediated by a highly cadon ic region that interacts w ith the carboxyl-term inus o f  
the gp 9 1 '"A P -subunit (D eL eo et al., 1995a; N auseef et al., 1993).
The p47/WA tuncdon  itself is regulated by serine p h o sp h o n iad o n . N eutrophil acdyadon 
results in phosphorylation at m ultiple serine residues; and seyeral species o f  p4~'” 
phosphoprotein  ha\ e been identified (R otrosen and Leto, 1990). T he p h o sp h o n iad o n  o f  
p47 '/YA occurs in two stages, a cytosolic stage required for translocadon o f  p47;>/"A, and a
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m em brane-bound  stage. M em brane translocation requires phosphorylation at a single 
serine residue only (at position 379) (Faust et al., 1995). Phosphorylation induces a 
conform ational change in the p47/,/,"A pro tein  that enables the interaction with the 
flavocvtochrom e b5SH by exposing a before h idden SH3 protein-binding dom ain (Faust et 
al., 1995; Park and Babior, 1997; Swain et al., 1997). T he tw o m ost phosphorylated  form s 
o f  p47/,/^ are absent in the activated neutrophils o f  patients w ith the X-linked form  o f  
chronic granulom atous disease (X -CG D ) patients w ho are lacking flavocvtochrom e bjix 
(O kam ura et al., 1988), indicating that phosphorylation continues after m em brane 
association. Evidence suggests that p47/v"A undergoes continuous rounds o f  
phosphory lation  and dephosphoryla tion  in activated cells (Heyworth and Badwey, 1990).
1.1.2.6 The cytosolic factor p67phox
T h e cvtosolic co m p o n en t p67/>/YA was initially identified  bv virtue o f  its absence from  the 
neutrophils o f  patien ts w ith an au tosom al recessive fo rm  o f  C G D  in w hich p47/,/YA 
p ro tein  is p resen t (N unoi et al., 1988; Y olpp et al., 1988). T ranslocation  o f  p67/,/"A to the 
m em brane is dep en d en t on p47/VYA and is absen t in the neu troph ils o f  p47-''^-deficient 
A R -C G D  patients (H evw orth et al., 1991). As described here prev iously  p67/WA exists in 
the cvtosol in com bination  w ith p47/WA and p4(F"A, due to  the am ino-acid sequence o f  
p67’v"A containing a proline-rich region and two SH 3 dom ains, w hich m ediate the 
in teraction  w ith p4(F'/A and p47'v"iV (de, 1 et al., 1994).
1.1.2.7 The cytosolic factor p40p/'OA
T he 40kD a cytosolic p ro te in  p4(P,"A was identified bv co-purification w ith p67;V'A in 
resting hum an neu troph ils (Tsunawaki et al., 1994; W'ientjes et al., 1993). In these cells 
p4(F"A is tightly associates w ith p67/’"'A as a co m p o n en t o f  the 240-290kD a cvtosolic 
activation com plex (Tsunawaki et al., 1996) and binding to b o th , p47/VYA and p67/V A has 
been dem onstra ted  (Fuchs et al., 1995; Fuchs et al., 1996; Ito et al., 1996). D uring  
activation of the N A D P H  oxidase, the p4(F'YA pro tein  is com plexed to  p67/,/"A and 
translocates to the m em brane, which is m ediated  bv p67/,/YA (Dusi et al., 1996; Som eva et
9
Chapter 1: Introduction
al., 1996; W ientjes et al., 1993), b u t p40/>/,&' is n o t required to reconstitu te  oxidase activity 
in recom binan t cell-free system s (A bo et al., 1992; L opes et al., 1999; Lopes et al., 2004; 
Park et al., 1997; R otrosen  et al., 1993).
W hilst there are several rep o rts  w hich show  p40,0/'6A a possible stim ulatory role in 
N A D P H  activation (Cross, 2000; Kuribayashi et al., 2002; Tsunawaki et al., 1996), o th er 
rep o rts  have show n p40/>/'ftV in an inh ib itory  role (Sathyam oorthy et al., 1997; Y ergnaud et 
al., 2000). T h o u g h  m ore recently, p40'0/,A has been  indicated as a negative regulator 
th rough  p h o sphory la tion , w hich leads to  an inh ib itory  con fo rm ation  that blocks oxidase 
activation (Lopes et al., 2004).
In  addition the role o f  p40''/,ftX in N A D P H  activation appears to be in the stabilization o f  
p 6 7 ^ A and their initial assem bly in to  the 240-290kD a activation com plex, m ediated  
th rough  the p40/,;'ax am ino-acid  sequence con tain ing  a single SH3 dom ain th a t has been 
im plicated in the in teraction  w ith  p 4 7/>/">A (Ito  et al., 1996; W’ientjes et al., 1993) as well as 
a novel ‘P C ’ m o tif  that m ediates the in teraction  w ith the SH3 dom ains o f  p 67p'JOX 
(N akam ura et al., 1998).
1.1.2.8 The GTP-binding protein p21 rac
T h e  activation o f  the electron  flow from  N A D P H  th rough  the FA D and the haem  
groups o t the flavocvtochrom e b,-,-* is d ep en d en t on the presence o f  the small 
rho-related (guanosine triphosphate) G T P -b in d in g  pro teins p2\rac  (Racl o r Rac2, 
depend ing  on the species and phagocytic cell).
T h e  R J jo  family o f  p ro te ins are low m olecular w eight G T P -b ind ing  pro teins. B oth  
m em bers rac 1, w hich is expressed ubiquitously and rac2 are expressed in phagocytic 
cells; while rac2 is restric ted  to  m yeloid cells and accounts for over 96%  o f  total rac 
p ro tein  in neutrophils (H eyw orth  et al., 1994), and is less abundan t in m acrophages 
from  w hich racl was originally isolated (Abo et al., 1991).
Rs/c p rotein  has been found to be absolutely required for oxidase function in the cell-free 
system (Abo et al., 1991). In the cvtosol of resting neutrophils, p2\rac  exists in an 
inactive G D P -b o u n d  form , and is m aintained bv association w ith the G D P -d issoc ia tion
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inh ib ito r r/w -G D l. O n  activation, the G D P -d issocia tion  stim ulator (G D S) facilitates the 
fo rm ation  o f  active G T P -b o u n d  rac by d issociation o f  G D P  and rac translocates to  the 
plasm a m em brane (A bo et al., 1994; A bo  and Pick, 1991; H eyw orth  et al., 1993; K w ong 
et al., 1993; Pick et al., 1993).
B oth  rac\ and rac2 are capable o f  reconstitu ting  N A D P H  oxidase function in the cell- 
free svstem  in the presence o f  p47/>','ftX and p67/>/"1A (H eyw orth  et al., 1993) and in teraction  
betw een  rac and p67/>/'ftX has been  rep o rted  (D iekm ann et al., 1994), which is required  for 
oxidase function  and they may therefo re  translocate together (A hm ed et al., 1998; 
Prigm ore et al., 1995; Ridlev et al., 1992). In  contrast, translocation  o f  p21rati2 has been 
show n to occu r in the absence o f  either p47/,/,ftX o r p 61phos, suggesting that alternative 
m echanism s exist for oxidase activation (D usi and Rossi, 1993; H eyw orth  et al., 1994).
W hilst N A D P H -o x id ase  activitv is d ep en d en t on  con tinued  recep to r occupancy, and 
continued  association o f  oxidase co m p o n en ts  at the m em brane, the te rm ination  o f  the 
response is n o t simply m ediated  bv the release o f  p 4 ” ' x and p6?',Aax in to  the cytosol, 
w hich have been  show n to  rem ain in association w ith the m em brane well after the bu rst 
has stopped  (Dusi and Rossi, 1993). T h e  p h osphorv la tion  state o f  the guanine 
nucleotide o f  the G T P -b in d in g  p ro te in  p21rar is the p o ten t regulator o f  te rm in atio n  o f  
N A D P H -ox idase  activity.
T h e  role and function  in N A P D H —oxidase activity o f  an o th er small G T P -b in d in g  
pro tein , R ap lA , w hich has been show n to co-purifv w ith the flavocvtochrom e b , ,v, is 
unknow n (D inauer, 2005; G o ld b la tt and T hrasher, 2000; M ’R abet et al., 1998; Q u in n  et 
al., 1989).
1.1.3 Activation of electron transport
Naturallv, activation o f  the ‘resp iratory  b u rs t’ by com plex fo rm ation  o f  the co m p o n en ts  
o f  the N A D P H  oxidase betw een cvtosolic and m em brane bo u n d  co m p o n en ts  is 
initiated bv opson ised  particles and o th e r soluble in flam m atory  m ediators during 
phagocytosis. A m odel o t the phagocyte N A D P H  oxidase in its resting and activated 
assem bled state is p resen ted  in Figure 2.
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Figure 2: Schematic representation o f  the complex formation and activation o f  the
phagocyte N A D PH  oxidase
Shown is a model o f  the N A D PH  oxidase activation (‘respiratory7 burst’): A. In 
its resting state the multi-component N A D PH  oxidase co-exists as membrane- 
bound and cytosolic protein components, which requires assembly for 
activation. Two subunits gp91/>*“  and p22/,*ax form the membrane-bound 
flavocytochrome b5W, as a heterodimer. The cytosolic components p40r>A&v, p47/>/wx 
and p tiT ^  exist together as a ~240-290kDa complex, while in its inactive G D P- 
bound state, the small cytosolic GTP-binding protein Rac (also known as 
p2irac2) is bound to Rho GDP-dissociation inhibitor R^oGDI. B. Upon  
activation p4Qf>box, p41pha< and p61phax become stably associated with the plasma 
membrane through interactions o f  p47'p/** and the subunits o f  
flavocytochrome by** This translocation process is accompanied by the release 
o f  Rac from R/wGDI and the phosphorylation o f  p47piex (at multiple sites), 
p4 0 »*ftv an£j p6 7 />*®f Binding o f  the cytosolic components is associated with a 
conformation change o f  the flavocytochrome bssg> which is conducive to 
electron transport from N A D PH  to oxygen, via the flavin and haem redox 
centers in gp9V /KX , to form O 2' ( red dashed line). The associated excess o f  
oxygen consumption is known as the ‘respiratory burst’. Termination o f  the 
reaction is controlled by hydrolysis o f  GTP bound to Rac, and 
dephosphorylation o f  oxidase components. The compartment labelled ‘inside’ is 
the cytoplasmic space; ‘outside’ refers either to the extracellular or phagosomal 
space. Adapted from (Heyworth et al., 2003).
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1.1.4 Genetics and molecular Pathology of CGD patients
A b o u t tw o-thirds o f  all C G D  cases are inherited  in an X -ch rom osom e linked fashion, 
hence term ed  X -C G D , and are caused by variety o f  d ifferen t m utations in the gene 
(CYBB, Xp21.1) w hich encodes the gp91/,''av (3-subunit o f  the flavocytochrom e b,-,-x.
T h e  o th e r th ird  o f  C G D  paden ts have been found  to  inherit the im m unodeficiency in 
an au tosom al recessive m anner (A R -C G D ), arising from  m utations in the genes for 
p22/,/'av (CYBA, 16q24), p47-Mav (N C F-1, 7 q ll .2 3 ) , o r p 6 7 /,ft'  (N C F-2, lq25) (Clark et al., 
1989; O chs et al., 1999; Rae et al., 1998; Roos et al., 1996), while there has only been 
one rare case o f  an inh ib itory  p21 rac m u tad o n  discovered in an infant boy associated 
w ith a hum an  neu troph il im m unodeficiency  syndrom e (A m bruso  et al., 2000; Williams 
et al., 2000), b u t no  m olecular lesions resu ldng  in C G D  caused by m utadons in the 
genes for p 4 0 ’Aav, Rap la  and R //rhave been  rep o rted  (D inauer, 2005).
N otew orthy, the inciden t o f  p47/W'av deficiencv has been  found  to be abou t five dm es 
m ore com m on  than  p22/’aax o r p 67p'l(/x deficiencv, and m u tad o n s in N CF-1 gene (p47/,/"A) 
account for approxim ately 25%  o f  all C G D  cases (Casim ir et al., 1992; C asim ir et al., 
1991; C hanock  et al., 2000)
Protein affected Gene Chromosome locus CGD Subtypes Incident
gp91p'K,x CYBB Xp21.1 X91°, X9T, X91 + -  65%
p22phox CYBA 16q24 A22°, A22+ -  5%
p47p/XM NCF-1 7ql 1.23 A47° ~ 25%
PQjphOX NCF-2 lq25 A67° ~ 5%
T ab le  1: G e n e t ic  s u b g ro u p s  o f  ch ro n ic  g ra n u lo m a to u s  disease.
T h e  m o d e  o t  inher i tance  is ind ica ted  bv X (X-linked) and  A (au tosom al  
recessive); the  supe rsc r ip t  svm bols  indicate w h e a th e r  the  level o t  a tfec ted  
p ro te in  is u n d e te c ta b le  ("), d im in ished  ( ) ,  o r  n o rm a l  (*). X91* and  A 2 2 ’ 
r ep resen t  de tec tab le  bu t  n o n  functional  prote in .
M utadons described in g p 9 F y"A deficient X -C G D  patien ts show  a high degree o l 
heterogeneity, w hich include large and small deledons, po in t m utations and insertions,
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errors at splice junctions, and m utad o n s in the 5 'u p stream  regulatory region o f  the 
CYBB gene, m any o f  them  family-specific (N oack et al., 1999; Patino et al., 1999; Rae et 
al., 1998; Rae et al., 2000). A nd  while in m ost gp91jW"A deficient C G D  patien ts no  
detectable levels o f  gp91/l/,ftX p ro te in  have been found, in less than  10% X -C G D  is 
caused due either non-functional o r low  levels o f  gp91'v'6A p ro te in  (G oebel and D inauer, 
2003; Roesler et al., 1999; R oos et al., 1996).
In  contrast, the m ajority o f  p47/,;'"A deficient C G D  patients (A47° C G D ) were found  to 
have only a single co m m o n  m uta tio n  (Casim ir et al., 1991; Iwata et al., 1994; Roesler et 
al., 2000; Roos et al., 1996; V olpp and Lin, 1993) based on  a d inucleotide deletion 
(AGT) at a G T G T  repeat at the beginning  o f  exon 2, w hich predicts a fram eshift and 
p rem atu re  stop  co d o n  at am ino acid 51 (Casim ir et al., 1991). O nly  in one A47" C G D  
patien t w ho  was heterozygous fo r AGT, was d iagnosed for a single nucleotide deletion 
and rem ains the only n o n -A G T  m u tad o n  rep o rted  (Yolpp and Lin, 1993).
T he  discovery o f  the existence o f  a pair o f  98%  hom ologous p47/,''0A pseudogenes 
(referred to  as \j/N C F -l), each o f  w hich contains the G T  deledon  and which are located 
in close proxim ity to  the funcdonal NC F-1 gene at the ch ro m o so m e locus 7 q l l .2 3  
(G orlach et al., 1997), suggested that the predom inace o f  the A G T  m u tad o n  is caused 
bv recom binadon  events betw een the funcdonal N CF-1 gene and its highly h o m ologous 
pseudogenes (Roesler et al., 2000; Vazquez et al., 2001).
1.1.5 Treatment and current therapy of CGD
Since chronic granu lom atous disease (C G D ) was first described as a hereditary  
cond id o n  affecdng neu troph il fun cd o n  in 1957 (Berendes et al., 1957), the prognosis for 
C G D  patients has im proved  significandv over the past two decades. Classically, patien ts 
w ho suffer severe, recu rren t bacterial and fungal infecdons are treated bv an tib iodc 
prophylaxis w ith trim ethoprim -su lfam ethoxazole, which greatly im proved the survival 
rate o f  C G D  patients (W eening et al., 1983). A dm inistration o f  in terferon -gam m a 
(IFN-y) has been show n to restore superoxidase acdvitv in patients w ith X -C G D  
(Fizekowitz et al., 1988; N ew burger et al., 1988) and found to be a safe and effective
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adjunctive therapy to reduced  the recurrence o t life-threaten ing  infections fo r m any 
patients (Bemiller et al., 1995). H ow ever recom binan t hum an  IF N -y  therapv is no t 
routinelv available to  all C G D  patients, n o t onlv due to  its high costs bu t also that it has 
n o t been equally efficient as large studies in the USA and E u ro p e  were able to 
d em onstra te  (G oldblatt and T hrasher, 2000). T herapv  w ith corticostero id  had som e 
beneficial w ith a few patients (Chin et al., 1987) and although the first a ttem pts to  treat 
C G D  bv bone m arrow  transp lan ta tion  failed due to  tissue rejection (G oudem and  et al., 
1976), successful trea tm ent by allogenic granulocyte transfusions has been reported  
(Bielorai et al., 2000).
W ith recent advances in research and developm ent for bone m arrow  transp lan ta tion  
(BAIT), allogenic stem  cell transp lan ta tion  has been successful w ith several patients 
disease free for several years afte r transp lan t (Del, I et al., 2003). Particularly, som atic 
gene therapv  in com bination  w ith  BAIT w hich overcom es the problem s o f  allogeneic 
transp lan ta tion , and is n o t lim ited bv supplv o f  suitable d o n o r m aterial, the m ost 
p rom ising  gene therapy trial fo r C G D  began  in 2004 using retroviral vectors and has 
been the first to  show  a significant im provem en t in the clinical cond ition  o f  the patien ts 
(O tt et al., 2006; O tt et al., 2007).
H ow ever, the overall success in this trial was found  to be d ep en d en t on insertional 
activation o f  genes regulating m yeloid d ifferentiation, resulting  in the clonal expansion 
o f  transduced cells. T his augm ented expression is th o u g h t to have arisen from  the 
choice o f  retroviral vec to r em ployed, w hich was based on  the spleen focus-fo rm ing  
virus (SFFV). T his vector, contains a strong  enhancer in the viral LTR used to drive the 
transgene and this was th o u g h t to  be ultim ately responsible for the insertional 
m utagenesis rep o rted  (O tt et al., 2006; O tt et al., 2007). H aem atopo ietic  clones bearing 
vector insertions in specific loci becam e dom inan t in the m veloid b lood  co m p artm en t, 
suggesting that the clonal expansion had originated from  an im m ature m veloid 
p rogen ito r ra ther than from  a stem  cell (O tt et al., 2006; O tt et al., 2007).
As the recent death  o t one o f  the patients treated has show n, the risks o f  retroviral 
vector induced insertional m utagenesis are too  serious that for gene therapv to becom e 
a routine trea tm ent to r C G D  in the tu ture, it will depend  on the developm en t o f  new  
vector system s which are as efficient b u t w ith added biosafety profiles.
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1.2 Vectors for use in Gene Therapy
A large num ber o f  vectors have been  identified w ith characterisdcs useful for gene 
therapv applications. T hese include non-viral m ethods: naked and com plexed D N A ; 
non-in tegrating  viral vectors based on D N A  viruses: adenovirus, adeno-associated  
viruses, and herpesviruses; and in tegrating  viral vectors based on  R N A  viruses: onco- 
retroviruses (now term ed gam m a-retrov iruses) and m ore recently, lentiviruses w hich are 
used in laboratory  and clinic to achieve som atic gene transfer. Because o f  the particular 
properties each vector system  has its ow n advantages and disadvantages, and are limited 
by definition o f  their application range depend ing  on factors such as packaging capacity, 
host range, cell- o r tissue-specific targeting, replication com petency, genom e in tegration , 
safety' and dura tion  o f  transgene expression (Table 2).
O w ing  to  their well characterised  genom e, life cycle and possibility o f  generating  vectors 
w hich do  n o t express viral p ro te ins and are free from  replication com peten t virus, 
vectors based on the m urine leukaem ia virus (MLV), were the first to be developed and 
used in a hum an gene therapy trial in peripheral b lood  T  lym phocytes o f  patien ts w ith 
adenosine deam inase deficient severe com bined  im m une deficiencv (A D A -SC ID ) 
(Blaese et al., 1995).
Subsequently, there has been an im pressive increase o f  b o th  the num ber o f  genes 
identified that are associated w ith hum an  disease and the num b er o f  vec to r system s 
available for therapeutic gene delivery. W'hile gam m a-retroviruses require cell division 
for stable gene transfer, lentiviruses, adenovirus, adeno-associated  virus, and herpes 
sim plex virus can infect non-d iv id ing  cells.
T he first gene therapv trial for cystic fibrosis (CF) em ployed recom binan t adenovirus 
(rAd) vectors (Crystal et al., 1994), w hich was followed bv the first use o f  recom binan t 
adeno-associated virus (rAAV) (F lotte et al., 1996) and rAAY2 (F lotte et al., 2003) 
vectors expressing the cystic fibrosis transm em brane conductance regulator (CFTR) 
gene in C F patients; and an AAV vecto r expressing b lood coagulation factor IX in 
haem ophilia B patients (Kay et al., 2000). H ow ever, first generation  adenovirus vectors 
provided p o o r long-term  expression and induced dose-d ep en d en t im m une and
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in flam m atory  responses, w hich even led to the death  o f  one paden t w ith  o rn ith ine  
transcarbam vlase deficiency (O T C D )(R aper et al., 2003). In  con trast, reco m b in an t 
adeno-associated  viral vectors have been  successfully applied in various dssues, including 
lung (C onrad et al., 1996; F lo tte  et al., 2003; F lotte et al., 2005), liver (M anno et al., 
2006), m uscle (Fisher et al., 1997; K essler et al., 1996), brain  (Janson et al., 2002) and 
redna (Acland et al., 2001). H ow ever, a lthough AAV vectors m ediate stable gene 
transfer to  host cells w ithou t causing any significant innate im m une response o r 
insertional m utagenesis, they possess only lim ited packaging capacity o f  just 5kb and in 
general show  lower levels o f  transgene expression  than  that seen w ith adenovirus.
H erpes sim plex virus (HSV) based  vectors are large and com plex D N A  viruses, w hich 
have been em ploved prim arily for gene transfer to  the nervous system  (M ata et al., 
2006), taking advantage o f  their ability o f  gene transfer and long-term  expression  in 
non-d iv id ing  cells, b u t have the po ten tial to  cause an innate and adaptive im m une 
response.
Lentiviral vectors w ere first p ro p o sed  as a carrier o f  an antisense oligonucleotide 
sequence targeted to regions o f  the H IV  genom e w ith the aim o f  treating H IV  infection 
(M acG regor, 2001) and fo r gene therapy  o f  m ucopolysaccharidosis type III A (MPS 
III A) (A nson et al., 2007). In  general lentiviral vectors are p rom ising  tools due to their 
capacity to package relativelv large sequences (~9kb) and their ability to stably transduce 
o f  a broad  range o f  d ifferen t cell types, particularlv non-d iv id ing  and dividing cells 
(Am ado and C hen, 1999; N aldini et al., 1996). H ow ever, like w ith gam m aretroviruses, 
there rem ain safetv concerns regarding the non-specific nature o f  lentiviral in tegra tion  
into the hum an  genom e w ith their p reference for insertion  in to  gene sequences in active 
chrom atin  regions (Schroder et al., 2002) potentiallv increasing the risk o f  insertional 
m utagenesis.
T he application o f  gam m aretrov irus-based  vectors in po ten tial gene therapv approaches 
for treating disease is now  well established (Miller, 1992; Palu et al., 2000; Takeuchi and 
Pizzato, 2000). In the haem atopoie tic  system  specifically, the v irtues o f  low 
pathogenicity, acceptably high titre, and the ability to efficientlv inco rporate  the vec to r 
genom e into the host ch ro m o so m e have m ade retroviral vectors the svstem  o f  choice.
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Victor Advantages Disadvantagaa Applications
m  im s fs .
Gamma - 
Retrovirus
wed understood and characterised
Highly efficient entry into mitotic cells
Stable integration and gene transfer into 
hoet cell (8-12 kb)
titer concentration and
broad host range through pseudotyping
Safety concerns due to insertional 
mutagenesis with secondary malignancy
Infection limited to dividing cells
overexpression of transgene as welt as gene 
silencing over time
relatively low titer
ex vivo treatments, like ADA-SCID. 
X-SCID. CGD. familial 
hyperlipidemia; tumor vaccines; 
general marker studies
LantMrua Stable integration and gene transfer into 
host cells (<9 kb)
Efficient infection of non-dividing ceils
Safety concerns insertional mutagenesis with 
secondary malignancy
and risk of replication competent HIV
broader target ceH range than 
retroviruses, e.g. denthtic cells and 
hematopoietic stem cells; gene 
therapy application in HIV and 
mucopolysaccharidosis type VII 
(MPS)
Adenovirus High titer
Efficient entry into most ce l types
High level of expression 
low pathogenic potential
Infection of non-dividing ceBs
ability to package large transgenes with 
helper-dependent adenovirus (< 30kb)
Immunogenic, stimulating T and B o d  
responses, innate immunity
tropism not wetl understood
Vectors contain viral genes. Generation of 
replication-competent virus
transient gene transfer 
long-term effectiveness poor
targetted in vivo gene transfer (no 
integration into host) Cystic fibrosis 
(CF) and short-term treatments for 
canoer, e  g Mesothelioma and 
Colon cancer, cardiovascular and 
bver disease, e  g Ornithine 
transcarbamytase deficiency (OTCD)
Adeno-associated 
virua (AAV): e.g. 
rAAV2
site specific integration
minimal or no innate host immune 
response
Infection of nort-dividing ce ls  with 
varying tissue tropisms
durable transgene expression
no human pathology, less immunogenic 
than adenovirus
Limited packaging size (< 5 kb)
Delayed transgene expression in vivo
lower expression levels than that seen with 
adenovirus
inefficient integration into host genome
localised in vivo gene transfer, which 
requires long-term transgene 
expression in lung, e  g Cystic 
fibrosis (CF); brain, e  g autosomal 
recessive Caravan disorder; retina, 
e.g. Leber congenital amaurosis 
(LCA); muscle, e  g Hemophilia B. 
and Alpha-1 antitrypsin (AAT) 
deficiency
Herpesvirus (HSV) High titer relatively complex Neurological d seases .
High efficiency of gene transfer to non­
dividing cefls
potential for innate and adaptive immune 
response
brain tumors and colon cancer
Neurotropic
M um 1 Mm a fIVOIrVra WCIDFV





High level of safety
transient: no integration
improved uptake with the use of 
liposomes
Inefficient gene delivery and uptake 
transient gene transfer
DNA vaccines for topical and/or 
mechanical applications including 
skin and vasculature; and liposome 
facilitated direct in vivo applications 
metastatic cancer, cardiovascular 
disease, cystic fibrosis (CF)
T ab le  2: A d v an tag es  and  d isadvan tages  o t  d i f te ren t  v ec to r  sys tem s in use to r  som atic
gene  t ran s fe r  an d  the ir  app licat ion  range.
Indeed, in term s of clinical usage to r haem atopoietic gene therapv, retroviral vectors 
have been used m ore widely and m ore successfully than anv o th er (Aiuti et al., 2002;
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Blaese et al., 1995; B renner, 1996; Cavazzana-C alvo et al., 2000b; K ohn, 1997; O tt  et al., 
2006; T h rash er et al., 2006).
In  spite o f  their popularity, p rob lem s w ith these vectors still exist. T he  possibility o f  
oncogenic transfo rm ation  o f  h o st cells as a result o f  random  non-specific insertion  o f  
retroviral D N A  into the host ch ro m o so m e has always been a concern . In  addition their 
inability to efficiendy transduce quiescent cells, transcrip tional silencing (Pannell and 
Ellis, 2001; Sadelain et al., 2000) and p o o r levels o f  dssue-specific expression 
(Cavazzana-Calvo et al., 2000b) all limit the applicadon o f  retroviral vectors.
However, as genetic diseases, in particu lar m onogeneic diseases affecdng haem atopo iedc 
cells, require long-lasdng th erap eu d c  gene expression, the po tendal benefits o f  the use 
o f  gam m aretroviral vectors sdll outw eigh the risks, it seems w orth  exploring 
m ethodo log ies to  im prove their safety profile w ithou t affecdng their virtues.
In  particular, the m any o f  the p rob lem s w ith gam m aretroviral vectors used in gene 
therapy  curren tiy  can be traced to their s trong  transcrip tional con tro l sequences w ithin 
their long  term inal repeats (LTRs) and the duplication o f  these term inal enhancer 
regions. Together, these characteristics can activate neighbouring  genes, e ither th rough  
cis acting enhancer in teractions o r by in troducing  new  p ro m o te r activity from  their 
3’LTR (Baum et al., 2003; T hom as et al., 2003).
F u rth erm o re , o th er studies have show n positive and negative dosage-dependen t effects 
o f  transgene expression in m ouse and hum an  cells, that the level o f  expression  will 
likely correlate w ith risk and in som e cases should  be kept w ithin a therapeutic  level to 
limit side effects (Baum et al., 2003). T herefo re , a reassessm ent o f  such risks, vec to r 
design, safety testing and the search for possible solutions are at the fo re fro n t o f  the 
field o f  gene therapy today (H aviernik and B unting, 2004; Yi et al., 2005).
T he following paragraphs will therefo re describe the biologv o f  retrov iruses, their 
m odifications as vectors, targeting strategies and their use in gene transfer into 
haem atopoietic stem  cells.
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1.2.1 Biology of Retroviruses
R etroviruses belong  to a large and diverse family o f  R N A  enveloped viruses, the 
Retroinridae, w hich are united by co m m o n  features o f  virion structu re and replicative life­
cycle. T hey  possess an 8-12 kb R N A  genom e and the ability to  ‘reverse tran sc rib e’ their 
genom e from  R N A  to D N A . Com m onlv, retroviruses contain  specific p ro te ins that 
carry o u t five basic functions (reviewed by (Coffin et al., 1997)): (1) viral genom e 
condensation  in to  an R N A -pro te in  com plex; (2) packaging o f  this com plex in a p ro tein  
capsid; (3) enclosure o f  the capsid in a lipid m em brane, o r envelope; (4) m odification  o f  
the envelope by displaying surface p ro te ins that recognise cellular receptors; and (5) 
copying o f  the retroviral R N A  in a newly infected  h o st cell. A lthough m ost enveloped 
viruses are in fact m ore com plex , w ith  either two o r m ore pro teins sharing each 
function , o r one p ro te in  carrying o u t several functions, the sim pler retrov iruses, like 
m urine leukaem ia virus (MLV) provide the basic m odel for the understand ing  o f  the 
structu re  and functionality  o f  a retrov irus particle (Coffin et al., 1997).
1.2.2 Structure of a retrovirus particle
A retroviral particle (virion) m easures abou t 80-120nm  in diam eter, w hich consists o f  a 
lipid bilayer envelope derived from  the plasm a m em brane o f  the h o st cell w ith localised 
retroviral E nv  g lycoproteins on  its surface (Figure 3). T hese  g lvcoproteins are fo rm ed  
by two polypeptide subunits: the transm em brane (TM) that anchors the g lvcoprotein  
in to  the envelope lipid bilayer and the surface subunit (SU), w hich binds to  the specific 
cellular receptors. T he  virus core, a p ro te in  shell fo rm ed  bv capsid p ro te ins (CA), 
contains two identical copies o f  p lus-strand genom ic R N A  m olecules, w hich are 
condensed  w ith nucleocapsid p ro teins (NC). T h e  retroviral integrase (IN) and reverse 
transcriptase (RT), w hich p rom otes the synthesis o f  double stranded D N A  from  the 
viral R N A  tem plate in the host cell, are also contained in the capsid, the inner p o rtio n  
o f  the virion that defines the viral core (Jones and M orikawa, 1998). O utside  the viral 
core a layer o t m atrix p ro teins (A1A, m em brane associated) in teract w ith the envelope 




Figure 3: Schematic structure o f  a mature retroviral particle
A retroviral virion measures about 80-120nm in diameter and contains two 
identical copies o f  the viral RNA genome complexed with nucleocapsid 
proteins. The structural gag proteins consisting of: (MA) Matrix protein, (CA) 
capsid protein, (NC) nucleocapsid protein; the Pro-Pol proteins: (PR) retroviral 
protease, (IN) integrase and (RT) reverse transcriptase; and the viral (Env) 
envelope glycoproteins: (TM) transmembrane components, (SU) surface 
components anchored into an envelope lipid bilayer are indicated. Adapted 
from Retroviruses (Coffin et al., 1997)
1.2.3 Genetic Organisation of the Retroviral Genome
T he G enom e o f  all retroviruses is organised into four genes: g a g , p ro , p o l  and e n v  
(Figure 4). T he g a g  is an acronym  for group-specific antigens (ag), and its sequence 
encodes the three m ajor structural proteins o f  the viral core com prising: m atrix (MA), 
capsid (CA) and nucleocapsid (NC), the R N A  genom e binding proteins and the m ajor 
proteins o f  the viral core. T he gag proteins are cleaved by the retroviral protease (PR), 
which is encoded by the p r o  sequence and is responsible for the m aturation  o f  viral 
particles during and after their budding process. T he  p o l  sequence encodes for bo th , 
the integrase activity (IN) and the reverse transcriptase (RT) (Baltimore, 1970; M izutani 
et al., 1970; Tem in and M izutani, 1970), w hich carries ou t the reverse transcription 
process that takes the retroviral R N A  genom e to a proviral double-stranded D N A  pre-
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in tegration  form . T he  two m ajor functions o f  the reverse transcrip tase during  the 
retroviral life cycle are a D N A  polvm erase activity and an RAAreH acuvity (M oelling et 
al., 1971) that funcdons as a ribonuclease during  the reverse transcrip tion  o f  the viral 
genom e by degrading the R N A  tem plate from  R N A -D N A  hybrids p rio r to its 
in tegradon  in to  the host genom e. T h e  integrase (IN) is a separate p ro te in  derived from  
the carboxy term inus o f  the pol gene, w hich catalvses the in teg radon  o f  the proviral 
D N A  into the host genom e. T h e  e n v  sequence encodes a polypro tein  that is post- 
transladonally cleaved in to  two subun its o f  the envelope glvcoproteins: the
transm em brane dom ain (TM) and an external glycosylated surface dom ain  (SU) w hich 
determ ines the h o st range o f  the virus.
Figure  4: G e n e t ic  o rgan isa t ion  o f  a genera l ised  p rov irus
T h e  to p  d o u b le  line sh o w s the  p rov ira l  D N A  as it is in se r ted  in to  the  h o s t  D N A  
sequence ,  flanked at each e n d  w ith  th e  long  term inal  repea ts  (LTRs) c o m p o s e d  
o t  U3,  R, and  US e lem ents .  L T R  sequences  that  are im p o r ta n t  t o r  t ran sc r ip t io n ,  
e.g. the  en h an c e r ,  p r o m o te r ,  and  the  polv(A) add it ion  signal,  are indicated . T h e  
gag, pro, pol, and  env seq u en ces  are loca ted  c o n se rv e d  in the  po s i t io n s  sh o w n  in all 
re troviruses.  A ccesso ry  g enes  are loca ted  as indica ted , w h ich  can  also o v e r lap  env 
and  U 3 and  each o th e r ,  and  occasionally  in o th e r  locat ions .  T h e  se c o n d  line 
sh o w s  the  R N A  that  is the  p r im ary  t ranscr ip tiona l  p ro d u c t .  I m p o r ta n t  
sequences  to r  replica t ion  a n d  g e n e  express ion  are m ark ed  at the  a p p ro x im a te  
p o s i t io n s  in w h ich  they are typically to u n d ,  e.g. (PBS) P r im er -b in d in g  site; (\\l) 
psi packag ing  signal sequence ;  (SD) splice d o n o r  site; (FS) f ram esh if t  site; (SA) 
splice a cc e p to r  site; (PPT) p o lvpur ine  tract; (PA) po lvadenvla t ion  signal; and  
(AAA) poly’(A) tail. T h e  th ird  line, at the  b o t to m ,  indicates the  spliced 
m esse n g er  R N A  to r  the  }:nv  p ro te in .  R e trov iruses  with  accessory  g enes  have 
o th e r  spliced m R N A s ,  and  c o n ta in  o th e r  splice d o n o r  and  splice a cc e p to r  sites 
as well. A d a p ted  t r o m  R e tro v iru se s  (Coffin  et al., l ti ti7).
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In  addition m ore ‘com plex’ retrovirus, like lendviruses have additional accessory genes, 
which regulate viral gene expression, assem bly o f  in fectious particles and m odulate  viral 
replication in infected cells (Tang et al., 1999).
1.2.4 Long terminal repeats (LTRs)
In  simple retroviruses such as the M olonev m urine leukem ia virus (M o-M LV), the LTR 
sequences contain  m ost rti-acting elem ents required  for the transcrip tional initiation and 
expression o f  the viral genes as described  above. T h e  retroviral cap site is defined by 
the 5 'e n d  o f  the R region. T h e  R region fo rm s a d irect repeat at b o th  ends o f  the LTR 
and provides the  hom ology  sequence necessary for strand transfer during  the reverse 
transcrip tion  process in w hich the U 5 and U3 regions are duplicated. T h e  3 'R  is 
polvadenvlated w ith abou t 50-200 nonco d in g  adenylate residues(C offin  et al., 1997; Palu 
et al., 2000).
T ranscrip tion  is regulated by the sequences w ithin the U3 region o f  the LTR, w hich can 
be distinguished in to  the p ro m o te r region w ith TA TA  box and a set o f  positive re­
acting regulatory signals th a t lie im m ediately upstream  (Graves et al., 1986) and the 
enhancer region approxim ately 150bp upstream  o f  the TATA elem ent, w hich 
constitu tes two 75bp direct repeats (Levinson et al., 1982) that con tro l gene expression 
and tropism  in d ifferent cellular env ironm ents th rough  a variety o f  cellular transcrip tion  
factors binding sites, w hich are closely packed o r overlapping (Figure 20)(C offin et al., 
1997; Palu et al., 2000) .
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1.2.5 Reverse Transcription of the viral RNA genome
T he process o f  reverse transcription o f  the viral RN A  genom e yields in a linear D N A  
double stand by which the U5 and U3 regions are duplicated (Figure 5). A s a result the 
proviral D N A  product is longer than the R N A  tem plate at bo th  ends, w hich is the origin 
o f  the tw o long terminal repeats (LTRs), each consisting o f  U3, R and U5 regions that are 
characteristic to the proviral D N A  form  o f  the retroviral genom e.
Figure 5: Reverse transcription o f  viral R N A  to Viral D N A  (provirus)
The integrated pro virus is larger than the viral genom e but its complexity is the 
same. D ue to the duplication o f  U3 and U5 during reverse transcription, the 
wild-type provirus is able to initiate a new round o f  replication. Adapted from  
Retroviruses (Coffin et al., 1997).
Reverse transcrip tion is initiated by the reverse transcriptase by com plem entary  
alignm ent o f  the 3 'term inus o f  a prim er t-R N A  to the prim er binding site (PBS), w hich 
is located pardy w ithin the un translated  region (leader region) at the 5 'e n d  o f  the 
retroviral genom e, next to  the 3 'en d  o f  the U5 region. T h e  step-by-step process o f  




Step-by-step Process o f  Reverse Transcription
The location o f  the R, U5, and U3 regions, the polypurine tract (PPT), and the 
primer-binding site (PBS) are indicated. The entire process is catalyzed by 
reverse transcriptase which has both D N A  polymerase and RNase H activities, 
(black coloured line) RNA; (orange coloured line) minus-strand D N A s; (red 
coloured line) plus-strand D N A . (1) A retrovirus-specific cellular tRNA  
hybridizes with a complementary region called the primer-binding site (PBS). (2) 
A minus-stand D N A  segment is extended from tRNA based on the sequence o f  
the retroviral genomic RNA. (3) The viral 5'R and U5 sequences are removed 
by RNase H. (4) First jump: D N A  hybridises with the remaining R sequence at 
the 3'end. (5) The minus D N A  strand is extended from the 3'end. (6 ) Most viral 
RNA is removed by RNase H, the polypurine tract (PPT), located upstream o f  
the U3 functions as the initiation site o f  positive strand D N A  synthesis. (7) The 
second (positive) D N A  strand is extended from the viral RNAs polypurine tract 
(PPT), and both tRNA and the remaining viral RNA are removed by RNase H. 
(8 ) Second jump: The PBS region o f  the second strand hybridises with the PBS 
region o f  the first strand. (9) Extension on both D N A  strands by D N A  
synthesis completing the pro virus flanked by LTRs. Adapted from Retroviruses 
(Coffin et al., 1997).
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1.2.6 The Retroviral Life cycle
T he life cycle o f  a rep lication-com peten t retrovirus begins in the nucleus o f  an infected  
cell and is illustrated in (Figure 7). A t this stage the retroviral genom e is a d o u b le ­
stranded D N A  elem ent in tegrated  in to  and covalent attached to  the D N A  o f  the h o st 
genom e. T he transcripdon  o f  full-length retroviral R N A s is initiated at the beginning  o f  
the 5 'LTR. T he  viral R N A  transcrip ts undergo  splicing and polyadenylation events in 
the cell nucleus o f  the host cell, sim ilar to  those o f  the h o st cell R N A  transcrip ts and 
are translocated to  the cytoplasm  bv nuclear export. U nspliced full-length viral R N A  
molecules act as tem plate fo r the  translation  o f  the gag-pol proteins, while spliced R N A  
species lead to  the p ro d u c tio n  o f  envelope proteins. G ag and pol are translated  as 
e ither gag p ro te in , o r a gag-pol po lypro te in  precursor. T h e  viral p ro tease cleaves the 
p recu rso r p ro te ins in to  m ultiple subunits. E nvelope glycoproteins are also translated  as 
a precursor, w hich are then  cleaved by endogenous proteases to yield the m ature surface 
glycoproteins. T h e  cleaved p ro te ins translocate at the cell surface and assem ble to 
retroviral core particles, w hich encapsidate two m olecules o f  full-length unspliced 
genom ic viral RNAs. H ereby  the genom ic viral R N A  species are identified  and 
distinguished from  o th er R N A  in cells by a special psi sequence (packaging signal, \\f) 
(Joshi et al., 1990), w hich is required  to r  encapsidation  o f  the R N A  in to  new lv fo rm ed 
virion particles that are released by budd ing  and proteolytic m atu ra tion  from  the cell.
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Figure 7: A schematic representation o f  the life cycle o f  a retrovirus
The life cycle o f  a retrovirus begins with the (1) transcription o f  the proviral 
D N A  genome into full-length RNA transcripts. (2) RNA transcripts undergo 
splicing events in the nucleus o f  the host cell. (3) Nuclear export o f  spliced 
RNA species. (4) Translation o f  the RNA genome into viral proteins and (5) 
packaging and assembly o f  genomic RNA into viral core proteins. (6 ) release o f  
new progeny by budding and proteolytic maturing o f  virus particles. (7) 
Adsorption to specific receptor to a new host cell. (8 ) Fusion o f  the membranes 
with loss o f  envelope and (9) entry’ o f  the viral core into the cytoplasma o f  the 
host cell. (10) reverse transcription o f  the viral RNA template to double stand 
D N A . (11) Nuclear translocation o f  retroviral D N A  into the nucleus and 
integration into the host genome until a new round o f  replication is initiated. 
Adapted from Retroviruses (Coffin et al., 1997) and (Palu et al., 2000).
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T h e  free virus particle can infect new  cells by b inding  to specific cell surface receptors. 
T he  in fecdon  process begins w ith the in teraction  o f  the envelope p ro teins o f  the viral 
particle w ith the plasm a m em brane o f  the target cell, which prim arily determ ines the 
specificitv o f  the virus—cell in teraction. B inding o f  the viral glycoprotein  to  a specific 
recep to r com plex on  the cell surface causes viral and cell m em branes to fuse, w hich 
process leads to injection and uncoating  (loss o f  envelope) o f  the virus core particle 
in to  the cell cytoplasm a. O nce inside the cell, the viral core is partially degraded  to fo rm  
a large nucleoprotein  particle contain ing  the viral genom e (prein tegration  com plex).
D uring this process, the retroviral reverse transcrip tase reverse transcribes the viral 
R N A  genom e in to  doub le-stranded  D N A  copies o f  the proviral genom e as show n in 
(Figure 5). U p o n  com pletion  o f  reverse transcrip tion , the viral integrase, m ediates 
in tegra tion  o f  the double stranded  proviral D N A  in to  the h o st chrom osom e.
T h e  process o f  en try  in to  the nucleus differs betw een gam m a-retroviruses (e.g. ATI A7) 
and lentiviruses (e.g. HIA7). F o r lentiviruses it has been  show n that efficient tran sp o rt to  
the nucleus is active by utilisation o f  the h o st cells nuclear im p o rt m achinerv (Bukrinsky 
et al., 1993), while the en try  o f  M LV transcrip ts to  the nucleus are d ep en d en t on  m itosis 
w hen the nuclear m em brane is d isassem bled, b u t can n o t transit th rough  the pores o f  
the nuclear m em brane o f  qu iescent cells (Lewis and E m erm an , 1994; Roe et al., 1993).
As provirus, the retroviral D N A  is fully in tegrated  as p art o f  the h o st genom e until the 
provirus is transcribed to give rise to  new  viral genom ic R N A  and viral p ro te ins required 
for the fo rm ation  o f  new  virions, thereby  initiating a new  ro u n d  o f  rep lication  and 
com plete a new  retroviral life cycle (Palu et al., 2000).
1.2.7 Development of recombinant retroviral vectors
As retroviruses are potentially pathogenic, their clinical use im plies the developm en t o f  
vectors carrying the therapeutic sequence(s), b u t are rep lication-incom peten t and are 
unable to transfer viral functions. H ence, the retroviral genom e was trim m ed dow n to 
provide in as just the signals essential for replication and packaging o f  vec to r R N A , 
while packaging cell lines were developed to express and supply the viral genes gag, pro,
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pol and env in trans using m olecular construc ts  w hich can n o t be packaged in to  retroviral 
particles.
1.2.8 Generation of recombinant Retroviral Vectors
As described above, replication-com petent retroviruses (such as wild-type retroviruses) 
carry gag, pol and env genes. T heir genom e also bears a cis-acting sequence {if/} necessary 
for encapsidation in to  viral capsids.
By contrast retroviral vectors lack gag, pol and env w hich are replaced by ano ther gene (for 
example, a therapeutic gene) w hich renders them  replication incom petent. V ectors 
therefore are transfected  in to  ‘packaging cells’ that constitutively express gag, po l and env 
genes from  transfected  expression plasm ids, to produce recom binant retroviral vectors. 
T he  R N A  that is transcribed from  the retroviral vector carries no  gag, po l o r env sequences, 
bu t only the gene(s) o f  interest. I t  can be packaged in to  viral capsids, ow ing to the 
inclusion o f  the encapsidation sequence (W ). Retroviral vectors produced  in such a 
m anner can infect o ther perm issive cells, bu t thev can no  longer replicate because thev do 
no t carry' gag, pol and env genes.
Since recom binan t retroviral vectors for gene delivery m ust be rep lication -incom peten t 
their genom e was trim m ed dow n to  provide in cis just the signals essential for replication 
and packaging o f  vec to r RN A . T h e  rem aining non-essential signals and packaging 
com ponen ts  are provided  in trans by the helper svstem  in p ro d u cer cells. Such helper- 
free packaging lines are capable o f  p roducing  all the necessary trans p ro te ins - gag, pol, 
and env - that are required for packaging, processing, reverse transcrip tion , and 
in tegration o f  recom binan t genom es. In  this configuration the capacity o f  the vec to r to 
accom m odate exogenous D N A /R N A  w ithou t losing its packaging capacity is restric ted  
to the size o f  an insert o f  m aximally ~7-7.5 kb (Verma and Som ia, 1997).
Retroviral vectors p roduced  in such a m anner can infect o th er perm issive cells, bu t thev 
can no longer replicate, because they do no t carry the /W an d  env genes.
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Figure 8: Schematic structure o f  a packaging cell.
The packaging functions (gag, pro, pol and env) are supplied in trans using separate 
molecular constructs. Only the recombinant retroviral vector expressing the 
therapeutic gene is packaged into newly formed virions without replication 
function. Adapted from (Marin et al., 1997)
T h e production  o f  recom binant vectors is induced by transfection  o f  the recom binan t 
vector in to  ‘packaging cells’ that constitutively express gag, po l and env genes. For safety 
reasons by the p roduction  o f  recom binant retroviral vectors, the  gag, po l and env gene are 
replaced by the gene o f  interest, e.g. a rep o rter gene a n d /o r  the therapeutic gene.
R ecom binant retroviruses were first p ioneered by Richard M ulligan and D avid 
Baltim ore w ith the psi-2 lines and analogous retrovirus packaging systems, based on  
N IH  3T3 cells (M ann et al., 1983).
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T h e three m ost com m only used packaging cell lines are: the am pho top ic  PA317 (Miller 
and B utdm ore, 1986), the am p h o tro p h ic  G P + envA M 12 (M arkowitz et al., 1988), and 
the g ibbon ape leukaem ia virus based P G 13 (Miller et al., 1991). Later, a hum an  
fibrosarcom a cell line H T 1080 was selected for their ability to release h igh-u tre  viruses 
that are resistant to  inacdvadon by hum an  serum . Two H T 1080-based packaging cell 
lines were created, w hich p roduce  M oloney m urine leukemia virus cores w ith envelope 
glvcoproteins o f  either am p h o tro p ic  m urine leukem ia virus (FLYA13 line) o r cat 
endogenous virus R D 114 (FLY R D 18 line) origin (Cosset et al., 1995). H ow ever, due to 
lengthv process o f  identifying a h igh-d tre  producer cell clone, transient packaging 
systems, like the 3 plasm id packaging system  with CO S a n d /o r  2 9 3 T /1 7  cells 
dem onstra ted  to  be the system  o f  choice, w here rapid high-dtre and helper free viral 
p ro d u cd o n  is required  (Soneoka et al., 1995). S econd-generadon retrovirus p ro d u cer 
lines for the generauon  o f  helper free ecotropic and am pho trop ic  re troviruses called 
Phoenix™  by (Kinsella and N olan , 1996) were soon developed. T h e  latter two 
packaging svstems will be described in m ore details later in this thesis.
1.2.9 Retroviral mediated gene therapy for CGD
As an attractive candidate d iso rder for correction  by gene therapy, chronic 
g ranulom atous disease (C G D ) has been used as a m odel system bv a num b er o f  g ro u p s 
in the field looking to develop im proved  therapies to those currently  available (Barese et 
al., 2004; C urnutte , 1993; C urnu tte  and Babior, 1987; D inauer et al., 2000; D inauer, 
2005; G oebel and D inauer, 2003; G oldb latt and T hrasher, 2000; G rez et al., 2000; K um e 
and D inauer, 2000; M alech et al., 1997b; M alech et al., 1997a; M alech, 1999; O tt  et al., 
2006; P o rter et al., 1993; P o rte r et al., 1996a; Schwickerath et al., 2004; Stein et al., 2006; 
T hrasher et al., 1992; T h rash er et ah, 1993; T hrasher et al., 1994; T h rash er et ah, 1995; 
W’inkelstein et ah, 2000).
T he first successful in vitro co rrec tion  o f  C G D  was achieved bv retroviral m ediated  gene 
transfer into B cell lines derived from  p47/,/"N-deticient patients (T hrasher et ah, 1992). 
Similar correction  o f  X -C G D  cell lines followed soon after (P orter et ah, 1993). In vitro 
correction  o f  superoxide generation  was subsequently  achieved in colonies derived from
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transduced C D 3 4 +  cells harvested  from  C G D -p ad en t peripheral b lood  firsdy, for 
p47/,/av-deficient (Sekhsaria and M alech, 1993) and subsequently  for b o th  fo rm s o f  
cytochrom e b,-^-deficient (Li et al., 1994) and the rem aining au tosom al recessive form s 
o f  C G D  (D e Leo et al., 1996; P o rte r et al., 1996b).
H igh levels o f  co rrec tion  o f  bo n e  m arrow -derived  long te rm  culture initiating cells 
(LTC-ic) from  X -C G D  patien ts were also rep o rted  (P orter et al., 1996a). O n  the basis 
o f  these results a clinical trial o f  C G D  gene therapy was instigated at N1H  (Barese et al., 
2004; M alech et al., 1997b). A lthough  the levels o f  superoxide generation  and correc ted  
circulating neutrophils w ere vanishingly low, ranging betw een 0.004%  and 0.6% , 
sustained transgene expression  was achieved, w ithou t any untow ard effects on  the 
patien ts’ health  (M alech et al., 1997b; M alech et al., 1997a). These levels o f  phenotvpic 
co rrec tion  w ere clearly still som e orders o f  m agnitude below  therapeutically useful 
levels, suggesting  that m ore w ork  was required  to im prove gene expression and the 
overall efficiency o f  transduction  as gene corrected  myeloid cells do  n o t have anv 
proliferative selective advantage in this condition.
M ore recently, w ith the advances in bone m arrow  pre-condition ing , a clinical trial for 
C G D  rep o rted  the achievem ent o f  significant clinical benefits to  chronic infections for 
two patients (O tt et al., 2006; O tt  et al., 2007). Im pressive levels o f  co rrec ted  
neutrophils (10-30%) in peripheral b lood  were found  in the first few m o n th  p o s t­
transplant, w hich rapidly increased to  50-80%) after 4-6 m on th . It was found  th a t m ost 
o f  the corrected  cells originated from  the clonal expansion o f  m veloid p recu rso rs were 
the vector in tegration  had occurred  in o r close to the transcrip tional start site o f  three 
grow th  p rom oting  genes, w hich led to abnorm al haem atopoiesis.
All the retroviral vectors used in the studies outlined above m ade use o f  the en dogenous 
retroviral long term inal repeat (LTR) to contro l expression o f  the therapeutic gene.
T he LTR acts as a constitutive p ro m o te r/e n h a n c e r in m any differen t cells and tissue 
types, whilst certain strains of retroviruses show  preferential transcrip tional trop ism , 
they are also know n to contain  sequences that result in the suppression  o f  efficient 
expression of genes from  the viral enhancer. T his is especiallv true for vectors 
transduced in to  em bryonic stem  cells, w here the p h en o m en o n  o f  silencing in vivo, in
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w hich o u tp u t from  the gene gradually reduces w ith time, is well established (G rez et al., 
1990; Pannell and Ellis, 2001; R obbins et al., 1997; R obbins et al., 1998; Soriano et al., 
1991).
O n e strategy to  im prove the efficiency o f  gene therapy for C G D , has been to  try  to 
co n stru c t retroviral vectors capable o f  high-level, sustained expression specifically in 
mveloid cells. This m ight be achievable bv subsd tudng  the viral p ro m o te r/e n h a n c e r  
elem ents o f  the LTR w ith those  derived from  genes w ith p rom oters that co n fer high 
level myeloid-cell-specific tran scrip d o n  patterns.
T he m olecular basis o f  m yeloid-cell-specific transcripdon is therefore described below.
1.3 Myeloid specific Gene Expression
T h e  te rm  myeloid is derived from  the G reek  w ord for m arrow, and m veloid cells 
co n sd tu te  the m ain cellular p opu ladon  o f  the bone m arrow, nam ely granulocvtes, 
m onocytes and their com m itted  progenitors. M yeloid cells arise from  p lu rip o ten t 
haem atopo iedc stem  cells (HSCs), which represen t a rare popu lad o n  in the bo n e  
m arrow  -  estim ated to be approxim ately one per 1(T m arrow  cells (R osm arin et al., 
2005). T h e  ability o f  genedc m anipulation o f  HSCs, controlling  and d irecdng  
expression of a transduced  therapeudc gene to m ature b lood  cells lineages in a dssue- o r 
cell-specific m an n er has been o f  pardcular in terest to gene therapv app licadons for 
inherited  m o n o g en ed c  b lood  disorders and requires an understand ing  o f  
haem atopoiesis.
1.3.1 Haematopoiesis
H aem atopoiesis is defined as the life-long process o f  p lu ripo ten t HSC p ro lifera tion , 
self-renewal and differen tiation  that is responsible for the p ro d u c tio n  o f  m ature b lood  
cells (Keller, 1992). T he  process is driven by com plex coord inated  p a tte rn s  o f  gene 
expression under the influence of cytokines and h o rm o n es w herebv p lu rip o ten t HSCs 
undergo successive sym m etric and asvm m etric divisions involving self-renew al, 
differentiation and m aturation to  yield com m itted  p ro g en ito r cells o f  d istinct b lood  cell
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lineages (lvm phoid and myeloid) (D exter and  H eyw orth , 1994). A schem atic m odel o f  
haem atopoiesis is presen ted  in Figure 9.
C om m itted  lym phoid p ro g en ito r cells give rise to  T-cells and B-cells as well as natural 
killer (NK ) cells. In  the lym phocyte lineage, B- and T-cells represen t 25-35%  o f  all 
leukocytes that take p art in antibody m ediated  im m unity and cell m ediated im m unity7. 
B-cells circulate the b lood  and lvm phadc system s, and can m ature in to  plasm a cells that 
secrete andbodies. T-cell p recu rso r undergo  d iffe rendadon  in the thym us in to  two 
distinct types o f  T-cells, T -helper (Th) cells, w hich are C D 4 + , and the cytotoxic T  (Tc) 
cells, which are C D 8 + .
Mveloid p ro g en ito r cells give rise the red b lood  cells: erythrocytes, the cells that carry  
oxygen and  m egakaryocytes, the p recu rso r o f  b lood  platelets that facilitate b lood  
clotdng. In  pardcular, the m yeloid lineage gives rise to  the white b lood  cells, the second 
g ro u p  o f  leukocytes that provide innate im m unity  and subdivided into: neutrophils, 
eosinophils, basophils, and m onocytes. T h e  latter, w hich replenish resident m arcophages 
and dendridc cells.
T he  majority- o f  cells o f  the m yeloid lineage are granulocytes, especially neutrophils, 
w hich at 50-70%  o f  all leukocytes rep resen t the largest g ro u p  o f  nucleated cells in the 
b lood, and m acrophages; these two cell types being those m ost active in phagocytosis 
(as described in 1.1.1). E osinoph ils rep resen t w ith abou t 5% o f  leukocytes and are 
im p o rtan t in the elim inadon o f  p athogens too  large to  be engulfed. M ast cells are dxed 
in dssues and are though t to  originate from  the sam e p recu rso r cell as circuladng 
basophils (1% o f  all leukocytes), to g e th er they play a key role in the in flam m atory  
process.
M acrophages and dendridc cells are derived from  m onocytes (3-9%) and m ediate, as 
one o f  several bridges, betw een innate immunity- and adaptive im munity, by p resen ting  
antigens to im m u n o co m p eten t T-cells.
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Figure 9: Schematic model o f  haematopoiesis.
Pluripotent haematopoietic stem cells (HSCs) derived from the bone marrow 
have the ability to self-renew and to differentiate into a variety o f  lineages as 
indicated. Haematopoietic stem cells can becom e committed lymphoid or 
myeloid precursors (com m on lymphoid and myeloid progenitors, respectively). 
The lymphoid lineage produces B cells, T  cells and natural killer (NK) cells. The 
myeloid lineage produces erythrocytes (red blood cells), megakaryocytes 
(precursor o f  blood platelets), mast cells, basophils, eosinophils, neutrophils, 
and monocytes. Adapted from (Qasim et al., 2004))
1.3.2 Myeloid specific promoters, genes and transcription factors
D istinct lineages are characterised by the expression o f  lineage-specific genes. Such 
genes are regulated by the binding o f  a unique com bination o f  transcrip tion  factors to  
recurring p rom oter motifs.
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1.3.2.1 Myeloid specific promoters and genes
T he proxim al regions o f  m yeloid cell-restricted genes o ften  display lineage-restric ted  
activity in transien t transfection  assays. C om m only, m yeloid-specific p ro m o ters  lack 
TA TA  boxes, b u t have a clearly defined site o f  transcrip tion  initiation.
T hese include the p ro m o ters  o f  the  genes that encode the leukocyte in tegrin  subunit 
C D l lb  (Pahl et al., 1992), im m unoglobu lin  recep to r FcyR l (CD64) (E ichbaum  et al., 
1994; Perez et al., 1993), im m unoglobu lin  recep to r FcyR lII (CD16) (Feinm an et al., 
1994), m acrophage co lony-stim ulating  factor (M-CSF) recep to r (Zhang et al., 1994a; 
Z hang et al., 1994b), granulocyte colony-stim ulating factor (G-CSF) recep to r (Sm ith et 
al., 1996a), g ranu locv te-m acrophage colony-stim ulating factor (GM -CSF) recep to r 
(H ohaus et al., 1995), transcrip tion  factor PU .l (Chen et al., 1995a), endo tox in  
lipopolysaccharide recep to r C D 14  (Z hang et al., 1994c), p ro to -o n co g en e  c -fp s /fe s  
(c-fes) (H eydem ann et al., 1996), m acrophage scavenger recep to r (M oulton et al., 1994), 
pro in terleuk in  lb e ta  (IL-1(3) (K om inato  et al., 1995), m acrophage in flam m atory  p ro te in  
(M lP )la  (G rove and P lum b, 1993), n eu troph il elastase (O elgeschlager et al., 1996; 
Srikanth and Rado, 1994), C D l l c  in tegrin  gene (N oti et al., 1996), leukocyte integin 
C D 18 (Rosm arin et al., 1995), leukocyte integin CD1 Id  (N oti et al., 2000), phagocyte 
p47^'fl% (Li et al., 1997), haem atopo ie tic  cell kinase (H C K ) (Hauses et al., 1998), 
interleukin-8 (1L-8) recep to r (CXCR1) (W ilkinson and N avarro , 1999), cell surface 
glycoprotein C D 36 (Arm esilla et al., 1996), transm em brane ectopeptidase gene o f  
am inopeptidase N  (A P N )/C D 1 3  (Shapiro et al., 1991), p ro teinase 3 (S turrock et al., 
1996), neutrophil peptide defensins (Tsutsum i-Ishii et al., 2000), and lactoferrin  
(K hanna-G upta et al., 2000).
In  the position  at w hich TA TA -boxes are typically located, b inding sites for the Hts 
family transcrip tion  factor PU .l are repeatedly p resen t instead, w hich are em ployed to  
determ ine the transcrip tional start site for these genes, and PU.l has been  show n to 
interact w ith T A T A -binding p ro te in  directly (Flagem eier et al., 1993).
PLI.l plays a key role in myeloid developm ent and m yeloid-specific gene regulation. It 
has been dem onstra ted  to  be truly tissue-specific for myeloid cells and B cells b u t is n o t 
p resen t in T  cells and HeLa (non-haem atopoietic) cells (Chen et al., 1995a; C hen  et al.,
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1995b). In  particular, PU .l has been  show n to  be essential for p47/)tex p ro m o ter activity 
in m yeloid cells (Li et al., 1997; M arden  et al., 2003b). I t  has also been show n that PU .l 
regulates the expression o f  the h um an  n eu tro p h il elastase gene (Srikanth and Rado, 
1998) and that it is the essential activator fo r the expression o f  gp91/’,,"A gene in hum an 
peripheral neu trophils, m onocytes, and B lym phocytes (Suzuki et al., 1998). PU .l (Spi-1) 
regulates the m yeloid-cell-specific c-fes p ro m o te r (H eydem ann et al., 1996) and plays a 
critical role in the tissue-specific expression o f  cell surface m arker C D  14 in m onocytic 
cells (Z hang et al., 1994c).
In  con trast, the inhib ition  o f  PU .l function  in hum an  C D 34+  progen ito rs has been 
show n to  b lock m yeloid colony fo rm ation . T argeted  m utagenesis o f  the m urine PU .l 
locus has revealed the fundam ental role this p ro te in  plays in b lood  cell d ifferen tiation  at 
all stages o f  haem atopoiesis (yolk sac, fetal liver and b one  m arrow ). For exam ple, PU .l 
has been  d isrup ted  by tw o in d ep en d en t research g roups and b o th  strains o f  P U .l- 
deficient m ice exhibit abnorm alities in B cell, T  cell, m onocyte and neu troph il 
developm ent (Sim on, 1998). O th e r  gene d isru p tio n  studies have show n th a t the 
expression o f  PU .l is n o t essential fo r earlv m yeloid lineage o r neu troph il co m m itm en t 
in mice, bu t is essential for m o n o cv te /m acro p h ag e  developm ent (A nderson  et al., 
1998a; A nderson  et al., 1998b).
1.3.2.2 Transcription factors involved in myeloid-specific gene expression
T ranscrip tion  factors play a vitally im p o rtan t role during  myeloid d ifferen tiation . 
H ow ever, there is no  single m aster m yeloid transcrip tion  factor that governs m yeloid 
linage com m itm ent alone (Rosm arin et al., 2005). Instead , m ultiple transcrip tion  factors 
w ork cooperatively and coordinately  to regulate b o th  tem poral and linage-specific gene 
expression (Shivdasani and O rkin , 1996). M ore than  a dozen  transcrip tion  factors are 
pivotal to  the regulation o f  m yeloid genes (Friedm an, 2002; Skalnik, 2002; T enen , 2003; 
Z hu and E m erson , 2002).
T ranscriptions factors for m yeloid-specific gene expression have been divided in to  
several families: the C C A A T /en h an cer b inding p ro te in  (C /E B P ) familv, w ith C /E B P a  
and C /E B P p ; the R u n t/P E B P 2 /C B F  family including AML1 /P E B P 2 a B /C B F a 2  and
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the E ts  family, w ith PU .l and Ets-1 o r  E ts-2 , the ub iquitous AP-1 g roup  and SP1 a 
single, universally expressed p ro tein , associated w ith p ro m o ters  w ithou t TA TA  boxes 
(D ynan et al., 1985).
In  pardcular, PU .l and the C C A A T /en h an cer b inding p ro te in  C /E B P a  are specifically 
required for n o rm al developm ent and differen tiation  o f  the myeloid linage by regulating 
several m yeloid specific genes. H ow ever, neither PU .l n o r C /E B P a  is exclusively 
m yeloid restric ted , while PU .l is also expressed by B lym phocytes and C /E B P a  is 
expressed  by liver and o th er organs.
In  the haem atopoietic  system  C /E B P a  has only been found in the m yeloid lineage and 
is th o u g h t to be im p o rtan t in early com m itm en t o f  p rogen ito r cells because the factor is 
dow n-regulated  w hen m yelom onocytic cells are induced to  differentiate (N atsuka et al., 
1992; S cott et al., 1992). C /E B P a  binding  sites are critical for m yeloid-specific 
expression o f  neu troph il elastase (O elgeschlager et al., 1996) and the recep to rs  for 
m acrophage colony-stim ulating factor (M -CSF), granulocyte colony-stim ulating factor 
(G-CSF), and granulocyte m acrophage colony-stim ulating factor (GM -CSF) (H ohaus et 
al., 1995; Sm ith et al., 1996a; Z h an g  et al., 1996).
Essentially, myeloid cell-restricted gene expression is due in p art to  the com binatorial 
action o f  m ultiple transcrip tion  factors p resen t in overlapping sets o f  haem atopo ie tic  
cells.
For exam ple, PU .l and Spl activate c-fes, C D l lb ,  and C D 18 gene p ro m o ters  (C hen et 
al., 1993); PU .l cooperates w ith C C A A T /en h an cer-b in d in g  p ro te in -a  (C /E B P a ) ,  c- 
myb, and AML1 in the activation o f  the neu troph il elastase gene p ro m o te r 
(N uchpravoon et al., 1994; N uchprayoon  et al., 1997; O elgeschlager et al., 1996); P U .l, 
AM L1, and C /E B P  activate the M -CSF recep to r p ro m o ter (Z hang et al., 1994a; Z han g  
et al., 1996); and PU .l cooperates w ith C /EB P(3 in the activation o f  the IL -1 [3 p ro m o te r 
(Yang et al., 2000), and w ith C /E B P a  to activate the G -C SF  recep to r p ro m o te r (Smith 
et al., 1996a). In addition, AML1 and c-m vb acting to g eth er in the activation o f  the 
m yeloperoxidase gene p ro m o te r (Britos-Brav and Friedm an, 1997), and C /F .B P  and Spl 
cooperate in the activation o f  the C D l l c  p ro m o ter (Lopez-R odriguez et al., 1997).
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In  con trast to the results o f  transien t transfection  experim ents, d istant cis regulatory 
elem ents are o ften  required in transgene co n stru c ts  to achieve m yeloid specific gene 
expression in vivo, although in m ost cases a detailed understand ing  o f  the m echanism s 
responsib le for directing appropriate  m yeloid cell-restricted expression are unknow n 
(Skalnik, 2002).
1.3.3 A ‘minimal’ myeloid-specific promoter
Studies o f  myeloid-specific p ro m o ter function  in transgenic mice indicated that fully 
regulated expression requires extensive regulator}’ sequence. F or m any m yeloid-specific 
genes, how ever, a relatively short 5’ proxim al p rom oter (generally 300bp o r less) is capable 
o f  directing m veloid-specific expression in vitro.
F o r example, 128bp o f  the C D  14 p ro m o ter can direct m acrophage-specific expression 
(Zhang et al., 1994c); 70bp o f  the G M -C S F aR  p rom oter directs m yeloid-specific 
expression (H ohaus et al., 1995); 106bp o f  the neutrophil elastase sequence directs 
mveloid-specificitv (Srikanth and Rado, 1994); 74bp o f  the G -C SFR  p ro m o ter directs 
mveloid-specific expression (Smith et al., 1996a); the m ajority o f  the m yeloid-specificity 
and activity o f  the M -CSFR p ro m o ter is contained w ithin 85bp (Zhang et al., 1994a); 
412bp o f  the C D l lb  p ro m o ter directs m veloid-specific expression, w ith the proxim al 
92bp retaining significant myeloid expression (Chen et al., 1993; Pahl et al., 1992); and 
446bp o f  the c-fes p rom oter was found to direct m veloid-specific expression in transgenic 
mice (H eydem ann et al., 2000).
A com parison o f ‘m inim al’ p rom oter sequences highlights a num ber o f  com m on  features. 
Firstly, a core p rom oter sequence com m onlv required for initiating basal transcription 
(TATA or Inr sequence) is often  absent. Secondly, a functional binding site for the Ets 
familv transcription factor PU .l is located close to the transcriptional start site. Thirdly, a 
binding site for at least one o ther transcription factor is located in close proxim ity to  the 
PU .l binding site. Any additional factors are generally o f  a restricted group that includes 
the C C A A T /enhancer-b inding  p ro te in -a  (C /F iB P a), polyom a virus enhancer binding 
lactor 2 /co re  binding factor (P E B P 2/C B F ) and the ubiquitous factor S p l.
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While evidence that P U .l, Spl and C /E B P a  can interact w ith the TA TA -binding protein  
com ponen t o f  the general transcription factor T F IID  in litro (Emili et al., 1994; Hagem eier 
et al., 1993; N erlov  and Ziff, 1995) suggests that in the absence o f  classical core p rom oter 
sequences, proxim al binding factors may facilitate recruitm ent o f  the basal transcriptional 
apparatus.
1.4 Objectives and aims of this investigation
As p art o f  a strategy to develop gene therapy for chronic granu lom atous d isorder 
(C G D ), this p ro jec t aim ed to  im prove the transcrip tional o u tp u t o f  retroviral vectors in 
myeloid cells, the cell type affected  in C G D .
As indicated  above, successful retroviral vectors have com m only  m ade use o f  the 
endogenous retroviral long term inal repeat (LTR) for expression o f  inserted  genes. T he  
LTR is a p o ten t constitu tive p ro m o te r /e n h a n c e r  that functions well in m any differen t 
cells and tissue types, b u t has been  associated w ith insertional m utagenesis, 
dysregulation, transgene silencing, and lack o f  specificity.
O u r approach to  im proving  the levels o f  m yeloid cell gene expression from  a retroviral 
vector was to take advantage o f  cellular p ro m o ters  from  endogenous genes that 
naturally have m veloid-cell-specific transcrip tion  patterns, and to co n stru c t vectors that 
substitu te the viral enhancer elem ents w ith those derived from  the cellular p rom oters. In 
this way we hoped  to optim ise expression from  the transgene in successfully transduced  
mveloid cells.
As an additional benefit it was surm ised that this mav also help to im prove the safety' 
profile o f  in tegrating vectors like retroviruses, bv reducing  the likelihood o f  
dow nstream  p rom otion , o r localised viral enhancer-m ediated  up-regulation  o f  adjacent 
genes.
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2 M a t e r i a l s  a n d  M e t h o d s
2.1 Materials
2.1.1 Reagents and Buffers
U nless otherw ise stated, all reagents were ob tained  from  Sigma. In som e cases the ca t.#  
is given, if  the exact supplier and batch is essential. Radioactive iso topes [y32P]-ATP, 
and [3:,S] dA T P were ob tained  from  IC N  Biom edical. D istilled MilliQ w ater was used to 
prepare all solutions, w hich w ere autoclaved at 121°C for 20 m in to sterilise.
Reagents and buffers used are listed as follows:
2.1.1.1 General Reagents and Buffers
50x Tris acetate buffer (TAE): 0.2M  Tris base, 1M glacial acetic acid (B D H ), 50m M  
E D T A , pH 8.0.
6x DNA loading buffer: 30%  G lvcerol (v /v ), 20m M  E D T A , 0.2%  b ro m o p h en o l blue 
(w /v).
PBS: PBS tablets (Oxoid) were dissolved 1 p er 100 ml w ater and autoclaved.
Sephadex: Sephadex G 50 was dissolved in distilled water, w ashed 2-3 tim es and 
resuspended in T E N  at 10% (w /v).
TE: lOmM T ns-H C l, pH 8.0 , Im M  E D T A
TEN: lOOmM N aC l, 10 mM  Tris-H C l, pH 8.0 , Im M  E D T A , pH 8.0
Tris borate buffer (TBE): 90m M  T ris-H C l, 90m M  boric acid, 1 m M  E D T A , pH 8.0 .
T4 Ligase lOx Buffer (Promega): 300m M  T ris-H C l (pH 7.8), lOOmM M gCF, lOOmM 
D T T  and lOmM  ATP. A liquots were stored  at —20°C.
2.1.1.2 Plasmid extraction solutions
Cell Suspension solution (Spin K it o r F low  K it, HYBA1D, UK): 50m M  T ris-H C l 
(pH8.0), 1 OmM E D T A , 100pg /m l R N ase A
Cell Lysis Solution (Spin K it o r Flow  Kit, HYBA1D, UK): 200m M  N a O H , 1% SDS 
(w /v ) '
Neutralising solution (Spin Kit, HYBAID, UK): 3.2M potassium  ace ta te /ace tic  acid 
(pH5.5) and guanidine hydrochloride, w hich is essentially d ifferen t to the H Y B A ID  
Flow Kit
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Wash Solution (Spin Kit, HYBAID, UK): contains ethanol, N aC l, E D T A  and Tris- 
HCl
Resuspension Solution (Flow K it o r Spin K it, H Y B A ID , UK): 50m M  Tris-H Cl 
(pH8.0), 10 m M  E D T A , 10 0 p g /m l R N ase A
Neutralising Solution (Flow Kit, HYBAID, UK): 3 .2M potassium  aceta te /acetic  
acid (pH5.5) only, which is essentially d iffe ren t to the H Y B A ID  Spin K it
Equilibration Solution (Flow Kit, HYBAID, UK): 600m M  N aCl, lOOmM sodium  
ace ta te / acetic acid (pH 5.0), 0 .15%  T rito n  X -100
Wash Solution (Flow Kit, HYBAID, UK): 800m M  N aC l, 100 m M  sodium  acetate /  
acetic acid (pH5.0)
Elution Solution (Flow K it, H Y B A ID , UI<): 1250m M  N aCl, lOOmM Tris-H C l 
(pH8.5)
2.1.1.3 Prokaryotic culture medium
LB (Luria-Bertani) bacterial growth medium: 2%  LB b ro th  base (w /v) 
(G ibcoB R L), solid m edia was supp lem en ted  w ith 15% bacto-agar (w /v) (Difco). All 
m edia w ere allowed to  cool below  50°C before addition  o f  A m picillin, lO O m g/m l o r 
K anam ycin, 4 0 m g /m l, respectivelv.
2.1.1.4 Eukaryotic culture medium
RPMI medium: R PM I 1640 (G ibcoB R L ), 10% FCS (v /v ), 2m M  L -G lutam ine 
(G ibcoBR L), lO pg /m l pen ic illin /strep tom vcin .
Freezing Medium: 90%  heat-inactivated  fetal ca lf serum  (FCS), 10% D M S O  (v /v )
Growth Medium (GM) for 293T Cells and Derivatives. T h e  follow ing are added 
directly to D M E M  (D ulbecco’s M E M  w ith G lu tam ax (G ibcoBR L) to give the indicated  
final concentrations: 10% heat inactivated fetal ca lf serum , lO O U /m l Penicillin, 
lOOU/ml S treptom vcin, 2m M  L-glutam ine
Hygromycin B (Boehringer Mannheim, cat.# 843-555 or Sigma, cat.#H3274):
250x stock solution ( lg /5 0 m l) was applied at 250-500)ug/m l final concen tra tion .
Diphtheria toxin (Calbiochem, cat.#322326 or Sigma, cat.#D2918): lg  d iph theria  
toxin from  Coryntbacterium diphtheriae dissolved in sterile PBS w ith 0.1%  BSA, aliquots 
stored at —80°C, used at l -2 p g /m l on  cells, select 1 week
PMA: p horbo l myristate acetate (Sigma), ln g /m l
Polybrene: 4 m g /m l (dissolved in PBS and subsequentlv  filtered th rough  a 0.2 jum filter 
and stored at either 4°C or —20°C) is the stock concen tra tion , used at 4 -8 p g /m l during  
infection on cells.
Flow cytometry staining buffer: PBS, 1% BSA (w /v), 0.01%  sodium  azide (w /v).
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2.1.1.5 Calcium Phosphate Coprecipitation Transfection Buffers
lx  HEPES: 21 mM  H E P E S , 0 .137M  N aC l, 5m M  K CL, 0.7 m M  N a 2H P 0 4, 5.5 m M  
glucose, pH7.1
2x HBS: 5.25g N a2H P 0 4 dibasic (FW  141.96, B D H ) dissolved in 500m l o f  w ater for 
stock soludon. 2x HBS was m ade o f  8.0g N aC l, 6.5g H E P E S  (sodium  salt, from  Sigma 
cat.#H -7006) and 10ml N a2H P 0 4 stock so ludon. B ecause the p H 7 .05+0.05 is very 
im portan t, it is recom m ended to m ake 3 batches pH 6.95 , pH 7 .0  and pH 7.05  using 
N a O H  o r HC1, filled up to a total volum e o f  500m l and  tested  fo r w hich one yields the 
best precipitate.
CaCl2 solution: 2.5M  CaCl2 so ludon  was filtered th ro u g h  a 0.2 pm  filter, aliquoted and 
stored at -20°C .
Chloroquine: 25 m M  ch loroqu ine stock so lu d o n  is p repared  in neither PBS o r g row th  
m edium  (GM ) and  sterile filtered th ro u g h  a 0.2 pm  filter and stored  at —20°C.
2.1.1.6 Northern Blot buffers
Hybridisation solution: 5x D en h ard ts  (v /v ), lOOpg/m l sonicated salm on sperm  
D N A  (denatured  at 98°C fo r 5 m in), 5x SSC (v /v ), 0.5%  SDS (w /v).
Denaturing solution: 1.5M N aC l, 0.5M  N aO H .
DEPC water: 0.1%  D E P C  (v /v ), incubated  overn igh t at room  tem peratu re  (RT) and 
autoclaved.
2 0 X S S C :  3M  N aCl, 0.3M  sodium  citrate
2.1.1.7 Western Blot buffers
Lysis buffer (Western): 4100pl w ater, 500pl 10% N P 40 , lOOpl 1M Tris pH 8 .0 , 130pl 
5M N aCl, 100 pi 500m M  NaF, 50pl m M  PMSF, lOpl N a 3V 0 4, com bined  in a b jiou-tube, 
sterile filtered and store at 4°C. lp l 5000x leupeptin , 5000x pepsta tin  and 5 pi 1M D T T  
was added to this lysis buffer just before  use.
Main gel buffer (Western): dissolve 91.05g Tris in 400m l water, adjust pH 8 .8  w ith 
HC1, add 2.5ml o f  20%  SDS solution and filled up to a total volum e o f  500m l w ith 
water
2x SDS buffer (Western): dissolve 0.76g Tris and 0.5m g b ro m p h en o l blue in 5ml 20%  
SDS, 10 ml glycerol and 20 ml water. A djust p H  to 6.8 w ith HC1 and fill up to 50m l and 
store at RT.
SDS-PAGE Running buffer (Western): 3g Tris, 14.4g glycine filled to 997.5m l w ith 
water. Add 2.5ml 20%  SDS and mix. Alternatively, p repare a 5x stock w ith 15g Tris, 72g 
glycine and 12.5ml 20%  SDS filled to 11 w ith water, mix and bottle. 200ml o f  5x stock 
can be diluted w ith 800ml w ater to yield a 1 x buffer
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2x SDS loading buffer: 125m M  Tris-H Cl, pH 6.8 , 20%  (v /v ) glycerol, 2%  (w /v ) SDS, 
2%  2-m ercaptoethanol, 0.001%  (w /v) b ro m o p h en o l blue (BD H ).
Stacking buffer (Western): 30.35g Tris dissolved in 400m l w ater, pH  to 6.8 w ith  HC1. 
A dd 10ml o f  20%  SDS and to p -u p  to  500ml w ith water, mix and bo ttle
Stripping buffer (Western): com bine 347pi |3-m ercaptoethanol, 12ml T ris-H C l pH 6.7 , 
5ml 20%  SDS, 41ml water
Transfer buffer (Western): 10ml 10x transfer b u ffer (58.2g Tris and 29.3g glycerine 
dissolved in 900ml water, pH  to 9.2 and fill up to 11, mix and bottle) w ith 70m l w ater 
and 20ml m ethanol, mix and use immediately.
SDS buffer (RNA preparation): 3.8%  SDS (w /v ), 0.038M  E D T A  pH 8.0 , 3.8 m g /m l 
proteinase K, 0 .77m g/m l yeast tR N A
SDS-PAGE electrophoresis running buffer: 25m M  Tris-H C l, pH 8.3 , 192m M  
glycine, 1% SDS (w /v).
SDS-PAGE resolving gel: 10%  a c r y la m id e  (w /v ), 0.27%  N ,N ’-m ethylene-bis- 
acrylam ide (w /v) (Protogel™ , N ad o n a l D iagnostics), 375m M  Tris-H Cl, pH 8.8 , 0.1%  
SDS (w /v ), 0.1%  am m onium  persu lphate  (w /v ), 0.1%  tem ed (v /v).
SDS-PAGE stacking gel: 4%  acrylam ide (w / v), 011%  N ,N ’-m ethylene-bis-acrylam ide 
(w /v) (Protogel™ , N ational D iagnostics), 125m M  T ris-H C l, pH 6.8 , 0.1%  SDS (w /v ), 
0 .1%  am m onium  persu lphate (w /v ), 0.1%  tem ed (v /v).
PBS-T: PBS, 0.05%  Tw een-20 (v /v ).
Blocking buffer (Western): 5%  n o n -fa t m ilk (Marvel) in PBS-T .
2.1.2 Plasmids
Plasm ids, subclones, cloning strategies and the creation o f  p ro m o te r co n tru c ts  and 
retroviral vectors are presen ted  in detail in the A ppendix . H ow ever the com m ercial 
plasm ids w ith the rep o rte r genes: luciferase and enhanced  green fluorescent p ro te in  and 
the retroviral vector backbones em ploved are m entioned  here brieflv.
2.1.3 Reporter and Marker Genes
2.1.3.1 Luciferase
T he pG L 3 Luciferase R eporter vectors from  Prom ega carry the luciferase gene o f  the 
firefly (.Pbotinus pyralis), w hich contains a m odified coding region for op tim ised  
m onitoring  o f  the transcrip tional activity in transfected  eukarvotic cells. H ere, the
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pG L3-B asic vector (Prom ega, see plasm id m ap 8.2.1) w ith o u t a eukaryotic p ro m o ter 
and enhancer sequences was used to r insertion  o t selected mveloid specific p ro m o ter 
sequences in tro n t o t the luciterase rep o rte r gene.
T h e  sensitivity o f  the luciferase assay provides the basis fo r fast and quantitative analysis 
o f  factors that potentially regulate m am m alian  gene expression by m aintaining relatively 
low background expression.
2.1.3.2 Green Fluorescent Protein
T he gene for the green  fluo rescen t p ro te in  (G FP) from  the jellyfish Aequorea victoris, is a 
repo rter m olecule for m o n ito rin g  gene expression. Its advantage is that it allows the 
evaluation o f  transduced  cells in vivo by d irect visualisation under a fluorescence 
m icroscope a n d /o r  by flow  cytom etry. In  the plasm ids p E G F P -N l (C lontech, see 
plasm id m ap 8.4.1) and p IR E S 2 -E G F P  (C lontech, see plasm id m ap 8.8.1) the 
fluorescen t p ro te in  is expressed u n d er the con tro l o f  the im m ediate early p ro m o te r o f  
the hum an  cytom egalovirus (CMV). T h e  eG F P  encoding the red shifted hum anised  
m u tan t was hum an  codon-op tim ised  (C orm ack et al., 1996). It contains a ch ro m o p h o re  
m utation  th a t p roduces fluorescence 35 tim es m ore in tense than  the w ild-type GFP. 
T h e  ‘e’ standing for enhanced.
2.1.4 Retroviral vectors
2.1.4.1 pMBA
T h e retroviral vector pM BA (see plasm id m ap 8.3.1) is a derivate o f  the pB abe series o f  
MLV (M orgenstern  and Land, 1990) (5 'LTR: 1-1375 and 1965-4125) and carries a 
m odified 3 LTR from  pM PSV  (1375-1965: 3 'LTRA ) w ith a deletion o f  the enhancer. 
T he pM BA vector was obtained  from  D r. C. Porter, C hester Beattv Laboratories, 
London. T h e  vector pMBA lacks the pol and env sequences, bu t carries its the ow n 
tfj-acting encapsidation sequence (if/) located betw een 5 'L T R  and the gag gene for 
packaging in to  viral capsids.
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2.1.4.2 Pinco
T he retroviral vector P IN C O  (G rignani e t al., 1998) was em ployed to generate high-titre 
retrovirus from  the Phoenix™  retroviral packaging cells (am photropic and ecotropic) by 
transient transfecdon  (Kinsella and N o lan , 1996). T h e  P IN C O  vector (see plasm id m ap 
8.5.1) contains the full length  M oloney LTRs, the extended T  sequence and a 
transcriprional cassette co m p o sed  o f  the CM V  p ro m o ter and the cD N A  for the 
E nhanced  G reen  F luo rescen t P ro te in  (eG FP). In  addition, the backbone o f  the 
P IN C O  plasm id also con ta ined  the  E B V  oriP  and EBN A -1 gene enabling the vec to r to 
replicate as an episom e. T h e  P IN C O  plasm id D N A  was a kind gift from  Prof. Dr. Pier 
G iuseppe Pelicci (E uropean  In stitu te  o f  O ncology, M ilan, Italy)
2.1.5 Mammalian Cell lines and routine culture
All cell lines were m ain tained  at a density  betw een 103-106cells/m l and cu ltured  at 
standard condition , 37°C, 5% C O „ in B IO H IT  tissue culture incubators.
2.1.5.1 Suspension Cell Lines
Suspension culture o f  haem atopo ie tic  cell lines, e.g. HL-60 cells, a hum an 
prom yelocytic cell line (Collins et al., 1977; G allagher et al., 1979; M ulder et al., 1981); 
U937 cells, a hum an prom yelocytic and histiocvtic lvm phom a cell line (S undstrom  and 
N ilsson, 1976); PLB985 cells, a hum an m yeloblastic leukem ia cell line (Tucker et al., 
1987); HEL cells, a hum an ervthroleukem ia cell line (M artin and P apayannopoulou , 
1982) and Jurkat cells, a hum an  T  cell leukaem ia cell line (Schneider et al., 1977) w ere 
m aintained in R P M I-1640 m edium  (G ibcoBR L, Lite Technologies) supplem ented  w ith 
10% fetal calf serum  (FCS), 2m M  L-glutam ine w ith Penicillin-Streptom vcin 
(GibcoBRL, Life Technologies). W hile TF-1 cells, a hum an ervthroleukem ia cell line 
(Kitam ura et al., 1989) required the addition o t 2 n g /m l rhG M -C SF to the suspension  
culture m edium .
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2.1.5.2 Adherent Cell Lines
A dheren t cell lines, e.g. NIH3T3 cells, a m urine fibroblasts cell line (A aronson  and 
Todaro, 1968); HeLa cells, a hum an  cervical carcinom a cell line (Scherer et al., 1953); 
293T/17 cells, a derivate cell line o f  the 293 h um an  em bryon ic kidney cells (G raham  et 
al., 1977), which expresses the sim ian virus 40 large T  antigen and the 293T  cell line 
nam ed Phoenix™ a retroviral p ro d u cer cell line w ere m aintained in D M E M  
(GibcoBRL., Life Technologies), su p p lem en ted  w ith 10%  fetal calf serum  (G ibcoBRL) 
and Penicillin-Streptom ycin (G ibcoB R L , Life Technologies).
Cells were passaged at a confluency  o f  70-80% , e.g. cells were detached from  the dssue 
culture flask on  incubation  w ith  try p sin -E D T A  at standard  culture cond ition  for 2m in, 
before  the trypsin  was inactivated  by the addition o f  cu ltu re /g ro w th  m edium , 
cen trifugation  at 1 2 00xg  fo r 5 m inutes and then  resuspended  in the appropriate  g row th  
m edium .
2.1.5.3 Phoenix™ retroviral producer cell lines
T he P hoenix™ -E C O  and P hoen ix™ -A M P H O  cell lines w ere ob tained  from  the 
A m erican Tvpe Culture C ollection (ATCC) for non-com m ercial use th rough  the N olan  
laboratory  (Stanford University7 M edical C entre, CA) up o n  a m aterial transfer agreem ent:
N am e A TC C  Inventor}7 N o. E nv
Phoenix™ -A M PH O SD3443 A m pho
Phoenix™ -EC O SD3444 Eco
T he Phoenix™  cell lines are based on the 293T cell line (a hum an em brvonic kidney line 
transform ed w ith adenovirus E l  a and carrying a tem perature sensitiye T  antigen co ­
selected w ith neom ycin). T h e  unique feature o f  this cell line is that it is highly
47
Chapter 2: Materials and Methods
transfectable w ith either calcium  p h o sp h ate  m ediated  transfection  o r lipid-based 
transfecdon  protocols.
T h e  Phoenix™  cell lines are a derivate o f  the a first generad o n  p rod u cer system  
established by G arry  P. N olan , W arren Pear, and M ard n  Scott in the labora to ry  o f  
D avid B aldm ore using 293T  cells as a packaging system  for helper-free retroviral 
p roduction  (Kinsella and N olan , 1996; Pear et al., 1993).
T he  N olan laboratory  m ade several im provem en ts over the first generations approaches. 
T he Phoenix™ -EC O  and P hoen ix™ -A M P H O  packaging cell lines were created  by 
placing construc ts to  be capable o f  p ro d u c in g  gag-pol and the envelope p ro te in  for either 
am photropic o r eco trop ic viruses in to  T 293 cells. T h e  gag-pol genes w ere in troduced  
w ith hygrom ycin as the co-selectable m arker, w hile the genes for the envelope pro teins 
were in tro d u ced  w ith  d ip theria  toxin resistance as the co-selectable m arker. In  addition  
an 1R ES-C D 8 surface m arker was in tro d u ced  dow nstream  o f  the reading fram e o f  the 
gag-pol co n stru c t to  m o n ito r gag-pol p ro d u c tio n  by flow  cytom etry.
T h e  P hoen ix™  cell lines o ffer g reat adyantages over previous stable system s in th a t they 
are fully com patib le w ith transien t and stable (episomal) retroviral vec to r gene 
p ro d u c tio n  and that virus can be p ro d u ced  in just a few days. T hey  also have been 
extensively tested  fo r helper virus p ro d u c tio n  and established as being helper-virus free 
by the the N o lan  laboratories.
Additionally, a line term ed  Phoenix™ -G P (SD3514) is available (that expresses only 
gag-pol-l¥£S\CD%-alpha) fo r pseudo typ ing  o f  retroviral v irons w ith o th e r envelope 
proteins such as g ibbon ape leukaem ia envelope, o r the vesicular stom atitis envelope 
p ro tein  (VSV-G).
2.1.6 Bacteria
C om peten t E . colt JM 109, D H 5 a , DM 1 and SU R E^ cells as supplied bv either 
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2.2.1 Bacterial growth
E . coli bacterial strains w ere g row n in sterile Euria-Bertani m edium  (LB) o r “Terrific 
B ro th ” (TB). T he selective expansion  o f  E . coli carrying plasm id D N A  was achieved by 
grow th in the presence o f  the ap p ro p ria te  anribiodc. E . coli carrying plasm ids encoding 
ampicillin resistance (amp) w ere selected in 10 0 p g /m l ampicillin; E. coli carrying 
plasmids encoding k a n a m y c in  resistance gene (karf) were selected in 50 p g /m l 
kanamycin.
2.2.2 Bacterial growth on semi-solid media
E. coli was g row n on  15%  LB agar plates in the presence o f  the appropriate  andbiotic. 
T ran sfo rm ed  bacteria was spread across the entire plate w ith a sterile glass rod; bacteria 
derived from  a clonal glycerol stock was streaked in lines w ith a sterile plastic rod. 
Plates w ere incubated  upside dow n fo r 12-16h at 37°C. Bacteria from  individual 
colonies was picked using a sterile plastic rod  and transferred  to liquid culture.
2.2.3 Bacterial growth in liquid culture
Individual bacterial colonies w ere expanded in liquid culture. A sterile culture o f  LB or 
TB  m edium  containing the appropriate  antibiotic was inoculated  w ith bacteria picked 
from  a single, freshlv grow n colony and incubated  for 12-16h. at 37°C w ith shaking at 
300 cycles/m in.
2.2.4 Preparation of frozen glycerol stocks
A one ml aliquot o f  bacterial culture grow n from  a single colony was m ixed w ith sterile 
glycerol to  a final concen tra tion  o f  20%  in a 1.8ml cryovial (N algene), and stored  at 
-70°C. Short-term  storage (3-6 m onths) at -70°C did n o t appear to affect the integrity 
o f  the sample.
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2.2.5 Preparation of competent cells
Treating bacteria cells w ith specific salt contain ing solutions, e.g. CaC l2 changes the 
m em brane charge in a way th a t these cells becom e tem porarily  perm issive to  the 
transfo rm ation  o f  D N A  molecules.
C om peten t E. coli JM 109, D H 5 a , DM 1 and SU R E  cells w ere p rep ared  asepdcally. 
Bacteria was streaked o n to  LB agar (w ithout antibiotic) and incubated  at 37°C  for 
14-16h. A single colony was picked and incubated  in 100ml LB m edium  in a 1 litre flask 
at 37°C w ith shaking at 300 cyc les/m in . until the  optical density7 (O D ) o f  the culture at 
550nm  reached 0.65—0.7 5 O D  units. T h e  culture was harvested  by cen trifugation  at 
5000Xg at 4°C. T h e  bacterial pellet was resuspended  in ice-cold 20m l o f  lOOmM CaCl2 
solu tion  and  incubated  o n  ice fo r 20m in. Cells w ere recovered by cen trifugation  at 
5 0 0 0 x g ? 4°C fo r 10 m in., resuspended  in  4m l ice-cold lOOmM CaCl2 so lu tion  50m l o f  
original culture. F o r the p rep ara tio n  o f  p erm an en t com peten t cells 1ml o f  sterile 
G lycerol was added to the cell suspension , vortexed o f  0.5m in and transferred  
im m ediately to aliquots o f  200pl p e r ep p e n d o rf tubes, which w ere shock frozen  in 
liquid N itrogen  and stored  at -70°C.
2.2.6 Preparation of plasmid DNA
Plasm id D N A  was am plified by g row th  o f  tran sfo rm ed  bacteria in liquid cu lture and 
purified on  a small ‘m in i-p rep’ scale from  a 5ml culture o r on  a large ‘m ax i-p rep ’ scale 
from  a 250m l culture. For optim al reproducible D N A  quality and puritv, the solu tions 
and p ro toco l o f  the com m ercial available Plasm id D N A  Purification  K its from  
Q IA G E N  Ltd, U K  o r H Y B A ID  U K  were essentially followed.
2.2.7 ‘MiniPrep’ isolation and purification of plasmid DNA
Small scale purification o f  plasm id D N A  from  bacteria culture was p erfo rm ed  using the 
H Y B A ID  RECOV ERY™  Q uick M ini Spin Kit (cat.#  RY-10250, H Y B A ID , U K ),
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following m anufactu rer’s instructions. T h e  p ro to co l involves isolation o f  plasm id D N A  
by alkaline/SD S lysis m eth o d  and a subsequen t spin o f  the neutralised lysate in a spin 
colum n, w here the plasm id D N A  is b o u n d  to  an ad so rp d o n  m atrix.
Briefly, cells w ere harvested  from  l-3 m l o f  bacterial culture by cen trifugadon  at 
m axim um  speed (approx. lOOOOxg) in a tab letop  m icrofuge, like all following 
cen trifugadon  steps. All traces o f  m edium  w ere rem oved carefully, and the bacteria 
pellet was resuspended  in 210pl Cell S uspension Soludon (H Y BA ID) by vortex ing  undl 
the suspension  was hom ogeneous. T h en , 210pl Cell Lysis Soludon (H Y BA ID ) was 
added and m ixed thoroughly  by inverting the tube several tim es and left for 5m in at RT 
for cell lysis. A fter this time, 280pl N eutralisation  Solution (H Y BA ID ) w ere added and 
m ixed im m ediately by inverting the tube until a hom ogenous phase was obtained . To 
clear the solu tion  for co lum n loading the m ixture was centrifuged at lOOOOXg for lOm in 
before the supernatan t was transferred  in to  a spin colum n (H Y BA ID ) that was placed 
in to  a 2m l receiver tube (H Y B A ID ). T h e  tube was centrifuged for lm in  and the flow ­
th rough  was discarded. In cu b atio n  w ith 500pl o f  so lu tion  G X  (H Y BA ID ) for 1 m in, 
centrifugation and disposal o f  the flow -through was recom m ended  as an op tional 
colum n wash for nuclease-rich bacteria. O therw ise the co lum n was subjected to  co lum n 
wash by addition o f  700pl o f  reconstitu ted  W ash solution (H Y B A ID ) and 
centrifugation at m axim um  speed fo r lm in . A fter the flow -through was discarded, it 
was essential to rem ove all residual so lution in an additional m icro cen trifugation  step. 
Finally, the plasm id D N A  was eluted bv placing the co lum n in a new  1.5ml m icrofuge 
tube and adding 75pl o f  sterile w ater (or lOmM  Tris-H C l, pH 8.0  buffer) directly o n to  
the center o f  the silica m atrix o f  the spin co lum n before cen trifugation  at lOOOOxg for 
2m in was perform ed. D N A  dissolved in w ater was stored at m inus 20°C.
2.2.8 ‘MaxiPrep* isolation and purification of plasmid DNA
Large scale purification o f  plasm id D N A  from  bacteria culture was p erfo rm ed  using the 
H Y B A ID  RECOV ERY™  Q uick Flow Maxi K it (cat.#  RY-14020, H Y B A ID , U K ), 
following m anufacturer’s instructions. T h e  p ro toco l involves isolation o f  plasm id D N A  
by alkaline/SD S lysis m ethod  and is based on gravity flow in com bination  o f  an an ion
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exchange resign, w hich is supplied in Q uick  F low  colum ns (H Y BA ID ) and results in 
ultra pure (CsCl grade) plasm id D N A .
Briefly, a 100-250ml bacterial culture were incubated  overn igh t for 12-14h and harvested  
at an density o f  approxim ately l x l O 9 ce lls /m l LB m edium  by cen trifugadon  (at 6000Xg 
in a B ecton  D ickinson Centrifuge). All traces o f  m edium  w ere rem oved carefully, and 
the bacteria pellet was resuspended  in 10ml R esuspension  Solution (H Y BA ID ) by 
vortex ing  until the suspension was hom ogeneous. T h en , 10ml o f  Cell Lysis Solution 
(HYBAID) was added and m ixed gently  by inverting  the tube several tim es and left for 
cell lysis for n o t m ore than 5m in at R T to avoid irreversibly denatu ring  the D N A . 
M eanwhile the Q uick Flow  colum ns w ere equilibrated w ith 30m l o f  E quilib ration  
Solution (H Y BA ID ) by gravity7 flow -through. 10ml o f  N eutralisa tion  Solution 
(H Y BA ID ) w ere added to the cell lysis m ixture and m ixed im m ediately by inverting the 
tube several times. To clear the so lu tion  before  co lum n loading the m ixture was 
cen trifuged  at 15000xg for 10 m in. T h e  supernatan t was transferred  p rom ptly  to  the 
equilibrated co lum n to  allow the lysate to  ru n  trough by gravity flow. T h e  colum n 
w ashed by addition o f  60ml o f  C olum n W ash Solution (H Y BA ID ) and allowed to 
em pty  by gravity flow. Finally, adding 15ml o f  E lu tion  Solution (H Y BA ID ) to the 
colum n eluted the plasm id D N A . T h e  precip ita tion  o f  the D N A  was carried ou t by 
adding 0.7 volum es isop ropano l (ultra grade) (10.5ml). T h e  D N A  was harvested  by 
centrifugation at 15000xg fo r 30m in. T h e  D N A  pellet was w ashed twice w ith 70%  
ethanol, air dried for lOm in and re-dissolved in a suitable volum e o f  buffer. D N A  
dissolved in water was stored  at -20°C.
2.2.9 Quantification of nucleic acid by spectrophotometry
T he purity and concen tration  o f  nucleic acid solutions w ere quantified  by optical density  
(O D ) m easurem ent at w avelengths o f  260nm  and 280nm  w ith a Philips PU 8620 
spectrom eter o r G E N Q U A N T  from  Pharm acia. A b so rp tion  o f  1 O D 260nm unit equals a 
concentration  o f  50pg /m l fo r double stranded  D N A , 4 0 p g /m l for single stranded  
D N A  or R N A  and 3 3 p g /m l for oligonucleotides. T h e  O D 26(lnm /  O D 280nm ratios o f  1.8
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and 2.0 indicate the purity  o f  sam ples for so lutions o f  D N A  and R N A  respectively, 
w hich were calculated autom atically using the G E N  Q U A N T  spectrom eter.
2.2.10 Quantification of nucleic acid by ethidium bromide fluorescence
T h e  concentration and purity  o f  diluted D N A  solutions (< 2 5 0 n g /m l) was carried ou t 
by agarose gel e lectrophoresis and estim ated  by com parison  o f  the in tensity  o f  
fluorescence o f  D N A  un d er shortw ave ultraviolet (LA7) radiation  (300nm) w ith th a t o f  
know n am ounts o f  lk b  o r lk b  plus D N A  ladders (G ibcoB R L  Life Technologies).
2.2.11 Restriction enzyme digestion of DNA
All restric tion  enzym es and their buffers w ere ob ta ined  from  Prom ega. D N A  was 
digested  accord ing  to  m an u fac tu rer’s instructions using lx  supplied restric tion  enzym e 
b u ffer and an excess o f  enzym e (5 -1 0 U /p g  D N A ). U nless o therw ise stated  all 
digestions to  p ro d u ce  fragm ents for subcloning were p erfo rm ed  in a total volum e o f  
50 j l l 1 reaction mix w ith 5-1 Opg plasm id D N A  and incubated  at 37°C for l-2 h  in  the 
appropriate  l x  d igestion b u ffer and p resence o f  restric tion enzym e (5 -1 0 U /p g  D N A ).
T h e  digestion o f  genom ic D N A  (10-25|ug) was carried o u t un d er the sam e condition , 
b u t w ith an ex tended  incubation  period  o f  14-16h and the addition o f  1 00pg /m l bovine 
serum  album in (BSA) and 4m M  sperm idine whilst lO U /p g  D N A  restric tion  enzvm e 
was used. T he  successful com pletion  o f  digestion was confirm ed  by agarose gel 
electrophoresis o f  approxim ately 10-20pl o f  the digested sample.
2.2.12 Analysis of nucleic acid by Agarose Gel Electrophoresis
1-2% A garose (G ibcoBRL) (w /v) gels were cast in lx  T A E  supp lem ent w ith 5 0 0 p g /m l 
ethidium  brom ide. D N A  sam ples were p repared  in lx  D N A  loading dye (6x stock 
solution), and loaded o n to  the gel along w ith D N A  m arkers, lp g  o f  lk b  o r lk b  plus 
D N A  ladders (G ibcoB R L Life Technologies). E lec trophoresis was p erfo rm ed  in lx  
T A E  electrophoresis buffer and a voltage gradient o f  15-20V /cm . Large D N A
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m olecules (>10kb) were separated  o n  0.8-1.0%  agarose; m olecules ranging from  1.3- 
lOkb were separated on 1% agarose, w hilst m olecules fragm ents o f  less than  1.3kb in 
size were separated on  2%  agarose. A fter electrophoresis the analysis o f  the gel was 
carried ou t and exam ined u nder UV transillum ination.
2.2.13 Purification of DNA
For rapid clean-up o f  o ligonucleo tides and  D N A  restricdon  fragm ents betw een lOObp 
and 15kb from  enzvm adc reacdons (e.g. labelling, d ep h o sphory ladon , restricdon  and 
tailing) the com m ercial available Q IA qu ick  Spin K its for ‘N ucleo tide R em oval’ and ‘G el 
E x tracd o n ’ from  Q 1A G E N  w ere used following m anufactu rer’s instrucdons. T he  
technique involves p H -d e p en d en t D N A  ad so rp d o n  to  a silica-m em brane w ith a high 
co n cen trad o n  o f  chao trop ic  salts (Vogelstein and Gillespie, 1979) while contam inants 
were w ashed  o u t and pass th ro u g h  a sp in-colum n during the m icrocen trifugadon  
process. Finally, the pure D N A  was eluted in Tris buffer o r water.
2.2.14 Excision of DNA fragments from agarose gel
D N A  restriction fragm ents w ere separated  by agarose gel e lectrophoresis and visualised 
by illum ination under shortw ave U V  radiadon  (300nm). F ragm ents were individually 
excised from  the gel w ith a clean, sharp  scalpel blade and transferred  in to  an ep p e n d o rf 
tube. D N A  purificadon was carried o u t follow ing essendallv the in stru cd o n  o f  the 
‘Q IA quick G el E x traction  K it P ro to co l’ (Q 1A G EN ). Briefly, the approxim ate w eight o f  
the gel slice was determ ined  and 3 volum es o f  B uffer Q G  (Q IA G E N ) to 1 volum e o f  
gel (lOOmg ~ lOOpl) were added to  the sample. T h e  gel slice was dissolved by 
incubadon at 50°C for abou t lOm in, and was vortexed undl the gel was com pletelv 
dissolved. T h e  provided B uffer Q G  contains a pH  indicator w hich is vellow at p H  <7.5 
and orange o r violet at higher pH , allowing easv d e term inadon  o f  the opdm al p H  for 
D N A  binding, which can be correc ted  bv adding 10p] o f  3M sodium  acetate. To allow 
optim al D N A  binding 1 gel volum e o f  isopropano l was added to the sam ple, m ixed and 
transferred  to  a Q IA quick spin co lum n in a provided 2ml collection tube. T h e  flow ­
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th rough  was discarded after 1 m in o f  cen trifugation  and by adding new  500pl B uffer 
Q G  in a second spin all traces o f  agarose w ere rem oved. T h e  co lum n was w ashed w ith 
750pl o f  B uffer P E  (Q IA G E N ), the spin flow -th rough  was discarded and any residual 
ethanol from  the B uffer P E  was rem oved com pletely  by an additional 1 m in spin at 
lOOOOxg. Finally, the sp in-colum n was p laced in to  a clean 1.5ml m icrofuge tube and the 
D N A  was eluted in 30-50pl w ater o r lO m M  T ris-H C l (pH8.5) buffer. F or subcloning 
D N A  fragm ents were eluted in absence o f  a buffering  agent and stored at -20°C.
2.2.15 Purification of D N A  fragments from aqueous solution
To rem ove prim ers < 10  bases, enzym es, salts, and un incorporated  nucleotides the 
‘Q IA quick N uc leod ide  rem oval K it P ro to co l’ (Q IA G E N ) was essentially followed. 
Briefly, 10 volum es o f  B uffer P N  (Q IA G E N ) were added to  the reaction sam ple and 
m ixed. F o r exam ple, 500pl o f  B uffer P N  was added to a 50pl reaction sam ple and 
transferred  in to  a Q IA quick  spin co lum n in a provided  2-m l collection tube. To bind  
D N A , the first spin was carried o u t at 6000 Xg for 1 min. T h e  flow -through was 
discarded and the co lum n was w ashed by adding 750pl o f  B uffer P E  (Q IA G E N ) 
followed by an o th er spin at 6000Xg. Residual ethanol from  B uffer P E  was com pletely 
rem oved w ith an additional centrifuge step at 10000Xg. Finally, the sp in-co lum n was 
placed in to  a clean 1.5ml m icrofuge tube and the D N A  was eluted in 50-lOOpl w ater o r 
lOmM  Tris-H Cl (pH8.5) buffer. F or subcloning  D N A  fragm ents were eluted in absence 
o f  a buffering agent and stored  at -20°C.
2.2.16 Preparation of vector DNA for subcloning
Vector D N A  (5-1 Opg) was linearised by restric tion  enzym e digestion and if  necessarv 
separated from  unw anted D N A  fragm ents by agarose gel electrophoresis. T h e  D N A  
purification was carried o u t as described above w ith the Q IA quick Spin K its from  
Q IA G E N . Linearised vec to r D N A  w ith cohesive term ini was p hosphatase -trea ted  in 
order to prevent self-ligation.
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2.2.17 Dephosphorylation of DNA fragments
To prevent self-ligation o f  purified  vec to r D N A  the ‘Shrim p Alkaline P hosphatase 
D ephosphory la tion  P ro to co l’ from  U nited  States B iochem ical (USB) was essentially 
followed. Briefly, the shrim p alkaline pho sp h atase  has approxim ately  the sam e specific 
activity as the calf intestine enzym e (800-1 OOOU/mg at 25°C, pH 9.6) but, unlike the calf 
enzym e, it is com pletely and irreversibly inactivated in  Tris buffers at pH 8.0-8 .5  by 
simply headng for 15min at 65°C. T h e  rate o f  rem oval o f  the term inal 5 'p h o sp h a te  
from  double-stranded D N A  d ep en d s on  the  struc tu re  o f  the term inus. T erm ini w ith 5 ' 
p ro trud ing  ends are m ore reactive th an  th o se  w ith b lun t-ends o r those w ith 5 '-recessed  
ends. T he reacdon rate also d ep en d s on  the tem peratu re  and m agnesium  concen tradon . 
V ector D N A  (l-5pg) was incubated  at 37°C for one h o u r in l x  Shrim p Alkaline 
Phosphatase  B uffer (USB, supplied  10x Buffer: 200m M  T ris-H C l, pH 8.0  and lOOmM 
M gCh) and the recom m ended  enzym e co n cen trad o n  in a total volum e o f  50pl. F or a 
typical reacdon  using l.O pm ol o f  D N A  term ini (2.5pg o f  a 3kb plasm id), the following 
m inim um  am ounts w ere found  to  be effective: 5 ' -p ro tru d in g  (0.1U), b lun t (0.2U) and 
5 '-recessed  (0.5U). Shrim p A lkaline P hosphatase  treated  D N A  was purified after 15m in 
enzym e heat-inactivation at 65°C w ith Q IA quick  N ucleo tide Rem oval K it (Q U IA G E N ). 
T he  ex ten t o f  dep h o sp h o ry la tio n  was assessed by ligation and tran sfo rm atio n  o f  
d ephosphory la ted  vector. Successfully dephosphory la ted  vec to r should n o t religate o r 
consequently  p roduce no  colonies. T h e  concen tra tion  o f  vec to r D N A  was estim ated by 
ethidium  brom ide fluorescence from  5pl D N A  aliquot.
2.2.18 Preparation of insert DNA
Insert D N A  was p repared  by restric tion  enzym e digestion  and agarose gel 
electrophoresis. D N A  was purified  from  agarose follow ing the ‘Q IA quick  G el 
E xtraction K it P ro to co l’ (Q IA G E N ) and was resuspended  in 50pl o f  water. T h e  
concentration  o f  insert D N A  was estim ated by eth id ium  brom ide fluorescence from  5 pi 
D N A  aliquot.
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2.2.19 Ligation
To join two strands o f  purified vec to r D N A  and in sert D N A  betw een  the 5 '-p h o sp h a te  
and the 3'hydroxyl groups o f  adjacent nucleotides in  either a cohesive-ended o r b lunt- 
ended configuration the T 4 D N A  Ligase (Prom ega, C at.#M 1794 , 10-20U /pl) was 
em ployed. In  o rder to  avoid exposure to  frequen t tem peratu re  changes and 
consequently degradation  o f  the A T P  and D T T  in the Ligase 10x B uffer the T 4  D N A  
Ligase and its Ligase 10x B uffer (Prom ega) was sto red  in aliquots at -20°C and on  ice at 
all times during prepara tion  o f  the ligation reaction  sample.
T he cloning o f  an D N A  insert in to  a p lasm id vec to r was p erfo rm ed  using a m olar ratio 
o f  vector : insert D N A  o f  1 : 3 and  1 : 5 by applying the follow ing form ula:
ng o f vector x kb size o f insert , _ insert
--------------------------------------------  x molar ratio o f   = ng o f insert
kb size o f vector vector
T h e  typical ligation reaction  was ab o u t 100-200ng o f  vec to r D N A  w ith the appropriate  
am o u n t o f  insert, m ixed w ith 2pl o f  ligase 10x B uffer and lp l  T 4  D N A  ligase 
(Prom ega, 10-20U /p i), w hich was adjusted to a final reaction volum e o f  20pl w ith 
nuclease-free water. To allow annealing and ligation o f  the D N A  fragm ents, the ligation 
itse lf was carried o u t at the optim al incubation  tem peratu re for T 4  D N A  ligase, w hich is 
16°C and recom m ended  for efficient ligations. H ow ever, ligase is active at a broad  
range o f  tem peratures, and for rou tine  pu rposes such as subcloning, convenience o ften  
dictated incubation  tim e and tem perature, th a t ligations p erfo rm ed  at 4°C overn igh t o r 
at room  tem peratu re fo r 30m in o r a couple o f  hours usually w orked well too.
O nly 10pl o f  the ligation reaction  volum e was used for the tran sfo rm atio n  o f  
com peten t E.coli cells.
2.2.20 Transformation of competent cells by heat-shock
-  . (R^
Subcloning efficient JM 1 09, D M 1, D H 5 a  o r SU R E ' co m p eten t E.coli cells w ere used 
for transform ation  o f  plasm id D N A . F rozen  co m p eten t E.coli cells w ere thaw ed on ice. 
10pl o f  a ligation reaction m ixture o r abou t 50-100ng plasm id D N A  was m ixed w ith 
lOOpl o f  com peten t cells and left on  ice for lOmin. A fter this time, cells w ere subjected
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to a heat-shock in a preheated  w ater ba th  at 42°C  fo r ab o u t I - IV2 m in  and im m ediately 
re tu rned  on ice for 3 min. 1ml o f  LB m edium  (w ithout any antibiotics) was added, and 
the transform ation  m ixture was incubated  at 37°C for lh .  T ran sfo rm ed  bacteria cells 
were harvested by centrifugation at 6000Xg for 5m in, the su p ern atan t was rem oved and 
the bacterial pellet was resuspended  in rem aining m edia. T h e  total volum e was then  
plated on to  15% LB agar plates contain ing  the app ropria te  antibiotic. T h e  plates were 
incubated upside-dow n at 37°C  fo r 14-16h. Positive and negative con tro l 
transform ation  reactions con tain ing  closed circular plasm id D N A  and linear D N A  were 
perform ed in parallel. T ran sfo rm atio n  efficiency was assessed by perfo rm in g  a test 
transform ation  w ith closed circular p lasm id D N A . T h e  n um ber o f  colonies p roduced  
using 1 , 10  and lOOng D N A  prov ides an estim ation  o f  colony fo rm ing  units/jag.
2.2.21 Transformation of electro-competent cells by electroporation
Successful ligation and tran sfo rm atio n  efficiency is subject to  m any variables, e.g. 
concen tra tion , ligation ratio, term in i configuration  (e.g. cohesive o r b lun t-end  ligation), 
the perm eability  o f  the m em brane o f  the co m p eten t bacteria and the size o f  the 
plasm id D N A . To elim inate the the latter, it was som etim es necessary to  p erfo rm  
transfo rm ation  o f  ligation D N A  by electroporation .
This was carried ou t bv as follows: 50pl e lec tro -com peten t D H 5 a  cells were m ixed w ith 
lOpl ligation reaction sam ple and transferred  fu rther in a chilled elec troporation  cuvette 
(BIO R A D ) stored on  ice. T h e  e lec troporation  was p erfo rm ed  at 25pF, 2.5kV  and 200Q  
and im m ediately placed on  ice again, before 1ml o f  LB m edium  (RT) was added  and 
incubated at 37°C for lh . T ransfo rm ed  cells were harvested  by spinning and plated 
on to  an 15% LB agar plates contain ing  the approp ria te  antibiotic. C on tro ls were 
perfo rm ed  as described above for heat-shock transfo rm ation .
2.2.22 Analysis of recombinant bacterial transformants
Single colonies were picked and transferred  aseptically in to  2-5m l LB m edium  
containing appropriate antibiotic. T h e  liquid culture was incubated  at 37°C  fo r 12-16h
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w ith shaking at 300xg. For analysis an aliquot o f  1-2 m l was taken and the ex tracdon  
and purification o f  plasm id D N A  was p erfo rm ed  follow ing essentially the H Y B A ID  
RECO VERY ™  Q uick Mini Spin K it P ro toco l (H Y B A ID  U K ). Plasm id D N A  was 
analysed by restriction enzym e digestion and agarose gel electrophoresis. Positive 
identified clones were aliquoted fo r glycerol stock a n d /o r  stored  at 4°C fo r n o t m ore 
then  1-2 days before a expansion o f  the bacteria culture was p erfo rm ed  for ‘M axiP rep’ 
purification o f  plasm id D N A .
2.2.23 Transfection of mammalian Cells
Various transfection  m ethods w ere em ployed to  deliver plasm id D N A  in to  m am m alian 
cells. We used transfection  by e lec tropora tion  for suspension cell lines and transfection  
by L ID  com plex  o r transfection  by calcium  p h o sp h ate  precipitation  for adheren t cell 
lines.
2.2.23.1 Transfection of U937 and HL-60 cells by Electroporation
T he conditions used to  e lectroporate  U937 and H L60 cells for transien t expression  are 
essentially described in (Pahl et al., 1991), bu t w ere applied in a slightly m odified  way, 
w hich tu rned  o u t to  be m ore efficient in ou r hands.
Briefly, suspension  cells were diluted to lCPcells/m l and incubated  in fresh R PM I-1640 
m edium  16-24h p rio r to  transfection . A t the time o f  transfection , the cells were 
harvested by centrifugation at 500Xg for 5m in at room  tem peratu re  (RT). Cells were 
washed twice in 4°C cold R PM I-1640, contain ing  neither fetal ca lf serum  (FCS) n o r L- 
glutamine. Cells were resuspended  at 2.5-3x10 ce lls /m l in R PM I-1640, and a 450pl 
aliquot was added to  a chilled sterile elec troporation  cuvette (BioRad). T h en , in total 
20pg o f  plasm id D N A  (i.e. to  determ ine the relative transfections efficiency, the 
experim ental luciferase-expressing plasm ids were routinely co-transfected  w ith 
pE iG FP-N l plasm id D N A  at the sam e am ounts) were dissolved in 50pl R PM I-1640 (or 
sterile water) was added to the cell suspension in the cuvette and left on  ice for 
additional 15min before the e lec troporation  was perfo rm ed  w ith 200V at 960pF. T h e  
cuvette was re tu rned  to the ice bucket for fu rther 5m in before the cells w ere transferred
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and resuspended in 20ml o f  cold com plete R PM I-1640 m edia and th en  cultivated at 
37 °C for cell recovery in the cell culture incubator.
For cell induction experim ents w ith PM A, the cell suspension  above was split 50:50 bv 
transfer o f  10ml to a 50ml tissue culture flask w ith added PM A  (ln g /m l)  befo re  b o th  
flask (±PMA) were re turned  to  the incubato r to recover for 24-48 hours until harvested  
for luciferase assays at various times.
T he  transfection efficiency was de term ined  by fluorescence m icroscopy using red and 
green filters on  an ep ifluorescent m icroscope (N ikon) by coun ting  a m inim um  o f  102 
cells per transfection w ith a haem ocytom eter. T h e  percentage o f  eG F P  positive cells 
were used to  norm alize the luciferase R L U /m g  p ro te in  to the n u m b er o f  cells 
transfected.
2.2.23.2 Transfection of tissue culture cells with LID complex
T h e  following transfection  m eth o d  w ith L ipofectin  intergin targeting pep tide  : D N A  
com plexes (LID) (being developed and optim ised in o u r laboratory  at the time) was 
m ade available to  us by Drs. Steven H a rt and A im a U duehi (see (H art et al., 1994; H art 
et al., 1995; H art et al., 1997; H a rt et al., 1998; U duehi et al., 2003).
To begin with, the integrin targeting  pep tide  (the AS sequences for pep tide  6 and 8 are 
listed in the table fu ther dow n) required  stock solution preparation : T his cyclisation o f  
peptide was carried ou t by dissolving 2m g o f  pep tide to a concen tra tion  o f  O .lm g /m l in 
O ptiM EM * (G ibco Life Technologies) in a 20ml conical flask, w hich was left at 4°C 
overnight before it was sterile filtered, aliquoted and stored at -7 0 °C  until use.
No. AS sequence Supplier
Peptide 6 [K], 6G  a c r r e t a w  a c g Z insser Analytic, M aidenhead, K ent, U K
Peptide 8 [K]16G A C Q ID S PC A Z insser Analytic, M aidenhead, K ent, UI<
T he L ID  transfection com plex was form ulated  at a ratio o f  0.75 : 4 : 1 o f  
Lipofectin : Intergin peptide : D N A . T his ratio is applicable w hen peptides 6 o r 8 are
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used. F or o ther peptides the am ounts may need to  be altered so that com plexes w ith a 
net posidve charge o f  6.8 are form ed. U nless o therw ise stated p ep d d e  6 was used in 
ou r experim ents, which proved to be best for transfecdon  o f  haem atopo iedc cells (Drs. 
Steven H art and Aim a U duehi, personal com m unication  (H art et al., 1997; H a rt et al., 
1998; U duehi et al., 2003)).
F irst stock solutions o f  the L ID  com plex co m p o n en ts  w ere prepared: lipofectin  
(supplied as a 1 m g /m l solution, G ibco  Life Technologies) was dilu ted  to  0 .75p l/100p l 
OptiMEM® (G ibco Life Technologies), plasm id D N A  was diluted to  lpg /lO O pl 
OptiMEM® and cyclised pep tide  at O .lm g /m l in OptiM EM ® was used. T h e  
transfection com plexes w ere m ade sufficient for lp g  plasm id D N A  p er well in a 48 well 
plate, while the plasm id D N A  o f  the experim ental luciferase-expressing plasm ids were 
m ixed w ith p E G F P -N l p lasm id D N A  at the sam e am ounts to  assess the relative 
transfections efficiency. T h e  relative am oun ts for com plex fo rm ation  and o rder o f  
adding  to  the fo rm ulation  tube  were: (1) lipofectin: 0.75pl (0.75pg) in  lOOpl OptiM EM ®, 
(2) pep tide  (O .lm g/m l in O ptiM E M /5): 40pl (4pg) and plasm id D N A  (lp g /1 0 0 p l): lOOpl 
(lpg) w ere m ixed and left un d er am bien t conditions betw een 30m in and 2h to  allow the 
fo rm ation  o f  the L ID  com plexes.
T issue culture cells for transfection  w ere prepared  as follows: 16-24h p rio r to  
transfection, haem atopoietic cells, e.g. U937 o r H L 60 were diluted to lx lO A e lls /m l and 
incubated in fresh R PM I-1640 m edium . A t the tim e o f  transfection , the cells were 
harvested  by centrifugation at 1200xg  fo r 5m in at room  tem peratu re (RT) and w ashed 
twice in OptiM EM ®. T h e  cell concen tra tion  was determ ined  by using a 
haem ocytom eter, resuspended and seeded at a density o f  5 x l0 4 ce lls/300p l OptiM EM ® 
per well in to  48 well plate. 200pl L ID  com plex, form ulated  as described above, was 
added to each well m aking up a final concentration  o f  lp g  plasm id D N A  p er 
500pl/well. T ransfection o f  cells occurred  during 4h o f  incubation  in the B IO H IT  
incubator under standard tissue culture conditions (37°C, 5% C O t). A fter this tim e 
transfection excess m edium  was rem oved and replaced w ith 500pl fresh com plete 
RPM I-1640 grow th m edium .
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T he transfection  efficiency was determ ined  by fluorescence m icroscopy using red and 
green filters on  an epifluorescent m icroscope (Nikon) by coun ting  a m in im um  o f  102 
cells per transfection w ith a haem ocytom eter. T h e  percentage o f  eG F P  positive cells 
were used to norm alize the luciferase R L U /m g  p ro te in  to  the n u m b er o f  cells 
transfected. T he analysis o f  the transien t rep o rte r gene expression assay was carried  ou t 
at various times.
2.2.24 Luciferase assay
Luciferase activity7 in cell extracts was m easured  using the luciferase assay system  
(Prom ega U K  Ltd., S o u th am p to n , U K ) as described  by7 the m anufacturer.
F irst, cells w ere rinsed i n  l x  PBS and th en  re-suspended  in lOOpl o f  1 X R ep o rter Lysis 
B uffer (Prom ega) and lyTsed by incubating  for 15m in at 4°C. Sam ples w ere then  
subjected  to  one freeze-thaw  cycle and the cell suspension  pelleted by centrifugation  at 
1300Xg fo r 5min. T h e  su p ern a tan t was then  assayed for luciferase activity7 using the 
Luciferase Assay K it (Prom ega), e.g. 20pl o f  cell lysate was m ixed w ith  lOOp.1 o f  
L uciferase Assay R eagent and m easured  in  the A n thos Lucy m icroplate 
lu m in o m e te r/p h o to m e te r (Labtec In tl., Sussex, UK).
In  the luciferase assay, luciferin and M g2+A T P are added to  cellular extracts w hich 
induces the p roduc tion  o f  light. Total light em ission o f  each sam ple was m easured  for 
10 seconds as well as the p ro te in  co n ten t in co rresp o n d in g  sam ples was analysed using 
the B io-R A D  Pro tein  Assay K it (Bio-Rad Laboratories, H erts., U K) w ith BSA as a 
standard.
All data are expresses as RLU (relative light units) standardised to p ro te in  co n ten t 
(R L U /m g) and corrected  fo r transfection  efficiency, e.g. the percentage o f  eG F P  
positive cells were used to norm alize the luciferase R L U /m g  pro tein  to  the n u m b er o f  
cells transfected.
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2.2.25 Passage and Cultivation of Phoenix™ cells
T he Phoenix™  packaging lines w ere m aintained in GM . Care was taken to ensure that 
cells did n o t reach confluencv as this will reduce transfecdon  efficiency in the sh o rt 
term . To keep these cells in optim al healthy condition , a 1:5 “ split” o f  a 70-80%  
confluen t 100mm plate in to  new  plates was perfo rm ed  every 2-3 days. T h is  was carried  
ou t by aspirating old g row th  m edium , then rinsing cells gently w ith  lx  PBS (w ithout 
C a++ or M g++) and application o f  trypsin  (0.05%  try p sin /0 .5 3 m M  E D T A ) until the  cells 
detached. T rypsinisation was inactivated w ith G M  prio r to re-seeding cells in to  fresh 
medium.
2.2.26 Phoenix™ drug selection
E very few m o n th  the Phoenix™  cells w ere selected for one w eek in H y r g r o m y c i n  B 
(Sigm a-G enosys, Poole, U K ) at 3 0 0 p g /m l and D iph theria  Toxin from  corynebacterium 
diphtheria (Sigma) at l -2 p g /m l final concen tra tion  on cells. A fter one week o f  selection 
Phoenix™  cells p roduce high titre virus, w hich can be repeated every th ree m o n th  after 
a titre d ro p  occurs. Cells can be analysed and sorted  by FACS fo r expression o f  C D 8 (a 
proxy m easure o f  gal-pol in this cell line) and for surface expression o f  envelope p ro te in  
w ith 83A25 antibody (H ybridom a) as descrip t in (Evans et al., 1990).
2.2.27 Cell Freezing
Exponentiallv grow ing cells can be stored frozen for m any years using cryopro tective 
agent such as D M SO  and glycerol. S ubconfluent cells were w ashed w ith PBS, then 
trypsinised for a few m inutes and inactivated bv adding fetal calf serum  (FCS). T he  
cells are w ashed by centrifugation  at 500xg for 5 min and resuspended  in appropriate  
volum e o f  freezing m edia (10% D M SO , 90%  FCS) at 2-4 x 106cells/m l. A lquotes o f  
resuspended cells were then  transferred  im m ediately in to  a sterile 2ml crvogenic vial. 
These freezing vials were then  placed in a special freezing container (N algeneR Mr. 
Frost}7) containing isopropyl alcohol, to  provide the critical and repeatable l ° C /m in
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cooling rate required for successful cryopreservation o f  cells at -80°C overn ight before 
being transferred  to liquid n itrogen  the following day.
It was recom m ended to freeze m ultiple vials o f  each p roducer cell line after first 
receiving and expanding them . T his ensured a ready supply o f  backup vials to  allow 
un ifo rm  virus production  over several years. I f  the cells are subjected  to  selection 
m edia, this should n o t be applied until after the first passage.
2.2.28 Thawing 293 cells and Derivatives
A fter rem oval o f  the freezing vial from  liquid n itrogen  cells were thaw ed rapidly at 
37°C. 1ml o f  G M  was added  im m ediately  to  the freezing vial. T his so lu tion  was gendy 
transferred  in to  a 15ml sterile conical screw  cap tube and suspended  in fu rth e r 5ml o f  
G M  by gently m ixing the  tu b e  to  allow osm otic  equilibration. A fter adding  10ml o f  
G M , the  tube  was closed, inverted  several tim es and centrifuged at 500xg fo r 5min. 
Superna tan t was rem oved, and  cell pellet resuspended  in  G M  before transferred  to  a 
100m m  (or 150mm) tissue culture dish and g row n in a 37°C degree in cu b ato r 
contain ing  5%  C 0 2
2.2.29 Transfection of tissue culture by Calcium Phosphate Precipitation
T he calcium phosphate  transfection  m eth o d  for in troduction  o f  D N A  in to  m am m alian 
cells is based on the fo rm ation  o f  a calcium  p h o sp h a te -D N A  precipitate. T h e  calcium  
phosphate (C a P 0 4) is th ough t to  facilitate the binding o f  the D N A  to the cell surface. 
It is believed that the D N A  then  enters the cell by endocytosis. T he  m eth o d  was first 
developed by (G raham  and van der Eb, 1973) and was later m odified by (W igler et al., 
1977). T h e  p rocedure is routinely used to transfect a wide variety o f  cell types for either 
transient expression o r for the p roduc tion  o f  stable transform ants. T he  D N A  is m ixed 
directly w ith a concentrated  solution  o f  C aC f. This is then  added dropw ise to a 
phosphate buffer to form  a fine precipitate. A eration o f  the ph o sp h ate  b u ffer while 
adding the D N A -C aC f solution helps to ensure that the precipitate which fo rm s is as
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fine as possible. This is im p o rtan t because clum ped D N A  will n o t adhere to  o r en ter 
the cell as efficiendy.
Essentially, calcium p h o sp h ate  transfection  solutions were used as supplied by 
Invitrogen  (Paisley, UK) and em ployed as advised by the m anufacturer. F or exam ple, for 
transfection o f  retroviral packaging lines (2.1.5.3) by C a P 0 4 precip ita tion  the following 
procedure was carried out:
Unless otherw ise no ted , all cond itions are described  for 150m m  plates. 18-24h prio r to 
transfection, Phoenix™  cells w ere seeded at 5 x l0 6 cells per 150m m  plate w ere seeded in 
20ml o f  G M , wThich should  be approxim ately  70-80%  confluen t at the m o m en t o f  
transfection. Just p rio r to  tran sfec tio n  the m edium  was replaced w ith 20m l o f  fresh 
G M  contain ing  25pM  ch lo roqu ine , w hich has been  show n to enhance transfection  
efficiency by inhib iting  D N A  degradation  by lysosom es (L uthm an and M agnusson, 
1983).
T h e  transfection  cocktail was p repared  in a round  b o tto m ed  tube (BD Falcon™ ) by 
adding 20 to 40pg D N A  to sterile H 20  such th a t the final volum e is 9 0 0 p l T h e n  lOOpl 
2.5M  CaCl2 was added and m ixed, befo re drop-w ise addition  o f  1ml 2x H BS solution  
(H E P E S  buffered  saline, p H  7.05) by bubb ling  and m ixed thoroughly  for ab o u t 0.5m in 
w ith a pipette-aid to  assist the fo rm atio n  o f  a very fine precipitate. T his so lu tion  was 
then added im m ediately (within l-2m in) in single d rops to the cells and agitated gently  
to  ensure uniform  mixing. Cells were re tu rned  fo r 6-12h to the in cu b a to r at 37°C, 
before m edia was replaced w ith 20m l o f  fresh G M  for cell culture expansion  (or 
purom vcin selection) before harvesting  the retroviral supernatan t.
2.2.30 Production of high titre retroviruses by transient transfection
P roducer cells transfected  w ith retroviral constructs based on the P IN C O  vecto r 
backbone (carrying a purom vcin selectable m arker) were selected bv culture in m edium  
supplem ented w ith lp g /m l purom vcin for at least 3-4 days and re-seeded as required.
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In  general transien t viral supernatan t was collected 24-48h post-transfection  following 
incubation o f  transfected packaging cells covered w ith  a m inim al am oun t (e.g. 
~ 1 0 m l/ 150mm dish) o f  fresh G M  m edia at 32 °C for 8-24h before harvesting.
S upernatant was filtered th rough  a 0 .45pm  filter and used im m ediately for transduction  
o r stored at -70 °C until required.
2.2.31 Estimation of retroviral titre by FACS analysis
Retroviral titres from  su p ern a tan t o f  transien t and episom al stable transfections w ith 
P IN C O  vecto r and its m odified  derivates carrying the E G F P  m arker gene were 
harvested  from  the retroviral packaging cell lines (Phoenix™  am pho trop ic  and 
ecotropic) w ere determ ined  o n  N 1H  3T3 cells.
N IH  3T3 cells w ere seeded at a density  o f  exact 5 x l 0 4 cells per well in  a 24 well plate. 
T h en  1ml o f  an infection  cocktail, contain ing  retroviral supernatan ts ranging from  lp l  
to lOOpl, and G M  supplem ented  w ith 8 p g /m l polvbrene was added to  individual wells. 
In fection  was carried o u t overn ight at 37°C. T h e  following day, the in fection  cocktail 
was rem oved and 1ml o f  fresh m edium  was added. Cultivation o f  transfected  cells were 
carried o u t at standard  culture cond itions fo r a fu rth er 48h. T h en  the cells o f  each 
individual well were trypsinised, w ashed twice in PBS, and fixed w ith L eucoperm ™ . To 
determ ine the expression o f  eG F P  in the N IH  3T3 cells the cells w ere then  assayed and 
analysed by flow cytom etry (FACS). Scatter p roperties  o f  uninfected  N IH  3T3 cells 
were determ ined  and retrovirally transduced  cells w ere com pared  for n u m b er o f  
fluorescing cells. Retroviral titres were calculated by p lo tting  the percentage o f  
fluorescing cells against the volum e o f  viral supernatan t used. Retroviral titres were 
then determ ined  by calculation o f  the g rad ien t obtained.
2.2.32 Estimation of retroviral titre by Northern dot blotting
To estim ate the am ount o f  viral R N A  species from  viral vector construc ts  carrving the 
luciferase gene in cell-culture supernatan ts, the Q IA am p Viral R N A  M ini K it (Q IA gen) 
was em ployed for the purification  o f  viral nucleic acids from  supernatan ts bv following
66
Chapter 2: Materials and Methods
m anufactu rer’s instructions w ith Q IA gen  provided  buffers and so lu tions (2.2.32.1). 
A fter transfer o f  viral R N A  o n to  nitrocellulose m em brane and  hybrid isation  w ith 
luciferase radio labelled p ro b e  (2.2.32.2), and the quantitative analysis o f  the 
autoradiographic dot-b lo ts im age was carried o u t by densitom etry  using a B ioim age 
system  (Millipore).
2.2.32.1 Northern dot blotting: RNA Purification
T he Q IA am p Viral R N A  M ini K it com bines the selective b inding p roperties  o f  a 
silicagel-based m em brane w ith  the  speed o f  m icrocentrifugation  for sim ultaneous 
processing o f  m ultiple sam ples at the sam e time. Briefly, at first 140pl per sam ple o f  
virus con tain ing  cell-culture m ed ium  superna tan t - harvested  from  retroviral p roducer 
cells as described  above - was subjected  to  lysis and denatu ration  conditions by m ixture 
w ith  560pl o f  AVL b uffer (contain ing chaotropic salts and detergen t w ith added  carrier 
R N A  at 5.6pg p er 140pl sam ple). In  this initial step, R N A ses are inactivated and in tact 
viral R N A  isolated, while the addition  o f  carrier R N A  n o t only enhances b ind ing  o f  
viral R N A  to the silica m em brane b u t also reduces the chance o f  viral R N A  
degradation. F or this viral partic le lysis to  com plete, the solu tion was m ixed by pulse- 
vortexing for 15s and left at ro o m  tem peratu re  to incubate fo r lOmin. T h en  the 
buffering  condition  was adjusted fo r optim al b inding o f  the viral R N A  to the Q IA am p 
m em brane by adding 560pl o f  ethanol (96-100%) to  the sam ple, w hich was m ixed again 
by pulse-vortexing for 15s. A fter a b rie f centrifuge spin, to rem ove any d ro p s from  the 
inside o f  the lid, 630pl o f  the sam ple was loaded o n to  the Q IA am p M ini spin co lum n 
and subjected to centrifugation at 60 0 0 x g  for 1 min. This step was repeated  w ith the 
rem aining 630pl o f  sample. T he  adsorb tion  o f  the R N A  to the Q IA m p  silica 
m em brane occured during pass th rough  o f  the sam ple solution. T h e  pass th rough  was 
discarded each time. T h en  any contam inates were w ashed ou t using 500pl o f  d ifferen t 
washing buffers (AVT and AW2) in two steps. To elim inate any chances o f  possible 
residual buffer carry over, Q IA m p  Mini colum n was subjected to  additional lOOOOxg 
for 3min. Finaly, the Q IA am p Mini colum n was placed in to  a 1.5ml m icrocentrifuge 
tube (Eppendorf) to  collect the silica m em brane b ound  R N A , now  free o f  any p ro te in ,
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nucleases, contam inants and o th er inhibitors. Initial}7, 60pl o f  R N ase free buffer (AVE) 
was added on to  the silica m em brane  and  left fo r 1 m in incubation time, before 
centrifugation at 6000Xg for 1 m in  to  collect the retroviral RN A . F or d o t b lo ts this was 
repeated w ith the addition o f  an o th er 80pl o f  R N ase free buffer (AVE) to a total 
volum e o f  140pl ready for d irect use o r storage at -70 °C until required.
2.2.32.2 Northern dot blotting: Hybridisation with radio-labelled probe
For do t blots, a lOOpl aliquot p e r sam ple o f  the retroviral R N A  purified as described 
above was spo tted  u n d er vacuum  o n to  the surface o f  a nylon m em brane H y bond™ -N  
(A m ersham , B uckingham , U K ) using a d o t b lo t m anifold  (G IB C O -B R L , G aithersburg , 
M D, USA). T h e  nylon m em b ran e  was cross-linked w ith ultraviolet light using a 
S tratalinker (Stratagene C orp., La Jolla, CA, USA) and hybridised w ith a a - 32P-labeled 
luciferase cD N A  p ro b e  overnight.
T h e  radio-labelled p ro b e  was generated  w ith the help o f  the Prime-It® II R andom  
Prim er Labelling K it (Stratagene) follow ing the m anufactu rer’s p ro toco l, e.g. 20-100ng 
o f  luciferase cD N A  fragm ent in a to tal volum e o f  24pl were m ixed w ith  10pl o f  
o ligonucleotide p rim er and denatu rated  at 95°C for 5min. A fter addition o f  lOpl o f  5 x  
dA TP buffer and 5jul o f  [ a -32P]-dA TP (3000 C i/m m ole) and Ip l o f  E xo-K lenow  
polym erase (5U /pl) the labelling reaction  was p erfo rm ed  for 30m in at 37°C. U n ­
incorporated  nucleotides w ere rem oved by purification o f  the labelled p ro b e  using 
M icroSpin™  S-200 H R  colum ns (A m ersham , B uckingham , UK). A fter resuspension  o f  
Sephacryl resign by pulse vortex ing  and rem oval o f  the b o tto m  closure, the 
M icroSpin™  colum n was centrifuged dow n  at 735Xg for lm in  and then  placed in to  a 
new  1.5ml E p p en d o rf  m icrocentrifuge tube. T h en  the labelled p robe was added o n to  
the resin and eluted at 7 3 5 x g  for 2min.
A fter pre-hybridisation o f  the d o t p lo t m em brane placed in a hybridisation glass bo ttle  
(Hybaid, T h e rm o  Scientific) w ith hybridisation solution for lh  at 68°C under ro ta tion  in 
a hybridisation oven (Hybaid, T h e rm o  Scientific), the radio labelled luciferase p ro b e  was 
denaturated at 95°C for 5m in and added to  the pre-hybridisation m ixture.
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A fter hybridisation at 68°C overnight, the labelled m em b ran e  was w ashed once w ith 2x  
SSC 0.1%  sodium  dodecyl sulphate (SDS) at ro o m  tem pera tu re  fo r lOm in and twice in 
0.1 x  SSC, 0.1% SDS at 50°C for 20m in each. O n ce  the d o t b lo t was air dried, it was 
transferred  to  an X-ray film cassette, covered  w ith  cling film (SA R A N ™  wrap) and 
exposed to autoradiography using X -ray film (Agfa, EC ) w ith  intensifying screens at 
-70 °C for up to 3 days.
2.2.33 Retroviral transduction of cell lines
Various cell lines w ere tran sd u ced  accord ing  to  s tandard  protocols. V irus contain ing 
media was added to  cell lines in  the p resence o f  4 p g /m l polybrene. To enhance 
co-localisation o f  virus and  cells, several rounds o f  in fection  (spinoculation) w ere 
carried out. T h is  was do n e  by repeated  addition o f  virus at 6-8h intervals followed by 
cen trifugation  at 2500Xg fo r 90m in. A fte r each spinoculation , the transduced  cells w ere 
re tu rned  to  the incubato r fo r con tinous culture at 37°C.
2.2.34 Bone marrow isolation, transduction and transplantation
O n  day 1, 8-12 weeks old d o n o r m ice were injected intraperitoneally  (i.p.) w ith 5- 
fluorouracil (5-FU, 3 m g /k g  in n o rm al serum , Roche) to  enrich for and activate the BM  
stem  cell proliferation. O n  day 3 (after 48h) d o n o r bone m arrow  stem  cells (BM) w ere 
harvested from  fem ur and tibia by flushing w ith culture m edium  using a 3m l syringe 
(BD Biosciences). T he  iso lated  cells were then  cultured  at a density7 o f  1 x lO 6ce lls /m l in 
a 6-well-plate in RPM I (Invitrogen Life Technologies) contain ing  10% heat-inactivated  
fetal bovine serum  (FBS, Inv itrogen  Life Technologies), lO O U /m l 
strep tom ycin /penicillin  (Invitrogen Life Technologies), and 2 m m ol/1  L-glutam ine 
(Invitrogen Life Technologies) for 48h in the presence o f  lO O ng/m l recom binan t 
hum an interleukin-6 (1L6, PeproT ech), lOOng/m l recom binan t m urine stem  cell factor 
(mSCF, PeproTech) and 5 0 n g /m l m urine fms-like tyrosine kinase 3 ligand (Flt-3L, 
PeproTech).
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O n  day 5, equal am ounts o f  bone m arrow  cells in 3m l o f  BM  culture m edium  were 
seeded o n to  R etroN ectin™  (TaKaRa Bio Inc, Shiga, Japan) coated 6-well plate culture 
dishes w hich were preloaded w ith 1ml o f  retroviral su p ern atan t w ith 4 p g /m l polybrene 
(Sigma-Aldrich). To enhance co-localisation o f  virus and  cells, bone m arrow  d o n o r 
cells were then transduced by additional ro u n d s o f  sp inocu lation  at 2500Xg for 90m in 
w ith freshly harvested retroviral su p ern a tan t every 8h fo r over a period  o f  48h. A fter 
each spinoculation, the cells w ere re tu rn ed  to the  in cu b ato r for continu ing  culture at 
37°C.
O n  day 7, abou t 3 -4x106 cells w ere used for each transp lan ta tion  by intravenously 
injection in to  the tail vein o f  6-8 weeks old recip ien t mice, w hich were p re-cond itioned  
w ith a lethal dose o f  rad ia tion  o f  1000 R A D S (in a split dose o f  600 and 400 RAD S 
w ithin 24h). A fte r 6 weeks the  recipient m ice w ere sacrificed and analysed.
2.2.35 FACS-Analysis
Routinely, 10000-50000 cells from  each sam ple were analysed by flow cytom etry  in a 
fluorescent activated cell so rte r (FACS Calibur, B D  Biosciences). Initially by gating 
based on  forw ard and right-angle light scatter characteristics to  determ ine cell size and 
granularity; T h en  cells w ere simply coun ted  fo r transduction  efficiency calculations and 
m ean fluorescent intensitv  (M FI) o f  the eG F P  positive cell fraction o r gated  for 
fluorescence (eG FP) and re-analysed based o n  the expression o f  lineage-specific cell 
surface m arkers (m yeloid/lym phoid).
2.2.35.1 FACS-Analysis of bone marrow and spleen cells
To determ ine overall engraftm ent, m yeloid nature and lineage specificity" o f  eG F P  
positive cells from  bone m arrow  (and spleen) cells suspension  w ere analysed by flow 
cytometry.
At first, red b lood cells were lysed bv adding 2.5m L lysis buffer (155mM  N H 4C1, lOmM  
K H C 0 3, and 0.1 mM  ethylenediam ine tetraacetic acid); then  the rem aining leukocytes 
were w ashed in phosphate-buffered  saline contain ing  2%  fetal bovine serum , befo re
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cells were analysed for eG F P  fluorescent directly a n d /o r  stained w ith the following 
antibodies available from  B D  Pharm ingen: C D l lb ,  G r-1 , F 4 /8 0 , kappaB, C D 3 e .
T h e C D l l b  antibody identifies m yeloid cells, w hich express the  C D l l b  recep to r mainly 
p resen t on  granulocytes, m acrophages, dendritic  cells and  N K  cells. T h e  Gr-1 antibody 
labels myeloid cells w ith the Gr-1 recep to r expressed  on  neutrophils, granulocytes, 
m onocytes. W hile the F 4 /8 0  an tibody  is a m urine m acrophage-specific m em brane 
m arker to identify m acrophage cells derived from  BM  precursors and b lood  m onocytes, 
which is no t expressed by lym phocytes. W hereas the C D 3 s antibody was em ployed to 
label early T  cells and kappaB  to  visualise B- lym phocytes cells.
2.2.35.2 FACS-Analysis: Staining of cells for flow cytometry
lx lO 3 to  lx lO 6 cells w ere p re -incubated  w ith 10% rat serum  (in staining buffer) for 10- 
30m in, w ashed twice w ith  staining b u ffer and incubated  for 30-45m in o n  ice w ith first 
layer m onoclonal antibodies. W hen  appropriate, cells w ere w ashed twice betw een  30- 
45m in incubations w ith second and th ird  layer antibody-conjugates. Cells w ere w ashed 
twice in staining buffer, once w ith PBS-Azide and resuspended  in  200pl 1% 
paraform aldehyde in PBS-Azide. Cells w ere stored at 4°C  until analysis w ith in  7 days by 
flow cytom etry using C ellQ uest softw are (B ecton D ickinson). Cells w ere stained w ith 
iso-type-m atched antibodies labelled w ith P E  and the gates were set to exclude 99%  o f  
these cells.
T ransgene expression in cell populations was analysed by gating  based o n  forw ard and 
right-angle light scatter characteristics to  determ ine cell size and granularity. T h e  cells 
were then  gated for fluorescence (eG FP) and re-analysed based on  expression  o f  
lineage-specific cell surface m arkers (m yeloid/lym phoid).
2.2.36 Colony Assay
Bone m arrow  cells following retroviral transduction  o r harvested from  the long  bones 
o f  the recipient mice were plated (2 x l(T  o r 5 x l 0 3 cells per dish) in 0.66%  agar 
containing a-M E M , 20%  fetal calf serum , 2m M -glutam ine, 0.2%  N a-b icarbonate  and
71
Chapter 2: Materials and Methods
penicillin /streptom ycin . T h e  agar was supp lem ented  w ith  the cytokines m IL - la  
(lO ng/m l), m lL -3 (40ng/m l), rhM -C SF (lO ng/m l) and m SC F (200ng/m l). T h e  cell 
suspension in agar was overlaid on  a 1% a g a r/a -M E M  base. P lates w ere incubated  in  a 
hum idified incubator at 5% C O 2 fo r 14 days fo r colonies to  develop before  analysis for 
eG F P  fluorescence and phagocyte superoxide activity7 by N B T  assay.
2.2.37 NBT Assay: Phagocyte superoxide assay of bone marrow colonies
For evaluation o f  the level o f  reco n stitu tio n  and function  o f  the transduced  gene in the 
correct cell con tex t we p e rfo rm ed  the quantitative n itrobluetetrazo lium  test (NBT) on  
colonies to  assay the activity o f  the  N A D P H  oxidase com plex (R ichardson et al., 1998; 
W olf et al., 1995). In  this test the  yellow substrate is converted  (reduced) in to  a purp le  
blue fo rm azan  precip ita te in  cells w hich  express functional N A D P H  oxidase u p o n  PM A  
induction .
To assay colonies the cultures w ere overlaid w ith a 0.2%  N B T  so lu tion  in PBS 
containing p h o rb o l m yristate acetate (PM A, lm g /m l) . T h e  cultures w ere incubated  at 
37°C, 5% C O 2 fo r 60m in to  allow the precipitate to  fo rm  before the num bers o f  
positive /  negative colonies w ere scored un d er an inverted  m icroscope.
2.2.38 DHR Assay: Phagocyte superoxide assay of peripheral blood
To quantify the leukocyte oxidative bu rs t activity o f  m onocytes and granulocytes in 
heparinised w hole b lood  the ‘P h ag o b u rst Assay K it’ (O rpegen  P h arm a)(H irt et al., 1994) 
was em ployed, w hich is highly sensitive (Vowells et al., 1995).
First, the experim ental mice were bled by cardiac punctu re  before term ination . T h en , 
using flow cytom etry  this d ihydrorhodam ine (D H R) assay determ ines b o th  the 
percentage o f  phagocytic cells and their oxidase activity following PM A  induction  by 
detecting reactive oxidants th rough  the conversion o f  dihydro 123 (D H R 123) to 
rhodam inel23  (R123).
N eutrophils were identified based on  forw ard and side scatter characteristics. A  gate 
was established to include neutrophils and exclude lym phocytes while at least 10000
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events were collected in this gate for all studies. Analysis o f  neu troph il D H R  
fluorescence was perfo rm ed  by co n stru c tin g  a side scatter FL2 (D H R) d o t plot. W hilst 
the D H R  fluorescence has a w ide range o f  em ission spectra (excitation m ax 505nm , 
em ission max 534nm) that can be m easured  by either FL1 o r FL2 pho tom ultip lier tubes, 
we excluded the possible in terference o f  the eG F P  em ission (excitation m ax 489nm , 
em ission max 508nm) collected in the FL1 d e tec to r from  the cells o f  in terest 
(transduced w ith the bicistronic p47/>/,av cD N A  IR E S  eG F P  expression vectors).
D H R -positive cells w ere iden tified  by gating  based on  negative (untreated p47/)^ 'v/ ) and 
positive wild-type con tro l sam ples. In vivo co rrec tio n  o f  the neu troph il N A D P H  oxidase 
system was evaluated in  com parison  to  a standard  curve from  m ixed p47/>/'ftV'/ and wild- 
type bloods, e.g. ratios o f  0:100% , 20:80% , 50:50%  and 100:0%, p47/>w ‘ to  w ild-type 
b lood  w ere m ixed and used to  generate  a standard  curve o f  oxidase activity.
2.2.39 Western Blotting: Cell Lysis
Spleens and bone m arrow  cells w ere rem oved from  the reconstitu ted  m ice and an 
aliquot o f  approxim ately 5 x l0 6 cells w ere w ashed w ith PBS and lysed as follows: 200pl 
N P 40  lysis buffer (Sigma) w ere added to  the cell pellet, vortexed and left o n  ice fo r 
lOmin. Lysates were cleared by centrifugation  at 14000xg  and 4°C fo r 5m in. T h e  
supernatan t (200pl) was transferred  to a fresh tube and m ixed w ith 200pl 2x SDS 
sample buffer, boiled for 5m in at 100°C before  re tu rn  o n  ice o r s tored  in the freezer at 
-70°C.
2.2.39.1 Western Blotting: SDS-PAGE preparation
Flawless glass plates were w iped clean w ith 70%  ethanol. Spacers were placed at each 
side o f  one o f  the glass plates as well as a b o tto m  spacer and locked together. T h e  
second glass plate was placed on  top  and the spacer sponges w ere pushed  to  the edge o f  
the smaller plate and clam ped together w ith b inder clamps. T h e  gel was p repared  by 
m ixing acrylamide, buffer, water, T E M E D , and APS together in a universal tube using 
the appropriate concentrations, e.g. for a 10% gel, 6ml o f  30%  acrylam ide was diluted
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w ith 5ml o f  gel buffer, 8.8ml H 20, befo re  addition  o f  20pl T E M E D  and 200pl 10% 
APS. O nce the APS was added, the S D S-PA G E  gel was p oured  im m ediately in to  the 
top  corner o f  the assem bled and uprigh t o rien ta ted  glass plates until the gel covered 3A 
o f  the small glass plate and was overlaid w ith water. O n ce  the gel had polym erised, the 
w ater was rem oved and the 4%  stacking gel (m ade o f  1.3ml o f  30%  acrylam ide diluted 
in 2.5ml gel buffer and 6.1ml w ater befo re  adding  10pl T E M E D  and lOOpl 10%  APS) 
was poured on to  the m ain gel and  a com b  was in serted  and left to polym erise. O nce 
polym erised, the b inder clam ps w ere rem oved  and the gel assem bly was placed in to  the 
gel tank (H oefer, H arvard  B ioscience). A pproxim ately  500m l runn ing  buffer was 
poured in to  the top  and b o tto m  cham ber, respectively.
T he sam ples and m arker (full range ra inbow  m arker R PN 800, 150pg /m l pro tein , 
A m ersham  Life Science) w ere boiled  at 100°C for 5m in, quick centrifuged and loaded 
o n to  the gel. A liquotes o f  lOp.1 SDS sam ple buffer lysate, equivalent to  3 x l0 3 cells 
w ere applied to  a 10% polyacrylam ide gel w ith a 4.5%  stacking gel. T h e  sam ples and 
m arker w ere separated  by electrophoresis across 100-200V for lh  at 20°C until the 
run n in g  dye fron t reached the b o tto m  o f  the gel.
T h en  the p ro te in  was transferred  to  nitrocellulose m em brane by w estern  b lo tting  for 
im m unodetection .
2.2.39.2 Western Blotting: Protein transfer to nitrocellulose filters
W estern b lo tting  was p erfo rm ed  essentially as described by (G ilm our et al., 2000) using 
an anti-p47phox antibody (Prigm ore et al., 1995) (a kind gift from  Prof. A n th o n y  W  Segal, 
D ep artm en t o f  M edicine at the Ravne Institu te , U niversity College L ondon). P ro teins 
were electro-blotted  on to  a su p p o rted  nitrocellulose m em brane (Schleicher & Schuell, 
London, UK) using the Bio-Rad sem i-dry b lo tte r accord ing  to the m an u fac tu rer’s 
instructions.
First, about 6 pieces o f  W hatm ann  3M M  paper and one piece o f  n itrocellulose 
m em brane the same size as the area o f  the gel to  be transferred  was cut o u t and soaked 
in transfer buffer for 5min. T h en  the transfer stack was assem bled in the following 
order: 2 pieces W hatm ann, gel, n itrocellulose, 2 pieces o f  W hatm ann. A  10ml plastic
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pipette was used to rem ove any air bubbles betw een  each layer by rolling, before the 
p ro tein  transfer to the m em brane-supported  n itro-cellu lose filter (BD H ) was carried ou t 
in the B IO R A D  sem i-dry b lo tte r at 12V fo r 20-30m in.
2.2.39.3 Western Blotting: Immunodetection
T h e  m em brane was blocked in 5%  m ilk pow der-PB S w ith  0.05%  Tween 20 (blocking 
buffer) for lh  at room  tem peratu re  o r overn ight at 4°C before im m unodetection  w ith 
antibodies (3ml blocking b u ffe r w ith 6pl o f  p47/>/'ftx p ro te in  prim ary antibody) fo r 2-3h at 
RT. M em brane was w ashed  5 tim es w ith  PBS-T before  incubation  for 30-45m in in 
blocking buffer w ith  1:1000 an ti-rabb it H R P  secondary andbody. T h en  the m em brane 
was again w ashed  five dm es w ith PB S-T  before incubadon  for lm in  w ith enhanced  
chem illum inescence reagen t (ECL, A m ersham  Life Science) and exposed to  
au to radiography film (K O D A K  Biom ax) for 0.5-5m in.
2.2.39.4 Western Blotting: Stripping of nitrocellulose membranes
F or verification o f  the in tegrity  and equal loading o f  the p ro te in  lysates, an anti-f3-actin 
andbody (Sigma) was used as a control.
First, blots were stripped in p re-hea ted  S tripping B uffer (f3 -m ercap toethano l/SD S/T ris) 
at 50°C, the w estern b lo t added and incubated  at 50°C for 30m in and then  w ashed three 
dm es in PBS-T before being subjected to  im m unodetection  as described above using 
3 j l l 1 o f  and-(B-acdn andbody (Sigma).
D etection  was p erfo rm ed  by enhance chem ilum inescence (ECL, A m ersham  Pharm acia 
Biotech, GB) to a horseradish  peroxidase conjugated an ti-rabbit (Sigma, GB) and an ti­
m ouse antibody (Dako, C am bridge, U K), respectively.
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Prim ary antibody D ilu tion H orserad ish  peroxidase (HRP)- 
con jugated  second layer antibody
dilution
p47 1:2000 R abbit an ti-goat IgG , 0 .4 m g /m l 
(Santa C ruz B iotechnology)
1:500
M ouse anti-(3-actin 
m onoclonal IgG, 2 .2 m g /l 
(Sigma)
1:1000 Rat an tim ouse IgG , heavy chain, 
1 .O m g/m l (Serotec)
1:1000
2.2.40 Statistical Analysis
All luciferase data are rep resen ted  as m ean ± standard  deviation (±SD ) from  four 
in d ep en d en t tran sd u cd o n s o r transfecdons, while stadsdcal analysis was p erfo rm ed  by 
the M ann-W hitney  U test; p <0.05. For the d istribu tion  o f  m yeloid m arkers in  E G F P  
positive cells in con trast to  to tal bo n e  m arrow  cells the W ilcoxon signed-rank test was 
em ployed. B o th  m ethods are non-param etric  tests (distribution-free) w hich are used to 
com pare tw o indep en d en t g roups o f  sam pled data. T h e  P-value associated w ith this 
statistic was found  from  an appropria te  table.
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3 C e l l u l a r  p r o m o t e r s  f o r  g e n e  
e x p r e s s i o n  i n  m y e l o i d  c e l l s
3.1 Background
G enetic m odification o f  p lu rip o ten t haem atopo ie tic  stem  cells (HSCs) offers the 
possibility o f  p e rm an en t trea tm en t o f  several inherited  and acquired d isorders (D unbar,
1996). In  particular, gene tran sfer in to  h u m an  hem atopoietic  stem  cells w ith  expression 
targeted to  the m aturing  m yelom onocytic  p rogeny  has applications for gene therapy o f  
genetic diseases affecting  granulocytes and  m acrophages. D u e  to the com bination  o f  
accessibility7 o f  stem  cells and  heterogeneity  o f  tissue locations, the m yeloid cell is 
potentially  im p o rtan t as a carrier o f  therapeu tic  agents, w hich is o f  particular relevance 
to inherited  im m unodeficiencies, like o u r m odel system  — chronic g ranu lom atous 
d isorder (C G D ).
In  the last few years m eth o d s based on  viral vectors have been developed fo r transfer o f  
therapeutic o r m arker genes in to  these cells conventionally  u nder con tro l o f  strong  
constitutively active regulator sequences, e.g. the viral LTR o r exogenous p ro m o ters  
such as the im m ediate early (IE) p ro m o te r o f  the cytom egalovirus (CMV). H ow ever, 
exclusive expression o f  the inserted  gene in specifically affected lineages, ra th er than  in 
all progeny o f  the H SCs, desirable fo r treating certain  genetic d isorders m ore 
appropriately at clinically relevant levels, has n o t been show n. T h o u g h , retroviral 
m ediated gene expression in hum an  m yelom onocytic cells from  haem atopo ie tic  cell 
p rom oters, like C D l lb  has been  investigated in H L 60 (Malik et al., 1995), these vectors 
essentially retained the com plete LTR sequences.
Prelim inary reports from  transient transfections o f  cell lines have show n th a t p ro m o ters  
from myeloid- and m onocytic-specific genes are relatively m ore active in 
m yelom onocytic cell lines than in o th er cell types (H ickstein et al., 1992; Pahl et al., 
1992; Shelley and A rnaou t, 1991). How ever, few studies have com pared  the relative 
strength o f  these p rom oters in retroviral vectors w ith that o f  conventionally  used viral 
prom oters for applications in gene therapy. H ence, p rom oters o f  m yeloid-specific
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genes that are upregulated w ith  m yelom onocytic d ifferen tiation  may also upregulate 
expression o f  an exogenous gene in  a retroviral vec to r (Malik et al., 1995). T herefore, 
ou r aim was to identify a m yeloid p ro m o ter, w hich has sustained and durable expression 
in the myeloid lineages and w ould  function  successfully in a retroviral construc t w ithout 
interference from  a viral LTR.
M yeloid-specific gene expression  has b een  an extensive field o f  research and the 
transcriptional m echanism s w hich regulate m yelopoiesis have been the subject o f  a 
num ber o f  reviews (Clarke and  G o rd o n , 1998; R osm arin et al., 2005; Skalnik, 2002).
O ur initial plan was to  investigate a n u m b er o f  characterised bona fide m yeloid p rom oters 
and assess their suitability fo r in co rp o ra tio n  in to  a retroviral vec to r by assessm ent o f  
their ability to  d irect m yeloid-specific transcrip tion  o f  a rep o rte r gene following 
transien t transfection  in to  various m yeloid and non-m yeloid cell lines.
3.2 Cloning strategy of promoter constructs based on pGL3-Basic
To test fo r tissue specificity we co n stru c ted  a series o f  vectors contain ing either the 
luciferase rep o rte r gene (derived fo rm  the p G L 3  series, P rom ega) a n d /o r  the enhanced 
green fluorescent p ro te in  (eG FP) m arker gene (derived fo rm  the p E G F P -N  1, C lontech) 
under the contro l o f  e ither m yeloid-specific p rom oters: human c-fgr (Kefalas et al., 1995), 
human c-fes (H eydem ann et al., 1996; H eydem ann et al., 1997), human CD 11b  (H ickstein 
et al., 1992; Pahl et al., 1992), humanp47phox (Li et al., 1997; T h rash er et al., 1993), murine 
neutrophil elastase (N uchprayoon et al., 1994) and murine PU.1 (Chen et al., 1995a) o r n o n ­
specific prom oters: S V 4 0 , C M V  and human Elongation Factor I d  (M izushim a and N agata, 
1990).
T he pG L 3 Luciferase R eporter V ector system (Prom ega) was selected to provide the 
basis for the initial quantitative analysis o f  the p rom oters  available to  us. T h e  pG L 3  
Vectors are im proved and redesigned versions o f  the earlier pG L 2  Luciferase V ector 
System that provide increased levels o f  expression, due to  a m odified coding region for 
firefly (.Photinus pyralis) luciferase, w hich had been optim ized for m on ito ring  
transcriptional activity in transfected  eukaryotic cells. As a result, the p G L 3  rep o rte r
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vectors show ed significandy h igher expression  levels th an  those ob tained w ith the 
fo rm er pG L 2 reporter vectors, w hile m ain tain ing  relatively low  background  luciferase 
expression, hence the pG L 3 vec to r system  was chosen  to  provide significantly higher 
sensitivity, while the assay o f  this genetic rep o rte r  is rapid and quantitative.
C loning strategies and co n stru c tio n  o f  p ro m o te r co n stru c ts  based on  pG L 3 luciferase 
expression plasm id are all illustrated in the A ppend ix , (paragraph 8.1 and 8.2) however, 
they are presented here briefly:
T he pG L3-Basic vec to r (see p lasm id m ap 8.2.1) lacks eukaryotic p ro m o ter and enhancer 
sequences, allowing flexibility in clon ing  putative regulatory sequences. E xpression  o f  
luciferase activity in cells transfected  w ith  this plasm id depend  on  insertion  and p roper 
orien tation  o f  a functional p ro m o te r upstream  o f  luc+. H ence if  em ployed alone it 
serves as negative con tro l and  is used to  calculate the background levels o f  luciferase 
activity.
T h e  follow ing paragraphs in tro d u ce  the cellular p ro m o ters  available to us and cloning 
strategies o f  pG L 3  rep o rte r constructs.
3.2.1 Myeloid specific gene promoters
3.2.1.1 Murine neutrophil elastase
T he neu troph il elastase (N E) gene has been show n to be specifically expressed in 
im m ature myeloid cells (Fouret et al., 1989). T h e  N E  is a m icrobicidal p ro te in , a serine 
protease p resen t in the prim ary granules o f  m onocytes, granulocytes and is s tored  in the 
azurophilic granules o f  m ature neu troph ils w ith functions in tissue tu rn o v er and host 
defence m echanism  (Takahashi et al., 1988a). T h e  D N A  sequence o f  the m urine 
neutrophil elastase (m N E ) has been found to be significantlv hom ologous to the hum an 
neutrophil elastase (hN E ) gene (Srikanth and Rado, 1994). W ithin an abou t lOObp o f  
the 5'-flanking region o f  the m N E  and h N E  gene p ro m o te r sequences several 
functional elem ents have been identified, including b inding sites for P U .l, C /E B P , c- 
Myb (Oelgeschlager et al., 1996), and P E B P 2 /C B F  in the m urine bu t n o t the hum an
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gene (N uchprayoon et al., 1994). T ranscrip tion  is in itiated  from  a single 30bp sequence 
dow nstream  from  a T A T A A A -hom ologous site (Takahashi et al., 1988b).
For our investigation, an approxim ately  2400bp D N A  fragm ent o f  the m urine 
neutrophil elastase p ro m o te r was ob ta ined  by restric tion  digest from  the plasm id vector 
nam ed “pT Z 19R clone2” (N uchprayoon  et al., 1994) (see plasm id m ap 8.1.1) w ith 
H in d lll/N co l and inserted  in to  the  sam e restric tion  sites on  the luciferase expression 
vector pG L3-Basic to create p G L 3 -2 4 0 0 m N E -lu c  (see plasm id m ap 8.2.3). Similar, 
pG L 3-700m N E -luc (see p lasm id m ap 8.2.4) was cloned  from  an abou t 700bp size 
fragm ent by restric tion  o f  p T Z 19R clone2  plasm id D N A  via BgH l/N col, w hich was 
inserted in to  B gA l/N co l sites o f  pG L3-B asic.
3.2.1.2 Murine PU.l
T h e  m yeloid-specific transcrip tion  factor PU .l (SP-1) has been  show n to  be a critical 
co m p o n en t in  m yeloid d ifferen tiation  as a m em ber o f  the E ts  family o f  transcrip tion  
factors. PU .l is expressed p redom inan tly  in m yeloid cells (granulocytes, m onocytes and 
m acrophages) as well as in  B -lym phoid  cells o f  the haem atopoietic system, b u t n o t in  T  
cells (Chen et al., 1995a; K lem sz et al., 1990; T enen et al., 1997). PU .l is also p resen t in 
eosinophils and found at low7 levels in prim itive C D 3 4 +  haem atopo ietic  cells (Voso et 
al., 1994).
PU .l has been described as a m yeloid m aster regulator, w hich autoregulates it’s ow n 
expression in a positive-feedback system  th a t drives m yeloid cell deve lopm en t to 
com pletion (Chen et al., 1995a). T ogether w ith the transcrip tion  factor 
C C A A T /enhancer-b ind ing  p ro te in  (C /E B P a ) PU .l is essential fo r m yeloid 
differentiation into the granulocytic lineage (B orregaard et al., 2001; S tu rrock  et al., 
2004). D uring  haem atopoiesis, PU .l transcrip tion  is upregulated  during  early 
com m itm ent o f  p lu ripo ten t p rogen ito rs to the m yeloid lineages and is also required  for 
term inal myeloid gene expression and d ifferentiation (Sim on et al., 1996).
Im portan t PU .l binding sites have been found in nearly all m yeloid-cell restric ted  gene 
prom oters and enhancer sequences studied to  date, including genes that encode the 
grow th factor receptors, like m acrophage colony-stim ulating factor (M -CSF),
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granulocyte-m acrophage colony stim ulating factor (G M -CSF), and granulocyte colony 
stim ulating factor (G-CSF) (H ohaus et al., 1995; R eddy et al., 1994; Sm ith et al., 1996a; 
Z hang  et al., 1994b) and lysosom al enzym es expressed by m yeloid cells (Tenen et al.,
1997).
T he  m urine and the hum an P U .l gene p ro m o ters  have b o th  been  show n to  drive tissue- 
specific reporter gene expression  in m yeloid cell lines b u t n o t in  T  cells and non- 
haem atopoietic cells. Its  functional p ro m o te r regions w ere dem onstra ted  to  lie at two 
sites within the first lOObp o f  the P U .l p ro m o te r by deletion analysis (C hen et al., 
1995a).
For our investigation, we created  pG L 3 -P U .l-lu c  (see plasm id m ap 8.2.7) by 
linearization o f  pG L 3-B asic w ith  a single BgAI digest and ligation o f  a 334bp PU .l 
p ro m o ter fragm ent from  an BamH.1 d igest o f  p m P U .l-3 3 4 /lu c  (C hen et al., 1995a), (see 
p lasm id m ap 8.1.4) in to  the resulting  backbone o f  pGL3-Basic.
3.2.1.3 Human CDllb
C D l lb  is the hum an leukocyte in tegrin  a-subun it, o f  the C D l lb /C D 1 8  heterodim eric  
surface antigen, w hich is located  on  the surface o f  hum an  granulocytes and m onocytes. 
T he expression o f  C D l l b  gene, also called the a-chain  m acrophage-1 an tigen  (MAC-1), 
has been show n to be restric ted  to cells o f  the m yelom onocytic lineage, e.g. 
granulocytes, m acrophages, m onocy tes and natural killer cells. T h e  highest levels o f  
C D l lb  have been found  in the m o st m ature m yeloid cells, w hilst C D l l b  m essenger 
R N A  levels depend upon  the stage o f  differentiation. T he  C D l l b  p ro te in  (a-chain) 
form s a noncovalent associated heterodim eric  structure w ith the C D 18((3)-subunit, 
w hich as C D llb /C D 1 8  heterodim eric surface antigen m ediates m ultifaceted  adherence 
reactivity o f  myeloid cells (Bauer-TR et al., 1994; H ickstein et al., 1989; H ickstein  et al.,
1992).
A relatively small (1.7kB) 5 ' flanking sequence o f  C D l lb  gene was found to  d irect high 
level o f  transient rep o rte r gene expression in m ature myeloid cells, upon  induction  o f  
differentiation with either 12-O -tetradecaanoylphorbol-l 3-acetate (TPA) o r retinoic acid
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(Pahl et al., 1992). D eletion analysis o f  the C D l l b  p ro m o te r sequence iden tified  tw o 
consensus binding sites required for directing high levels o f  tissue-specific re p o rte r  gene 
expression. These b inding sites lie w ithin only 412bp proxim al to  the transcrip tional 
start site: a GATA m otif, for SP1 and a purine-rich region, a b ind ing  site fo r 
transcrip tion factors o f  the ets family. A nd in transgenic mice experim ents, the  1.7kb 
C D l lb  p rom oter sequence was confirm ed to contain the regulatory elem ents suffic ien t 
for myeloid-specific expression in m acrophages in vivo (D ziennis et al., 1995), w hile in 
com parative studies, w hich com pared  the C D l lb  p ro m o ter against C D 18 and  C D 34, it 
was established that the C D l l b  p ro m o ter showed the m ost favourable results in te rm s 
o f  levels o f  expression, inducibility w ith differentiation and lineage specifity (M alik et 
al., 1995),
For our investigation, the C D l l b  p ro m o ter (Hickstein et al., 1992; Pahl et al., 1992) was 
obtained as a kind gift from  D r. D. H ickstein in form  o f  the p $ G H - C D llb  v ec to r (see 
plasm id m ap 8.1.7).
F irst, we created p G L 3-1672C D l lb -luc  (see plasm id m ap 8.2.8) taking the 1672bp 
B am H l(blunted)/H incA ll fragm ent w hich was inserted  in to  the H in cA ll/N co l(blunted) 
sites o f  pGL3-Basic. T h e  resulting 1672bp sized CD1 lb-luciferase vec to r was then  
truncated  by 464bp th rough  BgAl digest and religation to p G L 3 -1 2 7 2 C D llb -lu c  (see 
plasmid m ap 8.2.9), while p G L 3 -7 3 2 C D llb -lu c  (see plasm id m ap 8.2.10) resulted  from  
982bp deletion by Sstl restric tion and religation o f  the pG L 3-1672C D l lb -lu c  plasm id.
3.2.1.4 Human c-fgr
T he hum an c-fgr gene is a pro to -oncogene, w hich belongs to  the src family o f  n o n ­
receptor pro tein  tyrosine kinases (Link et al., 1992). It is one o f  the m ajor 
m yelom onocytic p rom oters, w hich is active during d ifferentiation o f  m yeloid cells, w ith  
the m axim um  expression being detected  in the term inal stage o f  d ifferentiation. 
D om inant sites o f  fgr m R N A  expression are m yelom onocytic cells and tissue 
m acrophages, e.g. fgr p ro te in  has been found to accum ulate in hum an HL-6Q cells w hen  
these were induced tow ards m onocytic o r granulocytic differentiation (Miyazaki et al., 
1993).
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Previous studies o f  the c-fgr p ro m o ter have show n that - w ith respect to the 
transcriptional start site - the region from  nucleotide -344 to -116 is required  fo r basal 
activity o f  the c-fgr p ro m o ter in U937 cells, and that the 5 '-reg ion  from  nucleo tide -1211 
to -752 is responsive to  PM A (Kefalas et al., 1995).
For our investigation, the 1762bp D N A  sequence o f  the hum an  c-fgr p ro m o te r was re ­
cloned by Ncol (blunted)/H in d lll  digest from  pG L -3145 ((Kefalas et al., 1995) a p G L 2- 
derivate, see plasm id m ap 8.1.2) and inserted  in to  pG L 3-B asic in the S m a l/H in d lll  site 
to create pG L3-1762cfgr-luc (see plasm id m ap 8.2.5). Similar a 1231bp S m a l/S m a l 
fragm ent o f  the c-fgr p ro m o te r was ligated in to  the Smal site o f  pG L 3-B asic to  clone 
pG L3-1231cfgr-luc (see plasm id m ap 8.2.6).
3.2.1.5 Human c-fes
T h e  p ro te in  p ro d u c t o f  the  c-fes (c-jps/fes) p ro to -o n co g en e  encodes a n o n -recep to r 
tyrosine-specific cytoplasm ic p ro te in  kinase o f  92kD a. It has been  im plicated in the 
no rm al developm ent o f  haem atopoie tic  tissues (im m ature and differentiated  m yeloid 
cells, e.g. m acrophages, neu troph ils and granulocytes), to be involved in haem atopoie tic 
g row th  factor signalling and also to be expressed in vascular endothelial cells in adult 
m am m als (H eydem ann et al., 1996; H eydem ann  et al., 1997; H eydem ann et al., 2000).
Previously, a 13kb hum an genom ic co n stru c t o f  the c-fes gene was show n to d irect 
lineage restricted and in tegration  site in d ep en d en t expression in transgenic m ice (G reer 
et al., 1990), though transien t-transfection  experim ents dem onstra ted  th a t plasm ids 
containing only 446 base pairs o f  c-fes p ro m o ter linked to a luciferase rep o rte r  gene 
directed exclusive expression in myeloid cells, w hilst the functional binding sites fo r S p l, 
P U .l, and a novel nuclear factor F E F  (c-fes expression factor) required for m yeloid cell- 
specific expression were show n to be located w ithin 151 base pairs o f  c-fes 5 '-flanking 
sequences (Heydem ann et al., 1996). N o  o ther D N A  elem ent w ithin the 13kb hum an  c- 
fes locus were found to  contain  any o ther positive rti-acting elem ents, w ith the exception 
o f  a weakly active region w ithin the 3 '-flanking sequences (H eydem ann et al., 1996).
T he c-fes p ro m o ter was n o t available for ou r initial investigation; hence cloning strategy 
and reporter vectors are described in the following chapter.
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3.2.1.6 Human p47phox
As described, p47/>/'ax is one o f  the essential co m p o n en ts  o f  the phagocyte N A D P H  
oxidase (phox). Studies o f  the p47/,/'ftV p ro m o ter have show n th a t less than  500bp m ake 
up the essential sequence o f  the ^A lphox p ro m o te r (Li et al., 1997; Li et al., 1999; M arden 
et al., 2003a; M arden et al., 2003b) and th a t an essential PU .l consensus binding 
sequence (G A G G A A ) is located o n  the n o n -co d in g  strand  from  position  -40 to -45 
relative to  the transcrip tional s ta rt site o f  the p 41phox gene (Li et al., 1999; M arden  et al., 
2003b). W hile a p ro m o te r co n stru c t ex tending  to  -46 was sufficient to drive tissue- 
specific expression o f  the luciferase re p o rte r  gene, rep o rte r expression was significantly 
increased w ith  the ex tension  o f  the p ro m o te r from  -46 to  -48 (Li et al., 1999). T h e  
binding  avidity o f  the transcrip tion  factor PU .l to  these sequences is closely correlated  
w ith  the  capacity to  dictate re p o rte r gene transcrip tion. Point m utations in troduced  into 
the P U .l b ind ing  consensus sequence at position  -46 (G) a n d /o r  position  -47 (T) 
reduced  b o th  rep o rte r expression and PU .l binding, w hereas a p o in t m utation  at 
position  -48 had no  effect (Li et al., 1999). T h e  im portance o f  the functional PU .l 
b inding site was also confirm ed  in  parallel studies on  the p ro m o te r sequence o f  the 
C D 18 in tegrin  gene. M utations in troduced  fo r nucleotides G  and T  at positions -76 and 
-77 (which are the co rresp o n d in g  positions -46 and -47 in the p47/,'!'ftV p rom oter) reduced 
PU .l binding and p ro m o ter activity (Li et al., 1999).
T he  p47/)AftV p ro m o ter was n o t available for ou r initial investigation, hence cloning 
strategy and rep o rte r vectors will be discussed and described in C hap ter 4.
3.2.2 Constitutive Promoters
3.2.2.1 LTR
M ost studies w ith retroviral vectors in the m am m alian cells use vectors that drive gene 
expression from  the M oloney m urine leukem ia virus long-term inal repeat (MLV-LTR). 
This p ro m o ter drives strong  gene expression in num erous d ifferent cell types, how ever 
it also has been  found to be silenced in cells possessing stem  cell characteristics, such as
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em bryonic carcinom a cells, em bryonic stem  cells and haem atopo iedc stem  cells 
(G orm an  et al., 1985; K em pler et al., 1993; Lange and B lankenstein, 1997).
LTR driven vectors and retroviral construc ts will be discussed in  a later chapter, b u t the 
LTR as constitudve p ro m o ter is m endoned  here shordy  to  p resen t a com plete  list o f  the 
consdtudve p rom oters used as posidve controls in  ou r invesdgadon.
3.2.2.2 SV40
T he SV40 early p ro m o ter is used in m any com m ercial available expression system s and 
cloning vectors today. T h e  SV40 p ro m o te r originates from  the Simian V irus 40 (SV40), 
a polyom avirus that is found  in  b o th  m onkeys and hum ans. Like o th er polyom aviruses, 
the SV40 is a D N A  tu m o r virus, b u t com m only  persists as a la ten t infecdon. T h e  SV40 
virus itself is o f  approxim ately  5000bp in size and has been extensively investigated 
since its identification in  the  1950's as a m odel for eukaryotic transcrip tion  and 
replication.
In  the p G L 3 -C o n tro l plasm id (Prom ega, see plasm id m ap 8.2.2) the SV40 p ro m o te r is 
em ployed upstream  o f  the luciferase gene and used as a positive con tro l and in ternal 
standard  for p ro m o te r and enhancer activities expressed by pG L 3 recom binants, 
providing strong  constitu tive expression  o f  the luciferase rep o rte r gene in m any types 
o f  m am m alian cells.
To stay w ithin the plasm id nom encla tu re  o f  this thesis the p G L 3 -C o n tro l vec to r was re­
nam ed to pGL3-SV40-luc.
3.2.2.3 CMV IE
T he cytom egalovirus (CMV) m ajor im m ediate early (IE) p ro m o ter is one o f  the 
strongest constitutive p ro m o ters em ployed and is used in m any com m ercial available 
eukaryotic expression system s and cloning vectors todav. T h e  strength o f  the CM V 
prom oter results from  its ow n enhancer elem ent, which contains an arrav o f  im perfect 
direct repeats w hich have binding properties to transcrip tion factors like, nuclear factor
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kappa-B (N F-kB) and cA M P response elem ent binding p ro te in  (CREB) (Sam bucetti et 
al., 1989; W ilkinson and Akrigg, 1992).
For our initial experim ents, we created pG L 3-C M V /T 7-luc  (see plasm id m ap  8.2.11) 
w ith the CM V p ro m o ter taken from  Inv itrogen’s expression vec to r p D N A 3 C A T  
(Invitrogen, see plasm id m ap 8.1.8 ) from  a digest w ith B g /L l/H w d lll, w hich was 
inserted in to  the sam e restric tion  sites o f  pG L 3-B asic backbone plasm id. A  second 
CM V luciferase expression vec to r was created  from  pA T C M V !X C A T 3 (see 8.1.9) 
carrying an approxim ately 850bp Xho\/H indVW  fragm ent w ith the CMV7 im m ediate early 
(CMV IE) p ro m o ter (with an  In tro n X  sequence at the 3’end) w hich was inserted  
X h o l/H in d ill  in to  pG L3-B asic to  create pG L3-850C M V -luc (see plasm id m ap 8.2.13).
3.2.2.4 Elongation factor l a  (E Fla)
T h e  p ro m o te r o f  the  translation  elongation  factor 1 alpha (E F la )  gene was identified to  
drive pow erful m am m alian expression  from  a plasm id vec to r (M izushim a and N agata,
1990). E F l a  is one o f  the m o st abundan t p ro teins in  eukaryotic cells and a coun ter 
p a rt o f  E .coli E F -T u, w hich p ro m o tes  the G T P -d ep en d en t binding o f  am inoacyl-tR N A  
to ribosom es. E F l a  is expressed constitu tive in  alm ost all kinds o f  m am m alian cells 
and its p ro m o te r was previously used fo r reconstitu tion  o f  gp91/,/7av in (Z hen  et al., 1993).
For our vectors, we m ade use o f  a 1189bp fragm ent o f  the hum an  E F la  flanked by 
E coR l/H m dL ll taken from  p E F -P G K -N e o  ((M izushim a and N agata, 1990; Z h en  et al.,
1993), see plasm id m ap 8.1.5) and ligated it in to  the Ncol (blunted) /H lndL ll sites o f  the 
pG L3-Basic cloning vector, w hich resulted to in the plasm id p G L 3 -l 18 9 E F la lp h a-lu c  
(see plasm id m ap 8.2.14 ).
These constructs were then tested  for rep o rte r gene expression by transien t assays.
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3.3 Transient expression of reporter genes driven by cellular promoters
M yeloid cell lines such as PLB985, H L-60 and U937 provide an excellent m odel system  
for studying myeloid differentiation due to their ability7 to  d ifferentiate from  their 
im m ature state into cells, that m orphologically  and functionally resem ble m ature 
granulocytes and m acrophages on  exposure to  various chem ical inducers (Pahl et al.,
1991) and consequently  these cell lines are used routinely  to  study the regulation o f  
differentially expressed genes and their cellular prom oters.
For our initial investigation, we p erfo rm ed  a series o f  transien t transfections w ith our 
pG L 3-prom oter construc ts (as described  in 3.2) to  assess the transcrip tional activity o f  
the luciferase rep o rte r gene u n d er co n tro l o f  various cellular p ro m o ter at 24 hours p o st 
transfection.
3.3.1 Transient Transfection by Electroporation
Since m yeloid cell lines are re frac to ry  to  transfection  by calcium  phosphate, the transien t 
transfection m eth o d  by elec troporation  developed by (Pahl et al., 1991) was em ployed 
w ith the aim to assay fo r d ifferences in p ro m o te r activity driving the luciferase gene in 
U937 (and H L 60 cells, data n o t show n).
T he  results show n in F igure 10 and Figure 11 indicated an enorm ous (over 200-300 X 
fold) quantitative difference betw een the transien t luciferase activities o f  the constitu tive 
p rom oters com pared  to the activity from  the m yeloid cell p ro m o ter co n stru c ts  in U937 
cells. W hile, the luciferase activity from  the m yeloid construc ts  in un trea ted  U937 was 
found to be too low for any com parisons betw een the various m yeloid p ro m o te r 
constructs, the addition o f  ln g /m l  p h o rb o l m yristate acetate (PMA) had an 
enhancem ent effect on  the rep o rte r gene activity in induced  U937 cells. T h e  largest 
increase in luciferase activity was observed  w ith the CM V p ro m o ter co n stru c ts  in 
induced U937 cells, while E F l a  appeared to be less o r n o t effected, and the SV40 
p rom oter activity was insignificantly low against the strength  o f  the CM V  and E F l a .  
A m ong the myeloid p ro m o ters  the PU .l and C D l l b  p ro m o ters p e rfo rm ed  best 
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Luciferase Acitivty in U937 celts after 24h postransfection 
by electroporation (corrected for transfection efficiency & 
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Figure 10: Transient luciferase activity and effect o f  ±PM A  on constitutive promoters in
U937 cells 24h posttransfection by electroporation.
Luciferase Activity in U937 cells (± PMA) 
24h posttransfection by Electroporation
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20 I
100 1 00
control basic 2400mNE PU.1
Figure 11: Transient luciferase activity and effect o f  ±PM A  on myeloid promoters in
U937 cells 24h posttransfection by electroporation (±PMA).
U937 cells were co-transfected with experimental pG L3-“promoter”-luc and 
pE G FP-N l plasmid D N A , as described in the Materials and M ethods (2.2.23.1). 
H alf o f  the cells were induced with ln g /m l PMA (red bars) and harvested 24h 
post-transfection. Cell-free supernatants were prepared and assayed for 
luciferase activity and total protein concentration (Materials and Methods:
2.2.24). Values are corrected for transfection efficiency by the number o f  
EGFP positive cells and standardised for pGL3-basic = 1 to correct the PMA  
effect on the background activity. Enzyme activity is expressed as relative light 
units per milligram (RLU/mg). The data are given as mean values o f  four 
independent transfections +  standard deviation (+SD ). The pG L3-“promoter”- 
luc constructs are abbreviated as indicated under each column set (Figure 10 
with constitutive promoters and Figure 11 with myeloid promoters) including a 
negative control without plasmid.
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C o-transfection w ith p E G F P -N l plasm id carrying the enhanced green  fluorescent 
pro tein  reporter gene indicated th a t transfection efficiencies o f  only ab o u t 4%  w ere 
achieved w ith U937 cells, w hich while low, were similar to  those observed  by o thers for 
cell lines o f  this type (Pahl et al., 1991). H ow ever, e lec troporation  efficiencies for H L60 
cells was significant lower at only 0.5-1%  (data n o t show n), w hich m ade it im possible to  
accurately assess luciferase activities in these cells.
O w ing to the problem s we encoun tered  w ith elec troporation  o f  m yeloid cells, e.g. high 
level o f  cell death, and p o o r viability o f  various m yeloid cell lines, as well as the tim e 
required for cell recovery and cell d ifferen tiation  longer than  48h transien t expression 
o f  luciferase repo rte r and standard isation  o f  the luciferase assay system , w e concluded  
that transfection by e lec tropo ra tion  seem ed inappropria te  to  achieve the goals set ou t 
for our p ro ject and we tu rn ed  to  a m ore gentle transfection  m eth o d  w ith 
L ipofectin  : in tegrin  p ep tide  : D N A  (LID ) com plexes.
3.3.2 Transient Transfection by LID complexes
T hough  still undergoing  con tinued  developm ent the availability o f  a new  transfection  
m ethod  developed by D r. Steve H a rt (H art et al., 1998; U duehi et al., 2003) at the tim e 
in the M olecular Im m uno logy  U nit, enabled  us to  experim ent w ith a m uch gentler and 
m ore efficient m ethod  o f  transfection . T h e  so-called “L ID  v ec to r” consist o f  the 
plasm id D N A  com plexed w ith L ipofectin  and a polycationic 16-lvsine tail peptide, 
w hich is conjugated to an in tegrin -targeting  ligand o f  ab o u t 10 am ino acid residues 
(H art et al., 1998). This technique has the advantage o f  a h igher transfection  efficiency, 
while m easuring repo rter gene activity from  a m uch smaller, b u t totally viable cell 
population.
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Figure 12: Transient luciferase activity o f  promoter constructs in N IH 3T 3 cells 36h post­
transfection by L ID  complex P 6  (±PMA)
N IH 3T 3 cells were co-transfected with experimental pGL3-“promoter”-luc and 
pE G F P -N l plasmid D N A , as described in the Materials and Methods (2.2.23.2). 
Half o f  the cells were induced with ln g /m l PMA (red bars) and harvested 36h 
post-transfection. Cell-free supernatants were prepared and assayed for 
luciferase activity and total protein concentration (Materials and Methods:
2.2.24). Values are corrected for transfection efficiency by the number o f  eGFP  
positive cells and standardised for pGL3-basic = 1 to correct the PMA effect on  
the background activity. Enzyme activity is expressed as relative light units per 
milligram (RLU/m g). The data are given as mean values o f  four independent 
transfections ±  standard deviation (±SD ). The pGL3-“promoter”-luc 
constructs are abbreviated as indicated by the relevant promoter under each 
column set and a negative control without plasmid.
T he tissue selectivity o f  the m yeloid specific construc ts is show n in (Figure 12). 
Luciferase assays were taken from  all o u r p ro m o te r construc ts 36h posttransfection  
from  fibroblastic N IH 3T 3 cells, representing a non-m yeloid cell line. W hile transfection  
efticiency - as determ ined by the p ro p o rtio n  o f  E G F P -positive cells - was roughly 
equivalent for all the p rom oter constructs (about 70-80%  in N IH 3 T 3  cells), the 
luciferase activity o f  the myeloid constructs (m N E , cfgr, C D llb ,  and PU .l) was 
negligible in com parison to  the luciferase activity o f  the constitutive p ro m o ter 
constructs (CMV, SV40 and E F la ) ,  implying that the myeloid p rom oters  functioned 
poorly in a non-m yeloid cell. In  contrast, to  w hat was observed in m yeloid cells, PM A
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had minimal effect on  the repo rte r gene activity in N IH 3T 3  cells, w hich is consisten t 
with the idea that PM A m ediates its effects th rough term inal d ifferentiation and  n o t 
directly on the prom oters.
T he results obtained for luciferase activity from  the constitutive p ro m o ter construc ts  in 
U937 cells are show n in Figure 13.
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Figure 13: Transient luciferase Activity o f  constitutive promoter constructs in U 937 cells
26h post-transfection by LID complex P 6  (±PM A).
U937 cells were co-transfected with experimental pG L3-“promoter”-luc and 
pE G F P -N l plasmid D N A , as described in the Materials and Methods (2.2.23.2). 
H alf o f  the cells were induced with ln g /m l PMA (red bars) and harvested 26h  
post-transfection. Cell-free supernatants were prepared and assayed for 
luciferase activity and total protein concentration (Materials and Methods:
2.2.24). Values are corrected for transfection efficiency by the number o f  eGFP  
positive cells and standardised for pGL3-basic =  1 to correct the PMA effect on  
the background activity. Enzyme activity is expressed as relative light units per 
milligram (RLU/mg). The data are given as mean values o f  four independent 
transfections ±  standard deviation (±SD ). The pG L3-“promoter”-luc 
constructs are abbreviated as indicated by the relevant promoter under each 
column set.
T he results obtained for luciferase activity from  the myeloid p ro m o ter construc ts  in 
U937 cells are show n in Figure 14, w hich includes a set o f  truncated  versions o f  the
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C D llb  prom oter constructs o f  1672bp, 1226bp, and 732bp respectively. E arlier studies 
on  the C D l lb  p rom oter sequence had dem onstrated  that only 412bp proxim al to  
transcriptional start site o f  the C D l lb  gene are required to  drive tissue-specific rep o rte r 
gene expression(Pahl et al., 1992), and therefore in foresight to  reduce the packaging 
load in a retrovirus vector construc t later, the 1672bp o f  the C D l lb  was reduced  to  
















Transient Luciferase Activity of myeloid promoter contructs 
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Figure 14: Transient luciferase Activity o f  P U .l and truncated versions o f  C D llb  
promoter constructs in U 937 cells 40h (±PMA) and 96h (+PM A) 
post-transfection by LID complex P 6
U937 cells were co-transfected with experimental pG L3-“promoter”-luc and 
pE G F P -N l plasmid D N A , as described in the Materials and M ethods (2.2.23.2). 
Half o f  the cells were induced with ln g /m l PMA (red bars) and harvested 40h  
and 96h post-transfection. Cell-free supernatants were prepared and assayed for 
luciferase activity and total protein concentration (Materials and Methods:
2.2.24). Values are corrected for transfection efficiency by the number o f  eG FP  
positive cells and standardised for pGL3-basic = 1 to correct the PMA effect on  
the background activity. Enzyme activity is expressed as relative light units per 
milligram (RLU/mg). The data are given as mean values o f  four independent 
transfections ±  standard deviation (±SD ). The pG L3-“promoter”-luc 
constructs are abbreviated as indicated by the relevant promoter under each 
column set.
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T he transfecdon efficiency in  U937 cells - as determ ined  by the p ro p o rtio n  o f  E G F P  
positive cells - was abou t 40% , representing  a significant im provem en t over the 
transfection efficiency achieved by electroporation  previously.
W hile the myeloid p ro m o ter construc ts if  com paired to the constitu tive p ro m o ters  
constructs perform ed poorly  in untreated  U937 cells, luciferase activity from  tru n ca ted  
C D l lb  reporter and the PU .l p ro m o ter construc ts  show ed inducibility w h en  U 937 cells 
were subjected to  induction  by PM A  40h and 96h posttransfection . K inetics o f  the 
PM A-induced transcriptional en hancem en t appeared  to  be similar to  th o se  obtained  
from  the electroporation transfections. T h e  induction  effect by PM A  was m o st visible 
w ith the truncated  C D l l b  co n stru c ts  (Figure 14).
3.4 Discussion
D esp ite  the  fact th a t the re p o rte r gene activity7 o f  m yeloid-specific p ro m o ters  construc ts  
was low  relative to  the constitu tive p ro m o ter constructs (SV40, CM V  and E F la )  
m yeloid-cell p ro m o ter activity in U937 cells could be dem onstrated , and this was 
enhanced  by induction  o f  cells w ith  p h o rb o l m yristate acetate (PMLA). In  particular, 
bo th  the human CD 11b  and  the murine PU.1 p ro m o te r construc ts were transcribed  at 
significantly h igher levels than  the activity7 o f  human c-fgr and murine neutrophile elastase. 
Indeed, the murine neutrophile elastase p ro m o te r co n stru c t was particularly weak displaying 
levels barely higher than  background , consisten t w ith similar results described  fo r this 
p rom oter (N uchprayoon et al., 1994).
Particularly interesting was the inducibility7 o f  the human CD 11b  constructs. T h e  1672bp 
C D l lb  p rom oter showed only background levels o f  luciferase activity w ith o u t PM A, 
w hich was similarly p o o r as obtained w ith the c-fgr p ro m o ter in un treated  cells (Figure 
11), b u t showed p o ten t induction  o f  up to 4 x  fold h igher levels o f  expression  after 
PM A treatm ent o f  U937 cells, and this was evident w ith either transfection  m ethods 
employed.
In  particular, the truncated  version carrying only 732bp o f  the CD 11b  m inim al 
prom oter sequence show ed itself to be best in term s o f  inducibility. T hese  results were 
consistent w ith previous reports show ing that endogenous CD11b  expression levels
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were low or undetectable in m yeloid precursors, and steadily increased during  m yeloid 
differentiation, reaching the highest levels in m ature neutrophils, m onocytes, and 
m acrophages (Dziennis et al., 1995).
In  contrast, the level o f  expression o f  the murine PU. 1 p ro m o te r co n stru c t, w hich  in 
untreated cells was 5 fold stronger than CD11b, p roved  to be less sensitive to  PM A  
induction, approxim ately 5 -6X induction. T hese  expression p a tte rn s  w ould be 
consistent w ith the fact that in vivo PU .l functions exclusively in a cell in trinsic m anner 
to control the developm ent o f  granulocytes, m acrophages, and B lym phocytes. T h u s 
PU. 1 is upregulated during early co m m itm en t o f  m ultipo ten tial p rogen ito rs and contro ls 
myelopoiesis by regulation o f  b o th  p ro lifera tion  and d ifferentiation pathw ays (Tenen et 
al., 1997).
Two d iffe ren t technologies w ere em ployed to in troduce D N A  in to  cell lines, w hich are 
quite resistan t to  transfection . A lthough each m ethod  has advantages and 
disadvantages, they required  com prom ise on  one o r the o th er aspect o f  the 
experim ental set-up and reproducibility.
Firsdy, e lec troporation  is the m o st versatile m ethod  o f  D N A  transfection  because it has 
been show n to w ork on a w ide variety o f  cell types. T his technique relies on  high- 
voltage pulses that cause the cell m em brane to  break dow n, p roduc ing  transien t pores 
through w hich D N A  can enter. By varying the electric field strength , and length o f  
time the cells are exposed to  the electric field, it is possib le to optim ise e lec troporation  
param eters for essentially any cell type, w hich represen ts the m ain advantage o f  this 
technique. However, this m ethod  also results in high cell m ortality  and necessitates 
greater quantities o f  D N A  than  liposom e-m ediated  techniques.
In  contrast, lipofectam ine-m ediated transfection  is based on  a m ixture o f  a polycationic 
synthetic lipid and a neutral fusogenic lipid w ith an am ine-group, w hich results in the 
form ation o f  unilamellar liposom e vesicles that have a net positive charge due to highlv- 
positive amine headed groups on these m olecules, which spontaneouslv  fo rm  lipid- 
D N A  com plexes due to the ionic in teraction to neutralize the negatively charged 
phosphate groups on the D N A  (Feigner et al., 1994; Feigner et al., 1987; R adler et al.,
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1997). These structures can then  fuse and pass through the plasm a m em brane to  deliver 
D N A  into cells, a process though t to be im proved upon  by in co rp o ra tio n  o f  in tegrin  
targeting peptides (H art et al., 1997; H art et al., 1998; U duehi et al., 2003). C onsequently , 
this gene delivery technique is less harm ful to  the cells than  e lec troporation , b u t may be 
limited by endosom al degradation and is variable depend ing  on  the cell type, and  effo rts 
were made in the design o f  d ifferen t integrin pep tide sequences to  partially overcom e 
this problem  (H art et al., 1998).
N onetheless, the results o f  transien t transfection  experim ents in general are probably  
n o t indicative o f  any effects o n  the regulation o f  the endogenous gene from  the 
induced expression o f  a m yeloid p rom oter. N o r are they necessarily a p red ic tion  o f  
stable expression patterns, due to  the lack o f  selectable markers.
A lthough  som e in fo rm atio n  was ob ta ined  that C D l l b  m ight be a candidate, it needed  
fu rth e r testing  in a stable transduced  cell env ironm ent and in a retroviral backbone 
in tegrated  in to  a h o st cell genom e to establish its suitability for the use in gene therapy. 
In  fact, previous results in o u r laborato ry  had show n that transien t assay results are n o t 
always a reliable p red ic to r o f  activity o f  stably in tegrated  construc ts (M arden et al., 
2003a; M arden et al., 2003b).
In  conclusion, in o rd er to  investigate the suitability o f  the one o r o th er m yeloid 
p rom oter in a stably in tegrated  h o s t cell en v ironm en t the follow ing C hap ter will focus 
on retroviral constructs utilising the C D 1 1 b and PU.1 p ro m o te r and the assay o f  their 
ability to drive repo rter gene expression in transduced  m yeloid cell lines, befo re  and 
after induced differentiation.
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l i n e s  t r a n s d u c e d  w i t h  r e t r o v i r a l  
v e c t o r s  c o n t a i n i n g  c e l l u l a r  
p r o m o t e r s
4.1 Background
T he use o f  retroviral vectors driving expression  o f  an  inserted  “ therapeudc  gene” from  
the viral LTR suffers from  a n u m b er o f  problem s. Firstly, these are o ften  subject to 
inconsistent levels and  d u ra tio n  o f  expression  due to  their natural p ropensity  to  acquire 
de novo m ethylation  in vivo (Challita et al., 1995; Challita and K ohn , 1994). Secondly, the 
levels o f  tran sc rip d o n  m ay be  highly sub-opdm al in  specific cell types; prev ious w ork  in 
o u r ow n labora to ry  had  suggested  th a t this may have con tribu ted  to a relatively low  level 
o f  oxidase expression in C G D -p a tien t B cells lines corrected  by transduction  w ith such 
a retroviral vec to r (T hrasher et al., 1992). Thirdly, the random  natu re o f  retroviral 
in tegration  m akes the transduced  cells susceptible to insertional m utagenesis and as 
indicated  earlier, a significant hazard  from  this derives from  the in fluence o f  the 
retroviral long  term inal rep eat (LTR), w hich as well as com m only  prov id ing  the vec to r 
w ith a p ro m o ter function, is also a p o te n t transcrip tional enhancer (Coffin et al., 1997). 
Because the enhancer is functional in  a broad  range o f  tissue types, genes adjacent to  
the site o f  retroviral in tegration  are susceptible to  m ajor up-regulation o f  their level o f  
transcription. This could have m ajor consequences i f  one o f  these is an  oncogene, 
w hich was b rough t sharply in to  relief recently, in the course o f  o therw ise highly 
successful clinical trials (Cavazzana-Calvo et al., 2000a; H acein-B ey-A bina et al., 2002a; 
O tt et al., 2006; T hrasher et al., 2006).
O ne strategy to im prove tissue o r cell-specific transgene expression has been the use o f  
vectors driving expression from  prom oters endogenously active in a particu lar lineage. 
However, it was found that the viral enhancer-p rom oter located in the 5’LTR interferes 
with the cis regulatory elem ents inserted  in the vectors, resulting in unstable proviral 
transm ission a n d /o r  p o o r transgene expression (E m erm an and Tem in, 1984; E m erm an
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and Temin, 1986a; E m erm an  and Tem in, 1986b; Persons and N ienhuis, 2000; 
P roudfoo t, 1986).
M ore recently, self-inacdvating (SIN) retroviral vectors that lack e n h a n c e r /p ro m o te r  
sequences carrying a deletion in the U3 region o f  the LTR  have been  used to  p roduce  
vectors lacking the LTR enhancer sequences (Kvakuma et al., 1999; Yu et al., 1986), 
which are though t to  activate adjacent genes, and to  drive transgene expression  from  
internal cis-regulatory sequences. W ith  this m ethodo logy  it should  be possib le to 
prevent the com petition  th a t has been  observed  betw een  inserted  p ro m o ters  and the 
LTR (Akgun et al., 1991; M acK enzie e t al., 1994; Scham bach e t al., 2006), and may also 
reduce the risk o f  insertional m utagenesis and  help to  circum vent the in vivo silencing o f  
gene expression th a t has b een  o bserved  w ith  viral p ro m o ters  (Challita and  K o h n , 1994).
C onsequently, we designed o u r vectors w ith  a deleted U3 region o f  the LTR. B ecause 
the 3 'L T R  is duplicated  during  the  retroviral life cycle and copied to the 5 'e n d  o f  the 
vec to r it is only necessary to  delete the 3 'L T R  to  p roduce a vector, w hich lacks 
endogenous regulatory elem ents in the p rovirus (as described previously, 1.2.5). T hus, it 
is possib le to delete enhancer sequences from  the 3 'L T R  w hilst still utilising an in tact 
5 'L T R  to d irect transcrip tion  in retroviral p ro d u cer cells. In  the target cells, the 
in tegrated  p rov irus obtains its 5 'L T R  sequences from  the 3 'L T R  carrying the enhancer 
deletion, and so the in teg ra ted  vec to r will lack any viral-derived enhancer sequences 
(A-LTR vector).
4.2 Tissue-specific promoters in viral vectors
Previous attem pts have been m ade to  p roduce retroviral vectors w ith a tissue-specific 
transcriptional tropism , this has been o f  particular relevance to  gene therapy approaches 
to treating cancer, w here it was crucial to restrict transgene expression specifically to the 
tum our (Jager et al., 1999; Malik et al., 1995; M avria et al., 2000; Miller and Vile, 1995; 
Vile et al., 1995).
Retroviral vectors directed at therapy o f  m onogenic inherited  conditions have generally 
accepted the wide tropism  o f  viral LTR for expression o f  inserted  genes, though  a few
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recom binant viral vectors have been  described which have in co rp o ra ted  tissue-specific 
enhancer elem ents in attem pts to  lim it o r optim ise transcrip tional acdvity to  the 
particular cell-type affected by the disease.
O ne such area has been in gene therapy fo r the thalassaem ias w here ob ta in ing  high level 
erythroid lineage expression is desired. V ectors inco rporating  globin gene p ro m o ter 
elements to drive the hum an  (3-globin gene have been  co n stru c ted  bu t, though  
erythroid-specific, these tended  to  suffer from  low and variable levels o f  expression 
(Sadelain et al., 1995). S ubsequen t studies have established that retroviral vectors could 
be markedly im proved by the  in co rp o ra tio n  o f  sequences from  the, norm ally  distant, 
locus con tro l region (LCR). T h e  L C R  is a chrom atin  region th a t functions to  regulate 
tissue specific and  tem pora l activity7 o f  the entire (3-like globin gene cluster. By 
inco rpora ting  core site vectors, the  H S2, H S3 and H S4 core sites o f  the h u m an  (3-globin 
LC R  in to  a retroviral vec to r they  acted as a pow erful erythroid  enhancer, b u t failed to 
provide the positio n -in d ep en d en t expression associated w ith the activity7 o f  the 
endogenous LC R  (Sadelain e t al., 1995; Sadelain et al., 2000).
D esp ite  patchy results, som e no tab le  successes have been rep o rted  in generating  vectors 
w ith tu m o u r specific expression  patterns. Vectors em ploying the m urine tyrosinase gene 
p ro m o te r to  drive cytokine genes, o r the H SV tk suicide gene expression in m elanom a 
cells (Vile et al., 1994a; Vile et al., 1994b; Vile and H art, 1993a; Vile and H art, 1993b). 
H ow ever, partial loss o f  specific gene expression from  these vectors was observed  due 
to p ro m o ter in terference by the strong  p ro m o te r /e n h a n c e r  elem ents in  the U3 region 
o f  the viral LTR and also by an additional in ternal viral SV40 p ro m o te r w hich  directed  
m arker gene expression (Vile et al., 1994a). T his led to the developm ent o f  alternative 
vector design w here the LTR enhancer a n d /o r  p ro m o ter sequences w ere in terchanged  
with corresponding  m inim al cellular regulatory  elem ents from  the hum an  tyrosinase 
prom oter. Resulting vectors dem onstra ted  expression o f  G M -C SF in tissue-specific 
m anner, how ever at relatively low levels o f  expression (Diaz et al., 1998).
A nother example, the endothelial-specific p repro-endothelin-1  (ppET-1) p ro m o te r 
(Mavria et al., 2000) has been em ployed to  limit expression to  endothelial cells. In  these
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constructs the ppET-1 p ro m o ter sequences were inserted  in to  a U 3-deledon  region in 
the enhancer o f  the M F G  vector, ra ther than  in the body  o f  the construc t. In  a tu m o u r 
model, therapeutic levels o f  expression from  this hybrid p p E T -1 /L T R  en h an cer w ere 
obtained (Mavria et al., 2005).
Two m ajor attem pts have been  m ade to  investigate the use o f  m yeloid-cell-specific 
prom oter elem ents in retroviral vec to r constructs. T h e  first o f  these m ade use o f  
p rom oters from  the [3-integrin genes C D l la ,  C D l l b  and C D 18 (B auer-TR  et al., 1994). 
W hen tested in H L60 cells these p ro m o ters  w ere only capable o f  directing  low  levels o f  
transcription, w hich show ed only m arginal increases on  induction  o f  m yeloid 
differentiation w ith  PM A  o r re tino ic acid. H ow ever, these construc ts  also con tained  
fully functional LTRs, so the levels o f  transcrip tion  may have been  seriously affected  by 
com petition  betw een  the  d iffe ren t p rom oters.
In  an o th er similar study, the  use o f  the C D l lb ,  C D  18 and C D 34 p ro m o ters  was 
com pared  w ith the activities o f  viral p ro m o ters  CM V  and SV40 in transduced  H L 60 
cells. In  this instance, som e evidence fo r tissue specificity and up-regulation o f  gene 
expression on  induction  o f  m yeloid d ifferen tiation  was obtained. In  particular, the 
CD1 lb  p ro m o te r show ed as m uch as an 8 fold increase in transcrip tion, w hen  the H L 60 
cells w ere d ifferentiated  to  granulocytes w ith retinoic acid.
I t  is n o t instantly  clear why the two studies d iffered so significantly b u t the precise 
regions o f  the p ro m o te r used appeared  to  be d ifferent, w ith the latter study surprisingly 
only using a 404bp proxim al region. Also, the second study assayed transcrip tion  by 
levels o f  glucocerebrosidase (GC) activity, th rough  inclusion o f  a G C  cD N A  in the 
vector ra ther than adenosine deam inase, as in the study by (Bauer-TR  et al., 1994). 
D eterm ining  G C  activity was co n fo u n d ed  to som e degree by the p resence o f  
endogenous G C  activity in the H L 60 cells, w hich may have influenced  the findings, 
though in general these were co rro b o ra ted  by N o rth e rn  blotting.
In  the following section we describe o u r results ob tained  using LTR enhancer-dele ted  
and non-deleted retroviral vec to r constructs. T hese  retroviral vectors used  the m o st
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prom ising o f  the myeloid specific-gene p ro m o ter elem ents, assayed earlier, to  drive 
reporter gene expression in a num ber o f  myeloid and non-m yeloid cell lines.
4.3 Cloning strategy and retroviral constructs based on pMBA
O ur initial invesdgadons were based on  the availability o f  the enhancer-deleted  
retroviral vector pM BA (see plasm id m ap 8.3.1), a kind gift from  D r. C. P o rter, C hester 
Beatty Laboratories, L ondon. T h e  pM B A  retroviral vec to r is derived from  the pB abe 
series o f  M LV retroviral vectors developed  by (M orgenstern  and Land, 1990). W hile the 
pM BA 5’LTR from  p o sid o n  1-1375 and  1965-4125 is from  the original pB abe vector, 
the D N A  sequence from  p o sid o n  1375-1965 carrying the 3’LTR enhancer deletion, 
originated from  eukaryotic expression  vec to r pM PSV  developed from  the 
m yeloproliferative sarcom a v irus (A rtelt et al., 1988).
C loning strategies and co n stru c tio n  o f  the retroviral vectors w ith the pM BA  backbone 
are illustrated in detail in the A ppendix  (paragraph 8.3), how ever a b rie f descrip tion  is 
p resen ted  here: D ue to  the fact that the pM BA plasm ids m ultiple cloning site (MCS) was 
lim ited to only three unique sites, w hich are B am H l, Clal and E cold  and the luciferase 
gene in pG L 3-B asic could only be taken ou t by a Clal digest, w hich essentially is the 
entire coding region o f  the luciferase re p o rte r gene including its polyA  signal, ou r 
cloning strategy was to in sert all p rom oter-luciferase re p o rte r units in anti-sense 
orientation to the 5’LTR o f  pM BA, in  o rder to avoid p rem atu re  te rm ination  o f  the 
retroviral R N A  transcripts during  retroviral packaging.
F urther we anticipated that w ith this cloning strategy, transcrip tion  o f  the rep o rte r  gene 
in target cells would occur exclusively from  the exogenous p ro m o ters  we were 
investigating, while also excluding any possible background leyels o f  rem aining LTR 
activity, though the enhancer deletion o f  the provirus.
First the retroviral backbone pM BA was linearised w ith a Clal d igest and 
dephosphorylated to avoid religation, before inserting the luciferase rep o rte r gene from  
pGL3-Basic (see plasm id m ap 8.2.1) as a C lal/C lal fragm ent. T he  o rien ta tion  o f  the 
insert was then tested by X bal digest to  verify the creation o f  pM BA-Basic-luc (see
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plasm id m ap 8.3.2). This construc t was designed to act as a negative co n tro l vector, 
w ithout an exogenous p ro m o ter driving the luciferase reporter.
4.3.1 Retroviral pMBA constructs with myeloid specific promoters
pM BA -2400m N E-luc (see plasm id m ap 8.3.4) was cloned by inserting  the approxim ately  
2400bp sequence o f  the m N E  p ro m o te r and luciferase rep o rte r from  p G L 3 -2 4 0 0 m N E - 
luc (see plasm id m ap 8.2.3) via the sam e C lal/ Clal c loning strategy, w hile for the 
creation o f  pM B A -700m N E -luc (see plasm id m ap 8.3.3) it was possible to  extract the 
truncated 700bp long m N E  p ro m o te r w ith  the luciferase rep o rte r gene by B g lll/B a m H l 
digest from  pG L 3-2400m N E -luc, w hich was inserted  in to  the Bam  H I unique cloning 
site o f  pM BA. T h e  o rien ta tio n  o f  the in sert was tested  again by X b a l digest.
H ow ever, based  o n  the w eak expression  data ob tained  previously (Figure 11), the m N E  
vectors w ere n o t investigated.
T h e  pM B A -PU .l-luc (see plasm id m ap 8.3.5) vector was created by inserting  the P U .l- 
luciferase sequence unit from  pG L 3-P U .l-luc  (see plasm id m ap 8.2.7) as C la l/C la l 
fragm ent in to  Clal linearised pM BA backbone. A X b a l digest was again used to  verify 
the o rien ta tion  o f  the insert.
pM B A -1672C D l lb -lu c  (see plasm id m ap 8.3.6) was m ade by Clal d igest o f  
pG L 3-1672C D l lb -luc  digest and ligation o f  the expression unit in to  the Clal site o f  
pMBA. Again, the orien tation  o f  the in sert was tested by X b a l digest.
4.3.2 Retroviral pMBA constructs with constitutive promoters
T he SV40-luc insert o f  pM BA-SV40-luc (see plasm id m ap 8.3.7) was taken via Clal 
digest from  pG L 3-C ontro l (see plasm id m ap 8.2.2) and orien ta tion  was tested  by X bal 
digest. As additional positive controls p M B A - C M V / T 7 - l u c  (see plasm id m ap 8.3.8) was
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created by cloning the C M V /T 7-luc insert from  pG L 3-C M V /T 7-luc  (see p lasm id m ap 
8.2.11) via BgAl/Bam H l digest into the BamH I site o f  pMBA. W hile pM BA-850CM V- 
luc (see plasmid m ap 8.3.9) was cloned using the Clal sites from  pG L3-850C M V -luc (see 
plasmid map 8.2.13) and pMBA.
Finally, pM B A -1189E F la was created by Clal d igest o f  p G L 3 -l 1 8 9 E F la -lu c  (see 
plasmid m ap 8.2.14) and ligation in to  the Clal site o f  pM BA. As before the o rien tad o n  
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Figure 15: S chem atic  d iag ram s o f  th e  re tro v ira l v e c to rs  b a sed  o n  pM B A
T h e  ex p an d ed  b o x  a t each  en d  re p re se n ts  th e  L T R  in w h ich  th e  g rey  area  
iden tifies th e  7 5 -b p  e n h an c e r rep ea t reg ion . T h e  e n h a n c e r  d e le tio n  in  th e  3 'L T R  
is in d ica ted  by th e  d o tte d  line an d  th e  c ro ss  in  th e  5 'L T R  in d ica te s  th a t th e  
de le ted  L T R  will be co p ied  an d  tra n sp o se d  to  th e  5 'e n d  in th e  p ro v iru s . W 
in d ica tes th e  lo ca tio n  o f  th e  p ackag ing  signal. T h e  arrow s ab o v e  each  v e c to r  
schem atics in d ica tes th e  luciferase  re p o rte r  g en e  tran sc rip tio n  u n it in an tise n se
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(dotted arrows) to the LTR driven transcripuon o f  genomic viral RNA. Detailed  
plasmid maps are listed in the Appendix 8.3.
A lthough the entire set o f  described pM B A -prom oter-luciferase vectors w ere created, 
virus was initially produced  only from  the constitu tive co n stru c ts  pM B A -C M V /T 7-luc  
and pMBA-SV40-luc as contro ls and p M B A -1 6 7 2 C D llb -lu c  and pM B A -P U .l-luc to  
investigate myeloid specificity (Figure 15).
4.3.3 Packaging and Retroviral Transduction with pMBA based vectors
Initially it was p lanned  to  use A M I2 (M arkowitz et al., 1988) o r FLY (C osset et al., 1995) 
packaging cell lines to  establish  stable virus p ro d u cer cell lines for each retroviral 
construc t. H ow ever, due to  the relatively h igh num ber o f  the various retroviral 
p ro m o te r co n stru c ts  at hand , the o therw ise tim e-consum ing traditional m eth o d  o f  
selective cloning fo r the estab lishm ent o f  stable viral p roducer cell lines was dism issed 
in favour o f  a transien t packaging system  developed for M LV-based retroviral vectors by 
(Soneoka et al., 1995).
In  this three-plasm id viral packaging system, two advantageous features w ere in troduced  
to  achieve high titre: Firstly, the in trans supplied viral structural co m ponen ts gag-pol and 
env are expressed from  the C M V  p ro m o ter, and secondly, the structural co m p o n en ts  are 
placed on separate plasm ids w hich con tain  the SV40 origins o f  replication. W hen  the 
three plasm id co m p o n en ts  are in troduced  by transien t co-transfection  in to  cell lines 
carrying the SV40 large T  antigen, e.g. highly transfectable hum an  293T  cell lines — and 
in the presence o f  sodium  butyrate to fu rth e r increase expression o f  each co m p o n en t 
- this com bination o f  features w ere rep o rted  to  enhance retroviral gene expression, and 
to obtain helper-free viral stocks o f  approxim ately 10 infectious u n its /m l w ith in  48 h 
after transient co-transfection  (Soneoka et al., 1995).
In  our hands however, sufficient titres could n o t be rep roduced  w ith o u r reco m b in an t 
pMBA vectors. A lthough transfection  efficiency via Calcium  P hosphate  precip ita tion  
was optim ised using the p H lT l 11 plasm id (Soneoka et al., 1995) carry ing  the lacZ
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reporter, the viral titre achieved were insufficient even to infect N 1H 3T 3 and  H eL a cells. 
A disadvantage o f  the system  seem ed to  be the inability to  select fo r the retroviral 
structural genes and the necessity for sim ultaneous transfection  o f  the th ree  d ifferen t 
plasmid for a sufficient dtre. H ow ever, transient p ro d u c tio n  system s have the  po ten tial 
to yield high-titre supernatan t and do n o t require the lengthy process o f  identify ing a 
high-titre producer cell clones typical o f  m ost stable packaging cell line system s (Yang et 
a l,  1999).
Fortunately, w ith the availability o f  a second generation  retroviral p ro d u cer cell line 
(Kinsella and N olan , 1996), we w ere able to  avoid the technical difficulties w e had  w ith 
the transient th ree-p lasm id  system  described  above. T h e  Phoenix™  p ro d u cer cell lines 
are based o n  a h u m an  293T  cell line, w hich  is highly transfectable w ith  either calcium  
phosphate-m ed iated  o r lip id-based transfection  p ro toco ls  and in w hich the nuclear 
rep lication  and  re ten tio n  functions o f  the E pste in -B arr virus (EBV) are utilised to 
m aintain  retroviral construc ts  episomally. D u e  to the gag-pol episom e in this cell line can 
be am plified w ith  hygrom ycin selection, while the envelope p ro te in  episom es carry a 
d iph theria  toxin resistance gene as a selectable marker.
4.3.4 Luciferase activity obtained with pMBA constructs
In  the first set o f  transduc tion  experim ents, we com pared  the perfo rm an ce  o f  the 
Phoenix A m pho  and P hoen ix  E co  packaging system  w ith o u r pM B A  constructs.
G iven that the Phoenix™  p ro d u ce r cell lines provide the viral packaging co m p o n en ts  
gag-pol and env (eco o r am pho) constitutively in trans, we only had to  p e rfo rm  a single 
plasm id transfection and w ere able to  ob tain  m easureable luciferase activity from  o u r 
constitutive p rom oter construc ts in a prelim inary com parison  o f  the luciferase activity 
in transduced N 1H 3T3 cells w ith virus derived from  b o th  packaging cell lines, 
Phoenix™  A m pho and E co  (Figure 16).
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Figure 16: Luciferase gene activity in N IH 3T 3 cells transduced with pMBA retroviruses
derived from Phoenix Am pho and Phoenix E co packaging cell lines.
N IH 3T 3 cells were subjected to a single round o f  transduction with same 
volum e o f  supernatant containing the experimental pMBA retroviral vectors 
derived from Phoenix A m pho and Phoenix E co producer cell lines as indicated. 
However, it was not possible to control for any differences in titre that may 
have resulted from the use o f  different promoter constructs. Cell-free 
supernatants were prepared and assayed for luciferase activity and protein 
concentration (Materials and Methods: 2.2.24). Background (control) activity 
was measured by assay from non-transduced N IH 3T 3 cells. Data are mean ±SD  
from four independent transductions and luciferase activity is expressed as 
R L U /m g protein.
T he im proved level o f  luciferase activity ob tained  w ith virus derived from  the 
Phoenix™  E co producer was n o t unexpected and this proved to  be beneficial to  o u r in 
vivo experim ents using p47/)*av knockout m ice planned later on  (described in detail in  the 
following chapter). By subjecting N IH 3 T 3  cells to  additional cycles o f  transduction  
with the am photropic vectors, a three fold increase in  luciferase activity from  ou r 
pM BA-CM V/T7-luc vector was achieved as show n below  (Figure 17).
■  Eco ■  Ampho
105
Chapter 4: Reporter Gene Expression in Cell lines transduced with retroviral vectors
containing cellular prom oters
Luciferase Activity in NIH3T3 cells 
after 3 cycles of transduction with 
pMBA derived retrovirus
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Figure 17: Luciferase activity in N 1H 3T 3 cells after 3 cycles o f  transduction with pMBA
vector packaged with Phoenix Ampho.
N IH 3T 3 cells were subjected to three rounds o f  transduction with experimental 
pMBA retroviral vectors (ampho) as indicated. Cell-free supernatants were 
prepared and assayed for luciferase activity and protein concentration (Materials 
and Methods: 2.2.24). Background (control) activity was measured by assay from  
non-transduced N 1H3T3 cells. Data are mean ±SD  from four independent 
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pMBA derived retrovirus
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Figure 18: Luciferase activity in U 937 cells after 3 cycles o f  transduction and
spinocculation with pMBA vector
U937 cells were subjected to three rounds o f  transduction with experimental 
pMBA retroviral vectors (ampho) as indicated. Cell-free supernatants were 
prepared and assayed for luciferase activity and protein concentration (Materials 
and Methods: 2.2.24). Background (control) activity was measured by assay from  
non-transduced U937 cells. Data are mean ±SD  from four independent 
transductions and luciferase activity is expressed as R L U /m g protein
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However, w hen we transduced the m yelom onocytic cell line U937 w ith pM B A -derived 
viral vector (Figure 18), even after repeated rounds o f  in fection  by sp inocculation, 
luciferase activity7 was p o o r relative to the levels obtained  w ith N IH 3 T 3  cells (Figure 17).
Despite the fact that we were able to  transduce m yeloid and non-m yeloid  cells w ith  
pMBA vectors after repeated cycles o f  in fection  using transien t packaging cell line 
(Kinsella and N olan, 1996), luciferase activity ob ta ined  from  transduced  cells w ere 
significantly lower than expected. A lthough  low levels o f  transduc tion  to  m yeloid cell 
lines had been reported  previously, we suspected  that p o o r titres may be a consequence 
o f  the an ti-sense-orientation  o f  the p rom oter-luciferase transcrip t in o u r viral co n stru c t 
in the pM BA vectors, w hich  we had  n o t an ticipated  in the con tex t o f  the  293T-based 
packaging cell line, particularly  w ith  the m yeloid specific p ro m o ter driving the transgene.
H ow ever, a m ore detailed analysis o f  the titres from  pM BA vectors was n o t carried ou t 
due to  the availability o f  an  alternative retroviral vec to r at the tim e w ith enhanced  
features and com patibility to  the P hoenix  A m pho  and E co  packaging cell lines for high- 
titre virus production . H ence, we tu rned  to  this alternative vec to r system , based o n  the 
retroviral expression plasm id P IN C O  (Figure 19), a hybrid E B V /re tro v ira l vector 
inco rp o ra tin g  a num b er o f  im p o rtan t features, that optim ise it fo r the use in the 
Phoenix™  packaging system: T h e  P IN C O  vecto r harbours a d ifferen t retroviral
backbone to pM BA vector, it carries the E B V  origin o f  replication and encodes the 
E pstein-B arr V irus N uclear A n tigen  (EB N A ) facilitating its m ain tenance as a stable 
episom e and it can be selected fo r using a p u r o m y c in  resistance marker. In  addition, it 
carries the green fluorescent p ro te in  (G FP) rep o rte r gene un d er con tro l o f  the 
im m ediate early CAIV p rom oter, for in vivo evaluation o f  transduced  cells. T h e  system  
has been shown to generate viral titres as high as 10 colony fo rm ing  u n its /m l and was 
successfully tested for high-efficiency gene transfer to  hum an  haem atopo ie tic  p ro g en ito r 
cells (Grignani et al., 1998).
While the P IN C O  vector carries the E G F P  rep o rte r gene under the con tro l o f  the sam e 
im m ediate early CMV p ro m o ter sequence as the luciferase rep o rte r gene in o u r pM BA- 
C M V /T 7-luc construct, P IN C O -C M V -luc (see plasm id m ap 8.5.6) was fast created  by
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exchanging the E G F P  gene o f  P IN C O  th rough a H w d ll l /N o t l  digest w ith  the 
luciferase repo rter gene H in d ll l /X m a ll l  from  pG L3-B asic (Prom ega, see p lasm id m ap
8.2.1) and tested in N IH 3 T 3  and U937 cells for transduced  luciferase activity th a t 




Nhe  I (449)
75 bp repeat 














\  Bam  HI (2299)
Eco RI (2320)
\ C la l  (2328)
\  hCMV immediate early promoter




75 bp repeat 
\  75 bp repeat 
3' LTR
\ XbaI (4124)
(  CAAT signaM (C/EBP)
\  \
\ TATA signal 
RSL





Schem atic  re p re se n ta tio n  o f  th e  re tro v ira l v e c to r  P IN C O .
L im ited  re stric tio n  m ap  (un ique  re s tric tio n  sites in red) and  fea tu res o f  th e  
P IN C O  vecto r: th e  E B V  orig in  o f  rep lica tio n  an d  th e  E B N A -1  g en e , w h ich  
facilitates rep lica tio n  as an e p iso m e ; th e  p u ro m y cin  resis tan ce  g en e  (se lec tab le  
m arker) u n d e r c o n tro l o f  the  P G K -1  p ro m o te r ;  th e  fu ll-leng th  M o lo n ey  L T R s, 
ex ten d ed  i f /  sequ en ce , and  th e  E G F P  re p o rte r  g en e  u n d e r  c o n tro l o f  th e  
ex o g en o u s C M V  IE  p ro m o te r . T h e  7 5 -b p  rep ea ts  (en h an cer), T A T A , C /E B P  
and  the  R reg ion  ste m -lo o p  (RSL) signals are id en tified  in  th e  L T R s, an d  th e  cis-
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exchanging the E G F P  gene o f  P IN C O  through a H indL Il/N o tl digest w ith  the 
luciferase reporter gene H in d ll! /X m a lll  from  pG L3-Basic (Prom ega, see p lasm id m ap
8.2.1) and tested in N IH 3 T 3  and U937 cells for transduced luciferase activity th a t 
dem onstrated the superiority o f  the P IN C O  vector (data n o t shown).
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Puromycin N-Acetyltransferase
Schematic representation o f  the retroviral vector PIN CO .
Limited restriction map (unique restriction sites in red) and features o f  the 
PIN CO  vector: the EBV origin o f  replication and the EBNA-1 gene, which  
facilitates replication as an episome; the puromycin resistance gene (selectable 
marker) under control o f  the PGK-1 promoter; the full-length M oloney LTRs, 
extended y/ sequence, and the EG FP reporter gene under control o f  the 
exogenous CMV IE promoter. The 75-bp repeats (enhancer), TATA, C /E B P  
and the R region stem-loop (RSL) signals are identified in the LTRs, and the cis-
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acting encapsidation sequence (PSI, if f ) located between 5 'LTR and the gag 
gene. Sequence data from (Grignani et al., 1998), personal communication.
Consequently, we decided to created a completely new set of constructs based on the 
PINCO retroviral backbone (Grignani et al., 1998), which were optimised for the use 
with the Phoenix™ packaging system (Nolan laboratories, Stanford, USA, see also 
Materials and Methods, 2.1.5.3).
4.4 Construction of enhancer-deleted (A-LTR) vectors based on PINCO
The vector backbone PINCO (see Figure 19 and detailed plasmid map in Appendix
8.5.1) was used as the basis for the construction of our enhancer-deleted vectors. To 
generate a A-LTR vector the 75bp enhancer repeats in the 3'LTR were removed by 
digestion with Nhel and Xbal (Figure 20) which produce compatible cohesive ends 
allowing the vector plasmid to be re-ligated.
Figure 20: Schematic representation o f  retroviral LTR and enhancer deletion
D etail show ing the enhancer deletion between Nhel and X bal. The deletion 
rem oves both o f  the 75-bp repeat sequences o f  the enhancer, which contains a 
number o f  transcription factor binding sites, but leaves the promoter intact, 
(adapted from (Coffin et al., 1997). The binding proteins that recognise the 
enhancer repeats are indicated: Positive-acting transcriptional control elements 
are represented by multiple members o f  the ETS family o f  transcription factors 
bind to two sites in each 75bp repeat unit (Gunther and Graves, 1994). The
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o>r c  - b i n d i n g  f a c t o r  ( . 'HI '  is a h c t e r o d i m c r i c  b i n d i n g  p r o t e i n  t ha t  r e c o g n i s e s  t h e  
e n h a n c e r  c o r e  r e g i o n  ( ) g a w a  et  a!., l (>T\ i ;  ( )ga \va  et al.,  l b b . T ;  W a n g  et a!.,
I ' ) ' *3! . ( i e n e t i c  a n d  b i o c h e m i c a l  e v i d e n c e  s u g g e s t s  t ha t  b. ts an i l  C H I '  p r o t e i n s  
c o o p e r a t e  t o  a c t u a t e  t r a n s c r i p t i o n  m e d i a t e d  In  t h e  e n h a n c e r  S u n  et al., l l)(b~>;
W o t t o n  et al., l l>()4 . N u c l e a r  f a c t o r  1 N i  l , b e l o n g s  t o  a s m a l l  t ami l v  o t  D N A  
b i n d i n g  p r o t e i n s  K e i s m a n ,  11>‘)< • wh i c h  b i n d s  t o  t w o  s i t es  in e a c h  r e p ea t .  
M a m m a l i a n  t vp e  ( r e t r o v i r u s  e n h a n c e r  t a c t o r  1 M(  R b . b  1 is a D N A  b i n d i n g  
p r o t e i n ,  w h i c h  o v e r l a p s  t h e  1 I S a n d  ( HI b i n d i n g  si tes .  T h e  g l u c o c o r t i c o i d  
r e c e p t o r  C»R a l s o  b i n d s  t o  t h e  e n h a n c e r  D c b r a n c o  a n d  Y a m a m o t o ,  1(>S6 .
( d u c o c o r t o i d s  h a v e  b e e n  r e p o r t e d  t o  a c t u  a t e  I . T R  d r i v e n  r e p o r t e r  g e n e s  
M i k s i c e k  et al., 1‘>K(> . T h e  ( i R  b i n d i n g  s i te o v e r l a p s  a n  b. b o x  e l e m e n t ,  w h i c h  u  
r e c o g n i s e d  bv severa l  t r a n s c r i p t i o n  t a c t o r s  t r o m  t h e  bas i c  he l ix  l o o p  he l ix  
b l l b l l  s t r uc t u r a l  t ami lv ( o r n e l i u s s e n  et al.,  N i e l s e n  et  al.,  1(>(P  .
N e g a t i v e  a c t i n g  t r a n s c r i p t i o n a l  c o n t r o l  e l e m e n t s  ar e  l o c a t e d  u p s t r e a m  o t  t he  
" H i p  r e p e a t ,  w h i c h  b i n d  t o  t h e  e m b r v o m c  l . T R  b m d m c  f a c t o r  b . I .P  , w h i c h  is a 
m e m b e r  o t  t h e  n u c l e a r  h o r m o n e  r e c e p t o r  s u p c r t a m i l v  T s u k i v a m a  et  al., l ' ) l*2 
a n d  h a s  b e e n  s h o w n  t o  h a v e  m o d e s t  r e p r e s s o r  act ivi tv o n  t h e  I . T R .  A n o t h e r  
c e l l u l a r  t a c t o r ,  u p s t r e a m  c o n s e r v  e d  r e g i o n  b i n d i n g  p r o t e i n  I ( R B P ;  a l s o  k n o w n  
as Y i n  't a n g  1 A Y  1 o r  N b  1.1 b i n d s  t hi s  r e g i o n  a n d  m e d i a t e s  r e p r e s s i o n  o t  
t h e  I . T R  m  t r a n s i e n t  e x p r e s s i o n  a s savs  b l a n a g a n  et  al.,  l l)(P  .
T<> c r e a t e  a n  I T R - d r i v c n  v e c t o r ,  t h e  ( ' M Y  p r o m o t e r  w a s  d e l e t e d  a n d  v e c t o r s  w e r e  a l s o  
c o n s t r u c t e d  i n  w h i c h  t h e  1.(11 P  s e q u e n c e s  w e r e  r e p l a c e d  b v  a l u c i f e r a s e  r e p o r t e r  g e n e  
w h i c h  c o u l d  b e  q u a n t i f i e d  m o r e  a c c u r a t e l y
4.4.1 Cloning strategy and retroviral vectors derived from PINCO
( d o n i n g  s t r a t e g v  a n d  c o n s t r u c t i o n  o f  t h e  P I N C O  d e r i v e d  v e c t o r s  a r e  d e s c r i b e d  in t h e  
A p p e n d i x ,  p a r a g r a p h  S . 5 , h o w e v e r  s o m e  a r e  a l s o  p r e s e n t e d  h e r e  b r i e f l v :
P / A V  D - A :  T o  c r e a t e  P 1 N C O - A  ( a b b r e v i a t i o n  o f  P 1 N C (  ) - A - C M Y - e ( i  1 P, e n h a n c e r -  
d e l e t e d  . V 1 T R  w i t h  ( . M \  p r o m o t e r ,  s e e  p l a s m i d  m a p  S .5 .5)  t h e  f o l l o w i n g  s u b - c l o n i n g  
s t e p s  w e r e  c a r r i e d  o u t ,  f i r s t ,  p l a s m i d  p d . V B a s i c  P r o m e g a ,  p l a s m i d  m a p  S .2 .1 )  w a s  
d i g e s t e d  w i t h  Y C 1 A /v / I  a n d  r e l i g a t e d  t o  r e m o v e  t h e  , \ / d  A / w l  s i t e s ,  c r e a t i n g  
p (  i l . V A  N X  s e e  p l a s m i d  m a p  S .5.2) .  W e  t h e n  t o o k  a Y//1 .V//1 f r a g m e n t  t r o m  t h e  
r e t r o v i r a l  e x p r e s s i o n  v e c t o r  P 1 N ( . ( )  a n i l  s u b - c l o n e d  it i n t o  t h e  Y//1 s i t e  o t  p ( d . 3 - A - N \  
t o  c r e a t e  p ( d .  V A N \  I . T R  s e e  p l a s m i d  m a p  S N A .  D i g e s t i o n  o t  t h i s  c o n s t r u c t  w i t h  
A M  A d d  a n d  r e l i g a t i o n  r e s u l t e d  in p (  11. V A N  X A - l  T R  P e e  p l a s m i d  m a p  S .S .4 ) ,  w h i c h  
c a r r i e d  t h e  d e l e t i o n  o t  t h e  .VI . ' PR  e n h a n c e r  r e g i o n  b e t w e e n  A M  a n d  A  A/1, f i n a l l y ,  t h e
1 K»
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Safli/Saiy fragment was returned to PINCO-A^A/Atf/I to create PINCO-A (plasmid map 
8.5.5).
A-LTR-eGFP: (abbreviation of PINCO-A-Basic-eGFP, enhancer-deleted 3'LTR without 
CMV promoter, see plasmid map 8.5.8) was created by Notl/BamHl digest of 
PINCO-A. The resulting backbone was ligated with the Bg/lI/No/I EGFP fragment of 
pEGFP-Nl (Clontech, see plasmid map 8.4.1).
+LTR A-LTR
6 .. '=  nrii ■" ■ m
CMV
EF1a
v  /X |  CMV | IUC |
• •





X fcOHbl luc  T
v  /
x I P U 1 I  luc  I
p47phox I P47 I luc
Figure 21: Schem atic representation o f  PIN C O  derived retroviral vectors and the
enhancer-deleted derivates with luciferase (or EG FP) reporter gene expression.
Schematic diagrams o f  the PIN C O  vectors with luciferase (or eG FP, not 
show n) reporter gene under control o f  various promoters as indicated. Vectors 
with wild-type LTRs (+LTR) are on the left panel, enhancer-deleted derivates 
(A-LTR) are on  the right. The expanded box at each end represents the LTR in 
which the grey area identifies the 75-bp enhancer repeat region. The enhancer- 
deletion in the 3'LTR is indicated by the dotted line and the cross in the 5'LTR  
indicates that the deleted LTR will be copied and transposed to the 5 end in the 
provirus. T he arrows underneath each vector schematics indicates the luciferase 
reporter gene transcription unit. Detailed plasmid maps are listed in the 
Appendix 8.5.
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Luciferase activity obtained with PINCOA-CMV-luc (enhancer-deleted 3'LTR) and 
PINCO-CMV-luc (intact LTRs) vectors form transduced U937 cells (±PMA) were 
compared in a preliminary experiment (Figure 22). Whilst PMA induced cell 
differentiation increased luciferase activity in U937 cell under control of the CMV 
promoter (without LTR enhancer) about 1.6x fold, luciferase activity' obtained from 
PINCO-CMV-luc was enhanced by 2.4x fold.
Comparison of Luciferase Activity from 














Figure 22: Com parison o f  Luciferase Activity obtained with PINCOA-CM V-luc and
PIN CO -CM V -luc vector transduced U937 cells (±PM A).
U 937 cells were transduced by spinocculation with PINCOA-CM V-luc and 
PIN CO -CM V -luc retroviral vectors (ampho) as indicated and induced ±PM A  
before assayed for luciferase activity as described in the Materials and Methods 
(2.2.24). Background activity (control) was measured by assay from non­
transduced U 937 cells. Data are mean ± S D  from four independent 
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4.4.2 Effects of the LTR enhancer deletion on titre and transcription
T o  t e s t  t h e  e f f e c t s  o t  t h e  e n h a n c e r  d e l e t i o n  o n  t i t r e ,  t h e  w i l d - t v p e  a n d  A - I T R  v e c t o r s  
c a r r y i n g  t h e  l .C d  P  r e p o r t e r  w e r e  u s e d  t o  t r a n s d u c e  3 T 3  cel l s .  R e t r o v i r a l  t i t r e ,  a s  
e s t i m a t e d  I n  t h e  p r o p o r t i o n  o t  EX i T ' P - p o s i t i v e  ce l l s  ( 'Tab le  3) ,  w a s  n o t  s i g n i f i c a n t l y  
a t t c c t c d  b y  t h e  e n h a n c e r  d e l e t i o n .
Vector Titre (ifu/ml)
Promoter A-LTR WT-LTR
Basic (LTR) 1.16 x107 1.07 x107
CMV 1.12 x 1 0 7 1.24 x 1 0 7
1189EF1a 0.94 x 107 1.03 x107
1672CD11b 1.10 x 1 0 7 1.70 x 1 0 7
1226CD11b 0.53 x107 0.78 x107
732CD11b 0.64 x 107 0.95 x 1 0 7
PU.1 0.78 x107 1.03 x107
p47phox 0.61 x 107 1.49 x 107
446cfes 1.00 x107 0.90 x107
T a b l e  v E f f e c t  o t  e n h a n c e r  deict ic >n o n  r e t ro v i r a l  t i t re:  LXi l  P  v e c t o r s
T h e  e t t e c t  o t  e n h a n c e r  d e l e t i o n  o n  r e t r o v i r a l  t i t re  is r e p r e s e n t e d  In  c o m p a r i s o n  
o t  it'u m l  t r o m  A - I . T R  vs \ \ T  L T R  c o n s t r u c t s  w i t h  t h e  I X J 1 T  r e p o r t e r  g e n e .  
T i t r e  w . o  d e t e r m i n e d  u s i n g  a m o u n t ' -  o t  vi ral  s u p e r n a t a n t  be t w e e n  1 a n d  sui  I U1 
a n d  t h e  v a l u e  l tu  m l  c a l c u l a t e d  t r o m  t h e  p o p u l a t i o n  o t  l .Cil P  p o s i t i v e  
M U  ' T '  ce l l s  t a k e n  in t he  l i nea r  r e g i o n  o t  t h e  c u r v e .  D e s c r i b e d  m  t h e  M a t e r i a l s  
a n d  M c t l n  >ds 2 . A 3 1 .
h o l l o w i n g  c o n s t r u c t i o n ,  t h e  l u c i t e r a s e  v e c t o r s  w e r e  t e s t e d  t o r  t i t r e  b y  N o r t h e r n  d o t  b l o t  
f r o m  r e t r o v i r a l  s u p e r n a t a n t s  d e r i v e d  t r o m  e a c h  c o n s t r u c t  f i g u r e  23 ; .
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A-LTR WT-LTR
•  • Basic
CMV
•  • 1189EF1a
•  • 1672CD11b
•  • 1226CD11b
•  • 732CD11b
•  . • PU.1
•  • 446cfes
•  • p47phox
Figure 23: E ffect o f  enhancer deletion on retroviral titre: Luciferase vectors.
T he effect o f  enhancer deletion on  retroviral titre is represented by comparison 
o f  the density o f  ‘northern dot b lots’ from viral R NA in supernatant derived 
from A-LTR vs WT-LTR constructs with the luciferase reporter gene. WT, 
vectors with unmodified LTR; A-LTR, vectors carrying enhancer deleted LTR.
Basic =  LTR driven vector without internal promoter driving the luciferase 
reporter gene in addition to WT-LTR or A-LTR are indicated. (Materials and 
M ethods: 2.2.32).
As determined by the density of each dot blot pair (A-LTR vs WT-LTR construct) 
similar amounts o f viral RNA genome were present in all the supernatants, which 
indicates that the enhancer deletion did not affect this.
There were however some differences in titer between the various promoter constructs, 
while a direct correlation between the titre estimated from eGFP constructs and the 
titre estimated by northern dot blot with a luciferase probe could not be drawn 
conclusively. These differences may simply account for differences in viral RNA 
processing of each promoter construct.
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4.4.3 Retroviral Transduction with PINCO derived vectors
The A-LTR vector constructs harbouring the eGFP reporter gene were used to 
transduce NIH 3T3 cells (Figure 24). Flow cytometry for eGFP expression showed 
that, whilst titre on these murine fibroblasts was not severely affected, reporter gene 
expression from the A-LTR-CD1 lb construct was reduced by approximately two orders 
of magnitude (Figure 24, middle panels). The A-LTR-CMV construct showed a smaller 
reduction in expression that mainly revealed itself as a greater level of heterogeneity in 







Figure 24: E ffect o f  enhancer deletion on titre and transcription in N IH  3T3 cells.
Retroviral transduction o f  N IH 3T 3 cells analysed by flow cytometry for EG FP  
expression. Fluorescent gates (M l) were set based on mock transduction with 
no virus (plot not shown, 1%). Wild type (+LTR), unmodified PIN C O  vector 
with intact LTR; A -LTR , enhancer-deleted vector. Basic = without internal 
promoter. C D l l b  = 732bp C D l l b  promoter. The percentage o f  positive cells 
is show n at the top right o f  each panel and mean fluorescent intensity (MFI) o f  
the positive cell fraction is shown below  the x-axis.
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T o  (q u a n t i t a t e  t h e  e t t e c t  o t  t h e  e n h a n c e r  d e l e t i o n  o n  t r a n s c r i p t i o n ,  e q u i v a l e n t  ‘w i l d - t v p e ’ 
P I \ ( X  ) - b a s i c - l u c ,  w t - I T R )  a n d  e n h a n c e r - d e l e t e d  v e c t o r s  (PI  X C O A - b a s i c - l u c ,  A - L T R )  
h a r b o u r i n g  t h e  l u c i f e r a s e  g e n e  in  p l a c e  o t  e C i b ’P  w e r e  u s e d .  ' T r a n s c r i p t i o n  in 
f i b r o b l a s t i c  c e l l s  w a s  a g a i n  s i g n i t i c a n t l v  r e d u c e d .  L u c i f e r a s e  a c t i v i t v  in  b o t h  X I I I . V T 3  
a n d  1 l e l . a  c e l l s  t r a n s f e c t e d  w i t h  t h e  A - L T R  v e c t o r s  d e m o n s t r a t e d  a s i g n i f i c a n t  r e d u c t i o n  
i n  c o m p a r i s o n  w i t h  t h e  i n t a c t  w t - I . T R  ( F i g u r e  2 5 ,  A).
T h e  m a j o r  l o s s  o t  r e p o r t e r  g e n e  t r a n s c r i p t i o n  c o u l d  t h e r e f o r e  b e  a t t r i b u t e d  t o  d e l e t i o n  
o t  t h e  r e t r o v i r a l  e n h a n c e r .  I n t e r e s t i n g l v  h o w e v e r ,  w h e n  t h e  ‘b a s i c ’ A - L T R  v e c t o r  
e n h a n c e r - d e l e t e d  L T R  a n d  n o  i n t e r n a l  p r o m o t e r )  w a s  u s e d  t o  t r a n s d u c e  m v e l o i d  cel l  
l i n e s ,  P L B  P S 3  a n d  I  c)3~ ,  o n l v  a s m a l l e r  l o s s  o t  r e p o r t e r  g e n e  ac t i v i t v ,  a s s o c i a t e d  w i t h  
e n h a n c e r  d e l e t i o n ,  w a s  d e t e c t e d  F i g u r e  2 5 ,  B) .  H o w e v e r ,  t h i s  d i d  n o t  h o l d  t r u e  t o r  t h e  
i m m a t u r e  e r v t h r o l e u k a e m i a  ce l l  l i ne ,  T 1 -1 ,  i n  w h i c h  e x p r e s s i o n  w a s  a l s o  s e r i o u s l v  
c o m p r o m i s e d  b v  e n h a n c e r  d e l e t i o n  T i g u r e  2 5 ,  B) .
' T h e s e  o b s e r v a t i o n s  s u g g e s t e d  t h a t  t h e  e n h a n c e r - d e l e t e d  A - I T R  v e c t o r ,  a l t h o u g h  
s e r i o u s l v  c o m p r o m i s e d  t o r  t r a n s c r i p t i o n ,  m i g h t  st i l l  f u n c t i o n  e t t e c t i v e l v  in a m v e l o i d  cel l  
e n v i n  > n m e n t .
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PLB 985 U937 TF1
Cell Type
I a c u t e  2 A 1 i s sue  v p e c i t i c i n  a n d  l . t t e c t  <>t e n h a n c e r  I c I c t ! < >n o n  t r a n s c r i p t i o n  m  f i b r o b l a s t i c  
1 1 11 lint ' ' '  in c o m p . u i M i n  w i th t r a n s c r i p t i o n  in h a e m a t o p o i e t i c  ce ll l ines.
T r a n s c r i p t i o n  f r o m  ' b a s i c '  r e t r o v i r a l  v a l n i s  w i t h o u t  e x o g e n o u s  p r o m o t e r '  
w i t h  u n m o t l i t i e t l  P I N C O  bas i c  lue \ \  1 1.1 K, w h i t e  b a r s  a n d  e n h . i n t e r  
d e l e t e d  P I \ (  ( ) . \  b as i c  lue  A  I .TR ,  hl . iek h. i r s  in f i b r o b l a s t i c  A a n d  
h . i e m u t o p o i e t i e  H eel l  l ine' ' .  D. i t . i  .ire n i e . ui  j S I )  t r o m  t o u r  i n d e p e n d e n t  
t r . i n s d u c t i o n v  All  t h e  t l i t t e r e n e e s  b e t w e e n  w i l d n p c  a n d  e n h a n c e r  i l e letet l  
\ e c t o r s  w e r e  s i g n i f i c a n t  at p  * < ».< 'A M a n n  \ \  h i t nev  I tes t
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4.4.4 Comparison of Cellular Promoters driving the Luciferase Reporter gene
In order to analyse and compare the performance of myeloid specific promoter 
constructs in myeloid cell lines, luciferase assays of transduced PLB965, U937 and TF1 
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Figure 26: Luciferase activity by effect o f  PMA inducted cell differentiation on promoter
constructs and enhancer deletion in transduced myeloid cell lines (PLB985, 
U 937 and TF1).
Myeloid cells lines were transduced by spinocculation with retroviral vectors as 
indicated and induced ±PM A for 48h before assayed for luciferase activity as 
described in the Materials and M ethods (2.2.24). Data are mean ± S D  from four 
independent transductions and luciferase activity is presented as R L U /m g  
protein normalised to wild type LTR (+LTR) ±PM A = 100%. Normalisation is 
made in order to enable comparison between different cells line and under the
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a s s u m p t i o n  that  P M A  has  n o  ef fect  tin the  t r an sc r i p t io n  t r o m  the wi ld type 
L TR ,  that  solely t he  ef fect  o t  P M A  o n  t he  internal  p r o m o t e r  can  he  analysed.
T h e  blue bars  r e p r es e n t  wi l d t yp e  L T R  c o n s t r u c t s  w i t h o u t  P M A  + I .TR P M A ' ,  
whi le  t he  beige ye l low bars  r e pr es en t  the  wi ld type L T R  c o ns t r u c t s  wi th  P M A  
+ I T R  - P M A h  The p uqs l e  bars  r ep re se nt  e n h a n c e r d e l e t e d  L T R  ( I .TR A 
L T R  c o n s t r u c t s  w i t h o u t  P M A  M T R  P M A '  and  t he  black ba rs  r ep re se nt  the 
e n h a n c e r  d e l e t ed  L T R  c o n s t r u c t s  wi th  P M A  ( L T R  + P M . V .
I n  o r d e r  t o  c o m p a r e  t h e  l u c i f e r a s e  ac t i v i t v  d a t a  t r o m  i n d u c e d  a n d  u n i n d u c e d  ce l l s ,  t h e  
r e s u l t s  in  F i g u r e  2 6  a r e  p r e s e n t e d  b v  n o r m a l i s i n g  all o t  t h e  d a t a  t o  w i l d  t v p e  L T R  
( A P M A )  t o  100 °  (i. T h i s  n o r m a l i s a t i o n  w a s  b a s e d  o n  t h e  n o t  u n r e a s o n a b l e  a s s u m p t i o n  
t h a t  P M A  h a s  n o  e t t e c t  o n  t h e  t r a n s c r i p t i o n  f r o m  t h e  w i l d  t v p e  L T R  ( + L T R )  a n d  
p e r m i t s  n o t  o n l v  t o  i s o l a t e  t h e  e f f e c t  o f  P M A  i n d u c t i o n  o n  t h e  v a r i o u s  i n t e r n a l  
p r o m o t e r  t r o m  c o n s t r u c t s  w i t h  t h e  e n h a n c e r - d e l e t e d  L T R  ( A - L T R )  t r o m  c o n f o u n d i n g  
e x t e r n a l  f a c t o r s ,  b u t  a l s o  t o  e n a b l e  t h e  c o m p a r i s o n  o t  t h e  p e r f o r m a n c e  o t  t h e  s a m e  
p r o m o t e r  i n  d i f f e r e n t  t r a n s d u c e d  t r a n s d u c e d  ce l l s  l i ne s ,  w h i c h  m a v  d i f f e r  m a r k e d l v  in 
t r a n s d u c t i o n  e f f i c i e n c v .
W h i l e  all m v e l o i d  p r o m o t e r  c o n s t r u c t s  w i t h  e n h a n c e r  d e l e t e d  L T R  p e r f o r m e d  o n l v  
p o o r l v ,  in P L B ()85  a n d  I  6 3 "  ce l l s ,  n o  a c t i v i t v  w a s  o b s e r v e d  in  t h e  T L 1  cel l  l i ne ,  w h e r e  
l u c i f e r a s e  a c t i v i t v  c o u l d  o n l v  h e  o b t a i n e d  t r o m  c o n s t r u c t s  w i t h  w i l d  t v p e  L T R .
I n t e r e s t i n g l v ,  t h e  C M V  p r o m o t e r  c o n s t r u c t  w i t h  e n h a n c e r  d e l e t e d  L T R  d e m o n s t r a t e d  
p o t e n t  i n d u c i b i l i t v  in  r e s p o n s e  t o  P M A  in  all cel l  l i n e s  t e s t e d  ( F i g u r e  2 6 ,  b l a c k  c o l u m n ) .
I n  c o n t r a s t ,  P M A  i n d u c t i o n  s e e m e d  t o  h a v e  a n e g a t i v e  e t t e c t  o n  all t h e  m v e l o i d  
p r o m o t e r  c o n s t r u c t s  in  P L B 9 8 5  a n d  I  9 3 ”  ce l l s ,  b u t  n o  s i g n i f i c a n t  e t t e c t  o n  t h e  L F l c x  
p r o m o t e r ,  w h i c h  a s  s h o w n  in p r e v i o u s  e x p e r i m e n t s  w i t h  t r a n s i e n t  a s s av s ,  s e e m e d  t o  h e  
i n e r t  t o  P M A  i n d u c t i o n  a n d  in a d d i t i o n  d o e s  n o t  a p p e a r  t o  h e  a f f e c t e d  b v  e n h a n c e r  
delet i< >n < >t t h e  I ,TR .
H o w e v e r ,  w i t h  r e g a r d  t o  t h e  o t h e r  e n h a n c e r - d e l e t e d  v e c t o r s  w i t h  e x o g e n o u s  p r o m o t e r ,  
t h e  e v a l u a t i o n  s e e m e d  t o  h e  l e s s  c o n c l u s i v e  w i t h  o n e  e x c e p t i o n  p r e s e n t e d  b v  t h e  C M Y  
p r o m o t e r  s h o w i n g  a s i g n i f i c a n t  i n c r e a s e  o t  l u c i f e r a s e  act iv i tv in  I  6 3 ”  a n d  P L B 9 8 5  ce l l s  
w h e n  i n d u c e d  w i t h  P M A .
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A  n u m b e r  o t  o t h e r  g r o u p s  h a v e  a l s o  r e p o r t e d  e l e v a t e d  l e ve l s  o t  t r a n s c r i p t i o n  t r o m  t h e  
C M Y  p r o m o t e r  in  m v e l o i d  ce l l  l i ne s  i n d u c e d  t o  m a c r o p h a g e  d i t t e r e n t i a t i o n .  T h i s  e t t e c t  
h o w e v e r ,  c o u l d  h e  i n d i c a t i v e  o t  t h e  p r e s e n c e  o t  a  P M A  r e s p o n s i v e  e l e m e n t  in  t h e  C M Y  
p r o m o t e r  s e q u e n c e ,  r a t h e r  t h a n  a s  a r e s u l t  o t  t h e  i n d u c t i o n  o t  t e r m i n a l  cel l  
d i t t e r e n t i a t i o n  ( C h a n  e t  al . ,  1 9 9 6 ;  S a m b u c e t t i  e t  al . ,  198 9 ) .
H o w e v e r ,  t h e  t i m e  c o n s t r a i n t s  a n d  t h e  c o s t s  o t  t h e  m a t e r i a l s  p r e c l u d e d  c o n f i r m a t i o n  o t  
t h e s e  e x p r e s s i o n  p a t t e r n s .
4.4.5 Comparison of Cellular Promoters driving the eGFP Reporter gene
I n  p a r a l l e l  t o  t h e  l u c i t e r a s e  v e c t o r s ,  w e  a l s o  h a d  c r e a t e d  a n  e q u i v a l e n t  s e t  o t  p r o m o t e r  
c o n s t r u c t s  w i t h  t h e  e G F P  r e p o r t e r ,  w h i c h  w e  w a n t e d  t o  e v a l u a t e  b v  t h e  u s e  o t  v a r i o u s  
i n d u c e r s  o t  m v e l o i d  d i t t e r e n t i a t i o n ,  i n c l u d i n g  t h o s e  d i r e c t i n g  d i t t e r e n t i a t i o n  t o w a r d s  t h e  
g r a n u l e  >cv t i c  l i n e a g e .
In  p a r t i c u l a r ,  t h e  h u m a n  m v e l o m o n o h l a s t i c  l e u k e m i a  ce l l  l i ne  P L B 9 8 5  ( T u c k e r  e t  al. ,  
1 9S"~ p r o v i d e s  a g o o d  m o d e l  t o  s t u dv  m v e l o i d  d i t t e r e n t i a t i o n .  I n  t a c t ,  a g p 9 1 ' '  
k n o c k o u t  ce l l  l i ne  o t  P I . B 9 8 5  ce l l s  w a s  t h e  f i r s t  t o  h e  d e v e l o p e d  t o  s t u d v  X - C G D  a t  t h e  
ce l l  l eve l  ( / l i e n  e t  al . ,  1 99 3 ) .  T h e  a d v a n t a g e  o t  P I . B 9 8 5  ce l l s  is t h a t  t h e v  c a n  h e  t r e a t e d  
w i t h  r e t i n o i c  a c i d  ( R A )  o r  d i m e t h v l t o r m a m i d e  ( D M F )  t o  i n d u c e  g r a n u l o c v t e  
d i t t e r e n t i a t i o n ,  o r  12 - m v r i s t a t e  1 3 - a c e t a t e  ( P M A )  t o  i n d u c e  m a c r o p h a g e  d i t t e r e n t i a t i o n ,  
r e s p e c t i v e lv .
H e n c e  w e  c h o o s e  t o  e v a l u a t e  o u r  m v e l o i d  v e c t o r s  w i t h  t h e  e G F P  r e p o r t e r  g e n e  in  t h e  
P L B 9 S 5  cel l  f i r s t ,  a l t h o u g h  l e v e l s  o t  t r a n s d u c t i o n  w i t h  I  9 3 ”  ce l l s  h a d  s h o w n  t o  h e  m o r e  
e f f i c i e n t .  P I . B 9 S 3  ce l l  l i n e s  w e r e  d i f f e r e n t i a t e d  a t t e r  t r a n s d u c t i o n  w i t h  e G F P  v e c t o r s  b v  
t r e a t m e n t  w i t h  0.1 u.M p h o r b o l  1 2 - m v r i s t a t e  1 3 - a c e t a t e  ( P M A )  t o r  4 8 h  ( m a c r o p h a g e  
d i f f e r e n t i a t i o n )  a n d  bv 6 0 m M  d i m e t h v l t o r m a m i d e  ( D M F )  f o r  a n  a d d i t i o n a l  2 4 h  
(g r an u l e>cv t e  d i f f e r e n t i a t e > n ) .
I ' n f o r t u n a t e l v ,  d u e  t o  t h e  t i m e  c o n s t r a i n t s  o t  t h e  p r o j e c t  w e  h a d  t o  p r e c l u d e d  t h i s  p a r t  
o f  o u r  i n v e s t i g a t i o n  t o o  a n d  w i t h  t h e  av a i l ab i l i t v  o f  a s e t  o t  p 4 ”  d e f i c i e n t  m i c e  w e  
p r i o r i t i s e d  p r e p a r a t i o n s  t o  t e s t  a n e w  s e t  o t  o u r  v e c t o r s  ni vivo.
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4.5 Discussion
I n  r e t r o s p e c t ,  w e  e s t a b l i s h e d  t h a t  e n h a n c e r  d e l e t i o n  o t  t h e  L T R  h a d  m i n i m a l  e t t e c r s  o n  
t i t r e  ( T a b l e  3 a n d  F i g u r e  2 3 ) ,  b u t  a d r a m a t i c  e t t e c t  o n  t h e  l eve l s  o t  t r a n s c r i p t i o n  in 
f i b r o b l a s t s  ( F i g u r e  2 4  a n d  F i g u r e  25 ) .  T r a n s d u c t i o n  e f f i c i e n c y  i n t o  h a e m a t o p o i e t i c  cel l  
l i n e s  w a s  s i g n i f i c a n t l y  l o w e r  t h a n  f i b r o b l a s t i c  ce l l s ,  1 ' 9 3 7 ce l l s  b e i n g  t h e  m o s t  
s u s c e p t i b l e ,  a n d  T F - 1  b e i n g  t h e  m o s t  r e s i s t a n t  a n d  c o n s e q u e n t l y ,  r e s u l t s  t r o m  T F 1  ce l l s ,  
i n  p a r t i c u l a r  w e r e  i n c o n c l u s i v e  ( F i g u r e  26 ) .
W h i l e  e n h a n c e r  d e l e t e d  c o n s t r u c t s  p e r f o r m e d  p o o r l y  i n  t r a n s d u c e d  X J H 3 T 3  a n d  H e L a  
ce l l s ,  p o s s i b l y  t h e  m o s t  i n t e r e s t i n g  f i n d i n g  w a s  t h a t  o u r  ‘b a s i c ’ e n h a n c e r  d e l e t e d  v e c t o r  
p e r f o r m e d  s u r p r i s i n g l y  w e l l  i n  h a e m a t o p o i e t i c  ce l l  l i ne s  ( F i g u r e  25) .  T h e  m e a n  
f l u o r e s c e n t  i n t e n s i t y  ( M F I )  d a t a  ( F i g u r e  2 4 )  p u t  t h e  ‘b a s i c ’ v e c t o r  a t  s a m e  l eve l  w i t h  
C D l l b ,  a l t h o u g h  t h e  l eve l  o t  e x p r e s s i o n  o t  t h e  m v e l o i d  p r o m o t e r s  i n  t h e  m v e l o i d  cel l  
l i n e s  w a s  g e n e r a l l y  d i s a p p o i n t i n g  b e i n g  m u c h  l o w e r  t h a n  e x p e c t e d  a n d  in  a d d i t i o n  
s h o w i n g  l i t t le  o r  n o  i n d u c i b i l i t v  o n  m v e l o i d  d i f f e r e n t i a t i o n  ( F i g u r e  26) .
I n t e r e s t i n g l y ,  t h e  C M C  p r o m o t e r  s h o w e d  a p e a k  r e s p o n s e  t o  P M A  i n d u c t i o n  ( F i g u r e  26 )  
as  w e  w e r e  a b l e  t o  o b t a i n  a l r e a d y  t r o m  t h e  t r a n s i e n t  l u c i f e r a s e  a s s a y s  ( F i g u r e  I P  a n d  
F i g u r e  13) e a r l i e r ,  w h i c h  c o n f i r m e d  o b s e r v a t i o n s  m a d e  e l s e w h e r e  ( C h a n  e t  al . ,  1 9 96 ;  
S a m b u c e t t i  e t  al . ,  19 89 )  t h a t  t h e  C M Y  p r o m o t e r  m i g h t  h a v e  a P M A  r e s p o n s i v e  e l e m e n t  
in  t h e  C M Y  p r o m o t e r  s e q u e n c e  ( C h a n  e t  al. ,  199 6 ;  S a m b u c e t t i  e t  al. ,  1989 ) .
F ina l l y ,  it w a s  c o n c l u d e d  t h a t  t h e  d a t a  o b t a i n e d  t r o m  t r a n s d u c e d  cel l  l i ne s  - a f t e r  s o m e  
t i m e  c o n s u m i n g  a n d  e x t e n s i v e  a n a l y s i s  - w e r e  d i s a p p o i n t i n g l y  i n c o n c l u s i v e .  N o n e  o t  t h e  
c o n s t r u c t s  h a r b o u r i n g  m v e l o i d  p r o m o t e r s  s h o w e d  a n y  r ea l  e v i d e n c e  o t  e f f i c i e n t  m v e l o i d  
ce l l  s p e c i f i c  t r a n s c r i p t i o n  a n d  n o n e  s h o w e d  e v i d e n c e  t o r  u p - r e g u l a t i o n  in r e s p o n s e  t o  
i n d u c e d  m v e l o i d  d i f f e r e n t i a t i o n .  It is n o t  u n r e a s o n a b l e  t o  s u g g e s t  t h a t  t e s t i n g  o t  
p r o m o t e r  c o n s t r u c t s  u n d e r  t h e s e  c o n d i t i o n s  r e q u i r e s  t h e  s e l e c t i o n  o t  cel l  p o p u l a t i o n s  in 
w h i c h  100".» o f  t h e  ce l l s  a r e  s t a b l v  t r a n s d u c e d .  W i t h o u t  t h i s  c r i t e r i o n  b e i n g  s a t i s f i e d ,  it 
is likely t h a t  t h e r e  a r e  t o o  m a n y  v a r i a b l e s  t o  o b t a i n  r e l i a b l y  i n f o r m a t i v e  d a t a ,  w h e n  t h e  
l e ve l s  o t  e x p r e s s i o n  a r e  t h i s  low.
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S t a b l e  t r a n s d u c t a n t s  w o u l d  a l l o w  t h e  d i r e c t  c o m p a r i s o n  o f  t r a n s c r i p u o n  f o l l o w i n g  
i n d u c t i o n  o t  d i f f e r e n t i a t i o n  o v e r  l o n g e r  p e r i o d s  a n d  m u l t i p l e  r e p e a t s ,  w h i l s t  a v o i d i n g  t h e  
v a r i a b i l i t v  a s s o c i a t e d  w i t h  m u l t i p l e  t r a n s d u c t i o n s .
' b a k i n g  t h e s e  d a t a  t o g e t h e r ,  it w a s  f e l t  t h a t  t h e  o n l v  r e l i a b l e  w a v  t o  a s s a v  t h e  p o t e n t i a l  o t  
t h e  m v e l o i d  p r o m o t e r  c o n s t r u c t s  w o u l d  b e  t o  t e s t  t h e m  d i r e c t l v  in  a n i m a l s .  W e  w e r e  
f o r t u n a t e  t h e r e f o r e  t h a t  a  k n o c k o u t  m o u s e  m o d e l  o t  p4~ ’ x r e c e n t l y  d e v e l o p e d  a t  I ' C I ,  
b e c a m e  a v a i l a b l e  t o  u s  (a k i n d  g i f t  o t  D r .  J u r g e n  R o e s  a n d  P r o f .  T o n v  Se g a l )  a t  t h e  t i m e  
( J a c k s o n  e t  ah ,  1 9 9 5 ;  M e s s i n a  e t  ah ,  2 9 0 2 ;  P o l l o c k  e t  ah ,  1 9 9 5 ;  S e g a l  e t  ah ,  1 9 9 9 ) ,  t o  
e n a b l e  f u r t h e r  t e s d n g  o t  o u r  r e t r o v i r a l  c o n s t r u c t s .
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5 C o r r e c t i o n  o f  p 4 7 p h o x  k n o c k o u t  
m o u s e  m o d e l  o f  C G D  u s i n g  
e n h a n c e r - d e l e t e d  v e c t o r s
5.1 Background: Murine models of CGD
' l b  study d iffe ren t aspects o f  som atic  gene therapy  in C G D  in vivo, several m urine 
m odels have been  developed  to r  b o th  X -linked (gp9P  x ) and an au tosom al recessive 
(pd” " 'A ) fo rm  o f  C G D  by gene ta rg ed n g  (Jackson et ah, 1995; M essina et ah, 2002; 
Pollock et ah, 1995; Segal et ah, 1999). T hese  k n o ck o u t m ouse m odels show  
abnorm alities  in h o st defence and in flam m ation  due to the lack o f  phagocy te  
superox ide  p ro d u c tio n , and are vulnerable to in fec tion  w ith Aspergillus and  Staphylococcus, 
rep resen tin g  a sim ilar p h en o ty p e  to  th a t seen in hum an  C G D , w hich co n firm s the 
im p o rtan ce  o f  the  resp ira to ry  b u rs t fo r innate  im m unity  (G o ldb latt and T h ra sh er, 2000; 
Jackson et ah, 1995; Pollock et ah, 1995) . T h ere fo re , these geneucallv eng ineered  m ice 
have b eco m e essential to r  in vivo studies o t N A D P H -o x id ase  function  in phagocvtic and 
n o n -p h ag o cv tic  cells, the u n d ers tan d in g  o t the role o t superoxide in the host response  
to in fec tion  and in flam m atio n  and to r  the d eve lopm en t o f  novel therapies.
In  m urine C G D , re trov ira l-m ed ia ted  gene transfer in to  b one  m arrow  cells has been 
show n to  co rrec t the resp ira to ry  b u rs t oxidase acuvitv in phagocytes in vivo and  to  
im prove the d efec t in the h o st defence against bacterial and fungal p a th o g en s 
(B jo rgv insdo ttir et ah, 199“’; D in au e r et ah, 1999; M ardinev, III et ah, 1997 ; Sadat et ah, 
2003; Schw ickerath  et ah, 2(104). T h ese  studies were som e o t the first to  show  that gene 
therapy  could  alleviate the  clinical sym ptom s o t an inherited  d iso rder, using an anim al 
m odel that closely resem bles the h u m an  disease.
f o r  o u r investigation  a p 4 ”v "x defic ien t m ouse was used as a disease m odel to r  C G D , 
w hich lacks p hagocy te  superox ide  p ro d u c tio n , thus reflects an identical p h en o ty p e  to 
that seen in h u m an  C G D . 'I h e  p4~v 'A m ouse (gene knockou t, N C h - l)  develops 
severe sp o n tan eo u s  bacterial and fungal in fections sim ilar to th o se  developed  bv hum an  
C G D  patients.
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5.2 Bicistronic retroviral Vector with therapeutic gene and eGFP marker
In o rd e r to resto re superoxide g en era tio n  in these m ice o u r vectors w ere m odified  to  
in co rp o ra te  the p 4 -r x c l)N A  coup led  by an in ternal rib o so m e en try  sequence (IRKS) 
o f  the encephalom vocard itis  v irus (KCM Y) to the PX iPP m arker gene (see plasm id 
m aps 8.9). T h ese  vectors m ake a single b icistronic m R N A  transcrip t en co d in g  b o th  
pro teins, w hich are transla ted  separately. T h e  p resence o t the K G F P  allow ed to r 
in d ep en d en t d e tec tio n  o t tran sd u ced  cells and  the assessm ent o t viral titre.
5.2.1 Cloning strategy of retroviral constructs for bicistronic expression
T h e  clon ing  strategy  and  c o n s tru c d o n  o t the b icistronic retroviral vectors based on 
P IX (X ) are described  here briefly  w ith  the co rresp o n d in g  detailed restric tion  m aps 
listed in the A ppendix , parag raph  8.9,
In o rd e r to  insert the p4~’cD X A  trom  the vec to r p V /l-N C .’l T k  (kind gitt tro m  D r 
A dam  Rod a wav, see p lasm id m ap 8.6.1) in to  the b icistron ic expression  vec to r pIR K S2- 
eCiK'P from  C lon tech  (see p lasm id m ap  8.8.1) the follow ing subclon ing  steps w ere 
carried out: T h e  p 4 ~ cD X A  was sub -c loned  in to  the p C l-V ec to r (P rom ega, see plasm id 
m ap 8.A1) using l u o R l  and X/jA  sites, to  create  p C I-4 ~ cD X A  (see p lasm id m ap 8A.5). 
Finally, p4 "V D X A -IR K S 2 -eG F P  (see p lasm id m ap 8.8.3) was created  by cu ttin g  the 
p IR H S 2 -eG F P  vec to r (C lon tech , see p lasm id  m ap 8.8.1) w ith I uyAW and .W 1, w hilst the 
p 4 ~ cD X A  fragm ent was taken / ar/R I/ Sa/\ tro m  p C I-4 T D X A  (see plasm id m ap 8 .” .5).
-+-ITR: (abbreviation  for P1XCC )-Basic-p4~’cD X  A -IR K S2-eG I P, w ild-tvpe .V I'PR  
w ithou t CM Y  p ro m o te r, see p lasm id m ap 8.9.1): To create + 1 T R -p 4 T D X A -IR K S 2 - 
eCd P, the / a/yRl / ,\V>/1 fragm ent tro m  p 4 ” cD X  A-l R1 ,S2-e( 1 I P (see plasm id m ap 8.8.3) 
was cloned in to  the I uoR\ / Xo/ \  sites o f  P IX C O  (see plasm id m ap 8.5.1).
A -IT R  (abbrev iation for P1X(X )-A -B asic-p4^cD X  A -lR K S 2 -e (d ;P, en hancer-dele ted  
3 1.'PR w ithou t (2 \1 \’ p ro m o te r, see p lasm id m ap 8.9.2) was created  bv c lon ing  the
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i u ' o R \ / \ o / \  tragm cnt tro m  p 4 ” cD X  A -]R L S 2 -eG F P  (see p lasm id m ap 8.8.3) in to  
P IX C C )-A -O M Y -eG FP (equal to PIXCC )-A, see p lasm id  m ap 8.5.5).
A -LTR-CM Y: (abbrev iation  for P1NCC )-A -C M Y -p4” cD X  A -IR L S 2-eG F P ,
en h an cer-d e le ted  3 'L T R  w ith C M Y  p ro m o te r, see p lasm id m ap 8.9.3) was created  In­
com ing  the Wind111 (blunted)/.\7y/I cassette  o t p 4 ” c D X A -lR L S 2 -e G lP  (see p lasm id 
m ap  8.8.3) in to  l:roK\ (b lunted)/.W M  ot PIXCC )-A -eG F P  (see plasm id m ap 8.5.5).
Id  create A-lAR-(.D11b (abbreviation to r  P IX C C )-A -” 3 2 C D l 1 b -p 4 ”cD X A -IR L S 2 - 
e G IP , enhancer-de le ted  3 'L T R  w ith o u t CM Y  p ro m o te r plus ” 32bp o t the C D l l h  
p ro m o te r, see plasm id m ap  8.9.4), the I : ioK\ (b lu n te d ) /3 w l fragm ent trom  p 4 ” cD X A - 
IR E S 2 -eG I;P (see p lasm id m ap  8.8.3) was c loned  in to  Bawl (b lun ted)/.\X /1  d igested  A- 
L T R - '3 2 C D llh - e G F P (X l)  (equal to  P lX C O -A -” 3 2 C D l lb -e G F P (X  1), see p lasm id 
m ap 8.5.32), w hich was created  bv sub-c lon ing  the “'3 2 C D 1 1 b -e G F P  B gA l/AX/I 
fragm ent tro m  p X  1-C M Y -” 32C L )11 b -e G F P  (see plasm id m ap 8.4.5) in to  the 
AX/I Bawl 11 viral vec to r b ack b o n e  o t  A -IT R -e G F P  (equal to PIXCC )-A -B asic-eG FP, 
see plasm id m ap 8.5.8). 'The latter was created  bv exchanging the C M Y -eG FP  cassette  
[ \ o / \  Bawl \ I) o f  A -IT R -C M Y -F G F P  (equal to PIXCC )-A -CM Y -eG FP, see plasm id 
m ap 8.5.5) w ith the H G F P  (A7//L Bg’/Il) tro m  p F G F P -X l  (C lontech). p X l-C M Y - 
” 3 2 C D 1 1 b -e G F P  was created  bv tru n ca tin g  tull length (16~2bp) C D l l h  in p X l-C M Y - 
1CL2CD1 1 b -e G F P  with a .W I/-W I d igest and religation. pX  1 -C M Y -16"'2CD1 1 b -e G F P  
(see p lasm id m ap 8.4.3) was sub -c lo n ed  bv inserting  the / / /W il l /B a w W l  C D l l h  
p ro m o te r  from  p 0 G H C D l l b  (see p lasm id m ap 8.1.” , kind g itt tro m  Dr. D. H ickstein) 
in to  the BawWl  / //W ill side o t p F G F P -X l (C lontech).
A-1A R -1 .1 1 (X (abbreviation  to r PIXCC )-A -F H  (X-p4” cD X  A-1R1 )S2-eG l P, 
enhancer-de le ted  3 'L T R  w ithou t C M Y  p ro m o ter, but the F F 1 ( X  p ro m o te r instead , see 
plasm id m ap 8.9.'') was created  tro m  P1XCC )-A-F,F l(X-eGl P (see plasm id m ap 8.5.20) 
bv l .iolW /AX/1 digest and  insertion  o t the b icistronic unit trom  p4~ cD X  A-1RLS2- 
eG l P (see plasm id m ap 8.8.3) via the sam e restric tion  enzvm es.
l inallv, A -IT R -p 4 ” /abbrev iation to r  P1X C ( )-A -p4” p h o x -p 4 ”cD X  A-l R FS 2-eG F P , 
en hancer-dele ted  3 'L T R  w ith o u t C M Y  p ro m o te r, but the p 4 ” phox p ro m o te r instead ,
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see p lasm id m ap 8.9.5) was achieved by using the v ec to r P IN C O -A -p 4 7 p h o x -eG F P  
(see p lasm id m ap 8.5.36) as b ack b o n e  w ith  a EYoRI/iYo/I d igest and  in se ru o n  o f  the  the 
b ic istro n ic  unit from  p 4 7 cD N A -IR E S 2 -e G F P  (see p lasm id m ap  8.8.3) via the sam e 
re s tr icd o n  enzym es.
T h e  sam e cloning  strategy was used  fo r + IT R -p 4 7  (abbrev iadon  fo r P IN C O -p 4 7 p h o x - 
p 4 7 cD N A -lR E S 2 -eG F P , w ild-type 3 'L T R  w ith o u t C M V  p ro m o te r, bu t the p 4 7phox  
p ro m o te r  instead , see plasm id m ap 8.9.6 ) w ith  the P IN C ()-p 4 7 p h o x -e G F P  plasm id 
(see p lasm id  m ap  8.5.35) as backbone.
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Figure 27: Schematic diagrams o f  P IN C O  derived bicistronic retroviral vectors for the
transduction and reconstitution o f  p47Phos knockout mice.
The expanded box at each end represents the LTR in which the grey area 
identifies the 75-bp enhancer repeat region. The enhancer deletion in the 3'LTR  
is indicated by the dotted line and the cross in the 5 LTR indicates that the 
deleted LTR will be copied and transposed to the 5 end in the provirus. The 
arrows underneath the vector schematics indicates the p47iBA*xcD N A -IR ES2- 
eG F P  transcription unit. Detailed plasmid maps are listed in the Appendix 8.9.
A bove b icistronic vecto rs were used to  transduce bone m arrow  o f  p41fihox 1 d o n o r 
“ knockou t” m ice and analysed fo r transfection  efficiency.
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5.2.2 Retroviral Transduction o f bone marrow with bicistronic vectors
R etroviral supernatan ts  from  all the d iffe ren t vec to rs w ere used to  transduce to tal b o n e  
m arro w  from  a p47/>/,,‘x-de iic ien t m o u se  (M essina et al., 2002). T h e  tran sd u c tio n  
p ro to co l was derived from  on e  developed  fo r clinical usage and  was p e rfo rm ed  in 
cv to k in e-su p p lem en ted  serum -free  m ed ium , using m icro-titre  plates p re -co a ted  w ith 
fib ro n e cu n  fragm ent (Schilz et aL, 1998). In fec tio n  was fu rth e r enhanced  by the use of 
“ sp in o ccu la tio n ” to  concen tra te  re trov irus, hive ro u n d s o f  in fec tion  w ere p e rfo rm ed  
o ver a p e rio d  o f  48h. T h e  initial rates o f  tran sd u cd o n  w ere assessed by flow  cy to m etry  
(Figure 28) and  ranged  from  57%  fo r the W 'T-LTR v ec to r to  19% for the CD1 lb  vector.
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Figure 28: Flow  cytometric analysis o f  transduced bone marrow cells from 47 7 ‘knockout’
donor mice following transduction (before transplant).
Transduction efficiency o f  bicistronic vectors are indicated by FACS histograms 
as described in the Materials and Methods (2.2.35.1 and 2.2.35.2) and 
abbreviated as follows: A-LTR, vector with enhancer deleted LTR (left panel); 
WT-LTR, vector with unmodified LTR/enhancer (right panel) both without 
internal promoter, CMV, vector with enhancer deleted LTR and CMV as
internal promoter, E F la , vector with enhancer deleted LTR and E F la  as
internal promoter; C D  l i b ,  vector with enhancer deleted LTR and C D llb  as
internal promoter; p47Phox, vector with enhancer deleted LTR (left panel) and
unmodified W T-LTR (right panel) both with p47phox as internal promoter. The 
marker was placed using untransduced cells such that 99% were left o f  the 
marker. The percentage o f  E G FP-positive cells is shown at the top right o f  each 
panel.
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D u e to  the  lim ited availability at the  tim e, only ten p47 m ice w ere available fo r analysis, 
it was dec ided  to  m ake use o f  the follow ing v ec to r co n stru c ts  fo r tran sp lan ta tio n  in the 
p47/’>'“v-defcien t mice: W T-LTR , v ec to r w ith unm odified  L T R /en h an ce r; A -I.TR  vec to r 
w ith  en h an cer deleted  LTR; CMV, v ec to r w ith en h an cer deleted  LTR and C M Y  as 
in terna l p ro m o te r and CD1 lb , v ec to r w ith en h an cer deleted  LTR and CD1 lb  as in terna l 
p ro m o ter. T h e  rem ainder o f  the transduced  m arrow  cells from  these selected 
co n stru c ts  was th ere fo re  used to  tran sp lan t lethally irrad ia ted  p47/>/,“v-deficient recip ien t 
mice.
5.3 D etection o f retroviral vector in bone marrow o f reconstituted m ice
5.3.1 Flow cytom etric analysis o f bone marrow
Six w eeks a fte r tran sp lan tad o n  o f  the transduced  m arrow , the m ice w ere analysed for 
the p resence o f  the retroviral vector. B one m arro w  was isolated  and analysed by FAC'S 
fo r eCiFP fluorescence. T h e  p ro p o r tio n  o f  eG F P -p o sitiv e  cells ranged  from  
approxim ately  4 .3-13.0%  w ith the C D l l b  vec to r having the low est tran sd u c tio n  
frequency  and  the W T -L T R  v ec to r the h ighest (Figure 29, left-hand  panels). N o t 
unexpectedly, the in tact LTR vec to r show ed ev idence fo r a generally h igher level o f  
expression  than  the A -LTR vectors. H ow ever, we w ere particularly  in terested  to 
co m p are  the  p h en o ty p e  o f  cells expressing  E G F P  w ith the to tal m arrow  po p u la tio n .
B one m arro w  cells w ere isolated tro m  the transduced  recip ients and sub jected  to 
analysis bv flow  cy to m etry  using an d b o d ies  idendfy ing  m yeloid cells, these were: G r-1 , 
w hich stains m ainly g ranu locy tes and  m ature  m acrophages; F 4 /8 0 , a m acrophage  
m arker; and CD1 lb  itself, w hich is p resen t on  m ost phagocytes, particularly neu troph ils. 
F or this analysis, the total p o p u la tio n  o f  stained cells (Figure 29, righ t-hand  panels, ‘total 
BM ’) was co m p ared  w ith the an tib o d y  stain ing o t cells that were gated  to r  F iG FP 
expression  and hence con ta ined  the v ec to r g en o m e  (Figure 29, m iddle panels, m arked
‘E G F P + ’).
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Figure 29: Flow  cytom etric analysis ot transduced bone marrow cells trom reconstituted
p4“’ mice.
B one marrow (BM) cells trom mice transplanted with retrovirally transduced 
cells were analysed tor E G F P  fluorescence and by m veloid-cell-specitic 
m onoclonal antibodies as described in the Materials and M ethods (2.2.35). Lett- 
hand panels show  total FXiFP fluorescence in the bone marrow ot transplanted 
m ice and the percentage ot positive cells and MF1 is indicated. Panels marked 
F1GFP + show  antibody staining ot cells gated tor positive EG FP fluorescent' 
and GR 1 vs F 4 /8 0  ot FXiFP+ cells (middle panels).. Total BM (right-hand 
panels) show  antibody-staining pattern ot whole, ungated population. p-P  , 
show s marrow trom recipient pd"7"  -deficient mouse; WT-LTR and A-LTR, 
show s marrow cells trom mice transduced using wild-type and enhancer-deleted  
vectors as indicated previously. Summary ot quantitative data trom FACS dot 
blots ot all constructs are represented in Table 4.
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T h e  data  fo r all the co n stru c ts  are sum m arised  in Table 4.
Gr-1 + F4/80+ Gr-1 +/F4/80+ ■L CD11b+
EGFP Total EGFP Total EGFP Total EGFP Total EGFP Total ‘P=
PA1*** - 51.9 - 142 - 11 9 - 45.8 - 68.5
pAT1' - 58.4 - 7.6 - 67 - 40.7 - 64.5
+LTR (1) 67.4 632 51.1 113 29.5 88 11.0 34 3 76.4 71 8 0.025
♦LTR (2) 71.7 67.3 67.5 22.1 45.4 16 3 6.1 26.9 84.3 75.8
A-LTR (1) 78.4 728 6.7 56 5.2 53 20.0 279 83.7 802 0.025
A-LTR (2) 66.3 58.5 10.6 6.6 6.7 58 29.9 40.7 72.9 60.8
CD11B (1) 81.5 735 11.2 4.6 8.8 4 1 16.1 26.0 85.4 80.6 0.025
CD11B (2) 67.3 61.3 11.9 6.7 9.8 6 1 30.6 38.0 75.6 71.6
CMV (1) 69.4 660 6.5 30 4.6 27 22.9 33.8 75.2 660 0.025
CMV (2) 64.2 600 9.7 9 1 6.5 84 32.5 39 3 75.3 672
**P= 0.005 0 005 0.05 0.005 0 005
Table 4: D istribution ot mveloid markers in E G F P  positive and total marrow cells.
Values show n are percentage ot cells staining positive tor the myeloid cell 
markers. - / -  are cells that did not stain with either Gr-1 or F 4 /8 0 . Values are 
show n tor cells gated tor E.GFP expression and for the total bone marrow.
Where the value in the E G F P +  population is a higher proporuon than the 
proportion in the total marrow, the figures are show n in bold. Where the value 
in the E G F P + population is a lower proportion than the proportion in the total 
marrow the figures are in grev and bold. *p values were calculated for each 
construct using the three different myeloid markers onlv, using the W llcoxon  
signed-rank test. ~*P values were calculated tor each marker, or com bination, 
using the W ilcoxon signed-rank test.
S om ew hat unexpectedly, w ith all the vectors, includ ing  the W T -L T R  vector, we d e tec ted  
a m o d est p re feren ce  fo r m veloid cell exp ression ; co m p ared  w ith total m arrow , a slightly 
g rea te r p ro p o r tio n  o f  the K G F P -positive  p o p u la tio n  was also positive fo r the three 
m veloid-specific, surface m arkers (Gr-1 and F 4 /8 0 ; Figure 29, top  left, to p  right and 
b o tto m  right qu ad ran ts ; see also 'Fable 4). T h e re  was also a co n co m itan t red u ctio n  in 
the n u m b er o f  cells th a t w ere negative fo r b o th  Gr-1 and F '4 /80  (Figure 29, b o tto m  left 
quadran ts). T his p a tte rn  was m o st strik ing fo r the W T-LTR  vector, w hich, unlike the 
o th e r co n stru c ts , was also associa ted  w ith  a significant increase in the p o p u la tio n  o t
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G r - l+ /F 4 /8 0 +  cells (Figure 29, to p  right quadran t and Table 4). T hese w ere m ost 
p robably  m ature m acrophages, a lthough why they w ere n o t represen ted  w ith  the 
enhancer-deleted  vectors is unclear at present.
5.3.2 Colony assays
Som e o f  the rem aining m arrow  was used fo r plating in sem i-solid m edium . 
H aem atopoietic colonies were assayed after 14 days fo r the presence o f  the retroviral 
vector by analysis under a fluorescence m icroscope. Retrovirally transduced  colonies, 
absent from  the un transplan ted m ice (Figure 30), w ere clearly detected  by b righ t green 
fluorescence, indicating the p resence o f  E G F P  in the cells.












Figure 30: Colony assays: E G FP expression in reconstituted p47_/ mice.
Bone marrow cells were plated in semi-solid culture medium in the presence o f  
cytokines and colonies were allowed to develop for a further 14 days as 
described in the Materials and M ethods (2.2.36). The colonies were analysed for 
the presence and expression o f  the retroviral genom e by observation o f  E G FP  
fluorescence under an inverted UV microscope. Genotype and retroviruses as 
identified previously.
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T h e  intact LTR vector p roduced  the brightest colonies (Figure 30), though  a wide 
variation was observed  w ith  all the constructs. D esp ite  a generally reduced  level o f  
fluorescence, fluorescent colonies w ere also readily detected  w ith the A-LTR vecto r 
(Figure 30).
5.4 Analysis of pAlphox expression in tissues of the reconstituted mice
5.4.1 Western blot analysis of spleen and bone marrow
To begin the  analysis o f  p47/Aof expression, the spleens were rem oved from  the 
transp lan ted  m ice and assayed for presence o f  p47/>iox p ro te in  by W estern blot. P ro teins 
separated  by 10%  SD S-PA G E  w ere transferred  to  a nitrocellulose m em brane and 
incubated w ith  an ti-hum an  pA lpba>c.
wt 47- CD11b CMV A-LTR +LTR
p47p'wx 
actin
Figure 31: Western Blot o f  p47pA*v protein expression in reconstituted p477- mice.
The presence o f  p47/>**x protein in spleen cells (and bone marrow, same results 
not shown due to bad quality o f  the blot resulting from not enough material as 
marrow were needed for other experiments) was demonstrated by Western blot 
(as described in the Materials and Methods, 2.2.39) o f  total cell protein probed 
with anti-p47/>A*x peptide antiserum. Equal protein loading in each lane was 
confirmed by stripping and re-probing the blot with antibody to f5-actin. Wt, 
proteins from wild-type mouse, expressing normal levels o f  \A lphtx\ 47-, 
recipient p47 /- knockout mouse with no endogenous expression o f  p47/>A*x; 
C D llb ,  proteins from two p47v mice transplanted with transduced bone  
marrow using enhancer-deleted vector driven from C D llb  promoter; CMV, as 
before but with CMV-driven enhancer-deleted vector, A-LTR, A-LTR-driven 
vector; +LTR, unmodified LTR-driven vector.
N o  pro tein  was detectable in the  un transp lan ted  recipients (Figure 31, lane 47-). In  all 
cases, however, pA lpbtK could be detec ted  in the transplanted mice. T he  A-LTR vecto r 
(Figure 31, lane A-LTR) proved  to  have levels o f  pA lpbeK p ro tein  significandy greater
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than  either the C D l lb -  o r CM V-driven vectors (Figure 31, lanes C D l l b  and CMV, 
respectively), although the anim als transduced  w ith an in tact LTR (Figure 31, lane 
+LTR) had the h ighest levels o f  p47/A** expression.
5.4.2 NBT analysis of bone marrow derived colonies
H aving established that myeloid cells in the  m ouse bo n e  m arrow  were efficiently 
transduced by the enhancer-deleted  vectors, we investigated w hether p47/>/’“k function  
had  been restored  to  these cells by assaying their ability to  generate superoxide. B one 
m arrow  cells from  the transplanted mice were plated in to  sem i-solid m edium  and 
m yeloid colonies arising at day 14 o f  culture were assayed for the generation  o f  
superoxide by the addition  o f  n itroblue tetrazolium  (NBT). T h e  reduced fo rm  o f  this 
com p o u n d  fo rm s a dark-blue insoluble precipitate w hich can be used to  de tec t the  
presence o f  a functional N A D P H  oxidase in m yeloid colonies (Sekhsaria et aL, 1996).
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Figure 32: Colony Assays: N B T  Analysis o f  haematopoietic colonies for N A D P H  oxidase
activity in reconstituted p47-/' mice.
Oxidase activity was detected by in situ staining o f  bone marrow derived 
haematopoietic colonies using N B T  as described in the Materials and M ethods 
(2.2.36 and 2.2.37). Oxidase activity is revealed by the presence o f  a dark-blue 
precipitate in the cells. Examples o f  positive colonies are shown by red arrows.
It is noteworthy that with all the vectors blue-staining colonies were detected (Figure 
32), that were clearly absent in the untransduced recipients (Figure 32, top right panel).
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MR" Positive Colonies in Transduced Bone Marrow
90%
p47*/+ p47-/- CDllb CM/ A-LTR WT-LTR
construct
f  igure 33: Percentage o f  colonies in transplated mice scoring positive with N BT.
Oxidase activity was detected by in situ staining o f  bone marrow derived 
haem atopoietic colonies using N B T  as show n in Figure 32 and described in the 
Materials and M ethods (2.2.36 and 2.2.3"'). N B T  positive colonies were scored  
for each construct as indicted.. Data are mean ± S D  for two mice analysed in 
duplicate.
E n u m era tio n  o f  positive co lonies (F igure 33) again show ed that the h ighest p ro p o rd o n  
w ere found  in the m ice transduced  w ith the W T-L TR  vector, w here  nearlv 50%  o f  the 
co lonies scored  posiuve com pared  w ith approxim ately  70%  posiuve co lonies in n o rm al 
p 4 7 ~ m ice. S ignificant num bers o t co lonies show ing  evidence for superox ide 
g en e rad o n  w ere to u n d  in cells from  all the m ice transduced  w ith the A -LTR v ec to r sdll 
giving rise to  over 30%  posidve colonies.
5.4.3 Superoxide generation in peripheral blood
To com plete  this analysis we also investigated  superoxide g eneradon  in the peripheral 
b lood  o t these anim als. F o r this w e em ployed  an assay to r  superoxide d ep en d in g  o n  the 
red u cd o n  o f  d ih y d ro rh o d am in e  (F m m e n d o rffe r  et al., 1990; E m m en d o rffe r et al., 1994) 
w hich is d e tec ted  as a shift in the red  fluorescence o f  rhodam ine and can be analysed by
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FACS. T o calibrate the assay a s tandard  curve was g enerated  using m ixtures o f  w hite 
























Figure 34: Calibration ot N A D H  oxidase activity.
A standard curve was produced bv mixing blood in varying ratios trom wild- 
type and p4'v '<N-detlcient mice and the resulting oxidase activity was plotted  
against the percentage o f  wild-type cells as described in the Materials and 
M ethods (2.2.38). The regression analysis was used to calculate the values 
shown in Figure 35
S om ew hat surprisingly, very high levels o f  superox ide g en e ra tio n  w ere detec ted  in the 
transduced  cells, th ough  we curren tly  have no  exp lan ad o n  for the disparity in oxidase 
activity betw een  the m ice reco n stitu ted  w ith  the C D l l b .  We suspect, how ever, that the 
low er value is m ore  realistic as the h igher estim ate was from  a sam ple co m p ro m ised  by a 
p o o r recovery o f  cells. In the case o f  m ice tran sd u ced  w ith the W T-LTR vector, supra- 
no rm al levels o f  superox ide g en e ra tio n  w ere de tec ted  (Figure 35). M ore unexpectedly, 
perhaps, was the fact that superox ide gen era tio n  levels com parab le to those  o t no rm al 
cells w ere also o b ta in ed  from  A -LTR v ec to r transduced  cells, w hich gave the b est results 
o f  all the en h ancer-dele ted  vectors (Figure 35).
138
Chapter 5: Correction o f p47phox knockout m ouse m odel o f CGD using enhancer-deleted
vectors





^  120 -






CD11b1 C011b2 CMV1 CMV2 A-LTR1 A-LTR2 WT-LTR1 WT-LTR2
construct
f  igure 35: D H R  assav o f  N A D P H  oxidase activity in eGFP-gated peripheral blood cells ot
reconstituted mice.
D ihvdrorhodam ine (D H R ) assav was carried out as described in the Materials 
and M ethods 2.2.38. Values are mean + S D  (n = 4) and are shown specifically for 
eGF:P+ penpheral blood cells o f  each reconstituted m ouse, identified bv the 
retroviral vector used.
T his last o b serv a tio n  is o t particu lar relevance to  the trea tm en t o f  C G D , as it is well 
estab lished  that relatively low nu m b ers  o f  cells able to generate  n o rm al levels of 
superoxide can p ro v id e  p ro tec d o n  from  in fecuon  (Roos, 1994; Segal et al., 2000), 
w hereas cells w ith significant levels o t pardal acdvitv, even w hen p resen t in no rm al 
n um bers (B u-G han im  et al., 1995), are unable to eftecdvelv  kill engulfed pathogens. 
T h e  high levels o f  superox ide g eneration  we o bserved  in m ice transduced  w ith o u r 
A-LTR vector, co u p led  w ith its freedom  from  viral en h an cer elem ents, m ake it a highly 
p rom ising  cand ida te  fo r creating  a new  generation  o f  gene therapy  vec to rs w ith a 
m aterially im proved  safety profile.
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5.5 D iscussion
We have described  here the c o n s tru c d o n  o f  an enhancer-dele ted  v ec to r suitable for 
app licauon  in gene therapv  p ro to co ls  fo r tread n g  diseases that a ttec t the m yeloid 
lineage. A lthough  the th eo ry  and  p racdce  su rro u n d in g  enhancer-dele ted  and  self- 
inacdvating vec to rs has been  know n fo r som e tim e (Yu et al., 1986), only recently, 
especially w ith  the increased  levels o f  in te re st in H IV -derived lenuviral vectors, have 
their a ttribu tes been  considered  to  be o f  p rim arv  im p o rtan ce  (K raunus et al., 2004; 
Scham bach  et al., 2006; T h o rn h ill et al., 2008).
T h e  m ost com m only  en co u n te red  p ro b lem  w ith  the use o f  enhancer-dele ted  o r  self- 
inacdvadng  (SIN) vecto rs has b een  loss o f  d tre  (M iller and  W helan, 1997; S oriano  et al., 
1991; Yee et al., 1987; Yu et al., 1986). Interestingly, the  co n stru c ts  we have d escribed  
here d o  n o t ap p ear to  su ffer from  this p ro b lem  (see ch ap te r 4, 4.4.2), b u t the reasons fo r 
this are n o t ab u n d an d y  clear. It may be th a t sim ple deleuon  o f  the 3 'L T R  en h an cer 75- 
bp  repeats, leaving the p ro m o te r  essendally in tact, helps to m aintain  efficient 
po lvadenv lauon  o f  re troviral g en o m ic  R N A . M oreover, the absence o f  a second  
p ro m o te r o r enhancer, active in the  packag ing  cells in ad d id o n  to  the LTR, m ight help to 
m ain tain  d tre  bv avoidance o f  in te rfe ren ce  o r co m p ed d o n  betw een  the in ternal 
p ro m o te r and  the LTR. Such c o m p e d d o n  betw een  p ro m o te rs  could also pardally  
acco u n t for the failure o f  the G D I lb  p ro m o te r  to  enhance  tran sc rip d o n  over A -LTR in 
m yeloid targe t cells.
A lternatively, it may be that the loss o f  d tre  a ttrib u ted  to  o th e r  SIN  vecto r co n stru c ts  
can actually be accoun ted  for by reduced  levels o t tran sc rip d o n  in the target cells used 
for titration . Bv estim ating  titre using d o t b lo ts we have show n that som e ap p aren t loss 
o f  titre in the en hancer-dele ted  vec to rs is really due to  p o o r  levels o t transcrip tion  in 
3T3 cells w hen  expression  is driven from  a p ro m o te r m ore  active in m yeloid cells. 
W here tissue-specific p ro m o te r  elem ents are em ployed , it may be generally safer to 
estim ate d tre  using a m eth o d  th a t is in d ep en d en t o f  re trov iral-m ediated  gene expression  
like d o t b lo tting , or, b e tte r  still, real-tim e PCR.
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Perhaps the m ajor conundrum  in the w ork we have described has been the high level o f  
oxidase activity restored  by the A-LTR vector, w hich has no  enhancer and  only a 
retroviral prom oter. T h e  precise boundaries o f  the enhancer deletion in o u r construc ts 
have led us to  focus on  a transcrip tion  factor binding site hom ology  still p resen t in the 
enhancer-deleted  LTR; this is a site fo r the transcrip tion factor family C /E B P  (see 
Figure 36, red arrow ), which lies just dow nstream  o f  the X ba l site (Figure 36).
Figure 36: Detailed schematic representation o f  retroviral LTR.
Detail from the retroviral LTR showing the enhancer deletion between N M  and 
X bal, which removes both o f  the 75-bp repeat sequences containing a number 
o f  transcription factor binding sites as shown and described previously in Figure 
20. The deletion leaves the T A T A  element o f  the retroviral promoter and 
transcriptional start point intact, but also a C /E B P  binding site as indicated by 
the red arrow (adapted from (Coffin et al., 1997)
T h e  critical role o f  C /E B P  b inding factors in myeloid cell differentiation, particularly 
C /E B P a , has been well docum ented  (F riedm an et al., 2003; K um m alue and Friedm an, 
2003; N agam ura-Inoue et al., 2001). In  fact the differential expression o f  C /E B P a  
appears to  influence the lineage choice o f  b i-po ten t G /M  precursors to  either 
granulocytic o r m onocytic d irection  (Z hu and E m erso n , 2002), while C /E B P a  was 
found preferentially expressed in and required for the granulocytic lineage, b u t n o t for 
the m onocytic lineage (Z hang et al., 1997).
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6.1 General D iscussion
Im p ro v em en ts  in retroviral vectors, haem atopo ie tic  stem  cell transp lan ta tion  techn iques 
and  transduc tion  p ro to co ls  have lead to  the  ach ievem ent o f  successful gene therapy  
p ro to co ls  for the inherited  im m unodefic iency  diseases X -linked severe co m b in ed  
im m une deficiencies (S C lD -X l)(C avazzana-C alvo  et al., 2000a; T h ra sh e r et al., 2006) 
and adenosine deam inase defic ien t SC1D (A D A -S C lD )(A iu ti et al., 2002; G asp a r et al., 
2006) using retrov iral vectors. M ore recentlv  som e th erap eu d c  benefit has also been  
achieved fo r patien ts  su ffering  from  X -linked ch ron ic  g ranu lom atous d isease (X- 
C G D )(O tt et al., 2006), w ith  the p ro m ise  that gene therapy  may becom e a standard  
trea tm en t fo r this disease in the  future. H ow ever, a n u m b er o f  factors lim iting the 
effectiveness and safety o f  this trea tm en t are still u n d er investigadon and will require 
fu r th e r d ev e lo p m en t befo re  gene therapy  fo r C G D  becom es the trea tm en t o f  choice.
O n e  im p o rtan t co n sid erad o n  w here  C G D  differs from  S C ID  is that alternative and 
estab lished  m eth o d s  o f  trea tm en t for C G D  patien ts are available: the use o f  
prophvlactic  antib io tics and  in terfe ro n -y  (IFN -y), coup led  w ith trea tm en t o f  acute 
in fec tions and p ro lo n g ed  courses o f  antim icrobial trea tm en t have significantly im proved  
the clinical cou rse  o f  patien ts w ith C G D  (D inauer, 2005). W ith  life expectancies o f  at 
least 25 plus vears for the majority’ o f  C G D  patien ts, fo r gene therapy  to  be an 
acceptab le trea tm en t in C G D  it is essential th a t it is deem ed  b o th  sate and efficient 
befo re  it can be used in rou tine  clinical application.
C o n cern s over the safetv and lim itations o f  the cu rren t o f  technologies retroviral- 
m ediated  gene therapv  have been  b ro u g h t sharply in to  re lief in recent years, from  the 
experience o f  F ischer and his colleagues follow ing an o therw ise highly successful 
clinical trial (C avazzana-C alvo et al., 2000b; H acein-B ey-A bina et al., 2002b), o t gene 
therapv fo r X -linked severe co m b in ed  im m une deficiency (X -SC ID ) (H acein-B ey-A bina 
et al., 2003b; H acein-B ey-A bina et al., 2003c; K aiser, 2003; K o h n  et al., 2003). A 
nu m b er o f  patien ts in this trial developed  a gene therapy-induced  leukaem ia ow ing to
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the ran d o m  natu re  o f  retroviral in teg ra tion . In  every case, this leukaem ia arose from  
in teg ra tion  o f  the retroviral g en o m e in close proxim ity  to  the LM 02 gene, a gene 
involved in the co n tro l o f  T-cell p ro life ra tio n  and know n to  have the capacity  to  be 
oncogenic.
T h e  po ten tia l risks from  ran d o m  retrov iral in teg ra tion  have been  well d o cu m en ted  
(C o rn e tta  et al., 1991) and prev iously  have been  accep ted  as finite bu t fairly rem ote . 
H ow ever, the experience gained in the X -S C ID  clinical trial has renew ed the safety 
co n cern s  over the use o f  retroviral vec to rs in clinical gene therapy  p ro tocols.
A s revealed by the X -S C ID  inciden t, the ch ief risk arising from  ran d o m  in teg ra tio n  is 
leukaem ogenesis caused by in sertional m utagenesis leading to  inactivation  o f  a tu m o u r 
su p p resso r gene, o r -  as was the  case in th e  X -S C ID  trial o f  F ischer and co-w orkers 
(H acein-B ev-A bina et al., 2003b; H acein-B ey-A bina et al., 2003a; H acein -B ey-A bina et 
al., 2003c) — the activation o f  an oncogene.
F u rth e rm o re , the recent successful co rrec tio n  o f  X -linked C G D  was revealed to  be 
absolu telv  d ep e n d en t on  the expansion  o f  m ultiple haem atopo ie tic  clones carry ing  
in sertio n s  th a t e ither o ccu rred  in o r near P R  d o m ain -con ta in ing  zinc-finger gene loci. 
T h e ir  p red o m in an ce  in the m yeloid b lo o d  co m p artm en t also suggested  th a t clonal 
exp an sio n  o rig inated  from  an im m atu re  m yeloid p ro g en ito r ra th er than  a stem  cell (O tt 
e t al., 2006; O tt  et al., 2007). O n ce  again, som e o f  the genes involved w ere o f  know n 
o n co g en ic  p o ten tia l and this indicates th a t ex trem e caution  is required  in the fu rth e r use 
o f  this gen e  therapy  approach  even in a potentially  life-threaten ing  disease such as 
C G D .
B oth  experiences w ith these recent advances in the use o f  gene therapy have th e re fo re  
necessita ted  a reassessm en t o f  such the risks. H ence, novel vec to r design, safety issues 
and possib le  so lu tions are today high on  the agenda in the field o t gene therapy  and 
have been the subject o f  a n u m b er o f  reviews (Baum  et al., 2003; Baum  et al., 2006; 
H aviernik and B unting, 2004; Sinn et al., 2005; Yi et al., 2005).
O n e  p ro p o sed  strategy  to  reduce the risks in h eren t in the use o f  gene therapy  involves 
co -tran sd u ctio n  o f  a “ su ic id e -g e n e” un d er the co n tro l o f  an inducible p ro m o te r, as an 
im p o rtan t safety feature, since d estru c tio n  o f  transduced  cells can poten tially  be
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triggered  if  ab n o rm al g ro w th  is o b serv ed  (Pain ter et al., 2005). In  add ition , the 
cond itional expression  o f  the transgene  restric ted  to  the ap p ro p ria te  target cells via the 
co m b in atio n  o f  targeted  tran sd u c tio n , cell type-specific expression , and targe ted  local 
adm in istra tion  could  help to  increase the overall safetv o f  retroviral vec to r svstem s.
F u rth er, sp litting  o f  the viral gen o m e, use o f  self-inactivating (SIN) retroviral vectors, o r 
com ple te  rem oval o t the cod ing  sequences fo r gng, po/, and  etiv genes are all desirab le 
strategies to  em ploy in the  p ro d u c tio n  o f  re trov iruses for clinical usage, to  virtuallv 
elim inate the possibility  o f  g enerating  rep lication  co m p e ten t re trov iruses (RCR), w hich  
cou ld  con tam inate  clinical retroviral p repara tions.
Lately, the use o f  novel n o n -in teg ra tin g  lentiviral vectors has been  p ro p o se d  as a 
so lu tion  to  overcom e in sertional effec ts o f  the virus (P h ilpo tt and  T h rash er, 2007; 
Y anez-M unoz et al., 2006). W hilst this ho lds m uch p rom ise  for som e d iso rd ers that, 
involve gene tran sfe r to  p o stm ito tic  tissues, e.g. co rrec tio n  o f  inherited  retinal 
deg en era tio n , m uscle (A polonia et al., 2007), and  possib le vaccine d ev e lo p m en t, this 
ap p ro ach  m ay n o t necessarily be particularly  useful for haem atopo ie tic  co n d itio n s that 
require p e rm an en t and sustained co rrec tio n  o f  the d iso rd er in a p o p u la tio n  o f  
con tinuouslv  dividing cells.
A n u ltim ate so lu tion  to  this p ro b lem  will m o st p robab ly  be in re-engineering retroviral 
vec to rs so th a t the re troviral in sertio n  takes place only at the specifically desired  sites o f  
the h o st cell ch ro m o so m e  and th a t the transgene is expressed  at no rm al levels in a 
tissue-specific m anner.
6.2 Final Conclusions
In this study, we have described  the g en e ra tio n  and testing  o f  a series o f  en h an cer 
deleted  A-LTR retroviral vectors that a ttem p ted  to  co m b in e  high titre and tissue-specific 
transcrip tiona l activity to  p rov ided  highly efficient resto ra tio n  o f  superoxide generation . 
T hese  vectors w ere tested  in b o th  m veloid cell lines in vitro and in vivo in a m ouse m odel 
o f  au tosom al recessive C G D .
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T h e  A-LTR vecto rs gave accep tab le levels o f  gene tran sfer to  m ouse b o n e  m arro w  cells. 
E v idence for a slight preferen tia l exp ression  in m yeloid cells was ob ta ined  w ith  all the 
vectors stud ied  (Figure 29 and  T able 4). N itro b lu e  tetrazo lium  assav o f  superox ide 
gen era tio n  in m ouse b o n e  m arro w  derived haem atopo ie tic  colonies revealed th a t 
tran sd u c tio n  w ith  A-LTR vecto rs cou ld  resto re  functional N A D P H  oxidase to  cells 
from  these anim als. S uperoxide assay o f  peripheral b lood  co n firm ed  that, a lthough  
relatively low  nu m b ers  o f  cells w ere transduced , the A-LTR v ec to r was capable o f  
reconstitu ting  very high levels o f  oxidase activity, com parab le  to  that ob ta in ed  from  
no rm al cells.
We surm ise that, in the absence o f  a non-tissue-specific  enhancer, the  C /E B P  b ind ing  
site in the A-LTR v ec to r may be m ediating  tran scrip tio n  in m yeloid cells, albeit at 
som ew hat reduced  levels o f  expression  co m p ared  w ith an in tact LTR. In  su p p o rt o f  
this in te rp re ta tio n  is the  ob serv a tio n  that slightly larger deletions w hich also en co m p ass  
the viral p ro m o te r, so-called SIN  vec to rs (D elviks et al., 1997; Iw akum a et al., 1999; 
N aviaux et al., 1996; Yu et al., 1986), seem  to  ren d er the LTR transcrip tionallv  inert.
Interestinglv, a lthough  C /E B P  factors have the co rrec t tissue specificity for expression  
o f  p47/v*lv, their kinetics d iffe r qu ite  significantly and no  C /E B P  binding  sites have been 
identified  in the p47/V"A p ro m o te r  itse lf (Li et al., 1997; M arden  et al., 2003a; M arden  et 
al., 2003b). F o r exam ple, m axim al ex p ressio n  o f  C /E B P a  in neu troph ils  develops p rio r 
to  term inal d iffe ren tiation , declin ing  at a tim e w hen  p47/>y">x is norm ally  accum ulating. 
D esp ite  this d ifference, it does n o t ap p ear to  affect accum ulation  o f  p47/VftN in A -LTR 
v ec to r-tran sd u ced  cells p rofoundly . O n  the  o th e r  hand , it m igh t accoun t for the p o o re r 
rep resen ta tio n  o f  transduced  m acrophages in b o n e  m arro w  we ob serv ed  in the FACs 
analysis (Figure 29 and Table 4) co m p ared  w ith the W T -IT R  vector.
It is no tab le  th a t an alternative S IN -v ec to r app roach  to  the d ev e lo p m en t o f  vectors for 
C G D  retroviral gene therapy  has also been described  (R oesler et a/., 2002). 'Phis system  
has displayed im pressiye leyels o f  co rrec tio n  in C G D  p a tien t cells used to  transp lan t 
N O D /S C ID  mice. W hilst it possesses many, though  n o t all, o f  the yirtues o f  o u r ow n 
yec to r system , as it was based on  a lentiyiral yec to r b ackbone  it has poten tial adyantages 
for applications requiring  tran sd u c tio n  o f  qu iescen t cells. F lIY -based lentiyiral vec to rs
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co n d n u e  to  show  m uch p rom ise  b u t also have significant add idonal safety co n ce rn s  o f  
their ow n.
Unlike convendonal retroviral vectors, w hich  require cell division to  facilitate 
in teg rad o n , lenuviral vectors are p ro m isin g  too ls for the d eve lopm en t o f  gene therapv  
since they can infect and transduce efficiently  b o th  qu iescen t and dividing targe t cells 
(D elenda, 2004). H ence, lendviral vec to rs are pardcularly  a ttracdve vehicles fo r gene 
delivery to  h aem ato p o ied c  stem  cells, since these cells tend  to  be qu iescen t and  are 
th ere fo re  difficult targets for vec to rs th a t require dividing cells. T hey  also can p rov ide  
h igher levels o f  gene expression  th ro u g h  the in co rp o rad o n  o f  enhancing  regulatory  
elem ents, like the w oodchuck  p o s t-tran sc rip d o n a l regulatory  e lem ent (\Y PR E), w hich 
has been show n to  have significant beneficial effects o n  transgene expression  and  viral 
d te r  in b o th  gam m a-retrov iruses and  lendv iruses (H lavaty et al., 2005; W erner e t al., 
2004; Z ufferey  et al., 1999).
H ow ever, the  m ajor lim itadon  o f  using lendviral vec to rs in clinical trial are the safety 
co n ce rn s  related  to  their H1Y origin and m ore recently  a p ropensity  to  induce liver 
tu m o u rs  in m ice (K ingsm an et al., 2005; T h em is et al., 2005).
A s the p o ten d a l benefits  o f  the use o f  gam m a-retrov ira l vecto rs sdll outw eigh the  risks, 
it seem s w o rth  exp lo ring  m eth o d o lo g ies  to  im prove their safety profile w ith o u t 
drasdcally  a ffecd n g  their virtues.
It seem s fair to  say th a t the general availability o f  enhancer-dele ted  o r SIN  vectors, 
lacking pow erfu l en h an cers , hereby  a reduced  m utagenic p o ten d al and w ith  im proved  
dssue specificity th ro u g h  an en d o g en o u s  p ro m o ter, should  enable the d ev e lo p m en t o f  
m aterially safer retrov iral gene therapv  p ro to co ls  than  those curren tly  in clinical usage. 
H ence, the A-LTR v ec to r desc ribed  here could  provide the basis fo r a new  g en e rad o n  
o f  retroviral vectors w ith  im proved  safety.
It is ho p ed  that w ith these  small b u t consisten t technical advances, gene therapy  will in 
the near fu ture b eco m e a ro u d n e  clinical reality. As A nd erso n  has p o in ted  o u t 
(A nderson , 2000): “ G en e  T h erap y  will succeed w ith dm e. A nd  it is im p o rtan t that it 
does succeed, because n o  o th e r  area o f  m edicine holds as m uch p rom ise fo r p rov id ing  
cures for the m any devasta ting  diseases that now  ravage h u m an k in d ” .
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8 A p p e n d i x :  P l a s m i d  M a p s  a n d  C l o n i n g  S t r a t e g i e s
T h e  follow ing list o f  plasm id restric tion  m aps w ere draw n up w ith the help o f  the V ectorN T I D N A  sequence database softw are from  In forM ax , Inc. 
(Invitrogen) to  rep resen t each plasm id, subclones and cloning strategies used in this study. R estriction m aps w ere based on  the D N A  sequence 
ob tained  from  G enB ank  NCB1 database o r w here no  sequence data was available the know n base pair length and restric tion  site positions o f  the 
D N A  fragm ent are indicated. U nique restric tion  sites are p rin ted  in red, w hile o th er restric tion  sites are p rin ted  in black. P ro m o ter d irection , gene 
coding  sequences (cds) and reading fram e o rien ta tion  are indicated  by an arrow, w hereas transcrip tion  factor binding sites, IRES, exon and in tron , ori, 
poly-A  signal locations are specified at their know n positions.
A p p e n d ix : P lasm id  M aps an d  C lo n in g  S tra teg ies
8.1 Plasmids with origin of promoters for investigation
8.1.1 pTZ19R clone2 (murine neutrophile elastase promoter)
Prom oter: m urine neutrophile elastase (~2400bp) 
Reference: (N uchprayoon et al., 1994)
A P r
Eco R1 (160) 
j s s t l  (170)













unknow n se q u en ce  data
Bglll (1911)
m urine neutrophil e la s ta se  prom oter
\  M co I(26 ii )
Exon 1
Intron 1
Xma III (3021) 
Exon 2
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A p p e n d ix : P lasm id  M a p s a n d  C lo n in g  S tra teg ies
8.1.2 pGL-3145 (human c-fgr promoter)
Prom oter: c-fgr 
Backbone: pGL2-Basic 
Reference: (Kefalas et al., 1995)




p G L - 3 1 4 5
8841 bp
Clal (4686)
M » I  (1530)





Eco RI (2505) 
fgr exonM I 
X h o l(2809)
Xma III (3109) 
fgr exonM 4
Sma I (3248) 
\SsfK 3263)
\ :N h e l  (3273 )
\Xho I (3278)
I I*I Bgl11(3282) 
//m d lll (3292) 




A p p en d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8.1.3 p446 (human c-fes promoter)
Prom oter: hum an c-fes
R eporter gene: luciferase
Reference: (H eydem ann et al., 1996;




S m a I (200)
human c-fes prom oter
CAAT1
A 'm alll (298)





\  X h o l (540)
\  Btffll (5 4 4 )6K3 hr
//m dlll (554)




S a il  (3251)
Bam HI (3245)
N ote: the p446 plasm id has 36x 
Tsp5091 restriction sites, however 
the c-fes p ro m o ter in the p446 
plasm id is flanked by only one 
Tsp509l site (at position  4) and 
one unique Hindi II site (at 
position  554) restriction sites, 
while all o th er Tsp509I sites are 
outside the c-fes prom oter. 
Tsp509l restriction produce 








« t  <573-1 \  I I  I W .I/B M



































A p p e n d ix : P lasm id  M ap s a n d  C lo n in g  S tra teg ies
8.1.4 pm PU .l-334/luc (murine PU .l promoter)
Prom oter: m urine PU.l 
R eporter gene: luciferase 
Reference: (Chen et al., 1995a)
murine PU.1 promoter
M e l  (154) 1 




♦1  (transcriptional start)
Bam HI (484)
I I PU.1 SsS (533)
I I  I I
L 1 1
m urine PU .l (Spi-1) p rom oter (pm PU -334/luc insert)
569 bp
8.1.5 pEF-PGK-Neo (human EFlalpha promoter)
Prom oter: hum an E F la lp h a  
R eporter gene:
Reference:(M izushim a and Nagata, 1990; Z hen  et al., 1993)
EcoU (1599)
1 Smal (1613) 
BnmHI (1617)
Smal (34) I / X b a l ( l629) 
H in d in (21) human EFlalpha promoter Sill(1241) Amo III (1636) 
G a l ( u )  TATA Signal W 1 (979) Xhol (1378) Moll (1636)
hum an EFlalpha prom oter (fragm ent in pEF-pgK-Neo)
1688 bp
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A p p e n d ix : P la sm id  M a p s  an d  C lo n in g  S tra teg ies
8.1.6 pC A T -X R N  (hum an p 47phox prom oter)
Prom oter: p47phox 
R eporter gene: CAT
Reference: (M arden et al., 2003a; M arden et al., 2003b)











Promoter E(p47-phox) 1 M13REV PRIM BIND SITE
Hindlll (2243)
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A p p en d ix : P lasm id  M a p s a n d  C lo n in g  S tra teg ies
8.1.7 p<2>GH-CDllb (hum an C D llb  prom oter)
Prom oter: C D l l b  
R eporter gene:








Bglll (448) \  I 5'UTR(ITGAM) 1
p g  1 \  \ Ncol (744) s«a (94a) j I 1 Bom  HI (1*70))  M l  I :  i I I I  (
human C D llb  promoter - (PCR-Linker insert of pOGHCDUb)
1674 bp
S»<l (942)
human C011b promoter (1226 bp)






PU.1 \  \  Ncol (744)






human C D llb  promoter - (PCR-Linker insert of pOGHCDllb) 
1674 bp
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A p p en d ix : P lasm id  M a p s a n d  C lo n in g  S tra teg ies
8.1.8 p c D N A 3 /C A T  (C M V /T 7  prom oter)
Prom oter: C M V /T 7 
R eporter gene: CAT 
Reference: Invitrogen
Sal I (6 2 2 8 ) Bglll (13)









6 2 2 9  bp
N c o l (1442)
H in d lll (1677)
Sst I (1693)
Bam H I (1695)
Xma 111 ( 1709)
Eco RI (1726)
Xba I (4051)
Sail (4 0 4 4 )
SV40 POLY A
N c o l (3 4 9 9 )
NEO(R) iN ofl (1753) 
Xma n i  (1753)
Xhol (1759) 
Xba K1771) 





Sma I (2 8 8 0 )
A m a I II  (2973)
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A p p e n d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
8.1.9 pATCMVIXCAT3 (CMV IE promoter)
P rom oter: CM V IE  (~850bp)
R eporter gene: CAT
Reference: n /a
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Appendix: Plasmid M aps and Cloning Strategies 
8.2 Plasmids based on pGL3-Basic with the luciferase reporter gene
8.2.1 pGL3-Basic (without promoter)
Prom oter: no  p ro m o ter S s f l ( l2) 
Clal (4814) / Nhel (22)
R eporter gene: luciferase Primer Bind 3 Sma I (29)
Reference: Prom ega
PolyA Signal 2 Misc Feature 1
Clal (4710) \ \  11 Xhol (,33)
X m a III (4652) A 1 (37)
Not I (4652) U — Wmdlll (54)
Rep Origin 2 /  ' Nco1 ® 7)
^  Primer Bind 1
M  CDS(luc+) 1
S  pGL3-Basic
4818 bp I  
CDS(AmpR) 2 M
y  m  ^ I(1743) 
III (1756)
\  Xma UI (1760)
PolyA Signal 1
\ \ \C la l (1998)




A p p e n d ix : P la sm id  M ap s an d  C lo n in g  S tra teg ies
8.2.2 pG L3-C ontrol (SV40 prom oter)
Equal to pG L3-SV40-luc 
P rom oter P I: SV40 p rom oter 
R eporter gene: C D S(luc+) luciferase 
PolyA Signal 1: SV40 late ploly(A) signal 
Enhancer: SV40 E nhancer 
Rep O rigin 2: F I ori 
Reference: P rom ega

















Promoter P 1 
\  HmdHI (251) 
N col (284) 
Primer Bind 1 
CDS(luc+) 1
Xba I (1940) 
Xma III (1953) 
Xma III (1957) 
PolyA Signal 1 
\ \  \  Clal (2195)
Enhancer 1 




8.2.3 p G L 3-2400m N E -luc
Prom oter: m urine neutrophile elastase (■ 
R eporter gene: luciferase 
C loning Strategy:
B ackbone plasmid: pG L3-Basic 
D igest: H in d l l l /N c o l  
In sert plasmid: pTZ 19R clone 
Digest: H in d l l l /N c o l  
Reference: this thesis
A p p en d ix : P lasm id  M a p s a n d  C lo n in g  S tra teg ies
2400bp)
Primer Bind 2
S a il  (4387)
Bam  HI (438
Clal (4374)
PolyA Signal 1
Xma III (4136) 
Xma III (4132) 
X ba  K4119)




Primer Bind 3 
PolyA Signal 2
Clal (7 0 8 6 )
Xma III (7 0 2 8 )




Ssr I (17) 
Tie I (27) 
ma  I (34)
p G L 3 -2 4 0 0 m N E -lu c
7189 b p
X h o l (3 8 )
B glll (4 2 )
H in d lll  (59)
Bam  HI (549)
unknow n s e q u e n c e  data
BgR  I (1759)
prom oter
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A p p e n d ix : P lasm id  M a p s an d  C lo n in g  S tra teg ies
8.2.4 PG L 3-700m N E -lu c
Prom oter: m urine neutrophile elastase 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: pG L3-Basic 
D igest: B g lll /N c o l 
Insert plasmid: pT Z19R clone2 
Digest: B g lll /N c o l 
Reference: this thesis
Prim er Bind 3 




C /al (1) 









n o  se q u e n c e  da ta  
u rine neu troph il e la s ta se  p ro m o te r 
TATA Signal 1 
Prim er Bind 1
CDS(luc+) 1
X b a I (2402) 
X m a III (2415) 
X m a III (2419)




Prim er Bind 2
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A p p e n d ix : P lasm id  M a p s an d  C lo n in g  S tra teg ies
8.2.5 pG L3-1762cfgr-luc
Prom oter: c-fgr (1762bp) 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: pG L3-Basic 
Digest: S m a l/H in d ll l  
In sert plasmid: pG L-3145 
Digest: N c o l (b lu n t)/H in d lll 
Reference: this thesis













Bam HI (3 7 4 7 ) ^ ^ 2  
Clal (3740) ”  
PolyA Signal 1
Xma III (3502) 





\  Xhol (879)
Bam HI (885) 
human c-fgr promoter (1762 bp) 
£co RI (1009) 
fgr exonMI 
X hol (1313)









Primer Bind 1 
CDS(luc+) 1
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A p p e n d ix : P lasm id  M a p s a n d  C lo n in g  S tra teg ies
8.2.6 pGL3-1231c-fgr-luc
Prom oter: c-fgr (1231 bp) 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: pG L3-Basic 
Digest: Sm al
Insert plasmid: pG L-3145 
Digest: Smal 
Reference: this thesis
P rim er B ind 3 
PolyA  S ig n a l 2
Clal (5946 )
X m ain  (5 8 8 8 )
Not I (5 8 8 8 )
R ep O rig in  2
CDS(AmpR) 2
Clal (1) 
Sst I (17) 
Nhel (27)
p G L 3-1231cfgr- lu c
6 0 4 9  bp
P rim er B ind 2
Sail (3 2 4 7 )
Bam H I (3241)
Clal (3 2 3 4 ) 
PolyA  S ignal 1
Sma  I (34 )
X h o l (3 9 2 )
B am  H I (3 9 8 )
Eco RI (522) 
fg r exonM I 
X h o l (8 2 6 )
X m a III  (1126) 
Sma I (1265) 
o l  (1269)
p g m  (1273)
H in d i II (1290)
\
N c o l (1323) 
P rim er B ind 1 
CD S(luc+) 1
X b a I (2979) 
X m a III (2 9 9 2 ) 
X m a III (2 996 )
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8.2.7 PG L 3-m P U .l-lu c
A p p e n d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
P rom oter: m urine PU .l 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: pG L3-Basic 
D igest: B glll
Insert plasmid: p m P U .l-3 3 4 /lu c  
Digest: B am H I
Insert orientation confirm ation 
Digest: N h e l and N c o l 
Reference: this thesis






C D S(A m pR) 2






X h o l(38)
N col (184)
Nhel (194 )
murine PU.1 promoter 
Sp1 
GATA-1















A p p e n d ix : P la sm id  M ap s an d  C lo n in g  S tra teg ies
8.2.8 p G L 3-1672C D llb -lu c
Prom oter: C D l l b  (1672bp) 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: pG L3-Basic 
Digest: H in d l l l /N c o l  (blunt) 
In se rt plasmid: p $ G H - C D llb  
D igest: B am H I(b lu n t)/H in d IIl 
Reference: this thesis










C D S(A m pR ) 2
Sma I (34)




BamHI (3649) j / / l
Clal (3642) /
PolyA Signal 1



















> Nco I (1731)
Primer Bind 1 
CDS(luc+) 1
187
A p p e n d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
8.2.9 p G L 3-1226C D llb -lu c
Prom oter: CD1 lb  (1226bp)
R eporter gene: luciferase 
C loning strategy7:
B ackbone plasmid: pG L 3-1672C D l lb  
Digest: B glll 
D eledon: 464bp 
Religation
Reference: this thesis






/S st I (17) 
N hel (27) 














N co l (338)
Sst I (536) 







Bam H I (1264)
N col (1268)
Primer Bind 1 
CDS(luc+) 1
Xba I (2924) 
Xma III (2937) 
Xma III (2941)
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A p p en d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
8.2.10 P G L 3-732C D llb -lu c
Prom oter: C D l l b  (732bp)
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: p G L 3 -1 6 7 2 C D llb  
Digest: SstI 
D eletion: 982bp 
Religation
Reference: this thesis
P rim er Bind 3 




R ep Origin 2
CDS(AmpR) 2
p G L 3 -7 3 2 C D llb - lu c
5475 bp
Clal (1)
I Sst I (17)
hum an  CD11b p ro m o te r (732 bp)






B am H I (745)
N co I (749) 
Prim er Bind 1 
CDS(luc+) 1
X b a I (2405)
X m a III (2418)
\  ’  Xma III (2422)
PolyA S ignal 1 
I (2660)
B am H I (2667)
Sail (2673)
Prim er Bind 2
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A p p e n d ix : P la sm id  M ap s a n d  C lo n in g  S tra teg ies
8.2.11 p G L 3-C M V /T 7-lu c
P rom oter: CM V 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: pG L3-Basic 
Digest: B g lll /H in d ll l  
In se rt plasmid: p cD N A 3 /C A T  
Digest: B g lll /H in d lll  
Reference: this thesis
Not l (5512) 
Rep Origin 2
Clal (5674) 
Prim er Bind 3 
PolyA S ignal 2
Clal (5570) 
X m a III (5512)
1














Sst I (843) 
Hindlll (914) 
T 7-Prom oter 
Nco I (947) 
Prim er Bind 1 
CDS(luc+) 1
B am H I (2865) 
Clal (2858)
Xba I (2603) 
Xma III (2616) 
Xma III (2620) 
PolyA Signal 1
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A p p e n d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8.2.12 p G L 3-C M V /T 7-eG F P
Prom oter: CM V 
R eporter gene: eG F P  
C loning strategy:
B ackbone plasmid: pG L 3-C M V /T 7-luc  
Digest: H in d ll l/X b a l  
In se rt plasmid: p E G F P -N l 
Digest: H in d ll l /X b a l  
Reference: this thesis
Clal (4774)
Primer Bind 3 S s r l ( ia )
PolyA Signal 2 Nhel (2 2 )
Clal (4670) 111 11 Sma I (29) 













Eco RI (921) 
T7-Promoter 
|V S a/I (931)
Sma I (950) 
B am H I (952) 
Nco I (969) 
COS(egfp) 1 
V N ofl (1693)
\ \  Xma ID  (1693)\\\
X ba I (1703)








A p p e n d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8.2.13 pG L 3-850C M V -luc
Prom oter: CM V IE  (~850bp)
3’end o f  CM V possibly includes In tro n X  (no sequence 
data)
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: pG L3-Basic 
D igest: X h o l /H in d l l l  
In se rt plasmid: pA ICM VIXCAT.3 
Digest: X h o l /H in d l l l  
Reference: this thesis
Prim er Bind 3 
PolyA S ignal 2
Clal (5537)
X m a  III (5479)
Not I (5479)
R ep Origin 2
CDS(AmpR) 2
Clal (1)
S s t I (17)





Prim er Bind 2
Sail (2838 ) 
BamHI (2832) 
Clal (2825)
X b a l (44)
Sst I (54)
Ssf I (69)
hCMV im m ediate  early  p ro m o te r
Nco I (450)
Sst 1 (658 )
no  se q u e n c e  d a ta  (incl. add itional BamHI side)
BamHI (8 6 0 )
HmdHI (881)
\ N co I (9x4)
Prim er Bind 1 
CDS(luc+) 1
X b a l (2570)
Xma III (2583)
Xma III (2587)
PolyA S ignal 1
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A p p e n d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8.2.14 PG L 3-1189E F -la-luc
Prom oter: E F - la  (1189bp) 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: pG L3-Basic 
Digest: N c o I(b lu n t) /H in d llI  
In sert plasmid: p E F -P G K -N eo  
Digest: E co R I/H in d H I 
Reference: this thesis
P rim er B ind 3 
PolyA  S ignal 2
Clal (6 2 6 4 )
X m a III  (6 2 0 6 )
Clal (1) 
'Sst I (17) 
Nhe 1 (27) 
Sma I (34)
Not I (6 2 0 6 ) 
R ep O rigin 2
CDS(Am pR) 2
p G L 3 -1 1 8 9 E F la lp h a -lu c
6 367  bp
P rim er B ind 2
Sail (3565)
Bam H I (3559) ^ ^  /  .
Clal (3552)
PolyA  S ignal 1
Xma III  (3314) /  
X m a  III  (3310)
X b a l (3297)
X b o l (38)
Bglll (42)
Windlll (59)
S m a I (72)
TATA sig n a l
h u m an  E F la lp h a  p ro m o te r
Bglll (1017)
Sst 1 (1279)
X h o l (1416)
Eco RI (1637)
P rim er B ind 1 
CDS(luc+) 1
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A p p e n d ix : P lasm id  M ap s a n d  C lo n in g  S tra teg ies
8.2.15 pG L 3-1189E F -la-eG F P
Prom oter: E F - la  (1189bp)
R eporter gene: eG F P  
C loning strategy:
B ackbone plasmid: p G L 3 -E F la -lu c  
Digest: E co R I/X b a l 
In se rt plasmid: p E G F P -N l 
Digest: E co R I/X b a l 
Reference: this thesis
Primer Bind 3 
PolyA Signal 2
da l  (5386) 
Xma III (5328) ^  ^




H indlll (59) 
S m a l (72)
C DS (A mp R ) 2
pG L 3-l 189EFlalpha-EG FP
5489 bp
Clal (1)











B am HI (1668)
Nco I (1685)
CDS(egfp) 1 
iM N ofl (2409)
Xma III (2409)
'X b a l (2419)
Xma III (2432)
X ma III (243b)
PolyA Signal 1 
Clal (2674)




A p p e n d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8.3 Retroviral V ectors based  on  pM B A
8.3.1 pMBA
Derivate o f  pB abe (M orgenstern and Land, 1990) (5’LTR: 
1-1375 and 1965-4125) and pM PSV  (1375-1965: 3’LTRA)
Reference: kind gift o f  Dr. C. Porter, C hester Beatty 
Laboratories, L ondon











Xm a III (669)
gag MLVMO
B am H I (1375) 
Sm a I (1381)
\ \
\  £co  RI (1385)
Clal (1410)
3' LTR MPSV 
U3 deletion (Xbal/Nhel) 
3’ LTR MPSV 
Sst I (1695)
3' LTR MoLV (3'end)
Sma I (1756)
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A p p e n d ix : P la sm id  M a p s  an d  C lo n in g  S tra teg ies
8.3.2 p M B A -B asic-lu c
E ndogenous P rom oter: 5’LTR 
E xogenous P rom oter: no 
M odification: enhancer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: pMBA 
Digest: Clal
In se rt plasmid: pGL3-Basic 
Digest: Clal
In se rt orientation confirm ation 







3‘ LTR MoLV (3 'end)
Sst I (3697)
3' LTR MPSV 





Sma I (3381) 





P rim er Bind 1
Xbal (180)
5' LTR MoLV




PSI p ackag ing  signal
X m a III (669) 
gag  MLVMO
B am H I (1375) 
x S m a I (1381) 
E coR I (1385)
Clal (1410) 
PolyA Signal 1 
X m a III (1646) 
X m a III (1650) 
X b a l (1663)
CDS(luc+) 1
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A p p en d ix : P lasm id  M a p s a n d  C lo n in g  S tra teg ies
8.3.3 p M B A -700m N E -lu c
E ndogenous P rom oter: 5’LTR 
E xogenous P rom oter: m N E  (~700bp) 
M odification: enhancer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: pMBA 
Digest: Bam H I
Insert plasmid: pG L3-2400m N E -luc 
Digest: B g lll/B am H I 
Insert orientation confirm ation 








3’ LTR MoLV (3'end)
SstI (4317) \
3’ LTR MPSV 
U3 deletion (Xbal/Nhel)
3' LTR MPSV 
Clal (4032)
EcoRI (4007)
Sma I (4003) 
no sequence data 
murine neutrophil elastase promoter 









Xma III (669) 
gag MLVMO








A p p e n d ix : P lasm id  M a p s  a n d  C lo n in g  S tra teg ies
8.3.4 p M B A -2400N E -lu c
E ndogenous P rom oter: 5’LTR 
E xogenous P rom oter: m N E  (~2400bp) 
M odification: enhancer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: pMBA 
Digest: Clal
Insert plasmid: pG L 3-2400m N E -luc 
Digest: Clal
Inse rt orientation confirm ation 
Digest: X bal 
Reference: this thesis
A Pr
X m a III (7189)
Not I (7189) 
pUC ori 
Sma I (6129)
3' LTR MoLV (3 'end)
Sst I (6 0 6 8 )
3* LTR MPSV 
U3 dele tion  (Xbal/Nhel)








B am H I (5233) 
unknow n s e q u e n c e  da ta
X b a l (180)
5' LTR MoLV 
S s f l (3 0 0 )
Sma I (361)
PSI p ack ag in g  signa l 
Xma III (669) 
gag  MLVMO 
BamHI (1375)
pM B-delta-2400m N E-luc




olyA S ignal 1 
X m a III (1646)
IxmaHI (1650)
\  X b a l (1663)
CDS(luc+) 1 
P rim er Bind 1 
TATA S ignal 1 
m urine  neu troph il e la s ta s e  p ro m o te r 
Bgtll (4023 )
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A p p e n d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
8.3.5 p M B A -P U .l-lu c
E ndogenous P rom oter: 5’LTR 
E xogenous P rom oter: PU .l 
M odification: enhancer deleted 3 ’LTR 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: pM BA 
Digest: Clal
In se rt plasmid: pG L 3-PU .l-luc 
D igest: Clal
Inse rt o rientation  confirm ation  




Not I (5300) 
pUC ori 
Sma I (42 io )
3* LTR MoLV (3'end)
SstI (4179)
3* LTR MPi 
U3 deletion (Xbal/Nhel)








murine PU.1 promoter 
Sp1 
GATA-1






p M B - d e l t a - P U . l - l u c
6339 bp
PSI packaging signal
Xma III (669) 
gag MLVMO
BamHI (1375)
’ Sma I (1381)
Eco RI (1385)
Clal (1410)
PolyA Signal 1 
Xma III (1646) 
Xma III (1650) 
X bal (1663) 
CDS(luc+) 1
Hindi11 (3352)
Nco I (3319) 
Primer Bind 1
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A p p e n d ix : P lasm id  M ap s an d  C lo n in g  S tra teg ies
8.3.6 p M B A -1672C D llb -lu c
E ndogenous P rom oter: 5’LTR 
E xogenous Prom oter: C D l l b  (1672bp) 
M odification: enhancer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: pMBA 
Digest: Clal
Insert plasmid: pG L 3-1672C D l lb -luc  
Digest: Clal
Inse rt orientation confirm ation 
Digest: X bal 
Reference: this thesis
Xm a III (6457)
Not I (6457) \ 
pUC ori 
Sma I (5397)







Nhel (5 0 2 3 ),
Sma I (5020) \
Xhol(5012)
Bgtll (5008)
H m dlll (4991)
PU
Bgtll (4545) I  
NcoI (4504) ,





pM B-delta-1672CDl lb -luc
7496 bp
V
_  _ S st I (300) 
f  Sma I (361)
PSI packaging signal 
Xma m  (669) 
gag MLVMO 
B am H I (1375) 
Sm a I (1381) 
£coR I (1385)
I (1410)
A Signal 1 
X m a i n  (1646) 
Xma III (1650) 












A p p e n d ix : P la sm id  M ap s a n d  C lo n in g  S tra teg ies
8.3.7 pM B A -SV 40-luc
E ndogenous P rom oter: 5’LTR 
Exogenous P rom oter: SV40 
M odification: enhancer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: pMBA 
Digest: Clal
Insert plasmid: pG L 3-C ontro l (= pGL3-SV40-luc) 
Digest: Clal
Inse rt orientation confirm ation 
D igest: X bal 
Reference: this thesis
APr
X m a III (5010)




3* LTR MoLV (3 'end) ^
Sst I (3 8 8 9 ) \
3 ' LTR MPSV 
U3 d e le tio n  (Xbal/Nhel)
3’ LTR MPSV 
Clal (3 6 0 4 )
Sst I (3594)
N he1 (3576)
Sma 1 (3573) "
X h o l (3565)
Sglll (3561)
Misc F ea tu re  1 
P ro m o te r  P 1 
H indlll (3352) 
N co I (3319) 
Prim er Bind 1
/
X b a l (180)
5' LTR MoLV
Sst I (3 0 0 )
Sma I (361)
PSI p ac k a g in g  signa l
X m a III (669 ) 
g a g  MLVMO
_  B am H I ( 1375)
\  Sma I (1381) 
E coR I (1385)
Clal (1410)
PolyA S ignal 1 
X m a III (1646) 
X m a III (1650) 
X b a l (1663)
CDS(luc+) 1
p M B -delta-SV 40-luc
6 0 4 9  bp
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Appendix: Plasmid Maps and Cloning Strategies
8.3.8 p M B A -C M V /T 7-lu c
E ndogenous P rom oter: 5’LTR 
Exogenous Prom oter: C M V /T 7  
M odification: enhancer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: pMBA 
Digest: B am H I
Insert plasmid: pG L 3-C M V /T 7-luc 
Digest: B g lll/B am H I 
Insert orientation confirm ation 




Not I (5644) 
pUC ori
\
Sma I (45843 
3' LTR MoLV (3'end)
SstI (4523)
3' LTR MPSV 
U3 deletion (Xbal/Nhel)
3* LTR MPSV \ \
Clal (4238)
Eco RI (4213)












PSI packaging signal 




PolyA Signal 1 
Xma III (1620) 








8.3.9 pM B A -850C M V -luc
A p p e n d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
E ndogenous P rom oter: 5’LTR 
E xogenous P rom oter: CM V850 
M odification: enhancer deleted 3’LTR 
R eporter gene: luciferase 
Cloning strategy:
B ackbone plasmid: pM BA 
Digest: Clal
In se rt plasmid: pG L3-850CM V -luc 
Digest: Clal
In se rt o rientation confirm ation  
Digest: X bal 
Reference: this thesis
A P'
Xm a III (5640)
\
Not I (5640) 
pUC ori 
Sm a I (458Q)
3' LTR MoLV (3'end)
Sst I (45^ )
3' LTR MPSV 
U3 deletion (Xbal/Nhel)








Ssf I (4172) 
hCMV im m ediate early prom oter 
Nco 1(3783)
Ssf I (3583)
no seq u en ce  data (incl. additional BamHI side)
Bam H I (3373) 






Sm a I (361)
PSI packaging signal 
X m a III (669) 
gag MLVMO 
Bam H I (1375)
Primer Bind 1
Nco I (33*9)
Sm a I (1381) 
£coR I (1385) 
\ | c i a l  (1410) 
PolyA Signal 1 
X m a III (1646) 
Xma III (1650) 
X b a l (1663) 
CDS(IUC+) 1
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A p p e n d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
8.3.10 pMBA-1189EFla-luc
E ndogenous P rom oter: 5’LTR 
Exogenous Prom oter: E F la  (1189bp) 
M odification: enhancer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: pM BA 
Digest: Clal
Inse rt plasmid: p G L 3 -l 189E F la-luc  
Digest: Clal
Inse rt o rientation  confirm ation  
Digest: X bal 
Reference: this thesis
APr
X m a III (6367)
Not I (6367) 
pUC ori \
Sma I (5307) \
3' LTR MoLV P 'e n d ) 1 
Sst I  (5246)11 
3' LTR MPSV 
U3 dele tio n  (Xbal/Nhel)




Sma I (4930 )
X h o l (4922)
Bglll (4918) /
H m d ll l  (4901)
Sma I (4892)
TATA sig n a l 
h u m an  E F Ia lp h a  p ro m o te r
Bgtll (3943)
X b a l (180)
5' LTR MoLV
Ssf I (3 0 0 )
Sma I (361)
PSI p ack ag in g  sig n a l
X m a III (669 )
p M B - d e l t a - 1 1 8 9 E F l a l p h a - l u c
7406  bp
gag  MLVMO
B am H I (1375) 
S m a I (1381) 
Eco RI (1385)
\  )C/aI (1410) 
PolyA S ignal 1 
X m a III  (1646) 
X m a  III  (1650) 
X b a l (1663) 
CDS(luc+) 1
P rim er Bind 1
Eco RI (3323) 
X b o l (3544)
Ssf I (3689 )
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A p p en d ix : P lasm id  M ap s a n d  C lo n in g  S tra teg ies
8.4 Plasmids based on pEGFP-Nl and pNl subclones
8.4.1 pEGFP-Nl
Prom oter: CM V IE  
R eporter gene: eG FP  
Reference: C lontech
pUC ori
HSV TK poly A








SV40 P rom oter
en h an ce r region 






X h o l (614)
Ssf I (621)
W m dlll (623)
Eco RI (630) 
Sail (640)
\  Sma I (659) 
Bam HI (661) 
Nco I (678) 
CDS(egfp) 1 
\ N o t  1(1402)
\  Xma  III  (1402) 
Xbal (1412) 
SV40 POLY A 
f1 origin 
KN(R) P rom oter
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A p p en d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8.4.2 pNl-CMV-PU.l-eGFP
Prom oter: m urine PU.1 
R eporter gene: eG FP  
Cloning strategy:
Backbone plasmid: p E G F P -N l 
Digest: B am H I
Insert plasmid: pm P U .l-3 3 4 /lu c  
Digest: B am H I
Insert orientation confirm ation 
Digest: N h e l (221 bp  correct /  
399bp w rong orientation) 
Reference: this thesis
pUC ori






Xma in (3 1 4 6)













H indlH  (623)
Sma I (659)
B am H I (661)
Nco I (803)
N Iw I (813)




B am H I (1143)
Nco I (1160) 
CDS(egfp) 1 
N ofI (1884)





A p p en d ix : P lasm id  M aps an d  C lo n in g  S tra teg ies
8.4.3 pNl-CMV-1672CDllb-eGFP
Prom oter: C D l lb  (1672bp) 
Reporter gene: eG FP  
Cloning strategy:
Backbone plasmid: p E G F P -N l 
Digest: H in d lll/B a m H I 
Insert plasmid: p 0 G H -C D l lb  
Digest: H in d lll/B a m H I 
Reference: this thesis
pUC ori
HSV TK poly A














BglI I  (610)
Xhol (614)
Ssf I  (621)
p N l-C M V -1672C D llb -eG F I
6363  b p
SV40 POLY A
GATA




N co I (1365)
uman CD11b promoter
Ssf I  (1563) 
Eco RI (1957)
5'UTR(ITGAM) 1
B am H I (2291)
Nco I (2 3 0 8 ) 
CDS(egfp) 1
i N o fI (3032)
| Xma II I (3032) 
Xbal (3042)
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A p p e n d ix : P lasm id  M ap s an d  C lo n in g  S tra teg ies
8.4.4 pNl-CMV-1227CDllb-eGFP
P rom oter: CD1 lb  (1227bp)
R eporter gene: eG F P  
C loning strategy:






e n h a n c e r  region
MV im m ediate early  p rom oter
Nco I (361)
TATA box




C J a l(3769)
SV40 ORI 
Nco I (3658)
SV40 P rom oter
KN(R) P rom oter





N h el (592)
6 9 0 1 (610)
Nco I (651)
Nco I (906)
Ssf I (1104) 







B am H I (1832)
Nco I (1849)
CDS(egfp) 1




A p p en d ix : P lasm id  M ap s an d  C lo n in g  S tra teg ies
8 .4 .5  p N l - C M V - 7 3 2 C D l l b - e G F P
Prom oter: CD1 lb  (732bp)
R eporter gene: eG FP  
Cloning strategy:







hCMV immediate early promoter
Nco I (361)
TATA box
  Nhel (592)
B9ai (6l°)
HSV TK poly A





























A p p e n d ix : P lasm id  M ap s an d  C lo n in g  S tra teg ies
8.4.6 pNl-CMV-1672CDllb-luc
Prom oter: CD1 lb  (1672bp)
R eporter gene: luciferase enhancer region
hCMV immediate early promoter
C loning strategy: // Nco I (361)
TATA box
Backbone plasmid: p N l-C M V -1 6 7 2 C D llb -eG F P pUCori N he1 (5 9 2 )
/ /  B p f l l (610)
Digest: H in d l l l /N o t l HSV TK poly A xbol(6i4)
Nco I (5798) x s .  \  Ssf I (621)
Insert plasmid: pGL3-Basic KN(R) / NEO(R) H in d ll l  (623) 
X m a III (5272) \  £  P U 1
Digest: B g lll /X m a lll
Reference: this thesis, (Schwickerath et al., 2004)
Clal (5 206) X'xB Bglll (1069)
'  f  p N l - C M V - 1 6 7 2 C D l l b - l u c I  \  , ,
SV40ORI ■ 1  Nco I ( m o )■ 7341 bp  ■ — _\
N co I ( 5 0 9 5 ) .  Nco I (1365)
SV40 Promoter human CD11b promoter 
KN(R) Promoter ^  xS s f l d 563)
f1 origin ^  £a>RId957)
SV40 POLY A !  .  _____ Pu1
X b a l (4 0 2 0 ) ^
X m a II I  (4010) Sp1
N o fI (4010) / GATA
X b a l (3997) \  V 5’UTR(ITGAM) 1
\  \  N m d lll  (2 3 0 8 )




A p p e n d ix : P lasm id  M a p s an d  C lo n in g  S tra teg ies
8.4.7 pNl-CMV-732CDllb-luc
P rom oter: C D l lb  (732bp)
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: p N l-C M V -1 6 7 2 C D llb -lu c  
Digest: SstI 
D eletion: 982bp 
Religation
Reference: this thesis, (Schwickerath et al., 2004)
pUC ori

















. X hol (614) 
Ssf I (621)
p N l - C M V - 7 3 2 C D l  l b - l u c
6399 bp
\ human CD11b prom oter (732 bp)







\  Nco I (1399)
\
Primer Bind 1 
CDS(luc+) 1
l X bal (3055) 
N ofI (3068) 
Xma III (3068) 
X bal (3078)
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A p p e n d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8.5 Retroviral Vectors based on PINCO and relevant subclones 
8.5.1 PINCO (equal to PINCO-CMV-eGFP)
A  schem atic represen ta tion  o f  the 
retroviral vector P IN C O  (equal to  
P IN C O -C M V -eG FP), p resented as 
circular plasm id (12886bp).
Reference: (Grignani et al., 1998), 
Plasm id D N A  and D N A  sequence 
data were obtained as kind gift from  
Prof. D r. P ier G iuseppe Pelicci, 
Milan, Italy
A dditonal positions o f  restriction 
sites are indicated, w hich were left 
ou t earlier (Figure 19), b u t are 
essential fo r the cloning strategies 
applied to  the following P IN C O  
derivates.
3  £








A p p en d ix : P lasm id  M ap s an d  C lo n in g  S tra teg ies
For better visulisation, a linear fragm ent o f  P IN C O  from  a 
few base pairs before the position o f  N bel (449) to Clal 
(7007) is presented here on the right.
Exogenous Prom oter: CM V IE
R eporter gene: eG F P




hCMV immediate early promoter
C/a I (2328)
£ c o R I(2320)
B am H I (2299)
X b a l (2288) 
pol MLVMO 
gag MLVMO 






75 bp repeat 





75 bp repeat 
75 bp repeat 
3* LTR 
X b a l (4124)
CAAT signal! (C/EBP)







6609 bp (molecule 12886 bp)
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A p p en d ix : P lasm id  M ap s a n d  C lo n in g  S tra teg ies
8.5.2 pG L 3-A N X
Prom oter: no  prom oter 
Reporter gene: luciferase 
C loning strategy:
Backbone plasmid: pGL3-Basic 
Digest: N h e l/X b a l 
Deletion: 1721 bp 
Religation
Reference: this thesis
Equal to pG L3-A -N X  (Schwickerath et al., 2004)
Clal (3093) 







Xma III (35) 










A p p en d ix : P lasm id  M ap s a n d  C lo n in g  S trategies
8.5.3 pG L 3-A N X -3’L T R
Insert: 3’LTR 
Cloning strategy:
Backbone plasmid: pG L3-A N X  
Digest: Sail
Insert plasmid: P IN C O  
Digest: Sail 
Reference: this thesis
Equal to pG L3-A N X -LTR (Schwickerath et a l,  2004)
Clal (5597) 





S s f I (12) 











A \  Xma III (630)
Nco I (829)
\ Sma I (853)
X bal (898)
Primer Bind 2






\  X bal (2449)
3 'LTR 





A p p en d ix : P lasm id  M ap s an d  C lo n in g  S trategies
8.5.4 pG L 3-A N X -3’L T R A
Insert: enhancer deleted 3’LTR 
Cloning strategy:
Backbone plasmid: pG L3-A N X -3’LTR 
Digest: N h e l /  X bal 
Deletion: 267bp
Ligation o f X b a l/X b a l Fragm ent to backbone plasmid 
O rientation test:
Reference: this thesis
Equal to pGL3-ANX-A LTR (Schwickerath et al., 2004)
Clal (5330) 









HI PolyA Signal 1










' Xma III (630)
\  Nco I (829)
\  Sma I (853)





y Sst I (2337)
3' LTR MoLV (3’end)
CAAT signall (C/EBP)
U3 deletion (Xbal/Nhel) 
3’ LTR MoLV
"
| Sal I (2527) 
Primer Bind 2
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A p p en d ix : P la sm id  M ap s a n d  C lo n in g  S tra teg ies
8.5.5 PINCOA (equal to PINCOA-CMV-eGFP)
(Equal to  PIN C O A -CM V -eG FP)
Exogenous P rom oter: CM V IE  
R eporter gene: eG FP  
M odification: enhancer deleted 3’LTR 
Cloning strategy:
B ackbone plasmid: P IN C O  
Digest: Sail
Insert plasmid: pG L 3-A N X -3’LTRA 
Digest: Sail
Insert orientation confirm ation 
Digest: K pn l 
Reference: this thesis
Equal to  P IN C O A  (Schwickerath et al., 2004)
H tn d lll (3010) 
hCMV immediate early promoter
Clal (2328)
Eco RI (2320)
B am H I (2299),















IS a /I (3779)
3' LTR MoLV
U3 deletion (Xbal/Nhel) X b a l (5408)
CAAT signall (C/EBP) 











6416 bp (molecule 12619 bp)
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A p p e n d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
8.5.6 PINCO-CMV-luc
Exogenous P rom oter: CM V IE  
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: P IN C O  
Digest: H in d l l l /N o t l  
In se rt plasmid: pG L3-Basic 





hCMV immediate early promoter






Xm alU  (1213)






75 bp repeat 







75 bp repeat 
75 bp n 
j3' LTR 













7658 bp (molecule 13836 bp)
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A p p e n d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8 .5 .7  P I N C O A - C M V - l u c
E xogenous P rom oter: CM V 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: P IN C O A  
Digest: H in d l l l /N o t l  
In sert plasmid: pG L3-Basic 




H in d i II (3010) 
hCMV immediate early promoter 




















3' LTR MoLV 
U3 deletion (Xbal/Nhel) 
CAAT signall (C/EBP) 








7376 bp (molecule 13569 bp)
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A p p e n d ix : P la sm id  M a p s  an d  C lo n in g  S tra teg ies
8.5.8 P IN C O A -B a s ic -e G F P
E ndogenous Prom oter: 5’LTR 
Exogenous P rom oter: no  p rom oter 
R eporter gene: eG FP
M odification: CM V deletion /  enhancer deleted 
3’LTR
Cloning strategy:
B ackbone plasmid: P IN C O A  
Digest: B a m H I/N o tl  
In se rt plasmid: p E G F P -N l 
Digest: B g U I/N o tl 
In sert o rientation  confirm ation 
Digest: Sail 
Reference: this thesis
Equal to A-LTR(eGFP) (Schwickerath et al., 2004)
U3 deletion (Xbal/Nhel) 
3' LTR MoLV
Sail (3108) 
Notl (3 0 9 1 ) ,  
CDS(egfp) 1 
B am H I (2350)
Sail (2329)
Eco RI (2319)^
H m d lll  (2312)
Xba K 2 2 8 8 ) 
pol MLVMO 
Bglll (1930) t 
gag MLVMO 




Xba I (716) \
5 'LTR 
75 bp repeat 
75 bp repeat 
N h e l (449)
CAAT signall (C/EBP)





S a il (5 3 4 5 )
Puromycin N-Acetyltransferase 
PGK1
C la l (6069)
F ra g m en t  o f  P IN C O -d e lta -b a s ic -E G F P
5738 bp (molecule 11948 bp)
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A p p e n d ix : P lasm id  M a p s  a n d  C lo n in g  S tra teg ies
8.5.9 PINCO-Basic-luc
E ndogenous P rom oter: 5’LTR 
E xogenous P rom oter: no 
R eporter gene: luciferase 
M odification: CM V deletion 
C loning strategy:
B ackbone plasmid: 
P IN C O -B asic-eG FP  
Digest: X h o l /N o tl  
Insert plasmid: pGL3-Basic 
















75 bp repeat 







75 bp repeat 
| 75 bp repeat
I ! IT  LTR










F r a g m e n t  o f  P I N C O - b a s i c - lu c
6968 bp (m olecule 13150 bp)
221
A p p e n d ix : P lasm id  M a p s  an d  C lo n in g  S tra teg ies
8.5.10 P IN C O A -B a s ic - lu c
E ndogenous P rom oter: 5’LTR 
E xogenous P rom oter: no  
R eporter gene: luciferase
M odification: CM V deletion /  enhancer deleted 3’LTR 
Cloning strategy:
B ackbone plasmid:
P IN C O A - B asic-eG FP 
Digest: X h o l /N o tl  
In se rt plasmid: pG L3-Basic 






Bgl II (1930) 
gag MLVMO 






75 bp repeat 
75 bp repeat 
Nhe I (449)





3' LTR MoLV 
U3 deletion (Xbal/Nhel) 
CAAT signah (C/EBP) 
3' LTR MoLV (3’end)







Cla K 7 004)
F r a g m e n t  o f  P I N C O - d e l ta - b a s i c - lu c
6708 bp (molecule 12883 bp)
222
A p p e n d ix : P lasm id  M ap s a n d  C lo n in g  S tra teg ies
8.5.11 P IN C O -P U .l-e G F P
E ndogenous P rom oter: 5’LTR 
Exogenous P rom oter: PU.l 
R eporter gene: eG F P  
C loning strategy:
B ackbone plasmid: P IN C O  (PIN C O -C M V -eG FP
Digest: B a m H I/N o tl
Inse rt plasmid: pN l-C M V -P U .l-eG F P
Digest: B g lll /N o tl
Insert orientation confirm ation
Digest: N h e l
Reference: this thesis
Sal I {359«>: 
N ot I (3573) 
C D S (e g fp )  1 






Nhe I ( a s ° ^
Bam HI (2350:
Sa l  K 2329)
JScoRl (231'
H ind lll ( 2 3 I 2 ) \ \ \










75 bp repeat 
75 bp repeat 
Nbe I (449)
1
TATA s ig n a l
Nhe I (3668)




! Ij X bal (39351 
' CAAT signall (C/EBP)
Xba  I (5486)
Puromycin (3'termlnus)





6475 bp (molecule 12697 bp)
223
A p p e n d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
8.5.12 P IN C O A -P U .l-e G F P
E ndogenous Prom oter: 5’LTR 
E xogenous P rom oter: PU.1 
M odification: enhancer deleted 3’LTR 
R eporter gene: eG F P  
C loning strategy:
Backbone plasmid: P IN C O A  (PIN C O A -C M V -eG FP)
Digest: B a m H I/N o tl
Inse rt plasmid: p N l-C M V -P U .l-eG F P
Digest: B g lll /N o tl
In se rt o rientation confirm ation
Digest: N h e l
Reference: this thesis
CDS(egfp) 1
B am  HI (3 8 3 2 )
PU.1
+1 (transcrip tional start) 
GATA-1 
Sp1
m urine PU.1 p rom oter
N h e l (2 5 0 2 )
B am  HI (2 3 5 0 )
S a il  (2 3 2 9 )
Eco RJ (2319)
H indi II (23x2)
X ba  I (2 2 8 8 )  
pol MLVMO 
B g tll (1930)  
gag  MLVMO 
PSI pack ag in g  signa l 
RSL 
TATA signal 
CAAT s ig n a ll  (C/EBP)
X ba  l  (716)
5' LTR 
75 b p  rep ea t 
75 bp  rep ea t 
N h e l  (4 4 9 )
JVofI 13573)
S a il  (3 5 9 0 )
3’ LTR MoLV 
U3 de le tion  (Xbal/Nhel) 
CAAT s ig n a ll  (C/EBP) 
3' LTR MoLV (3'end)
X b a  I (5219)
Purom ycin  (3 'term inus)
S a il  (5827)




6225 bp (molecule 12430 bp)
2 24
8.5.13 P IN C O -P U .l- lu c
E ndogenous P rom oter: 5’LTR 
Exogenous Prom oter: PU.1 
R eporter gene: luciferase 
Cloning strategy:
Backbone plasmid: P IN C O -1672C D 1 lb-luc)
Digest: X h o l /H in d l ll
Insert plasmid: pG L 3-PU .l-luc
Digest: X h o l /H in d l ll
Reference: this thesis









N he  1(2459)















Xba  I (4495)
Won (4508)
Sal 1 (4525)
N h e l (4603)
75 bp repeat 
75 bp repeat 
3 'LTR 
X b a I (4870)
CAAT signall (C/EBP)
X ba  I (6421)
Puromycin (3'terminus)
S a il  (7029)
Puromycin N-Acetyltransferas 
PGK1
G a l  (7753)
F ragm ent  of  P IN C O -P U .1 - lu c
7422 bp (molecule 13632 bp)
225
A p p e n d ix : P lasm id  M a p s  a n d  C lo n in g  S tra teg ies
8.5.14 P IN C O A -P U .l- lu c
E ndogenous P rom oter: 5’LTR 
Exogenous P rom oter: PU.1 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: PIN C O A -1672C D 1 lb -luc
Digest: X h o l /H in d l l l
In se rt plasmid: pG L 3-PU .l-luc










N h eI (2459)
X ba  I (2288) 
pol MLVMO 
B g lll (1930)
gag MLVMO 




X ba I (716)
5‘ LTR 
75 bp repeat 
75 bp repeat 
Nhe I (449)
X ba  I (449 5 )
N a tl  (4508)
So/I (45 *5)
3’ LTR MoLV 
U3 deletion (Xbal/Nhel) 
CAAT signall (C/EBP) 
3' LTR MoLV (3'end)
X b a I (6154)
TATA signal
Puromycin (3‘terminus)





7176 bp (molecule 13365 bp)
226
A p p e n d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8.5.15 P IN C O -4 4 6 c fe s -e G F P
E ndogenous P rom oter: 5’LTR 
Exogenous P rom oter: cfes (446bp)
R eporter gene: eG F P  
Cloning strategy:
Backbone plasmid: P IN C O  (PIN C O -C M V -eG FP
Digest: H in d ll l /E c o R l
Insert plasmid: p446
Digest: T sp 5 0 9 I/H in d III
Reference: this thesis
Sa l  I (3639  
N o d  (3623: 
eGFP 
H indi 11 (2870;
BglW  (2860;








Mam HI (2299: 
X b a l  (2288)  
pol MLVMO 
B g lll  (1930: 
gag MLVMO 






75 bp repeat 
75 bp repeat
Nhe I (449 )
TATA signal
Nhe  I (3717)
75 bp repeat 
75 bp repeat 
3' LTR 









6573 bp (molecule 12746 bp)
227
A p p e n d ix : P lasm id  M ap s a n d  C lo n in g  S tra teg ies
8.5.16 P IN  C O  A -446cfes-eG F P
E ndogenous Prom oter: 5’LTR 
E xogenous P rom oter: cfes (446bp)
M odification: enhancer deleted 3’LTR 
R eporter gene: eG F P  
C loning strategy:
Backbone plasmid: P IN C O A  (PIN C O A -C M V -eG FP)
Digest: H in d lll/E c o R I
Insert plasmid: p446
Digest: T sp 5 0 9 I/H in d III
Reference: this thesis
eGFP
/ / in d l l l  (28 7 0 )
HqlU (2 8 6 0 )





human c-fes promoter 
Sp1
Eco  RI (2 3 2 0 )
B am  HI (2 2 9 9 )
X ba  I (2 2 8 8 )  
pol MLVMO 
B g lll (1930) 
gag MLVMO 




X ba  K 716)
5 'LTR 
75 bp repeat 
75 bp repeat
N he  I (449 )
TATA signal
Nor I (3 6 2 2 )
S a il  (3639)
3' LTR MoLV 
U3 deletion (Xbal/Nhel) 
CAAT signall (C/EBP) 
3’ LTR MoLV (3*end)
X b a l (5268)
Puromycin (3'terminus)
S o il  (5876)
Puromycin N-Acetyltransferase 
/  /  PGK1
d a l  ( 6 6 0 0 )
Fragment of PINCO-delta-446cfes-EGFP
6275 bp (m olecule 12479 bp)
228
A p p e n d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8.5.17 P IN C O -4 4 6 c fe s - lu c
CDS(luc+) 1
Primer Bind 1
H indll 1 (2 8 7 0 ) 
B g lll  (2860I  
Nhe I (2851) 
Exon 1 
PU.1/EIM ' 




KcoRl (2320) \  \  \  
Bom HI (2299A  \ \  
X bal (2288j \ \  y  
pol MLVMO \A \ \ 





I Nhe I (4667)
75 bp repeat 
: 75 bp repeat 
3' LTR 
j I I X b a l(4934) 





X b a l (716) ■
5' LTR\








'  /  d a l  (7817)
TATA signal 
RSL
E ndogenous P rom oter: 5’LTR 
E xogenous P rom oter: cfes (446bp) 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: P IN C O -C M V -luc 
D igest: H in d ll l/E c o R I 
Inse rt plasmid: p446 
D igest: T sp 5 0 9 I/H in d III 
Reference: this thesis
Fragment of PINCO-446cfes-luc
7469 bp (m olecule 13696 bp)
229
8.5.18 PINCOA-446cfes-luc
E ndogenous P rom oter: 5’LTR 
Exogenous P rom oter: cfes (446bp) 
R eporter gene: luciferase 
Cloning strategy:
Backbone plasmid: PIN CO A-CM V-luc 
Digest: H in d ll l/E c o R l 
Insert plasmid: p446 
Digest: T sp 5 0 9 I/H in d III 
Reference: this thesis
A p p en d ix : P lasm id  M a p s a n d  C lo n in g  S tra teg ies



























CAAT signall (C/EBP) 
LTR MoLV (3'end)
X b a l (6218)
Puromycin (3’terminus)






7220 bp (molecule 13429 bp)
230
A p p en d ix : P lasm id  M a p s an d  C lo n in g  S tra teg ies
8.5.19 P IN C O -1 1 8 9 E F lo t-eG F P
E ndogenous P rom oter: 5’LTR 
E xogenous P rom oter: E F la  (1189bp) 
R eporter gene: eG F P  
C loning strategy:
Backbone plasmid: P IN C O -eG F P-B asic  
Digest: H in d l l l /N o t l  
Insert plasmid: p G L 3 -E F la -eG F P  
Digest: H in d l l l /N o t l  
Reference: this thesis
B am H l (3921) 
Sail (3900) 
£coR l (3890) 
Bglll (3270) 
human EFIalpha promoter 
TATA signal 
Hin d i l l  (2312)
Xba I (2288)
pol MLVMO
Bgl II (1930) 
gag MLVMO 














75 bp repeat 
| 75 bp repeat 
j |3* LTR









7565 bp (molecule 13786 bp)
231
A p p en d ix : P lasm id  M ap s a n d  C lo n in g  S tra teg ies
8.5.20 P IN C O A -1 1 8 9 E F la -eG F P
E ndogenous P rom oter: 5’LTR 
Exogenous P rom oter: E F la  (1189bp) 
R eporter gene: eG FP  
Cloning strategy:
Backbone plasmid: PINCOA-eGFP-Basic
Digest: H in d l l l /N o t l
Insert plasmid: p G L 3 -E F l a -eG F P
Digest: H in d l l l /N o t l
Reference: this thesis




human EF1 alpha promoter 
TATA signal 
//m d lll  (231a)
Xba 1(2288) 
pol MLVMO 
B 9/IIO 930) 
gag MLVMO 




Xba I  (716)
5’ LTRV








3’ LTR MoLV 
U3 deletion (Xbal/Nhel) 
CAAT signall (C/EBP) 








7300 bp (molecule 13519 bp)
232
A p p e n d ix : P la sm id  M a p s an d  C lo n in g  S tra teg ies
8.5.21 PINCO-1189EFla-luc
E ndogenous P rom oter: 5’LTR 
Exogenous Prom oter: E F la  (1189bp) 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid: P IN C O -1189E F1 a-eG F P
Digest: B a m H I/N o tl
In se rt plasmid: pGL3-Basic
Digest: B g U I/X m alll
In se rt orientation  confirm ation
Digest: H in d lll
Reference: this thesis
Prim er Bind 1
/ /in  d in  (3 9 3 8 ) 
S a il  (3 9 0 0 )  
Eco RI (38 9 0 )  
B g lll  (3270) 
human EF1 alpha promoter 
TATA signal 
/ / in d l l l  (23x2)
Xba I (22 8 8 )  
pol MLVMO 
B g lll  (1930)
gag MLVMO 
PSI packaging signal 
RSL 
TATA signal 
CAAT sig n a ll (C/EBP)
X b a l  (7x6)
5 'LTR 
75 bp repeat 
75 bp repeat 
N h e I (4 49 )
RSL
CDS(luc+) 1
X ba  I (5627)
N o t I (5640)
8 0 /1 (5657)
N l1* 1 (5735)
75 bp repeat 
75 bp repeat
i 1 13* LTR
X b a l (6 0 0 2 )
CAAT signa ll (C/EBP)
X b a  I (7553)
Purom ycin (3‘term inus)




8576 bp (m olecule 14764 bp)
233
A p p en d ix : P lasm id  M aps a n d  C lo n in g  S tra teg ies
8.5.22 PINCOA-1189EFla-luc
E ndogenous P rom oter: 5’LTR 
Exogenous P rom oter: E F la  (1189bp) 
M odification: E nhancer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: PIN C O A -1189EF1 a-eG F P
Digest: B a m H I/N o tl
Insert plasmid: pGL3-Basic
Digest: B g lll /X m a lll
In sert orientation confirm ation
Digest: H in d lll
Reference: this thesis
Primer Bind 1
H in d lll  (3938)  
S a il  (3 9 0 0 )  
Eco RI (3 8 9 0 )  
B glU  (3270)  
hum an EF1 alpha prom oter 
TATA signal 
H in d lll  (231a)
Xba  1 (2 2 8 8 )  
pol MLVMO 
BglU  (1930) 
gag MLVMO 
PSI packaging signal 
RSL 
TATA signal 
CAAT sig n a ll (C/EBP)
X ba  I (716)
5' LTR 
75 bp repeat 
75 bp repeat 
M e  I (4 4 9 )
CDS(luc+) 1
X ba  I (5627)
N o ll  (5640 )
Sal K 5657)
3* LTR MoLV 
U3 deletion (Xbal/Nhel)
CAAT signa ll (C/EBP)
3‘ LTR MoLV (3'end)
X b a l  (7286)
Purom ycin (3 'term inus) 
S a l1 (7 8 9 4 )
TATA signal
Puromycin N-A cetyltransferase 
PGK1
Cla  I (8618)
F rag m en t of P IN C O -delta-E F 1alpha-luc
8300 bp (m olecule 14497 bp)
2 34
A p p en d ix : P lasm id  M ap s a n d  C lo n in g  S tra teg ies
8.5.23 PINCO-1672CDllb-eGFP(Nl)
E ndogenous P rom oter: 5’LTR 
Exogenous P rom oter: C D l l b  (1672bp) 
R eporter gene: eG F P  
C loning strategy:
Backbone plasmid: P IN C O -B asic-eG F P  
Digest: X h o l /N o tl
Insert plasmid: p N l-C M V -1 6 7 2 C D llb -eG F P
Digest: X h o l /N o tl
Insert orientation confirm ation
Digest: B glll
Reference: this thesis
hum an  CD11b prom oter
Bg ttl (2758) 
PU.1 
H in d lll (2312)
X b a l (22 8 8 )  
pol MLVMO 
Bg  f l l  (1930)  
gag  MLVMO 
PSI packaging  signal 
RSL
TATA signal 
CAAT sig n a ll  (C/EBP)
X b a l (716)
5' LTR 
75 bp  repeat 
75 bp  repeat
N h e l (449 )





H of I (4721)
S a il  (4 738)
N h e 1(4818)
75 bp  repeat 
75 bp repeat 
3' LTR
X b a l (5083)
CAAT s ig n a ll  (C/EBP)
X b a l (6634)
/
Purom ycin (3‘term inus)
S a il (7242)






7678 bp (m olecule 13845 bp)
235
A p p en d ix : P lasm id  M ap s an d  C lo n in g  S tra teg ies
8.5.24 PINCOA-1672CDllb-eGFP(Nl)
E ndogenous Prom oter: 5’LTR 
E xogenous Prom oter: C D l l b  (1672bp) 
M odification: E nhancer deleted 3’LTR 
R eporter gene: eG FP  
C loning strategy:
Backbone plasmid: PIN C O A -B asic-eG FP 
Digest: X h o l /N o tl
In sert plasmid: p N l-C M V -1 6 7 2 C D llb -eG F P
Digest: X h o l/N o tl
In sert orientation confirm ation
Digest: B glll
Reference: this thesis






£coR I (3648) 
hum an CD11b prom oter 
B glll (2758)
B glll (1930) 
gag N
PSI packaging  signal 
RSL 
TATA signal 
CAAT s ig n a ll (C/EBP)
Xba  K 716) ^
5’ LTR 
75 bp repeat 
75 bp repeat
N h e l (449) .
CDS(egfp) 1
N ot I (4721)
S a il  (4 738)
3' LTR MoLV 
U3 deletion (Xbal/Nhel)
CAAT signa ll (C/EBP)
3' LTR MoLV (3'end)
X b a l  (6367)
Purom ycin (3‘term inus)
/  S a lH  6975)





7365 bp (molecule 13578 bp)
236
A p p en d ix : P lasm id  M ap s an d  C lo n in g  S tra teg ies
8.5.25 PINCO-1672CDllb-luc(Nl)
E ndogenous Prom oter: 5’LTR 
Exogenous P rom oter: C D l l b  (1672bp) 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid: P IN C O -B asic-eG FP  
Digest: X h o l /N o tl
In se rt plasmid: pN l-C M V -1672C D l lb -luc
Digest: X h o l /N o tl
In se rt orientation confirm ation
Digest: H in d lll
Reference: this thesis
Primer Bind 1






Eco R1 (3*4«  
hum an CD11b prom oter 




PSI packaging signal 
RSL 
TATA signal 
CAAT signall (C/EB 
Xba  I (716)
5’ LTR 
75 bp repeat 
75 bp repeat 
Nhe I (449 )
CDS(luc+) 1
Xba  I (5686)
; N<* 1(5699) 
(So! I (5716)
' Nhe I (5794)
1(2288)
75 bp repeat 
75 bp repeat 
j i ' LTR
Ixba I (6061)
CAAT signall (C/EBP)







0 0 1 (8944)
Fragment of PINCO-1672CD11b-luc(N1)
8669 bp (m olecule 14823 bp)
237
A p p e n d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
8.5.26 PINCOA-1672CDllb-luc(Nl)
E ndogenous P rom oter: 5’LTR 
E xogenous P rom oter: C D l l b  (1672bp) 
M odification: E n h an cer deleted 3 ’LTR 
R eporter gene: eG F P  
C loning strategy:
B ackbone plasmid: P IN C O A -B asic-eG FP  
Digest: X h o l /N o t l
In se rt plasmid: pN l-C M V -1 6 7 2 C D l lb -lu c
Digest: X h o l /N o t l
In se rt o rien ta tion  confirm ation
Digest: H in d lll
Reference: this thesis
Primer Bind 1






Eco RI (3646) 
hum an C011b promoter
119/11(2758)
PU.1
Hm d ill  (2312)
Xba  I (2288) 
pol MLVMO 
B gll  1 (193° )  
gag MLVMO 




Xba  I (716)
5'  LT R
75 bp repeat






3' LTR MoLV 
U3 deletion (Xbal/Nhel) 
CAAT signall (C/EBP) 








8360 bp (molecule 14556 bp)
2 3 8
A p p e n d ix : P lasm id  M ap s a n d  C lo n in g  S tra teg ies
8.5.27 PINCO-1226CDllb-eGFP(Nl)
E ndogenous Prom oter: 5’LTR 
E xogenous Prom oter: C D l l b  (1226bp) 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid:
P IN C O -B asic-eG FP  
Digest: B a m H I/N o tl 
In sert plasmid:
pN  1 -CM V-1672C D 11 b-eG FP  
Digest: B g lll /N o tl  
In sert orientation confirm ation 
Digest: EcoR I 
Reference: this thesis
CDS(egfp) 1




E ts - l '
Pu.1\
Eco  RI (3238)  
h um an  CD11b p rom oter (1226 I 
Sal  I (2329)
Eco R I(2319)
H in d lll  (2312) >
Xba  I (2288)  
pol MLVMO 
8 9 /I I  (1930) 
gag  MLVMO 
PSI packag ing  signal
r s l \
TATA signal \
CAAT sig n a ll (C/EBPj
X ba  I (7x6)
5‘ LTR 
75 bp  rep ea t
75 bp  rep ea t\
Nhe I (449 )
N ot  I (4313)
Sal  1 (4 3 3 0 )
N h e  I (44 0 8 )
75 bp  repea t 
1 75 bp  rep ea t 
I* LTR 
1 (4675)
CAAT s ig n a ll (C/EBP)




P urom ycin  (3‘term inus)
Sal I (6834)
P urom ycin  N-A cetyltransfera: 
PGK1
O a  I (7558)
Fragment of PINCO-1226CD11b-EGFP(N1)
7235 bp (m olecu le 13437 bp)
239
A p p e n d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
8.5.28 PINCOA-1226CDllb-eGFP(Nl)
E n dogenous P rom oter: 5’LTR 
E xogenous P rom oter: C D l l b  (1226bp) 
M odification: E n h an cer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasm id: 
P IN C O A -B asic-eG FP  
Digest: B a m H I/N o tl  
In se rt plasmid:
p N  1 -CM V -16 7 2 C D 1 1 b -eG F P  
Digest: B g l ll /N o tl  
In se rt o rien tadon  confirm ation  
D igest: E coR I 
Reference: this thesis






£ c o R l (3 2 3 8 ) 
h u m an  CD11b p ro m o te r (1226 bp)
S a il  (2 3 2 9 )
Eco  RI (2319)
H in d lll  (2312)
X b a 1 (2 2 8 8 ) 
pol MLVMO 
B glll  (1930)  
g ag  MLVMO 
PSI p ack ag in g  signal 
RSL
TATA signal 
CAAT s ig n a ll  (C/EBP)
X ba  I (716)
5' LTR 
75 bp  rep ea t 
75 bp  rep ea t
N h e 1 ( 4 4 9 ) .
TATA signa l
CDS(egfp) 1
N o tl  (4313)
S a il  (4 3 3 0 )
3' LTR MoLV 
U3 de le tio n  (Xbal/Nhel) 
CAAT s ig n a ll  (C/EBP) 
3’ LTR MoLV (3 'end)
X b a  1 (5 9 5 9 )
Purom ycin  (3 'term inus)
S a l  1 (6567)/
Purom ycin  N -A cety ltransferase
PGK1
C lal (729O
Fragment of PINCO-delta-1226CD11 b-EGFP(N1)
6944 bp (molecule  13170 bp)
24 0
A p p en d ix : P la sm id  M ap s  an d  C lo n in g  S tra teg ies
8.5.29 PINCO-1226CDllb-luc(Nl)
Endogenous P rom oter: 5’LTR 
Exogenous P rom oter: C D l l b  (1226bp) 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid:
P IN  C O -B asic-eG FP 
Digest: B a m H I/N o tl  
In se rt plasmid: 
pN  1 -CM V-1672C D 11 b-luc 
Digest: B g lll /N o tl  
In se rt orientation confirm ation 
Digest: E coR I 
Reference: this thesis
human CD11b promoter (1226 bp)
Sal I (2329) 










X b a l (716)
5‘ LTR 
75 bp repeat 
75 bp repeat 
Nhe 1 (449)
C D S (lu c+ ) 1
Primer Bind 1
/ / i n d l l l  (3S «9 )







75 bp repeat 











8184 bp (molecule 14415 bp)
241
A p p e n d ix : P lasm id  M ap s an d  C lo n in g  S tra teg ies
8.5.30 PINCOA-1226CDllb-luc(Nl)
E ndogenous P rom oter: 5’LTR 
Exogenous P rom oter: C D l l b  (1226bp) 
M odification: E nhancer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid:
P IN C O  A -Basic-eGFP 
Digest: B a m H I/N o tl 
In sert plasmid: 
pN  1 -CM V-1672C D 11 b-luc 
Digest: B g lll /N o tl  
In se rt orientation confirm ation 
Digest: E coR I 
Reference: this thesis
Primer Bind 1






Eco RI (3238) 




Xba  I (2288) 
pol MLVMO 
B g lll  (1930) 
gag MLVMO 
PSI packaging signal 
RSL 
TATA signal 
CAAT signall (C/E 
Xba 1 (716)
5 'LTR 
75 bp repeat 
75 bp repeat 
Nhe 1(4491
CDS(luc+) 1
Xba  I (5278) 
[Not I (5291) 
Sal I (5308)
3’ LTR MoLV 
U3 deletion (Xbal/Nhel)
CAAT signall (C/EBP)








d o  I (8269)
Fragment of PINCO-delta-1226CD11 b-luc
7959 bp (molecule 14148 bp)
242
A p p e n d ix : P lasm id  M a p s a n d  C lo n in g  S tra teg ies
8.5.31 PINCO-732CDllb-eGFP(Nl)
E ndogenous P rom oter: 5’LTR 
E xogenous P rom oter: C D l l b  (732bp) 
R eporter gene: luciferase 
Cloning strategy:
B ackbone plasmid:
P IN  C O -B asic-eG FP 
Digest: B a m H I/N o tl 
In se rt plasmid: 
p N  1-CM V -732CD 11 b-eG F P  
Digest: B g lll /N o tl  
In se rt orientation confirm ation 
Digest: E coR I 
Reference: this thesis
CDS(egfp) 1






Eco R I(2755) 
human CD11b promoter (732 
Sal 1 (2329)
Eco R I(2319)
Win dlU  (2312)








X ba  I (716) .
5’ LTR 
75 bp repeat 
75 bp repeat 
Nhe I (449)
TATA signal
N ot I (3830)
[sW I (3847)
Nhe 1 (3925)
75 bp repeat 










Fragment of PINCO-732CD11 b-EGFP(N1)
6719 bp (m olecule 12954 bp)
243
A p p e n d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8.5.32 PINCOA-732CDllb-eGFP(Nl)
E ndogenous Prom oter: 5’LTR 
E xogenous P rom oter: C D l l b  (732bp) 
M odification: E nhancer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
Backbone plasmid:
P IN C O A -B asic-eG FP
Digest: B a m H I/N o tl
Inse rt plasmid:
pN  1 -CM V-732CD11 b-eG FP
Digest: B g U I/N o tl
Insert orientation confirm ation
Digest: E coR I
Reference: this thesis
CDS(egfp) 1






Eco R I(2755) 
human CD11b promoter (732 bp)
S al I (2329)
Eco RI (23 »9 )
H in d lll (2312)
Xba  I (2288)  
pol MLVMO 
Bgl II (1930) 
gag MLVMO 




X ba  I (716)
5' LTR 
75 bp repeat 
75 bp repeat 
N b t  I (449)
TATA signal
N ot I (3830)
8 0 /1 (3 8 4 7 )
3' LTR MoLV 
U3 deletion (Xbai/Nhel) 
CAAT signall (C/EBP) 
3’ LTR MoLV (3’end)





c /o r  (6808)
Fragment of PINCO-delta-732CD11b-EGFP(N1)
6423 bp (m olecule 12687 bp)
244
A p p e n d ix : P la sm id  M a p s a n d  C lo n in g  S tra teg ies
8.5.33 PINCO-732CDllb-luc(Nl)
E ndogenous P rom oter: 5’LTR 
Exogenous P rom oter: C D l l b  (732bp) 
R eporter gene: luciferase 
Cloning strategy:
Backbone plasmid:
P IN C O -B asic-eG FP
Digest: B a m H I/N o tl
In se rt plasmid:
p N  1-CM V-732CD11 b-luc
Digest: B g lll /N o tl
In sert orientation confirm ation
Digest: H in d lll
Reference: this thesis
CDS(luc+) 
Primer Bind 1 











X b a l (2288)' 
pol MLVMO
B g lll  (1930:
gag MLVMO 




X b a l  (716)
5' LTR 
75 bp repeat \
75 bp repeat 
N hel (449)
j j X bal (5170)
CAAT signall (C/EBP)
TATA s ig n a l
X b a l(4795)
Hof I (4808)
S al K 4825)
N h eI (4903)
75 bp repeat 








Fragment of PINCO-732CD11 b-luc(N1)
7731 bp (m olecule 13932 bp)
245
A p p e n d ix : P lasm id  M ap s a n d  C lo n in g  S tra teg ies
8.5.34 PINCOA-732CDllb-luc(Nl)
E ndogenous Prom oter: 5’LTR 
Exogenous Prom oter: C D l l b  (732bp) 
M odification: E nhancer deleted 3’LTR 
R eporter gene: luciferase 
C loning strategy:
B ackbone plasmid:
P IN C O A -B asic-eG FP
Digest: B a m H I/N o tl
Inse rt plasmid:
p N  1 -CM V-732CD11 b-luc
Digest: B g lll /N o tl
In se rt orientation confirm ation











human CD11b promoter (732 bp)












N h e l (449)
B alll ( 193°
X bal (4795)
I N otl (4808)
S a i l (4825)
3' LTR MoLV 
U3 deletion (Xbal/Nhel)
CAAT signall (C/EBP)
31 LTR MoLV (3’end)
X b a l(6454)
Puromycin (3'terminus)
/  /  Sal K 7062)
/  Puromycin N-Acetyltransferase
/  /  / /  P°K1TATA signal 
RSL d a l  (7786)
Fragment of PINCO-de!ta-732CD11 b-luc(N1)
7470 bp (m olecule 13665 bp)
246
8.5.35 PINCO-p47phox-eGFP
A p p e n d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
E ndogenous P rom oter: 5’LTR 
Exogenous P rom oter: p47phox 
R eporter gene: eG F P  
Cloning strategy:
Backbone plasmid:
P IN C O -E F 1 a-eG F P  
Digest: H in d ll l/E c o R I  
Inse rt plasmid: 
p4 7 cD N A /p 4 7 p h o x  
Digest: H in d ll l/E c o R I 
Inse rt orientation confirm ation 
Digest: X bal 
Reference: this thesis
S a i l  (3664) 
N o t I (3647) 
CDS(egfp) 1 
B a m H l  (2906)
S a il  (2885)
E co R l  (2875)
B am  H I (2854)
X b a 1 (2 8 4 8 )  
Promoter E(p47-phox) 1 
H in  d i l l  (2312)
X b a l  (2288) 
pol MLVMO 
B g h l  (1930) 
gag MLVMO 




X ba I  (716)
5'LTR 
75 bp repeat 
75 bp repeat




X b a l  (4009}
CAAT signall (C/EBP)
X b a l  (5560)
Puromycin (3'terminus)
S a l  I ( 6 i6 8 )
Puromycin N-Acetyltransferase 
PGK1
d a l  (6 8 9 2 )
F ra g m e n t o f PIN C C M 7phox-E G FP
6594 bp (molecule 12771 bp)
247
A p p en d ix : P lasm id  M ap s an d  C lo n in g  S trategies
8.5.36 P IN C O A -p 4 7 p h o x -eG F P
Endogenous Prom oter: 5’LTR 
Exogenous Prom oter: p47phox 
M odification E nhancer deleted 3’LTR 
Reporter gene: eG FP  
Cloning strategy:
Backbone plasmid:
PIN C O A -EF1 a-eG F P  
Digest: H in d lll/E c o R I 
Insert plasmid: 
p47 /4 7
Digest: H in d lll/E c o R I 
Insert orientation confirm ation 
Digest: X bal 
Reference: this thesis
CDS(egfp) 1
Bam  H I (2906)
Sail (2885)
£co RI (2875)
Bam H I (2854)
X b a l  (2848)
Promoter E(p47-phox) 1
H in d ll l  (2312) 















3' LTR MoLV 
U3 deletion (Xbal/Nhel)
CAAT signaH (C/EBP)
3* LTR MoLV (3'end)
X bal (5393)
Puromycin (3'terminus)
S a l I (5901)
Puromycin N-Acetyltransferase 
PGK1TATA signal 
RSL C Jal (6625)
Fragm ent o f P IN C O -d elta -47p h ox-E G F P
6327 bp (molecule 12504 bp)
248
A p p e n d ix : P lasm id  M ap s a n d  C lo n in g  S tra teg ies
8.5.37 PINCO-p47phox-luc
E ndogenous Prom oter: 5’LTR 
Exogenous Prom oter: p47phox 
R eporter gene: eG F P  
Cloning strategy:
B ackbone plasmid:
PIN C O -E F 1 a -eG F P  
Digest: H in d ll l/E c o R I 
Insert plasmid: 
p 4 7 /4 7
Digest: H in d ll l/E c o R I 
Inse rt orientation confirm ation  




E co  M  (2875)
B a m  H I (2854)
X b a l  (2 8 4 8 ) 
Promoter E(p47-phox) 1 
t f i n d l l l  (2312)
X b a I (2 2 8 8 ) 
pol MLVMO 
8 9 /I I  (1930)
gag MLVMO 




X b a  I (716)
5 'LTR 
75 bp repeat 
75 bp repeat 
A/he I  (449 )
Xba I (4535)
N o t  I (4 5 4 8 )
S a i l  (4565)
A/he I (4643)
75 bp repeat 
! 75 bp repeat 
iy  LTR
X ba I (4910)
CAAT signal! (C/EBP)








F ragm en t o f P IN C O -47p h ox-lu c
7444 bp (molecule 13672 bp)
249
A p p e n d ix : P la sm id  M a p s  a n d  C lo n in g  S tra teg ies
8.5.38 PIN CO A-p47phox-luc
E ndogenous P rom oter: 5’LTR 
E xogenous Prom oter: p47phox 
M odification: E nhancer deleted 3’LTR 
R eporter gene: eG F P  
C loning strategy:
B ackbone plasmid: 
P IN C O A -47phox-eG F P  
Digest: E c o R I /N o tl  
In se rt plasmid: 
p G L 3 -E F la - lu c  
Digest: E c o R I/X m a lll  
In se rt o rientation confirm ation  






X b a I (2848) 
Promoter E(p47-phox) 1 
f lin d lll (2312)

















tS a ll (4565)
3 'LTR MoLV 
U3 deletion (Xbal/Nhel) 
CAAT signaM (C/EBP) 
3' LTR MoLV (3'end)
X ba I (6194)
Puromycin (3’terminus)





7252 bp (molecule 13405 bp)
2 5 0
A p p e n d ix : P lasm id  M a p s a n d  C lo n in g  S tra teg ies
8.6 Plasmids and subclones with p47phox cDNA and p47phox Promoter
8.6.1 pVZl-NCF-47k (p47phox cDNA)
(Equal w ith p V Z l p47cD N A )
B ackbone plasmid: pB lueScript+
Insert: hum an N C F-47k (p47phox cD N A ) flanked by 
linker sequence
Reference: kind gift from  Dr. A dam  Rodaway
A Pr
f1 (+) origin
p V Z l  p 4 7 c D N A  ( B S p lu s )
4637 bp
T 7 P
Not I (907) 
Xma in (907) 
Eco RI (914) 
Bgtll (1088) 
Bglll (1271)
tfm d lll  (2365)
SaZI ( 2 3 4 7 )  ~
T 3 P
Xbal (2341) 
B am H I (2335) 
Sma I (2332) 
Sstl (2324)
CDS(p47phox cDNA)
B am H I (1562)
\  Xhol (1579)
Xhol (1693)
X m a III (1969)
Sma I (1989)
X7ioI(i999)
\ Xma III (2053)
Nhel (2144)
PolyA Signal 1 
BcoRI (2314)
251
A p p en d ix : P lasm id  M ap s an d  C lo n in g  S tra teg ies
8.6.2 p 4 7 cD N A -p 4 7 p h o x
Cloning strategy:
B ackbone plasmid: 
pCAT-XRN  (8.1.6)
Digest: H in d ll l/X b a l 
Insert plasmid:: 
p V Z l-N C F 4 7 k  (8.6.1)
D igest: H in d ll /X b a l 
cD N A : p47phox cD N A  
Prom oter: p47phox p rom oter 
Reference: this thesis
f1 (+) origin
p 4 7 c D N A /p 4 7 p h o x
5149 bp
//fn d lll (2877)
T 3P
















PolyA Signal 1 
Eco RI (2314)
S sfl(2324)




A p p en d ix : P la sm id  M ap s an d  C lo n in g  S tra teg ies
8.7 Plasmids and subclones with chimeric Intron
8.7.1 pCI-Vector
Prom oter: CM V IE
M ammalian E xpression vector w ith chimeric in tron  
dow nstream  o f  the en h an cer/p ro m o te r region




p C I - V e c to r
4006 bp





Misc Feature 1 
Misc Feature 2 
Nhe K1053) 
X hol (1059) 














Appendix: Plasmid Maps and Cloning Strategies
8.7.3 pCI-eGFP(lxHindlll)
Prom oter: CM V IE  
C loning strategy: 
B ackbone plasmid: 
pCI-V ector 
D igest: E c o R I/N o tl  
Insert plasmid:: 
p E G F P -N l 
Digest: E c o R I/N o tl  














Eco RI (1064) 
T7 Promoter 
Sail (1074) 
Sma I (1093) 
BamHI (1095) 








A p p e n d ix : P lasm id  M ap s an d  C lo n in g  S tra teg ies
8.7.4 PCI-eGFP(2xHindIII)
Promoter: CMV IE Bgtll (4750) Promoter P 1
j  Nco I (514)
Cloning strategy:
Sst I (722)
Backbone plasmid: Hindi11 (749) 
Intron 1
pCI-Vector Nhel (1053)
Digest: X hol/N otl ^  Xhol (1059) M Sst 1 (1 0 6 6 )
Insert plasmid:: PCI-eGFP(2xHindIII) f =  T7Promoter
....M 4754 bp ■  \ \ \
pEGFP-Nl
CDS(ampR) 1 M M HindIH(io68) 
%  M  \yJS0 0RI (1075)
Digest: X hol/N otl M  Sail (1085)
Sma I (1104)
\  Bam HI (1106) 
Nco I (1123) 
CDS(egfp) 1 
f1 origin \Notl (1847)
Reporter gene: eGFP 
Reference: this thesis





Appendix: Plasmid Maps and Cloning Strategies
8.7.5 PCI-47cDNA(lxHindIII)




Digest: E co R I/X b a l
Insert plasmid: p V Z l-  N C F-47k
(equal pBS_linkerNCF-47k)
Digest: E c o R l/N h e l 
R eporter gene: N FC -47k (cDNA )
Reference: this thesis










5 2 1 8  b p
f1 origin






Bam  HI (1712)
X h o l  (1729)







H ot I (2311)
Xma III (231O 
PolyA Signal 1 
d a l (2549)
BamHI (2556)
257
Appendix: Plasmid Maps and Cloning Strategies
8.7.6 pCI-47cDNA(2xHindIII)
Prom oter: CM V IE  
C loning strategy:
Backbone plasmid: 
p C I-eG F P  (2xH indIII)
Digest: E c o R I/N o tl 
Insert plasmid:: 
pC I-47cD N A (l x H in d lll)
Digest: E c o R I/N o tl  



















Bglll ( 1 4 3 a )  
CDS(p47phox cDNA) 
BamHI (1723)
\  X hol (1740)
X bal (1854)
Xma  m  (2130)
Sma I (2150)
X hol (2160)




Xma  HI (2322)
PolyA Signal 1 
Clal (2560)
BamHI (2567)
258
